A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects With Active Ankylosing Spondylitis
Phase: PHASE2
Conditions: Ankylosing Spondylitis
Sponsor: UCB Biopharma SRL

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 1 of 136
PROTOCOL AS0013 AMENDMENT 3
A MULTICENTER, PHASE 2A, RANDOMIZED, 
INVESTIGATOR-BLIND, SUBJECT-BLIND, PARALLEL-GROUP 
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 
BIMEKIZUMAB AND CERTOLIZUMAB PEGOL IN SUBJECTS 
WITH ACTIVE ANKYLOSING SPONDYLITIS
PHASE 2A
EudraCT Number: 2017-000957-37
IND Number: 128708
Sponsor:
UCB Biopharma SPRL
Allée de la Recherche 60
1070 Brussels
BELGIUM
Protocol/Amendment number
Date
Type of amendment
Final protocol
19 Apr 2017
Not applicable
Protocol amendment 1
30 May 2017
Nonsubstantial
Protocol amendment 1.1 (CZ)
07 Sep 2017
Substantial
Protocol amendment 1.1 (DE)
09 Oct 2017
Nonsubstantial
Protocol amendment 1.1 (NL)
18 Sep 2017
Substantial
Protocol amendment 2
05 Mar 2018
Substantial
Protocol amendment 2.1 (CZ)
07 Mar 2018
Substantial
Protocol amendment 2.2 (DE)
07 Mar 2018
Substantial
Protocol amendment 2.3 (NL)
27 Apr 2018
Substantial
Protocol amendment 2.4 (CZ)
03 Jul 2018
Substantial
Protocol amendment 3
27 Feb 2019
Substantial
Confidential Material
Confidential
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.
PUBLIC COPY 
r:
P
r:
harma S
OP
harma S
e la Rec
CO
e la Rec
1070 
LIC 
1070 
PU
P
not be used to support any marketing authorization 
CTS 
oriz
CTS 
PRL
rt a
PRL
erche 60
por
erche 60
russels
upp
russels
ELGIUM
su
ELGIUM
d t
ed
ed
ed
ed
se
u
be
NL)
no
NL)
t
t canno
no
t 2.1 (CZ)
can
t 2.1 (CZ)
nn
ment 2.2 (D
t ca
ment 2.2 (D
ca
ent c
ndment 2.3
ent 
ndment 2.3
ment c
amendment
men
amendment
en
ume
ol amendm
um
ol amendm
This docume
um
s 
nd any extensions or variations thereof.
M
i
M
Dat
n
Dat
ns
19 A
te
19 A
te
3
x
3
ex
y e
ny
ny
ny
ny
ny
a
ion and
nd
an
DE)
io
DE)
n
atio
3 (NL)
atio
3 (NL)
icatio
t 2.4 (CZ)
ica
t 2.4 (CZ)
at
plic
ment 3
plic
ment 3
applic
pl

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 2 of 136
STUDY CONTACT INFORMATION
Sponsor
UCB Biopharma SPRL
Allée de la Recherche 60
1070 Brussels
BELGIUM
Sponsor Study Physician
Name:
Address:
UCB Celltech, 208 Bath Rd, Slough, Berkshire, SL1 3WE, UK
Phone:
Fax:
Exploratory Project Manager
Name:
Address:
Alfred-Nobel-Str 10, 40789 Monheim, Germany
Phone:
Fax:
Clinical Trial Biostatistician
Name:
Address:
UCB Celltech, 208 Bath Rd, Slough, Berkshire, SL1 3WE, UK
Phone:
Fax:
Clinical Monitoring Contract Research Organization
Name:
PAREXEL International (IRL) Limited
Address:
One Kilmainham Square, Inchicore Road, Kilmainham, Dublin 8, Ireland
Phone:
+353 1 473 9500
Fax:
+353 1 473 9501
PUBLIC COPY 
OP
0, 40789
IC C
0, 40789
C
LIC
B
PU
PUB
PUB
ot be used to support any marketing authorization 
a
3WE, UK
ketin
3WE, UK
ting
ke
a
y m
t a
Monheim
ppo
Monheim
po
upp
s
d t
us
B Celltech
t be
B Celltech
be
ot
This document canno
nn
ca
ca
ca
ca
Monitor
ent 
Monitor
:
e
ddress:
ocu
ddress:
um
Phone
do
Phone
oc
s
Fa
s
Fa
s d
s
be
not
an
an
and any extensions or variations thereof.
of
K
th
K
ere
th
ns
tio
va
m, German
s or
m, German
or
s
io
ns
ex
h, 208 Bat
any
h, 208 Bat
ny
d a
and
application 
n
ring Co
atio
ring Co
PA
ca
PA
ca
ic
pl
ap
n a

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 3 of 136
SERIOUS ADVERSE EVENT REPORTING
Serious adverse event reporting (24h)
Fax
Europe and Rest of the World: +32 2 386 24 21
US and Canada: +1 800 880 6949 or +1 866 890 3175
Email
Global: DS_ICT@ucb.com 
PUBLIC COPY 
uthorization 
za
ori
This document cannot be used to support any marketing aut
uth
application and any extensions or variations thereof.

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 4 of 136
TABLE OF CONTENTS
LIST OF ABBREVIATIONS..................................................................................................10
1
SUMMARY.....................................................................................................................15
2
INTRODUCTION ...........................................................................................................16
2.1 Axial spondyloarthritis.....................................................................................................16
2.2 Bimekizumab ...................................................................................................................17
2.2.1
Clinical experience with bimekizumab................................................................18
2.2.2
Nonclinical studies with bimekizumab................................................................19
2.3 Certolizumab pegol..........................................................................................................19
2.3.1
Clinical experience with CZP..............................................................................20
2.4 Study rationale .................................................................................................................20
3
STUDY OBJECTIVE(S).................................................................................................21
3.1 Primary objective.............................................................................................................21
3.2 Secondary objective.........................................................................................................21
3.3 Other exploratory objectives............................................................................................21
4
STUDY VARIABLES.....................................................................................................21
4.1 Efficacy variables.............................................................................................................21
4.1.1
Primary efficacy variable.....................................................................................21
4.1.2
Secondary efficacy variables ...............................................................................21
4.1.3
Other efficacy variables.......................................................................................22
4.2 Safety variables................................................................................................................22
4.2.1
Primary safety variables ......................................................................................22
4.2.2
Other safety variables ..........................................................................................22
4.3 Other PK and PD variables..............................................................................................22
4.3.1
Other PK variables...............................................................................................22
4.3.2
Other PD variables...............................................................................................22
4.4 Other immunological variable(s) .....................................................................................23
4.5 Other nonhereditary pharmacogenomic variables ...........................................................23
4.6 Other pharmacogenetic variables.....................................................................................23
5
STUDY DESIGN.............................................................................................................23
5.1 Study description .............................................................................................................23
5.1.1
Screening Period (minimum of 2 and up to 4 weeks)..........................................24
5.1.2
Treatment Period (Week 0 to Week 12)..............................................................24
5.1.3
Treatment Extension Period (Week 12 to Week 48)...........................................24
5.1.4
Safety Follow-up Period (Week 48 to Week 64).................................................25
5.2 Safety monitoring strategy...............................................................................................25
5.3 Imaging evaluation...........................................................................................................25
5.4 Study duration per subject................................................................................................25
PUBLIC COPY 
.
PY
.........
PY
........
..........
OP
..........
..........
CO
..........
.........
C C
.........
bles
LI
bles .....
LIC
.....
es
UB
es.......
UB
.......
..........
PU
..........
able
P
able
This document cannot be used to support any marketing authorization 
7
..
h
..18
hor
18
........
uth
........19
h
19
....
a
............
a
........
.....
ng
............
ng
.......
........
tin
............
in
....
...........
ke
...........
............
ar
............
............
m
...........
............
ny
............
............
a
............
...........
ort
...........
...........
po
............
o
.
............
up
............
............
s
............
............
to
...........
...........
ed
...........
es
u
es ..........
us
..........
es
e
es........
e
........
ables
t be
ables....
b
....
variables
ot 
variables
ological va
nno
ological va
hereditary
can
hereditary
harmacog
nt c
harmacog
UDY DES
en
UDY DES
Study des
ume
Study des
5.1.1
cu
5.1.1
5.1.2
doc
5.1.2
5
d
5
application and any extensions or variations thereof.
19
f
19
.....
e
.....20
eof
20
...........
her
...........20
e
20
............
th
............
.........
ns
............
s
...
............
tio
............
.....
iat
............
at
.......
..............
ar
..........
............
v
............
............
o
............
.........
ns
............
s
...
......
io
............
o
......
............
ns
............
............
te
............
............
ex
............
............
y
............
............
an
............
............
d
............
variable(s)
and
variable(s)
y pharmac
n a
y pharmac
genetic va
tion
genetic va
SIGN
cat
SIGN....
a
....
scription
plic
scription
Screeni
app
Screeni
Trea
ap
Trea

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 5 of 136
5.5 Planned number of subjects and site(s)............................................................................25
5.6 Anticipated regions and countries....................................................................................25
5.7 Schedule of assessments ..................................................................................................26
5.8 Schematic diagram...........................................................................................................31
5.9 Rationale for study design and selection of dose.............................................................32
6
SELECTION AND WITHDRAWAL OF SUBJECTS...................................................33
6.1 Inclusion criteria ..............................................................................................................33
6.2 Exclusion criteria .............................................................................................................35
6.3 Withdrawal criteria ..........................................................................................................38
6.3.1
Potential drug-induced liver injury IMP discontinuation criteria........................40
6.4 Study stopping rules.........................................................................................................41
6.5 Retesting/rescreening.......................................................................................................41
7
STUDY TREATMENT(S) ..............................................................................................42
7.1 Description of investigational medicinal product(s)........................................................42
7.2 Treatment(s) to be administered ......................................................................................42
7.3 Packaging.........................................................................................................................43
7.4 Labeling ...........................................................................................................................43
7.5 Handling and storage requirements..................................................................................43
7.6 Drug accountability..........................................................................................................44
7.7 Procedures for monitoring subject compliance................................................................44
7.8 Concomitant medication(s)/treatment(s)..........................................................................44
7.8.1
Permitted concomitant treatments (medications and therapies) ..........................45
7.8.2
Prohibited concomitant treatments (medications and therapies).........................45
7.8.3
Rescue medication...............................................................................................47
7.9 Blinding............................................................................................................................47
7.9.1
Procedures for maintaining and breaking the treatment blind.............................47
7.9.1.1
Maintenance of study treatment blind.......................................................48
7.9.1.2
Breaking the treatment blind in an emergency situation...........................48
7.10 Randomization and numbering of subjects......................................................................48
8
STUDY PROCEDURES BY VISIT ...............................................................................49
8.1 Screening Visit (Visit 1) ..................................................................................................49
8.2 Baseline (Visit 2, Week 0)...............................................................................................51
8.3 Week 2 (Visit 3)...............................................................................................................52
8.4 Week 4 (Visit 4)...............................................................................................................52
8.5 Week 6 (Visit 5)...............................................................................................................53
8.6 Week 8 (Visit 6)...............................................................................................................53
8.7 Week 10 (Visit 7).............................................................................................................54
8.8 Week 12 (Visit 8).............................................................................................................54
C COPY 
......
Y
......
........
PY
.........
Y
.
..........
CO
..........
PUBLIC C
.........
C C
.........
........
LIC
..........
C
..
ect com
BLI
ect com
/treatme
PUB
/treatme
itant tr
PU
itant tr
port any marketing authorization 
.33
or
33
......
th
......35
ho
35
..
a
............
au
..........3
...........
g
...........
............
ting
............
............
ke
............
....
a
............
ar
........
............
m
............
...........
y
...........
............
an
............
............
rt
............
t be used to suppo
............
po
............
............
upp
............
pliance
sup
pliance..
u
..
nt(s)
to
nt(s).......
to
.......
eatments (
ed t
eatments (
nt treatme
sed
nt treatme
...........
u
...........
.........
be
...........
e
..
This document cannot 
for maint
ot b
for maint
Maintenan
nno
Maintenan
Breakin
can
Breakin
ization an
t ca
ization an
DY PROC
ent
DY PROC
creening V
me
creening V
Baselin
cum
Baselin
8.3
do
8.3 Wee
oc
Wee
8.4
s d
8.4 W
8
s
8
or variations thereof.
8
f
8
...
e
...40
eof
40
.........
ere
.........41
e
41
........
th
............
h
....
............
s
............
..
o
............
on
..........
.........
ati
.............
............
ari
............
............
va
............
any extensions or
............
or
............
............
s
............
...........
on
...........
............
si
............
(medicati
tens
(medicati
ents (med
exte
ents (med
............
y e
............
...........
ny
...........
application and a
t
d
taining an
d a
aining an
nce of stud
and
nce of stud
ng the tre
n an
ng the tre
nd numbe
tion
nd numbe
CEDURE
atio
CEDURE
Visit (Vi
lica
Visit (Vi
ne (Visit 2
ppl
ne (Visit 2
a
k
a
k 2 (Vis
ap
2 (Vis
(

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 6 of 136
8.9 Week 16 (Visit 9), Week 20 (Visit 10), Week 28 (Visit 12), Week 32 (Visit 13), Week 
40 (Visit 15), and Week 44 (Visit 16)..............................................................................55
8.10 Week 24 (Visit 11) and Week 36 (Visit 14) ....................................................................56
8.11 Week 48 (Visit 17)/Early Withdrawal Visit ....................................................................57
8.12 Safety Follow-Up Visit (Week 64, Visit 18, 20 weeks after the final dose of IMP).......58
8.13 Early Withdrawal Visit ....................................................................................................58
8.14 Unscheduled Visit............................................................................................................58
9
ASSESSMENT OF EFFICACY......................................................................................59
9.1 ASDAS ............................................................................................................................59
9.2 ASAS20, ASAS40, and ASAS partial remission ............................................................60
9.3 BASDAI...........................................................................................................................60
9.4 Inflammation – BASDAI (mean of Questions 5 and 6) ..................................................61
9.5 Function – BASFI............................................................................................................61
9.6 Patient global assessment (PGADA) ...............................................................................61
9.7 PhGADA..........................................................................................................................61
9.8 Total and nocturnal spinal pain........................................................................................62
9.9 hs-CRP .............................................................................................................................62
9.10 Hospital Anxiety and Depression Scale...........................................................................62
9.11 PET-MRI or PET-CT scan...............................................................................................62
10
ASSESSMENT OF PHARMACOKINETIC/ 
PHARMACODYNAMIC/PHARMACOGENOMIC/ PHARMACOGENETIC 
VARIABLE(S) ................................................................................................................62
10.1 Pharmacokinetic variables ...............................................................................................62
10.2 Pharmacodynamic variables ............................................................................................63
10.3 Nonhereditary pharmacogenomic variables.....................................................................63
10.4 Pharmacogenetic variables...............................................................................................63
11
ASSESSMENT OF IMMUNOLOGICAL VARIABLE(S) ............................................63
12
ASSESSMENT OF SAFETY..........................................................................................64
12.1 Adverse events.................................................................................................................64
12.1.1
Definitions ...........................................................................................................64
12.1.1.1
Adverse event............................................................................................64
12.1.1.2
Serious adverse event ................................................................................64
12.1.1.3
Adverse events of special interest .............................................................66
12.1.1.4
Adverse events for special monitoring......................................................67
12.1.2
Procedures for reporting and recording adverse events.......................................67
12.1.2.1
Description of adverse events....................................................................67
12.1.2.2
Rule for repetition of an adverse event......................................................68
12.1.2.3
Additional procedures for reporting serious adverse events .....................68
12.1.3
Follow up of adverse events ................................................................................68
PUBLIC COPY 
.
Y
....
Y
...
........
PY
.........
Y
.
.........
CO
..........
O
.
C
.........
C
.........
..........
IC
..........
COKINE
BLI
COKINE
HAR
UB
HARMA
UBL
MA
..........
PU
..........
This document cannot be used to support any marketing authorization 
58
or
58
.....
th
.....59
ho
59
...........
au
...........59
h
59
...........
g a
...........
............
ing
............
..........
ket
............
t
..
............
ark
............
............
ma
............
...........
y
...........
............
any
............
............
rt
............
............
po
............
....
p
............
pp
........
TIC/ 
su
TIC/ 
COGENO
o s
COGENO
..
d
............
d to
..........
............
ed
............
...........
us
...........
ogenomic 
be u
ogenomic 
riables
t be
riables...
b
...
OF IMMU
not 
OF IMMU
T OF SA
nn
T OF SA
vents
ca
vents....
a
....
Definitio
nt c
Definitio
.1.1.1
men
.1.1.1
12.1.1.2
um
12.1.1.2
12.1
cu
12.1
1
1
d
1
application and any extensions or variations thereof.
9
f
9
....60
of
60
........
re
........60
eo
60
............
the
............
.......
s t
............
t
.....
..........
on
..............
....
ati
...........
atio
.......
............
ria
............
............
va
............
....
or
............
or
........
............
s o
............
OMIC/ PH
sion
OMIC/ PH
............
ns
............
..........
te
..............
............
ex
............
c variables
ny e
c variables
............
an
............
UNO
d
UNOLOG
d a
LOG
AFETY
an
AFETY.
............
n 
............
ons
ti
ons ......
tio
......
Advers
cat
Advers
2
Seri
ic
Seri
.1.3
ap
.1.3
A
p
A
.1.4
ap
.1.4

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 7 of 136
12.2 Pregnancy.........................................................................................................................69
12.3 Suspected transmission of an infectious agent.................................................................70
12.4 Overdose of investigational medicinal product ...............................................................70
12.5 Safety signal detection .....................................................................................................70
12.6 Laboratory measurements................................................................................................70
12.6.1
Evaluation of PDILI ............................................................................................72
12.6.1.1
Consultation with Medical Monitor and local hepatologist ......................77
12.6.1.2
Immediate action: Determination of IMP discontinuation........................77
12.6.1.3
Testing: Identification/exclusion of alternative etiology...........................77
12.6.1.4
Follow-up evaluation.................................................................................79
12.7 Other safety measurements..............................................................................................79
12.7.1
Vital signs ............................................................................................................79
12.7.2
Body weight and height.......................................................................................80
12.7.3
Physical examination...........................................................................................80
12.7.4
12-lead electrocardiogram ...................................................................................80
12.7.5
Tuberculosis and TB risk factor assessment and management ...........................80
12.7.5.1
Tuberculosis assessment by IGRA............................................................82
12.7.5.2
Chest X-ray for tuberculosis......................................................................82
12.7.5.3
Tuberculosis questionnaire........................................................................83
12.7.5.4
Tuberculosis management.........................................................................83
12.7.6
Pregnancy testing.................................................................................................84
12.7.7
Assessment of suicidal ideation and behavior.....................................................84
13
OTHER STUDY MEASUREMENTS ............................................................................84
13.1 Demographic and Baseline characteristics ......................................................................84
13.2 Medical history ................................................................................................................84
13.3 Ankylosing spondylitis history ........................................................................................84
13.4 Prior and concomitant medications..................................................................................84
14
STUDY MANAGEMENT AND ADMINISTRATION.................................................85
14.1 Adherence to protocol......................................................................................................85
14.2 Monitoring .......................................................................................................................85
14.2.1
Definition of source data .....................................................................................85
14.2.2
Source data verification .......................................................................................86
14.3 Data handling...................................................................................................................86
14.3.1
Case Report Form completion.............................................................................86
14.3.2
Database entry and reconciliation........................................................................86
14.3.3
Subject Screening and Enrollment log/Subject Identification Code list..............86
14.4 Termination of the study..................................................................................................87
14.5 Archiving and data retention............................................................................................87
LIC COPY 
......
Y
......
sment a
OPY
sment a
y IGRA
COP
y IGRA
losis
C C
losis...
C
...
onnaire
LIC
onnaire
PUB
nagemen
BLI
nagemen
.........
PU
.........
cidal i
PU
cidal i
support any marketing authorization 
.77
or
77
......
th
......77
ho
77
............
au
............7
...........
g
...........
............
ting
............
............
ke
............
...........
ar
............
............
m
............
...........
y
...........
nd manage
any
nd manage
............
rt
............
............
po
............
............
upp
............
not be used to su
...........
su
...........
............
to
............
eation an
d t
eation an
M
s
MENTS
sed
ENTS
e characte
e us
e characte
...........
be
...........
ylitis histo
ot b
ylitis histo
This document cann
mitant m
no
mitant m
ANAGEM
an
ANAGEM
ce to prot
t ca
ce to prot
itoring
ent
itoring .
.1
m
.1
Def
e
Def
4.2.2
cum
4.2.2
14.3
doc
14.3 Dat
oc
Dat
14
d
14
ons or variations thereof.
7
f
7
...
e
...79
eof
79
.........
ere
.........79
e
79
...
th
............
th
.........
............
s
............
............
on
............
...........
ati
...........
ement
aria
ement ....
............
va
............
..........
or
..............
............
s
............
d any extension
...........
on
...........
............
si
............
d behavio
ens
d behavio
............
xt
............
teristics
y ex
teristics
.......
ny
...........
ny
....
ory
d
ory .......
d a
.......
plication an
edication
nd
edication
MENT AN
n an
MENT AN
tocol
tion
tocol....
on
....
...........
at
...........
finition o
lica
finition o
app
Source d
ppl
Source d
handlin
ap
handlin
C

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 8 of 136
14.6 Audit and inspection ........................................................................................................87
14.7 Good Clinical Practice .....................................................................................................88
15
STATISTICS ...................................................................................................................88
15.1 Definition of analysis sets................................................................................................88
15.2 General statistical considerations.....................................................................................88
15.3 Subject disposition...........................................................................................................89
15.4 Subject characteristics......................................................................................................89
15.5 Planned efficacy analyses ................................................................................................89
15.5.1
Analysis of the primary efficacy variable............................................................89
15.5.2
Supportive analysis of the primary efficacy variable ..........................................90
15.5.3
Analysis of the secondary efficacy variables.......................................................90
15.5.4
Analysis of the other efficacy variables...............................................................90
15.6 Pharmacokinetic analyses ................................................................................................90
15.7 Immunological analyses...................................................................................................91
15.8 Planned safety and other analyses....................................................................................91
15.8.1
Safety analyses.....................................................................................................91
15.9 Handling of protocol deviations.......................................................................................91
15.10
Handling of dropouts or missing data....................................................................91
15.11
Planned interim analysis and data monitoring.......................................................91
15.12
Determination of sample size.................................................................................92
16
ETHICS AND REGULATORY REQUIREMENTS......................................................92
16.1 Informed consent .............................................................................................................92
16.2 Subject identification cards..............................................................................................93
16.3 Institutional Review Boards and Independent Ethics Committees..................................93
16.4 Subject privacy.................................................................................................................94
16.5 Protocol amendments.......................................................................................................94
17
FINANCE, INSURANCE, AND PUBLICATION.........................................................94
18
REFERENCES ................................................................................................................94
19
APPENDICES .................................................................................................................99
19.1 Modified New York (mNY) Classification Criteria for AS ............................................99
19.2 Markedly abnormal laboratory values ...........................................................................100
19.3 Protocol Amendment 1 ..................................................................................................101
19.4 Protocol Amendment 2 ..................................................................................................107
19.5 Protocol Amendment 3 ..................................................................................................117
20
DECLARATION AND SIGNATURE OF INVESTIGATOR .....................................135
21
SPONSOR DECLARATION ........................................................................................136
PUBLIC COPY 
......
Y
......
.........
PY
.........
..........
CO
..........
g data
C CO
g data.
C
.
d data m
LIC 
d data m
size
BL
size...
BL
...
OR
PU
ORY RE
PUB
Y RE
.....
P
.....
This document cannot be used to support any marketing authorization 
.89
or
89
......
th
......89
ho
89
............
au
............8
.......
g
...........
g
....
............
ting
............
............
ke
............
..
a
............
ar
..........
.....
m
............
m
.......
...........
y
...........
............
an
............
..............
rt
..........
............
po
............
onitoring
upp
onitoring
...........
su
...........
QUIREM
to s
QUIREM
........
d
............
d
....
............
se
............
ds and Ind
e us
ds and Ind
...........
be
...........
nts
ot
nts........
ot
........
SURANC
nno
SURANC
CES
a
CES ......
an
......
DICES
t ca
DICES .
ified New
ent
ified New
Markedly a
me
Markedly a
3
c
3 Protoco
cum
Protoco
19.4
doc
19.4 Prot
oc
Prot
19.5
s d
19.5 P
20
s
20
application and any extensions or variations thereof.
9
f
9
...
e
...90
eof
90
.........
ere
.........90
e
90
............
th
............
............
s
............
............
on
............
...........
ati
...........
............
ari
............
............
va
............
............
or
............
............
s
............
..........
on
...........
MENTS
nsio
MENTS.
............
en
............
............
xt
............
ndependen
y ex
ndependen
......
ny
...........
ny
.....
............
d a
............
CE, AND 
and
CE, AND 
............
n a
............
............
ion
............
w York (m
atio
w York (m
abnormal
lica
abnormal
ol Amend
ppl
ol Amend
ocol Am
ap
col Am
l

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 9 of 136
LIST OF TABLES
Table 5‒1:
Schedule of assessments ..................................................................................26
Table 5‒2:
Exposure to bimekizumab by dose ..................................................................33
Table 7‒1:
Treatments administered..................................................................................43
Table 7‒2:
Prohibited or restricted medications and required wash-out periods prior 
to Baseline........................................................................................................45
Table 12‒1:
Anticipated serious adverse events for the population of subjects with AS....65
Table 12‒2:
Laboratory measurements................................................................................71
Table 12‒3:
Required investigations and follow-up for PDILI ...........................................74
Table 12‒4:
PDILI laboratory measurements......................................................................77
Table 12‒5:
PDILI information to be collected ...................................................................79
Table 19‒1:
Modified New York (mNY) Classification Criteria for AS ............................99
Table 19‒2:
Definitions of markedly abnormal hematology values..................................100
Table 19‒3:
Definitions of markedly abnormal biochemistry values................................100
LIST OF FIGURES
Figure 5‒1:
Schematic diagram...........................................................................................31
C COPY 
matolo
Y
matolo
biochem
OPY
biochem
PUBLIC
T OF F
IC C
T OF F
.........
BL
.........
rketing authorization 
45
r
45
S
t
S....
th
....65
ho
65
...........
au
........... 7
........
ng
............
g
....
............
eti
............
port any mark
...........
rk
...........
for AS
ma
for AS .
a
.
values
ny m
values....
mistry valu
t any
mistry valu
This document cannot be used to supp
FIGURE
ppo
FIGURE
............
su
............
s thereof.
71
f
71
.....
e
.....74
eof
74
......
he
............
e
......7
ons or variations t
...........
s t
...........
............
on
............
............
at
............
ues
a
ues.......
ar
.......
application and any extension
ES
s
ES
............
on
............

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 10 of 136
LIST OF ABBREVIATIONS
AE
adverse event
AESI
adverse event of special interest
AESM
adverse event for special monitoring
ALP
alkaline phosphatase
ALT
alanine aminotransferase
ANCOVA
analysis of covariance
AS
ankylosing spondylitis
ASAS
Assessment of SpondyloArthritis International Society
ASAS20, 40, 5/6
Assessment in SpondyloArthritis International Society 20%, 40%, 5 out of 6 
response criteria
ASDAS
Ankylosing Spondylitis Disease Activity Score
ASDAS-ID
Ankylosing Spondylitis Disease Activity Score inactive disease
ASDAS-MI
Ankylosing Spondylitis Disease Activity Score major improvement
AST
aspartate aminotransferase
axSpA
axial spondyloarthritis
BA
bioavailability
BASDAI
Bath Ankylosing Spondylitis Disease Activity Index
BASFI
Bath Ankylosing Spondylitis Functional Index
BCG
Bacille Calmette-Guérin
BMI
body mass index
BP
blood pressure
BSA
body surface area
CD
cluster of differentiation
CDC 
Centers for Disease Control 
CDMS
clinical data management system
CHO
Chinese Hamster Ovarian
CI
confidence interval
COX-2 inhibitor
cyclooxygenase 2 inhibitor
CPM
Clinical Project Manager
CPMP
Committee for Proprietary Medicinal Products
CRO
contract research organization
CRP
C-reactive protein
CSR
clinical study report
PUBLIC COPY
e Activ
PY 
e Activ
ng Spon
BLI
ng Spon
ylosing S
PUB
ylosing S
Calme
PU
Calme
ot be used to support any marketing authorization 
0%, 40%, 
eting
0%, 40%, 
re inactive
ma
re inactive
Score maj
ny 
Score maj
ylitis Dise
sup
ylitis Dise
pondylitis 
to s
pondylitis 
e-
d
-Guérin
d t
Guérin
index
use
index
pressure
be u
pressure
dy surface
t be
dy surface
This document cannot
cluster o
not
cluster o
Cen
nn
Cen
X
c
X-
c
-2 inhib
cum
2 inhib
CPM
doc
CPM
CPM
s d
CPM
d any extensions or variations thereof.
5
h
5 out of 6
here
out of 6
e disease
tion
e disease
ajor improv
iati
ajor improv
ease Activ
ons
ease Activ
Functiona
sio
Functiona
e area
an
e area
application and
f differen
nd 
f differen
ters for D
an
ters for D
clinical d
on 
clinical d
Chine
atio
Chine
c
a
c
bitor
pp
bitor

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 11 of 136
C-SSRS
Columbia-Suicide Severity Rating Scale
CT
computed tomography
CZP
certolizumab pegol
DMARD
disease-modifying antirheumatic drug
DMC
Data Monitoring Committee
DVU
disco-vertebral unit
ECG
electrocardiogram
eCRF
electronic Case Report Form
EDC
electronic data capture
EPM
Exploratory Project Manager
ES
Enrolled Set
FAS
Full Analysis Set
FDA
Food and Drug Administration
FSH
follicle-stimulation hormone
GCP
Good Clinical Practice
GFR
glomerular filtration rate
GI
gastrointestinal
GMP
Good Manufacturing Practice
HADS
Hospital Anxiety and Depression Scale
HADS-A
Hospital Anxiety and Depression Scale—Anxiety 
HADS-D
Hospital Anxiety and Depression Scale—Depression 
HbcAg
hepatitis B core antibody
HbsAg
hepatitis B surface antigen
HBV
hepatitis B virus
HCV
hepatitis C virus
HIV
human immunodeficiency virus
HLA
human leukocyte antigen
hs-CRP
high sensitivity C-reactive protein
hPDSC
human periosteum-derived stem cell
IB
Investigator’s Brochure
IBD
inflammatory bowel disease
ICH
International Council for Harmonisation
ICF
Informed Consent form
IEC
Independent Ethics Committee
PUBLIC COPY 
ate
C C
ate
acturing P
BLI
acturing P
Anxiety a
PUB
Anxiety a
Anxi
P
Anxi
This document cannot be used to support any marketing authorization 
ractice
su
ractice
nd Depres
to 
nd Depres
ety and De
ed 
ety and De
Anxiety and
use
Anxiety and
tis B core 
be u
tis B core 
patitis B s
t be
patitis B s
hepatitis
not
hepatitis
hep
nn
hep
P
DSC
cu
DSC
IB
do
IB
IBD
s d
IBD
application and any extensions or variations thereof.
ssion Scale
nsio
ssion Scale
epression S
ten
epression S
d Depressi
ext
d Depressi
antibody
ny e
antibody
surface ant
any
surface ant
s B virus
nd 
s B virus
patitis C vi
an
patitis C vi
human im
ion 
human im
huma
atio
huma
h
a
h

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 12 of 136
IGRA
Interferon-Gamma Release Assay
IIV
interindividual variability
IL
interleukin
im
intramuscular
IMP
investigational medicinal product
IRB
Institutional Review Board
IUD
intrauterine device
IUS
intrauterine hormone-releasing system
im
intramuscular
iv
intravenous
IRT
interactive response technology
LTB
latent tuberculosis
LTBI
latent tuberculosis infection 
MAR
missing at random
MCID
minimal clinically important difference
MCP-Mod
multiple comparison procedure – modeling
MCS
mental component summary
MedDRA®
Medical Dictionary for Regulatory Activities
MI
multiple imputation
MMP
matrix metalloproteinase
mNY
Modified New York (criteria)
MOS
Medical Outcomes Study
MRI
magnetic resonance imaging
MTB
mycobacterium tuberculosis 
MTX
methotrexate
nr-axSpA
nonradiographic-axial spondyloarthritis
NRI
nonresponder imputation
NRS
numeric rating scale
NSAID
nonsteroidal anti-inflammatory drug
NTMB
nontuberculous mycobacteria
NYHA
New York Heart Association
OPV
oral polio vaccine
PCS
physical component summary
PD
pharmacodynamics
PUBLIC COPY 
ant differ
OP
ant differ
procedure
C CO
procedure
t summa
LIC 
t summa
onary fo
BLI
onary fo
mputatio
PUB
mputatio
etallo
P
etallo
used to support any marketing authorization 
nce
rt
nce
– modelin
port
modelin
y
u
y
Regulator
sup
Regulator
proteinase
ed 
proteinase
New York 
use
New York 
document cannot be
al Outcom
be u
al Outcom
agnetic res
t be
agnetic res
mycoba
not
mycoba
met
nn
met
This do
AID
cu
AID
NTMB
doc
NTMB
NYH
s d
NYH
y extensions or variations thereof.
ng
o
ng
ry 
o
ry Activiti
ons
Activiti
k (criteria)
ext
k (criteria)
application and any
mes Study
ny e
mes Study
sonance im
any
sonance im
acterium tu
nd 
acterium tu
hotrexate
an
hotrexate
nonradiog
ion 
nonradiog
nonre
atio
nonre
a

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 13 of 136
PDILI
potential drug-induced liver injury
PD-PPS
Pharmacodynamics Per-Protocol Set
PET
positron-emission tomography
PET-CT
positron-emission tomography – computed tomography
PET-MRI
positron-emission tomography – magnetic resonance imaging
PFS
pre-filled syringe
PGADA
Patient’s Global Assessment of Disease Activity
PhGADA
Physician’s Global Assessment of Disease Activity
PK
pharmacokinetics
PK-PPS
Pharmacokinetics Per-Protocol Set
PPS
Per-Protocol Set
PS
Patient Safety
PsA
psoriatic arthritis
PSO
psoriasis
Q2W
every 2 weeks
Q4W
every 4 weeks (monthly)
QTcF
QT interval corrected for heart rate using Fridericia’s formula 
RA
rheumatoid arthritis
RCTC
Rheumatology Common Toxicity Criteria
RIF
mycobacterium tuberculosis rifampin
RNA
ribonucleic acid
RS
Randomized Set
RUV
residual unexplained variability
SAE
serious adverse event
SAP
Statistical Analysis Plan
sc
subcutaneous(ly)
SD
standard deviation
SFU
Safety Follow-up
SI
sacroiliac
SpA
spondyloarthritis
SOP
standard operating procedure
SS
Safety Set
SSZ
sulfasalazine
STIR
short-tau-inversion recovery
PUBLIC COPY 
ly)
C C
ly)
cted for h
LIC 
cted for h
thritis
BLI
thritis
ology Co
PUB
ology Co
teriu
P
teriu
This document cannot be used to support any marketing authorization 
eart rate us
upp
eart rate us
mmon Tox
to 
mmon Tox
m tuberculo
ed 
m tuberculo
acid
use
acid
mized Set
e u
mized Set
sidual une
t be
sidual une
serious a
not
serious a
Stat
nn
Stat
SpA
doc
SpA
SOP
s d
SOP
application and any extensions or variations thereof.
sing Frider
s o
sing Frider
xicity Crite
nsio
xicity Crite
osis
te
osis rifamp
ten
rifamp
explained v
any
explained v
adverse ev
nd 
adverse ev
tistical An
an
tistical An
subcutane
ion 
subcutane
stand
atio
stand
S
a
S

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 14 of 136
SUVAUC
standardized uptake value by area under the curve
t½
half-life
TB
tuberculosis
TEAE
treatment-emergent adverse event
TNF
tumor necrosis factor
TNFα
tumor necrosis factor alpha
ULN
upper limit of normal
VAS
visual analog scale
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 15 of 136
1
SUMMARY
This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, parallel-group, 
study to investigate the efficacy and safety of bimekizumab (also known as UCB4940) and 
certolizumab pegol ([CZP]; Cimzia®) in adult subjects with active ankylosing spondylitis (AS).
Eligible subjects will have active AS, determined by documented radiologic evidence (X-ray) 
fulfilling the Modified New York criteria for AS (van der Linden et al, 1984), including 
symptoms for ≥3 months and age of onset <45 years. Furthermore, subjects will have moderate 
to severe active disease at Screening (Bath Ankylosing Spondylitis Disease Activity Index 
[BASDAI] ≥4 and spinal pain ≥4 [BASDAI Question 2]). 
The primary objective of the study is to evaluate the efficacy of bimekizumab administered 
subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of 
subjects with active AS. The primary efficacy variable is the change from Baseline in 
Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12. The secondary objective 
of the study is to assess the safety and tolerability of bimekizumab. The secondary efficacy 
variables include the determination of ASDAS inactive disease (ASDAS-ID) and ASDAS major 
improvement (ASDAS-MI) at Week 12. Primary safety variables include the incidence of 
adverse events (AEs), serious adverse events (SAEs), and AEs leading to withdrawal from 
investigational medicinal product (IMP).
Other exploratory objectives of the study are to evaluate the effect of bimekizumab or CZP on 
changes in bone formation, to assess the pharmacokinetics (PK) and immunogenicity of 
bimekizumab, to obtain additional biomarkers and clinical and imaging data as applicable, and to 
assess the efficacy and safety of bimekizumab or CZP during the Treatment Period and the 
Treatment Extension Period.
Multiple sites in North America, Europe, and the Asian-Pacific (APAC) region will randomize at 
least 60 subjects in a 2:1 ratio to receive either bimekizumab or CZP. 
The study consists of a Screening Period (2 to 4 weeks), Treatment Period (12 weeks), Treatment 
Extension Period (36 weeks), and a Safety Follow-up (SFU) Period (20 weeks after the final 
dose of the IMP). Therefore, the maximum duration of the study is 68 weeks. 
Screening Period
The Screening Period will last for a minimum of 2 weeks and up to 4 weeks. During the 
Screening Period, the Investigator will assess the eligibility of subjects according to the inclusion 
and exclusion criteria. The Screening Period will also enable washout of any medications not 
permitted for use during the study. 
PUBLIC COPY
y v
Y
y v
s), and A
PY 
s), and A
 to
C
 to evalu
CO
evalu
pharmac
C C
pharmac
markers 
LIC
markers 
mekizum
BL
mekizum
a, Eur
PU
a, Eur
annot be used to support any marketing authorization 
erate
ori
erate
ex
th
ex
ministered
g au
ministered
he treatm
ing 
he treatm
Baseline in
eting
Baseline in
The second
ket
The second
he second
ark
he second
SDAS
ma
SDAS-
a
-ID
a
ID
es include
y m
es include
Es leading
any 
Es leading
ate the eff
ort
ate the eff
kinetics (
ppo
kinetics (
and clinica
upp
and clinica
ab or CZP
sup
ab or CZP
ope, and th
ed t
ope, and th
ceive eith
sed
ceive eith
ing Period
e us
ing Period
s), and a S
be 
s), and a S
fore, the m
ot b
fore, the m
ent ca
eriod will
can
eriod will
riod, the I
t ca
riod, the I
ion criter
ent 
ion criter
This docume
ed for use
men
ed for use
and any extensions or variations thereof.
ed 
ed 
ment of 
reo
ment of 
in 
h
in 
ndary obje
the
ndary obje
dary effic
ns t
dary effic
D) and AS
ons
D) and AS
e the incid
atio
e the incid
g to withd
riat
g to withd
fect of bi
r v
fect of bi
(PK) and 
or
(PK) and 
cal and im
ns o
cal and im
P during th
ions
P during th
the Asian
ten
the Asian
her bimek
xte
her bimek
d (2
y
d (2 to
y e
to 4 w
e
4 w
Safety Fo
any
Safety Fo
maximum
d an
maximum
ation 
ll last for 
n a
ll last for 
Investigat
tion
Investigat
ria. The S
atio
ria. The S
applic
e during th
lica
e during th

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 16 of 136
Treatment Period
At Baseline/Day 1, subjects will be randomized in a 2:1 ratio to receive the following blinded 
study treatments during the Treatment Period:

Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in 
order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 

Certolizumab pegol 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 
200mg sc Q2W in Weeks 6 to 10.
The IMP will be administered sc in the clinic by trained site personnel. 
Treatment Extension Period
After completing the 12-week Treatment Period, subjects will enter a 36-week Treatment 
Extension Period and will receive the following treatments:

Subjects randomized to bimekizumab during the Treatment Period will receive bimekizumab 
320mg sc every 4 weeks (Q4W) from Week 12 to Week 44. 

Subjects randomized to CZP during the Treatment Period will receive CZP 400mg Q4W 
from Week 12 to Week 44. 
Subjects not responding to treatment will be withdrawn from the study as per Investigator’s 
discretion.
Safety Follow-Up Period
All subjects who complete the study or who discontinue early, including those withdrawn from 
study treatment, will have a SFU Visit at 20 weeks after their final dose of IMP. 
2
INTRODUCTION
2.1
Axial spondyloarthritis
Spondyloarthritis (SpA) is an umbrella term applied to a family of rheumatic diseases (including 
axial spondyloarthritis [axSpA], psoriatic arthritis [PsA], reactive arthritis, the arthritis of 
inflammatory bowel disease [IBD], and undifferentiated spondyloarthritis) that have features in 
common with each other and distinct from other inflammatory arthritides, particularly 
rheumatoid arthritis (RA). 
Axial SpA is a chronic inflammatory disease that impacts a substantial proportion of the 
population. Limited evidence exists regarding the exact prevalence of axSpA; however, recent 
data suggest that the prevalence is similar to that of RA in the US (axSpA: 0.7% to 1.4%; RA: 
0.5% to 1.0%) (Reveille et al, 2012; Myasoedova et al, 2010; Helmick et al, 2008). 
The Assessment of SpondyloArthritis International Society (ASAS) working group established 
classification criteria to distinguish 2 broad categories of SpA: peripheral SpA and axSpA 
(Rudwaleit et al, 2011; Rudwaleit, 2010; Rudwaleit et al, 2009b). This division is based on the 
body part predominantly involved in the inflammatory process. Therefore, peripheral SpA 
includes diseases affecting mainly peripheral joints, such as reactive arthritis and PsA, whereas 
axSpA comprises those diseases with mainly axial involvement (sacroiliac [SI] joints and spine), 
including AS diagnosed with radiographic involvement and nonradiographic axSpA (nr-axSpA). 
PUBLIC COPY
ent Peri
PY 
ent Peri
 withdra
CO
 withdra
udy or w
PUB
udy or w
U Visi
PU
U Visi
nnot be used to support any marketing authorization 
CZP 
ho
CZP 
eek Trea
etin
eek Trea
iod will re
mar
iod will re
d will rec
any
d will rec
wn from t
port
wn from t
ho discon
to s
ho discon
at 20 wee
d to
at 20 wee
ON
s
ON
dyloarth
be u
dyloarth
s an umbr
t be
s an umbr
[axSpA],
not 
[axSpA],
l disease 
nno
l disease 
This document ca
ch other a
an
ch other a
thritis (RA
t ca
thritis (RA
A is a chro
ent
A is a chro
tion. Lim
me
tion. Lim
a suggest t
cum
a suggest t
0.5% to 1.
ocu
0.5% to 1.
The
do
The A
o
A
clas
s 
clas
(
tion and any extensions or variations thereof.
tment 
her
tment 
receive bi
ons
receive bi
ceive CZP
riat
ceive CZP
the study 
or v
the study 
ntinue ear
sio
ntinue ear
eks after t
ens
eks after t
hritis
ny e
hritis
rella term
any
rella term
, psoriatic
d a
, psoriatic
[IBD], an
and
[IBD], an
applica
and
n
and distin
n a
distin
RA).
io
RA).
onic infla
catio
onic infla
mited evid
lica
mited evid
that the p
pplic
that the p
.0%) (Rev
app
0%) (Rev
men
a
men

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 17 of 136
Patients with axSpA have inflammatory back pain. The disease typically originates in the 
sacroiliac joints, then progresses to the spine. In the sacroiliac joints and the spine, active 
inflammation results in erosions, sclerosis, and fatty lesions seen on an magnetic resonance 
imaging (MRI). However, the most characteristic feature is new bone formation leading to 
ankylosis of the SI joints and syndesmophytes attached to the vertebral bodies. As a result of 
extended syndesmophyte formation, over time the spine may become fused. Objective signs of 
inflammation (such as enthesitis, dactylitis, peripheral arthritis, or uveitis), genetic features (such 
as the presence of human leukocyte antigen [HLA] B27), and laboratory parameters (such as 
elevated C-reactive protein [CRP]) may also be present (Braun, 2012; Rudwaleit et al, 2009a; 
Braun and Sieper, 2007). Disability in axSpA is related to both the degree of inflammatory 
activity, causing pain, stiffness, fatigue, and poor quality of sleep, and to the degree of bony 
ankylosis, causing loss of spinal mobility. Patients with AS show radiographic progression of 
disease with X-ray identified sacroiliitis, while "Bamboo spine" may develop when the outer 
fibers of the fibrous ring of the intervertebral discs ossify, which results in the formation of 
marginal syndesmophytes between adjoining vertebrae.
Nonsteroidal anti-inflammatory drugs are often rapidly effective for the symptoms (pain and 
stiffness) of axSpA (Poddubnyy, 2013; Poddubnyy et al, 2012), but many patients lose or never 
have clinically meaningful response and structural damage often progresses despite their use. 
Conventional disease-modifying antirheumatic drugs (DMARDs, eg, methotrexate [MTX] and 
sulfasalazine [SSZ]) have no proven efficacy in axial disease, but may benefit patients with 
peripheral joint disease (Haibel et al, 2007; Braun et al, 2006; Haibel et al, 2005). Therefore, 
DMARDs are recommended only in patients with predominantly peripheral manifestations 
(Braun et al, 2011). Patients who are intolerant of or have inadequately responded to nonsteroidal 
anti-inflammatory drugs (NSAIDs), or those in whom NSAIDs are contraindicated, have 
approved treatment options such as tumor necrosis factor (TNF) inhibitors.
Recently, the interleukin (IL)-17 cytokine family has been identified as a therapeutic target in 
axSpA and secukinumab, an IL-17A monoclonal antibody, has recently been approved as a 
treatment option in active AS. 
Treatment with tumor necrosis factor alpha (TNFα)-antagonists has demonstrated marked 
improvement in almost all features of AS, a subset of the axSpA population. For AS, many of the 
processes which lead to inflammation and subsequent damage, as in RA, are driven by 
dysregulated TNFα production, including extracellular matrix degradation due to matrix 
metalloproteinase (MMP) production (Davis and Mease, 2008).
2.2
Bimekizumab
Bimekizumab (UCB4940) is an engineered, humanized full length monoclonal antibody of 
immunoglobulin (Ig)G1 subclass of approximately 150,000 Dalton, which is expressed in a 
genetically engineered Chinese Hamster Ovarian (CHO) cell line. Bimekizumab has high affinity 
for human IL-17A and human IL-17F and selectively and potently inhibits the activity of both 
isoforms in vitro. Interleukin-17A and IL-17F are key proinflammatory cytokines believed to 
play important roles in autoimmune and inflammatory diseases. Therefore, bimekizumab permits 
an evaluation of the potential for additional efficacy, which may be conferred by dual inhibition 
of both cytokines, in patients suffering from diseases in which both cytokines are active. 
Bimekizumab is being developed for the treatment of patients with inflammatory diseases such 
as PsA, psoriasis (PSO), and axSpA. 
PUBLIC COPY
al, 
Y
al, 
damage
PY 
damage
rugs (DM
OPY
rugs (DM
in axial 
CO
in axial 
 Braun e
C C
 Braun e
ients wi
LIC 
ients wi
intoleran
BLIC
intoleran
s), or tho
UBL
s), or tho
h as tum
PU
h as tum
cy
P
cy
not be used to support any marketing authorization 
uch
iz
uch
as
o
as
009a;
tho
009a;
matory 
uth
matory 
ee of bony
au
ee of bony
progressio
ng a
progressio
p when
ting
p when th
g
th
n the form
keti
n the form
or the sym
ma
or the sym
 but many
y m
 but many
ften progr
any 
ften progr
MARDs, e
t an
MARDs, e
disease, bu
ort a
disease, bu
t al, 2006
por
t al, 2006
h predo
upp
h predom
p
m
nt of or ha
sup
nt of or ha
se in whom
o s
se in whom
or necrosi
d to
or necrosi
tokine fam
sed
tokine fam
17A mono
use
17A mono
rosis fact
t be
rosis fact
t all featur
ot 
t all featur
This document cann
d to inflam
nno
d to inflam
Fα produc
ann
Fα produc
nase (MM
t ca
nase (MM
Bim
nt 
Bim
kizumab (
me
kizumab (
muno
cum
munoglob
um
glob
geneticall
doc
geneticall
for hum
do
for hum
isof
s d
isof
s
nd any extensions or variations thereof.
y 
o
y 
on of 
eof
on of 
he outer 
ere
he outer 
mation of 
the
mation of 
mptoms (p
ons
mptoms (p
ny patients
atio
ny patients
gresses de
riat
gresses de
eg, metho
aria
eg, metho
ut may be
r va
ut may be
6; Haibel e
or v
6; Haibel e
minantly p
s o
minantly p
ave inadeq
ons
ave inadeq
om NSAID
sion
om NSAID
is factor (
nsi
is factor (
mily has b
xten
mily has b
oclonal an
ext
oclonal an
tor alpha (
any
tor alpha (
ures of AS
d a
ures of AS
application an
mmation 
and
mmation 
ction, inc
n an
ction, inc
MP) produ
on 
MP) produ
mekizum
atio
mekizum
(UCB494
plica
(UCB494
bulin (Ig)
ppl
bulin (Ig)
y engine
app
y engine
IL
a
IL-1

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 18 of 136
2.2.1
Clinical experience with bimekizumab
Four clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque psoriasis, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, 
and UP0031 in 12 healthy volunteers. 

UP0008 was a Phase 1, First-in-Human (FIH) randomized, subject-blind, investigator-blind, 
placebo-controlled, single-dose, dose-escalating study in 39 subjects with mild-to-moderate 
plaque PSO. In this study bimekizumab was administered by intravenous (iv) infusion of 
single ascending doses and was well tolerated at doses of up to 640mg. The maximum 
tolerated dose was not reached, and no safety issues were identified. Dose-proportional PK 
was displayed between bimekizumab 8mg and 640mg. The median t½ ranged between 
17.00 days and 25.55 days across the treatment groups. Dose-dependent improvements in the 
psoriatic lesion of interest were observed after bimekizumab administration for all features of 
plaque PSO in the study. 

RA0124 was an open-label, parallel-group, single-dose study to evaluate the absolute 
bioavailability (BA), dose proportionality, and safety and tolerability of 2 dose levels of 
bimekizumab given by sc injection versus bimekizumab given by iv infusion in 30 healthy 
subjects. Similar BA was observed for the 2 doses tested (0.656 and 0.631 for the 
bimekizumab 80mg and bimekizumab 160mg doses, respectively). No new safety issues 
were observed versus previous studies when bimekizumab was administered sc as a single 
dose of 80mg or 160mg, or iv at a dose of 160mg.

PA0007 was a randomized, subject-blind, investigator-blind, placebo-controlled, 
multiple-dose administration study to evaluate the safety, PK, and pharmacodynamic (PD) 
profiles of bimekizumab administered iv to subjects with active PsA who had an inadequate 
response to at least 1 nonbiologic disease-modifying antirheumatic drug (DMARD) and/or 
1 approved biologic DMARD. Bimekizumab was administered to 4 cohorts of subjects as a 
loading dose of 240mg, 80mg, 160mg, or 560mg followed by 2 maintenance doses at 
3-weekly intervals of 160mg, 40mg, 80mg, or 320mg, respectively. There were no 
unexpected clinically relevant safety findings and all doses were well tolerated.

UP0031, evaluated the relative bioavailability, safety and tolerability of 2 bimekizumab 
formulations (a histidine-based formulation 2x80mg and an acetate-based formulation 
1x160mg) administered by sc injection to healthy volunteers. Results showed similar 
geometric means for AUC between the 2 bimekizumab formulations 
(2x80mg=653.8day*μg/mL; 1x160mg=628.3day*μg/mL) and the relative BA for the 
bimekizumab 1x160mg versus 2x80mg formulations was calculated as 96.1% with a 95% 
confidence interval (CI): 72.7,127.0. The wide 95% CI was expected due to the small sample 
size in UP0031.
Additional studies of bimekizumab are ongoing. RA0123 is a Phase 2a, double-blind, 
randomized, placebo-controlled, multiple dose study to evaluate the safety, PK, PD, and efficacy 
of multiple doses of bimekizumab administered as add-on therapy to stable CZP therapy in 
subjects with moderate to severe RA. UC0011 is a Phase 2a study, which will evaluate the 
efficacy, safety, tolerability, and PK of an iv loading dose and 2 sc maintenance doses of 
bimekizumab in subjects with moderate to severe active ulcerative colitis. PS0010, PS0011, 
PS0016, and PS0018 are Phase 2 studies, which will evaluate the PD, PK, safety, and/or efficacy 
PUBLIC COPY
um
Y
um
es teste
PY 
es teste
g doses, 
OPY
g doses, 
en bimek
CO
en bimek
of 160m
C CO
of 160m
L
blind, i
LIC
blind, i
udy to ev
BL
udy to ev
ministered
PUB
ministered
P
ologic d
PU
ologic d
D
P
D
d to support any marketing authorization 
e
of 
o
of 
m 
th
m 
tional PK
uth
tional PK
between
au
between
provemen
g a
provemen
on for all
ting
on for all
valu
ark
valuate th
ark
ate th
ability of 
ma
ability of 
en by iv i
y m
en by iv i
(0
n
(0.656 an
ny 
.656 an
respective
t an
respective
izumab w
ort a
izumab w
g.
p
g.
nvestigato
upp
nvestigato
aluate the 
sup
aluate the 
iv to subj
to s
iv to subj
nnot be use
isease
d to
isease-
t
-mo
to
mo
Bimekizum
sed
Bimekizum
g, 160mg,
use
g, 160mg,
mg, 40mg
e u
mg, 40mg
elevant sa
be 
elevant sa
the relati
ot 
the relati
histid
nno
histidine
no
ine b
ocument ca
ministere
an
ministere
means fo
t ca
means fo
mg=653.8d
nt c
mg=653.8d
ekizumab 
men
ekizumab 
onfidence
ume
onfidence
size in U
cum
size in U
This do
Additio
doc
Additio
rando
s d
rando
of
s
of
nsions or variations thereof.
nts in the
eof
nts in the
l features 
ere
l features 
he absolut
s t
he absolut
f 2 dose le
ons
f 2 dose le
infusion i
tion
infusion i
nd 0.631 f
iat
nd 0.631 f
ely). No n
aria
ely). No n
was admin
va
was admin
or
n
or-blind, p
ns o
blind, p
e safety, P
ions
e safety, P
bjects with
sio
bjects with
and any exten
odifying 
ens
odifying 
mab was 
xten
mab was 
, or 560m
ext
, or 560m
g, 80mg, o
y e
g, 80mg, o
afety findi
any
afety findi
ive bioava
d a
ive bioava
based for
and
based for
application a
ed by sc in
n an
ed by sc in
or AUC be
on 
or AUC be
day*μg/m
atio
day*μg/m
b 1x160mg
icat
b 1x160mg
e interval 
plic
e interval 
UP0031.
ppl
UP0031.
a
l studie
ap
l studie

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 19 of 136
of bimekizumab administered sc to subjects with PSO. PA0008 and AS0008 are Phase 2b 
double-blind, randomized, placebo-controlled, multiple-dose studies to evaluate the efficacy and 
safety of bimekizumab in subjects with active PsA or AS, respectively.
Additional information on the clinical data for bimekizumab is available in the current version of 
the Investigator’s Brochure (IB).
2.2.2
Nonclinical studies with bimekizumab
Parallel inhibition of IL-17A and IL-17F has shown potent effects in a variety of animal models 
of inflammatory disease. Intravenously administered bimekizumab was well tolerated in repeat 
dose toxicology studies in Cynomolgus monkeys with a no adverse effect level of 
200mg/kg/week. The findings of note in toxicity studies were diarrhea related to infectious 
enteritis (observed in the single dose study) and asymptomatic mild colonic ulceration in a 
proportion of animals (in the repeat dose study); this latter finding was not associated with 
hematology abnormalities. Data suggest that bimekizumab has induced primary lesions to the 
mucosa associated lymphoid tissue via a pharmacologically-related mechanism. In a second 
repeat-dose study, none of the minor apoptosis/necrosis findings observed in gut associated 
lymph nodes were seen. In animals given the highest dose of bimekizumab in the study 
(20mg/kg/week), a slightly higher number of protozoa (Balantidium coli) was observed in the 
cecum and colon as compared to the control animals and low dose animals. Therefore, the gut 
associated lymph node lesions observed in the first study are considered to be accidental and/or 
linked to exaggerated pharmacology and proliferation of Balantidium coli and are considered to 
be the result of a change in local mucosal immunity. 
Additional information on the nonclinical data for bimekizumab is available in the current 
version of the IB.
2.3
Certolizumab pegol
Treatment with TNFα-antagonists has demonstrated marked improvement in almost all features 
of AS, a subset of the axSpA population. For AS, many of the processes which lead to 
inflammation and subsequent damage, as in RA, are driven by dysregulated TNFα production, 
including extracellular matrix degradation due to matrix metalloproteinase (MMP) production 
(Davis and Mease, 2008). 
The RAPID-axSpA study enrolled subjects with active axSpA with objective signs of 
inflammation, and the results indicated that baseline disease burden was similar between the AS 
and nr-axSpA subpopulations (Landewe et al, 2014; Sieper et al, 2013b). In the RAPID-axSpA 
study it was shown that CZP rapidly reduced the signs and symptoms of axSpA over 24 weeks of 
double-blind treatment in the broad axSpA population, including in the AS and the nr-axSpA 
subpopulations, and that the responses to the treatment were similar in both subpopulations 
(Landewe et al, 2014; Sieper et al, 2013b) and maintained up to Week 96 (Mease et al, 2014; 
Sieper et al, 2014).
Certolizumab pegol has a high affinity for human TNFα and binds with a dissociation constant 
(KD) of 90pM. Tumor necrosis factor alpha (TNFα) is a key pro-inflammatory cytokine with a 
central role in inflammatory processes. 
Certolizumab pegol does not contain a fragment crystallizable (Fc) region, which is normally 
present in a complete antibody, and therefore does not fix complement or cause 
PUBLIC COPY
os
Y
os
oa (
PY
oa (Ba
Y 
Ba
mals and 
OPY
mals and 
first stu
COP
first stu
oliferati
C CO
oliferati
al immun
IC C
al immun
nical da
BLI
nical da
b peg
PU
b peg
used to support any marketing authorization 
models
horiz
models
n repeat 
tho
n repeat 
infectious
g au
infectious
ceration in
ng 
ceration in
associated
eting
associated
primary le
ket
primary le
echanism
arke
echanism
bserved in
mar
bserved in
mekizuma
y m
mekizuma
ntidium co
ny 
ntidium co
ow dose a
t any
ow dose a
dy are con
ort a
dy are con
on of 
po
on of Bala
por
Bala
ity. 
p
ity. 
a for bim
sup
a for bim
ol
ed
ol
s has dem
use
s has dem
ument cannot be u
opulation
e us
opulation
nt damage
be 
nt damage
atrix degr
ot b
atrix degr
08).
no
08).
A study e
ann
A study e
and the re
ca
and the re
A subpop
nt c
A subpop
was shown
ent
was shown
-blind tre
me
blind tre
This docu
populatio
cum
populatio
(Landewe
docu
(Landewe
Sie
do
Sieper 
do
per 
Ce
s 
Ce
extensions or variations thereof.
s
in a 
re
in a 
d with
here
d with
esions to t
the
esions to t
m. In a sec
s th
m. In a sec
n gut asso
ons
n gut asso
ab in the 
tion
ab in the 
oli
ia
oli) was o
iati
) was o
animals. T
aria
animals. T
nsidered t
va
nsidered t
antidium c
or v
antidium c
ekizumab
ons
ekizumab
monstrated
exte
monstrated
plication and any 
n. For AS
y ex
n. For AS
e, as in R
ny 
e, as in R
gradation d
d an
gradation d
enrolled s
an
enrolled s
esults ind
on a
esults ind
pulations 
tion
pulations 
n that CZ
cati
n that CZ
eatment
lica
eatment
app
in
a
in
ons, and t
ppli
ons, and t
 et al, 20
app
et al, 20
, 201
a
, 201

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 20 of 136
antibody-dependent cell-mediated cytotoxicity in vitro. It does not induce apoptosis in vitro in 
human peripheral blood-derived monocytes or lymphocytes, or neutrophil degranulation.
2.3.1
Clinical experience with CZP
Certolizumab pegol is indicated for the treatment of adult patients with active AS in multiple 
countries around the world.
After the loading dose, the recommended maintenance dose of CZP for adult subjects with AS is 
CZP 200mg Q2W or CZP 400mg Q4W.
Additional information on the clinical data for CZP is available in the current version of the IB 
and the product information available in each country.
2.4
Study rationale
The first TNF blockers used for the treatment of patients with active AS showed great promise. 
(Brandt et al, 2000). However, despite good effects on signs and symptoms, C-reactive protein 
and inflammation as detected by MRI, the TNFα inhibitors did not appear to prevent new bone 
formation in the spine (van der Heijde et al, 2008). A 12-year longitudinal study shows that the 
higher the disease activity, the more the structural damage in the spine, and thus concluding that 
inflammation and new bone formation are related (Ramiro et al, 2014). Understanding the role of 
different cytokines in driving new bone formation allows for improved treatments for AS 
patients. There is a growing association, and interest, for the involvement of IL-17 signaling in 
bone pathology during spondyloarthritis disease progression. The role of IL-17A in driving bone 
loss and destruction is well documented (Chabaud et al, 2001). More recently, in vitro studies 
demonstrated that mesenchymal cells incubated in the presence of IL 17A and bone 
differentiation medium leads to the formation of extracellular calcified bone matrix with an 
increase in alkaline phosphatase activation (Osta et al, 2014), suggesting that IL-17A may have a 
role not only in bone destruction, but under the right conditions in driving new bone formation. 
Wein et al, demonstrated in in vivo mouse models that in the absence of Schnurri3, a key gene in 
osteoblast differentiation, leads to increased bone mass; a response enhanced in the presence of 
IL-17A (Wein et al, 2012). The presence of Schnurri3 and osteoclasts activation at a site of bone 
inflammation leads to bone destruction, however in the absence of these, the same inflammation 
will induce new bone formation. In the AS patient at the syndesmophytes when mesenchymal 
cells from vertebral ligaments are inflamed in the physical absence of osteoclasts, this will 
induce new bone formation (Miossec, 2017). Recently, IL 17-producing γδ-T cells have been 
associated with periosteal bone formation for fracture repair (Ono et al, 2016); the periosteum is 
also implicated in pathologic bone formation in SpA (Lories et al, 2009). Using a biomimetic 
human periosteum-derived stem cell (hPDSC) model of osteogenic differentiation demonstrated 
that either/both IL-17A or/and IL-17F are able to drive pathologic bone formation (Shah et al, 
2017). Inhibiting both IL-17A and IL-17F has the potential to impact the pathophysiology of 
new bone formation in AS patients.
AS0013, the current subject-blind and investigator-blind study has been designed to evaluate the 
efficacy and safety of bimekizumab in a clinical setting in subjects with AS. The features of bone 
lesions are both erosive and neo-appositive and it is not clear if the inflammatory and erosive 
process precedes the new formation of bone. 18F-fluoride positron-emission tomography –
computed tomography (PET-CT) or 18F-fluoride positron-emission tomography – magnetic 
resonance imaging (PET-MRI) will be used to investigate the effects of bimekizumab on the 
PUBLIC COPY
mage
Y
mage
Ramiro
PY 
Ramiro
on allow
OP
on allow
interest, 
CO
interest, 
isease pr
C C
isease pr
d (Chaba
LIC 
d (Chaba
s incuba
BLI
s incuba
e forma
UB
e forma
e activa
PU
e activa
n, bu
P
n, bu
used to support any marketing authorization 
S is
riz
S is
of the IB 
utho
of the IB 
howed gre
etin
howed gre
oms, C
rke
oms, C-
e
-re
e
re
ppear to p
ark
ppear to p
gitudinal s
ma
gitudinal s
he spine, a
y m
he spine, a
et al, 2014
any
et al, 2014
for impro
t an
for impro
for the inv
ort 
for the inv
ogression
ppo
ogression
ud et al, 2
upp
ud et al, 2
ed in the
sup
ed in the
on of ext
to s
on of ext
ion (Osta 
d to
ion (Osta 
t under th
ed 
t under th
vo mouse 
use
vo mouse 
ment cannot be u
s to increa
e us
s to increa
The prese
be 
The prese
ne destruc
ot b
ne destruc
formation
not
formation
l ligament
nno
l ligament
e formatio
can
e formatio
th periost
t ca
th periost
cated in p
ent 
cated in p
periosteum
men
periosteum
This docum
either/bot
um
either/bot
017). Inhi
ocu
017). Inhi
new bon
doc
new bon
AS0
s d
AS0
e
s
e
extensions or variations thereof.
eat promi
her
eat promi
eactive pr
the
eactive pr
prevent ne
ns t
prevent ne
study sho
ions
study sho
and thus c
atio
and thus c
4). Under
riat
4). Under
roved trea
vari
roved trea
volvemen
r va
volvemen
n. The role
or 
n. The role
2001). Mo
ns o
2001). Mo
presence 
ons
presence 
tracellula
sio
tracellula
a et al, 201
ens
a et al, 201
he right co
xten
he right co
models th
exte
models th
pplication and any 
ased bone
y ex
ased bone
ence of Sc
ny 
ence of Sc
uction, how
d an
uction, how
n. In the A
nd a
n. In the A
nts are infl
and
nts are infl
on (Mioss
n a
on (Mioss
teal bone 
tion
teal bone 
pathologic
atio
pathologic
um
lic
um-
c
-derive
ica
derive
ap
th IL
pli
th IL-
pli
-17A
ic
17A
ibiting bo
app
ibiting bo
format
ap
format

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 21 of 136
process of osteoproliferation as determined by the inhibition of osteoblast activity. Based on data 
showing that TNFα blockers have limited effect on osteoblast metabolism, the current study uses 
a TNFα inhibitor to show a potential differential inhibition of osteoblast activity between 
bimekizumab and CZP. 
3
STUDY OBJECTIVE(S)
This is a Phase 2a, multicenter, randomized, subject-blind and investigator-blind, parallel-group 
study to evaluate the efficacy and safety of bimekizumab compared to CZP in subjects with 
active AS. The effect of study treatments on the process of osteoproliferation will be evaluated in 
a subgroup of subjects at selected sites.
3.1
Primary objective
The primary objective of the study is to evaluate the efficacy of bimekizumab administered sc 
Q2W for 12 weeks compared to CZP in the treatment of subjects with active AS.
3.2
Secondary objective
The secondary objective of the study is as follows:

To assess the safety and tolerability of bimekizumab
3.3
Other exploratory objectives
The other exploratory objectives of the study are as follows:

To evaluate the effect of bimekizumab or CZP on changes in bone formation 

To assess the PK and immunogenicity of bimekizumab

To assess additional biomarker, clinical, and imaging data as available

To assess the efficacy and safety of bimekizumab or CZP during the Treatment Extension 
Period
4
STUDY VARIABLES
4.1
Efficacy variables
4.1.1
Primary efficacy variable
The primary efficacy variable for this study is as follows:

Change from Baseline in ASDAS at Week 12
4.1.2
Secondary efficacy variables
The secondary efficacy variables for this study are as follows:

ASDAS-ID at Week 12

ASDAS-MI at Week 12
PUBLIC COPY 
mab
PY
mab
ves
COP
ves
dy are as
C CO
dy are as
mab or C
LIC
mab or C
genicity 
UBL
genicity 
rker, cli
PU
rker, cli
not be used to support any marketing authorization 
up
iz
up
h
o
h
aluated in
tho
aluated in
b adminis
ting
b adminis
ive AS.
keti
ive AS.
follows:
por
follows:
ZP on cha
upp
ZP on cha
f bimekiz
o su
f bimekiz
nical, and 
d to
nical, and 
y of bime
sed
y of bime
ARIABL
be 
ARIABL
cy varia
ot b
cy varia
This document can
mary effi
nno
mary effi
fficacy var
ca
fficacy var
e from Ba
ent 
e from Ba
The secon
ocu
The secon

d

AS
o
AS

s

nd any extensions or variations thereof.
stered sc
ere
stered sc
anges in b
ns o
anges in b
zumab
ion
zumab
imaging 
ens
imaging 
ekizumab
xte
ekizumab
LES
ny
LES
ables
d a
ables
application a
ficacy va
and
ficacy va
ariable for
on a
ariable for
aseline in
atio
aseline in
Second
plic
Second
ndary effic
app
dary effic
ID
a
ID

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 22 of 136
4.1.3
Other efficacy variables 
Assessment time points for the other efficacy variables are specified in Table 5‒1. The following 
efficacy variables are exploratory and are assessed over the Treatment Period and Treatment 
Extension Period, as applicable:

Change from Baseline in ASDAS

ASAS20 response

ASAS40 response

Time to ASAS20 response

Time to ASAS40 response

ASAS partial remission

Change from Baseline in BASDAI

Changes in bone formation as measured by standardized uptake value by area under the 
curve (SUVAUC) and derived from PET-MRI or PET-CT at Baseline, Week 12, and Week 48 
4.2
Safety variables
4.2.1
Primary safety variables
The primary safety variables for this study are as follows:

Incidence of AEs and SAEs

Adverse events leading to withdrawal from IMP
4.2.2
Other safety variables
The other safety variables for this study are as follows:

Change from Baseline in vital signs (blood pressure, temperature, pulse rate) and body 
weight

Change from Baseline in physical examination

Change from Baseline in standard 12-lead electrocardiogram (ECG) intervals (RR, PR, QRS, 
QT, and QT intervals corrected for heart rate using Fridericia’s formula [QTcF]) 

Change from Baseline in clinical laboratory values (hematology, biochemistry, and 
urinalysis)
4.3
Other PK and PD variables
4.3.1
Other PK variables
The PK variables are plasma concentrations of bimekizumab and CZP.
4.3.2
Other PD variables
The PD variables assessed at time points specified in Table 5‒1 are the blood or blood derivative 
(eg, plasma) concentrations of cytokines and chemokines of relevance to IL-17A/F signaling 
PUBLIC COPY 
y are as 
C C
y are as 
thdrawa
PUB
thdrawa
aria
P
aria
This document cannot be used to support any marketing authorization 
e value by
mar
e value by
Baselin
y m
Baseline, 
m
e, 
follows:
ppo
follows:
from IMP
to s
from IMP
bles
sed
bles
s study a
us
s study a
n vital sig
be 
n vital sig
seline in p
nno
seline in p
m Baseline
can
m Baseline
QT interva
t ca
QT interva
ge from B
en
ge from B
inalysis)
me
inalysis)
4.3
o
4.3
4.3.1
s do
4.3.1
T
s
T
application and any extensions or variations thereof.
y area und
ons
y area und
Week 12
tion
Week 12
MP
n
MP
are as foll
ex
are as foll
gns (blood
any 
gns (blood
physical e
and
physical e
e in stand
n a
e in stand
vals correc
tion
vals correc
Baseline i
cati
Baseline i
Oth
pp
Oth

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 23 of 136
pathway, TNF signaling pathway, AS biology, and bone metabolism. Additional variables may 
include, but will not be limited to, serum complement concentrations and mononuclear cell 
subtypes.
4.4
Other immunological variable(s)
Immunological variables will allow evaluation of immunogenicity as well as immunological 
biomarkers. Anti-bimekizumab antibody and anti-CZP antibody detection prior to and following 
study treatment will be evaluated.
4.5
Other nonhereditary pharmacogenomic variables
Where local regulations permit, blood and urine will be collected at specific time points specified 
in Table 5‒1 and stored for up to 20 years to allow for potential exploratory analyses of 
ribonucleic acid (RNA), proteins, and metabolite biomarkers relevant to AS, bone metabolism. 
and the inflammatory and immune response processes. The nature and format of these tentative 
analyses will be determined at a later stage. 
4.6
Other pharmacogenetic variables 
Additional blood samples will be collected from subjects who consent to participate in the 
pharmacogenetic substudy at specific time points specified in Table 5‒1 and stored at -80°C for 
up to 20 years. Pharmacogenetic biomarkers may be measured to evaluate the relationship to 
response to treatment with bimekizumab, AS disease biology, bone metabolism, and 
inflammatory and immune response processes. The nature and format of these tentative 
sub-study analyses will be determined when the results of the main study are made available.
5
STUDY DESIGN
5.1
Study description
AS0013 is a multicenter, randomized, subject-blind and investigator-blind, parallel-group study 
to evaluate the efficacy and safety of bimekizumab compared to CZP in adult subjects with 
active adult-onset AS. 
To be eligible to participate, subjects must meet the following key inclusion criteria: 

Subjects will have active adult-onset AS, meeting Modified New York criteria for AS with: 

BASDAI score ≥4

Spinal pain score ≥4 (from BASDAI Question 2). 

hs-CRP levels should be above the upper limit of normal (ULN) at the Screening Visit. One 
re-test of hs-CRP is permitted during the Screening Period upon discretion of the 
Investigator.

Subject must have had an inadequate response to, have a contraindication to, or has been 
intolerant to at least 2 NSAIDs (inadequate response to an NSAID is defined as lack of 
response to at least 14 days of continuous NSAID therapy at the highest tolerated dose of the 
administered NSAID.) If taking NSAIDs at study entry, subjects must be on a stable dose for 
2 weeks prior to Baseline. 
PUBLIC COPY
ects w
Y
ects w
pecified
PY 
pecified
ay be me
OP
ay be me
S disease
CO
S disease
esses. Th
C C
esses. Th
when th
LIC
when th
N
UB
N
ption
PU
ption
This document cannot be used to support any marketing authorization 
ng
iz
ng
points spec
au
points spec
lyses of 
g a
lyses of 
bone met
ting
bone met
mat of the
ketin
mat of the
consent to
ny m
consent to
in
a
in Table
any
Table 5
y
5
asured to e
rt a
asured to e
biology, b
ort 
biology, b
e nature an
ppo
e nature an
results of
upp
results of
zed, subjec
sed
zed, subjec
ety of bim
us
ety of bim
ate, subje
ot b
ate, subje
ve active a
nno
ve active a
I score
can
I score ≥
n
≥4
nal pain sc
nt c
nal pain sc
CRP level
men
CRP level
e-
u
-test of h
um
test of h
Investig
ocu
Investig

d

Sub
o
Sub
application and any extensions or variations thereof.
ecified
of.
ecified
tabolism.
ereo
tabolism.
hese tentat
ther
hese tentat
to particip
atio
to particip
5‒
ri
‒1
ri
1 and s
riat
and s
evaluat
var
evaluate
r
e
bone met
r va
bone met
and forma
or 
and forma
of the main
ns o
of the main
ect
ex
ect-
x
-blind a
exte
blind a
mekizumab
ex
mekizumab
ects must 
d an
ects must 
adult
and
adult-
nd
-ons
d
ons
4
core
tio
core ≥
io
≥4 (f
on
4 (f
ls should 
lica
ls should 
hs
p
hs-
pl
-CRP is
plic
CRP is
gator.
app
gator.
mus
a
mus

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 24 of 136

In addition, the subject may not have been exposed to more than 1 TNF antagonist prior to 
the Baseline Visit and may not be a primary failure to any TNF antagonist therapy (defined 
as no response within the first 12 weeks of treatment with the TNF antagonist.
At least 60 subjects will be randomized to 1 of 2 treatment arms in a 2:1 ratio and will receive 
either bimekizumab or CZP up to Week 44 (final dose of IMP). 
AS0013 will include a Screening Period of 2 to 4 weeks, a 12-week Treatment Period, a 36-week 
Treatment Extension Period, and a 20-week Safety Follow-up Period (after the final dose of 
IMP). 
In approximately 25 subjects at selected sites, a PET-MRI or PET-CT scan will be performed at 
Screening and during the study at Week 12 and Week 48/Early Withdrawal Visit if PET-positive 
lesions were observed in the previous scan.
5.1.1
Screening Period (minimum of 2 and up to 4 weeks)
Assessments of eligibility as described in Section 6 will be initiated during the 2- to 4-week 
Screening Period. The informed consent will be obtained as described in Section 8.1. The 
Screening Period will also enable the washout of medications not permitted for use during the 
study.
The assessments at the Screening Visit are presented in Table 5‒1.
5.1.2
Treatment Period (Week 0 to Week 12)
Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
treatments: 

Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in 
order to maintain the blind vs the CZP loading dose at these visits. 

CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200mg sc Q2W in 
Weeks 6 to 10.
Study treatments will be prepared and administered by appropriately trained unblinded site 
personnel. 
5.1.3
Treatment Extension Period (Week 12 to Week 48)
After completing the 12-week Treatment Period, subjects will enter a 36-week Treatment 
Extension Period and will receive the following treatments:

Subjects randomized to bimekizumab during the Treatment Period will receive bimekizumab 
320mg sc Q4W from Week 12 to Week 44. 

Subjects randomized to CZP during the Treatment Period will receive CZP 400mg Q4W 
from Week 12 to Week 44. 
Subjects not responding to treatment during the Treatment Period will be withdrawn from the 
study as per Investigator’s discretion and will not enter the Treatment Extension Period.
The assessments during the Treatment Extension Period are presented in Table 5‒1.
COPY 
Y
nted in 
OPY
nted in 
Y
PUBLIC C
0 to We
CO
0 to We
a 2:1 rat
LIC 
a 2:1 rat
W 
PU
W from W
PUB
from W
at Base
PU
at Base
th
P
th
port any marketing authorization 
eek 
z
eek 
f 
o
f 
performed
auth
performed
if PET
g au
if PET-po
u
po
s)
ke
s)
uring the 2
arke
uring the 2
bed in
ma
bed in Sec
ar
Sec
ot permitte
y m
ot permitte
able
t a
able 5
an
5‒
a
‒1
n
1
nt cannot be used to suppo
eek 12)
port
eek 12)
o to receiv
upp
o to receiv
Week 0 thr
to s
Week 0 thr
line (Visi
d to
line (Visi
e CZP loa
sed
e CZP loa
eks 0, 2, a
us
eks 0, 2, a
prepared
ot b
prepared
reatment
ann
reatment
ting the 1
t ca
ting the 1
This documen
Period an
ent 
Period an
ubjects ran
me
ubjects ran
320mg s
cum
320mg s

d

Subj
oc
Subj
frfr
S
s
S
or variations thereof.
d at
f
d at
positive
of.
positive
2
s
2-
s
- to 4
s th
to 4-
t
-w
h
w
ction
ns
ction 8.1
ns
8.1
ted for use
tion
ted for use
tion and any extensions 
ive the fol
s o
ive the fol
rough We
nsio
rough We
it 2), Wee
ens
it 2), Wee
ading dos
xte
ading dos
and 4
y ex
and 4 (loa
ex
(loa
d and adm
d an
d and adm
t Extens
n an
t Extens
12
ti
12-
o
-
applicat
week T
ion
week T
nd will re
atio
nd will re
ndomized
plica
ndomized
sc Q4W fr
ppl
sc Q4W fr
cts rand
ap
cts rand
k

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 25 of 136
5.1.4
Safety Follow-up Period (Week 48 to Week 64)
All subjects who complete the study or who discontinue from the study early, including those 
withdrawn from the IMP treatment, will have a SFU Visit at 20 weeks after their final dose of 
IMP. The assessments at the SFU Visit are presented in Table 5‒1.
5.2
Safety monitoring strategy
An independent Data Monitoring Committee (DMC) will review study safety data on an ongoing 
basis. Details will be available in the DMC charter. Cardiovascular and Neuropsychiatric 
Adjudication Committees will review and monitor cardiovascular and neuropsychiatric events. 
Further details are provided in Section 12.5.
5.3
Imaging evaluation
In a subpopulation of AS0013, a PET-MRI or PET-CT scan of the entire spine will be performed 
at selected sites in approximately 25 subjects at Screening, and during the study at Week 12 and 
Week 48/Early Withdrawal Visit if PET-positive lesions were observed in the previous scan. 
The PET-MRI or PET-CT scan should be performed after confirmation of eligibility for the 
study based on screening assessments. All subjects at selected sites are eligible provided that a 
separate Informed Consent form (ICF) for the imaging evaluation has been signed.
5.4
Study duration per subject
For each subject, the study will last a maximum of up to 68 weeks, as follows:

Screening Period: minimum of 2 weeks and up to 4 weeks

Treatment Period: 12 weeks

Treatment Extension Period: 36 weeks

Safety Follow-up Period: 20 weeks after the final dose of IMP for subjects completing the 
study or discontinuing from the study early, including those withdrawn from study treatment.
The end of the study is defined as the date of the last visit of the last subject in the study.
5.5
Planned number of subjects and site(s)
It is anticipated that approximately 120 subjects will be screened in order to enroll at least 
60 subjects in the main study and at least 25 subjects in the PET-CT or PET-MRI substudy at 
multiple sites.
5.6
Anticipated regions and countries
The study sites will be located in North America, Europe, and APAC countries with possible 
extension to other regions.
PUBLIC COPY
sele
Y
sele
ging eva
PY 
ging eva
ect
CO
ect
imum of
C C
imum of
weeks an
BLIC
weeks an
d: 36 w
PU
d: 36 w
ed to support any marketing authorization 
oing 
riz
oing 
events.
tho
events.
ine will b
eting
ine will b
e study at
ket
e study at
ed in the p
arke
ed in the p
mation of 
ma
mation of 
sites are e
y m
sites are e
uation has
any
uation has
up to 68 w
ppo
up to 68 w
d up to 4 w
supp
d up to 4 w
eeks
d t
eeks
ment cannot be us
weeks afte
use
weeks afte
m the study
e us
m the study
ined as th
be
ined as th
ed num
not 
ed num
at approxi
ann
at approxi
he main st
can
he main st
s.
n
s.
cu
An
n
An
study site
um
study site
This doc
xtension t
ocu
xtension t
xtensions or variations thereof.
be perform
here
be perform
t Week 12
the
t Week 12
previous 
s th
previous 
eligibility
ions
eligibility
eligible p
atio
eligible p
as been sig
riat
as been sig
weeks, as
or 
weeks, as
weeks
ns
weeks
ation and any ex
er the fina
exte
er the fina
dy early, in
y ex
dy early, in
he date of 
any
he date of 
mber of s
nd a
mber of s
ximately 1
an
ximately 1
study and 
on a
study and 
pplica
nticipat
icat
nticipat
tes w
ppli
tes will be
plic
ill be
ap
to other r
app
to other r

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 26 of 136
5.7
Schedule of assessments
Table 5‒1:
Schedule of assessments
Study Period
SCr
Treatment Period
Treatment Extension Period
SFUa
Visitb/Week 
(Visit window ±3 days)
V1
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V15
V16
V17
V18
Procedures
SV
BL 
W0
W2
W4
W6
W8
W10
W12
W16
W20
W24
W28
W32
W36
W40
W44
W48
/WD
W64
Written informed 
consentc
X
Demographic data
X
AS history
X
Inclusion/exclusion 
criteria 
X
Xd
Significant past medical 
history and concomitant 
diseases
X
Xe
Prior and concomitant 
medicationsf
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Adverse events
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
C-SSRS
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
HADS
X
X
X
X
X
X
X
X
X
X
X
X
X
X
BASDAI
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
BASFI
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
PGADA
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
PhGADA
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Total and nocturnal 
spinal pain (NRS)
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
PUBLIC COPY 
Y
PY
OP
OP
OPY
OP
CO
C
O
IC
PUB
C
X
P
X
PU
P
be used to support any marketing authorization 
27 
n 
27
at
nsion Peri
au
nsion Peri
ut
V13
ng
V13
V
a
t g a
W28
ke
W28
W3
et
W3
et
et
eti
a
et
ar
y ma
y
ny
an
rt
n
rtrtrt
p ort
pp
to up
X
d t
X
to
to
to
se
to
X
us
X
se
se
se
e
nt cannot be use
X
b
X
X
 
X
e u
be
b
ot b
X
nn
X
X
ot
ot
ot
n o
X
c
X
X
n
X
nn
an
X
t c
X
This document ca
l
T
l
ca
nt a
X
e
X
X
nt
nt
nt
m nt
X
u
X
X
m
X
me
ocum
y extensions or variations thereof.
od
f
od
14
e
14
V15
eo
V15
of
re
32
t
32
W36
the
W36
he
th
s 
o
ati
ri
ari
ari
ari
ari
va
or
s
n on
X
te
X
X
ns
e en
X
X
x
X
ex
tion and any e
X
ny
X
y
a
X
d
X
an
a
X
a
X
X
nd
X
d
an
X
n a
X
an
an
an
n an
X
tio
X
application
X
n
X
n
on
X
c
X
X
at
X
tio
ca
X
plic
X
ica
ca
ca
app
pp
pp
pp ca

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 27 of 136
Table 5‒1:
Schedule of assessments
Study Period
SCr
Treatment Period
Treatment Extension Period
SFUa
Visitb/Week 
(Visit window ±3 days)
V1
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V15
V16
V17
V18
Procedures
SV
BL 
W0
W2
W4
W6
W8
W10
W12
W16
W20
W24
W28
W32
W36
W40
W44
W48
/WD
W64
Physical examination 
(incl. height and 
weight)g
X
X
X
X
X
Vital signs (BP, pulse, 
temperature)h
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
12-lead ECG (local)
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Tuberculosis 
questionnaire
X
X
X
X
X
X
IGRA TB testi
X
X
Pregnancy testj
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Hematology/
biochemistry/urinalysisk
X
X
X
X
X
X
X
X
X
X
X
X
Serology (HIV, 
Hepatitis B and C, 
HLA-B27)k, l
X
Blood samples for 
cytokines, complement, 
and biomarker analysisk
X
X
X
X
X
X
X
Blood sampling for 
bimekizumab and CZP 
plasma concentrationsk
X
X
X
X
X
X
X
Bimekizumab and CZP 
antibody detectionk
X
X
X
X
X
X
X
PUBLIC COPY 
X
Y
X
OPY
X
CO
X
X
P
X
OP
OP
OP
OP
X
C
X
CO
C
O
LIC
B
C
X
U
X
BL
PUB
X
PU
X
PU
P
be used to support any marketing authorization 
27 
n 
27
at
Period
tho
Period
ho
V14
au
V14
uth
th
th
g a t
W32
ting
W32
W
g
W
g
et g
ke
ma
e
X
y m
X
m
ny m
X
t a
X
an
ort
ort
ort
ort
p ort
up
up
upp
up
X
o s
X
s
to
X
d t
X
to
to
to
se
to
This document cannot be use
l
T
l
se
se
se
t be
se
X
t b
an ot b
X
an
an
nt an
X
me
X
e
cum
u
any extensions or variations thereof.
V15
f
V15
e
W36
ere
W36
W4
e
W4
eo
th re
X
h
X
th
th
the
o
th
X
ati
X
tio
ari
o
X
va
X
ar
ar
ar
ar
X
v
X
v
or
s
on
X
sio
X
ion
on
on
n on
X
e
X
ns
on and any exten
xt
a
e
an
an
a
a
cation
X
o
X
applicatio
ca on a
X
a
X
ca
ca
ca
pp
pp
pp
pp ca

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 28 of 136
Table 5‒1:
Schedule of assessments
Study Period
SCr
Treatment Period
Treatment Extension Period
SFUa
Visitb/Week 
(Visit window ±3 days)
V1
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V15
V16
V17
V18
Procedures
SV
BL 
W0
W2
W4
W6
W8
W10
W12
W16
W20
W24
W28
W32
W36
W40
W44
W48
/WD
W64
Blood sample for 
hs-CRPk
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Blood samples for 
pharmacogenetic 
variables
X
X
X
Blood samples for 
nonhereditary 
pharmacogenomic 
variables
X
X
X
X
X
Urine samples for 
biomarker research
X
X
X
X
Chest X-ray or CT scan 
of chest m
X
X
Sacroiliac joint X-rayn
X
PET-MRI or PET-CT 
scan as a substudy at 
selected siteso
X
X
X
Contact the IRT
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
IMP administrationp
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
AS=ankylosing spondylitis; BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; BASFI=Bath Ankylosing Spondylitis Functional Index; 
BL=Baseline; BP=blood pressure; CT=computed tomography; C-SSRS=Columbia Suicide Severity Rating Scale; CZP=certolizumab pegol; 
ECG=electrocardiogram; HADS=Hospital Anxiety and Depression Scale; HCV=hepatitis C virus; HIV=human immunodeficiency virus; HLA-B27=human 
leukocyten antigen B27; hs-CRP=high sensitivity C-reactive protein; IGRA=Interferon-Gamma Release Assay; IMP=investigational medicinal product; 
IRT=interactive response technology; NRS=numeric rating scale; PET-CT=positron-emission tomography-computer tomography; PET-MRI=positron-emission 
tomography – magnetic resonance imaging; PGADA=Patient’s Global Assessment of Disease Activity; PhGADA=Physician’s Global Assessment of Disease 
Activity; Q2W=every 2 weeks; Q4W=every 4 weeks; SCr=Screening; SFU=Safety Follow-Up; SV=Screening Visit; TB=tuberculosis; V=Visit; W=Week; 
PUBLIC COPY 
OPY
X
CO
X
OP
OP
OP
C
OP
LIC
UB
PU
PU
cannot be used to support any marketing authorization 
27 
n 
27
at
Period
tho
Period
ho
V14
au
V14
uth
th
th
g a t
W32
ting
W32
W
g
W
g
et g
X
rk
X
ke
ma
e
ma
ma
ma
ny ma
an
up ort
X
s
X
up
up
up
to up
to
to
to
se
to
se
se
se
se
u
ot be
X
nn
X
X
ot
ot
ot
n o
X
c
X
X
n
X
This document 
l
T
l
nn
an
=Bath Anky
t c
=Bath Anky
; CT=comp
ent 
; CT=comp
DS=Hospita
men
DS=Hospita
CRP=high
me
CRP=high
 technolog
cum
 technolog
ic resonanc
ocu
ic resonanc
ery 2 weeks
doc
ery 2 weeks
ca
n and any extensions or variations thereof.
V15
f
V15
e
W36
ere
W36
W4
e
W4
eo
th re
X
s
X
X
h
X
th
th
the
th
n
ari
o
ar
ar
ar
n or ar
ns
on
s
en
xt
e
y e
a
e
X
a
X
X
nd
X
d
an
application a
X
n a
X
an
an
an
n an
ylosing Spo
tion
ylosing Spo
puted tomo
atio
puted tomo
al Anxiety a
cat
al Anxiety a
h sensitivity
plica
h sensitivity
gy; NRS=nu
ppli
gy; NRS=nu
ce imaging;
app
e imaging;
Q4W=ev
ap
Q4W=ev
n

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 29 of 136
Table 5‒1:
Schedule of assessments
Study Period
SCr
Treatment Period
Treatment Extension Period
SFUa
Visitb/Week 
(Visit window ±3 days)
V1
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V15
V16
V17
V18
Procedures
SV
BL 
W0
W2
W4
W6
W8
W10
W12
W16
W20
W24
W28
W32
W36
W40
W44
W48
/WD
W64
WD=Early Withdrawal Visit; WHO=World Health Organization
a Safety Follow-Up Visit occurs 20 weeks after the final dose for all subjects who complete the study or who discontinue early, including those withdrawn from 
study treatment. 
b Visit windows of ±3 days from the first dose at all visits through Week 48. The SFU Visit window is -3 and +7 days from the final dose.
c A separate Informed Consent Form is required for subjects participating in the 2 sub-studies: 1) with biomarker, pharmacogenetic and nonhereditary 
pharmacogenomic blood-samples and 2) PET-MRI or PET-CT scans.
d Ensure there are no significant changes in medical history that would exclude the subject based on the exclusion criteria.
e Ensure that there are no significant changes in the medical history.
f Prior and concomitant medication at Screening and Baseline; concomitant medication only at all other visits.
g The physical examination includes the evaluation of signs and symptoms of active TB, risk for exposure to TB, height (Screening only) and weight (Screening, 
Week 12 and Week 48/WD only).
h Vital signs (blood pressure, pulse rate, and temperature) are to be measured prior to drug administration at all visits and at 30 minutes and 1 hour after dosing at 
Baseline/Day 1.
i QuantiFERON TB test or another WHO-validated IGRA test such as Elispot test, if QuantiFERON TB test is not locally available. 
j Pregnancy testing will performed on serum at Screening and on urine at all other visits. Pregnancy test results must be negative prior to administering IMP. 
k At dosing visits, all blood samples are taken prior to dosing. Blood samples for IMP and anti-IMP antibody detection will be processed as per instructions in the 
laboratory manual. After Screening, until Week 12, hs-CRP data will not be sent to the Investigator to protect the blinded nature of the treatment assignments.
l Subjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B surface antigen (HBsAg+); 2) positive 
for anti-hepatitis B core antibody (HBcAb+) are excluded; a positive test for HCV is defined as: 1) positive for hepatitis C antibody (anti-HCV Ab), and 2) 
positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are also excluded.
m If a subject has had a recent radiograph or CT scan of the chest within 3 months prior to the Screening Visit, it may be used as the Screening chest X-ray. The 
chest X-ray/CT scan of the chest at Week 48/WD is to be done if medically indicated only (eg, positive TB-test).
n If subjects have a previous X-ray documenting AS meeting eligibility criteria, they are eligible for study entry after reconfirming their eligibility by central 
reading. If no X-ray is available one must be performed at Screening. If the previous X-ray is more than 1 year old, and central read criteria for randomization 
are not met, another X-ray may be performed if permitted by local guidelines.
o A PET-MRI or PET-CT scan should be done up to 2 weeks before Baseline and within 2 weeks after the W12 and W48/WD Visit if PET-positive lesions are 
observed in the previous scan. If a subject withdraws from the study early, the PET-MRI or PET-CT scan must be repeated at the WD visit only, if the prior 
examination was done more than 12 weeks prior to the WD visit and the previous PET-scan showed positive lesions.
p CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200mg sc Q2W in Weeks 6 to 10 and 400mg Q4W from Week 12 to Week 44. 
Bimekizumab will be administered at a dose of 160mg sc Q2W from Week 0 through Week 10 and 320mg sc Q4W from Week 12 to Week 44. The IMP will be 
administered at the end of the visit after all assessments have been completed. Subjects randomized to bimekizumab will receive 1 placebo injection at Baseline 
PUBLIC COPY 
studie
PY
studie
the subjec
OP
the subjec
nt medica
C C
nt medica
oms of act
IC C
oms of act
e measur
BL
e measur
est such a
PU
est such a
nd on u
P
nd on u
This document cannot be used to support any marketing authorization 
27 
n 
27
at
l
T
l
Period
tho
Period
ho
V14
au
V14
uth
th
th
g a t
W32
ting
W32
W
g
W
g
et g
ke
who discon
ark
who discon
w is
w is -
m
-3 and 
y m
3 and 
) with biom
ny 
) with biom
based on th
t a
based on th
on only at 
por
on only at 
ve TB, risk
ppo
ve TB, risk
d prior to dr
sup
d prior to dr
Elispot tes
d to
Elispot tes
rine at all o
ed t
rine at all o
ood sample
sed
ood sample
data will n
use
data will n
is B by any
e us
is B by any
ded; a posit
be 
ded; a posit
ple, HCV p
t be
ple, HCV p
an of the ch
ot 
an of the ch
WD is to be
no
WD is to be
ti
a
ting AS me
ann
ng AS me
st be perfor
can
st be perfor
rformed if 
t ca
rformed if 
ld be done 
nt c
ld be done 
f a subject 
en
f a subject 
than 12 we
me
than 12 we
Weeks 0, 2, a
um
Weeks 0, 2, a
administere
ocu
administere
end of the v
doc
end of the v
application and any extensions or variations thereof.
V15
f
V15
e
W36
ere
W36
W4
e
W4
eo
th re
th
th
the
ntinue early
ns t
ntinue early
+7 days fro
tion
+7 days fro
marker, pha
iatio
marker, pha
he exclusio
var
he exclusio
all other vi
or v
all other vi
k for exposu
s o
k for exposu
rug admini
ons
rug admini
st,
n
st, if Quant
nsi
if Quant
ther visits. 
ten
ther visits. 
es for IMP 
xte
es for IMP 
ot be sent t
ext
ot be sent t
y of the foll
y e
y of the foll
tive 
n
tive test for
ny 
test for
olymerase 
any
olymerase 
he
d
hest within 
d a
st within 
e done if m
nd 
e done if m
eeting eligi
an
eeting eligi
rmed at Scr
n a
rmed at Scr
permitted b
ion
permitted b
up to 2 we
atio
up to 2 we
withdraws
cat
withdraws
eeks prior to
lica
eeks prior to
and 4 (load
plic
and 4 (load
ed at a dose
app
ed at a dose
sit after a
ap
it after a

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 30 of 136
Table 5‒1:
Schedule of assessments
Study Period
SCr
Treatment Period
Treatment Extension Period
SFUa
Visitb/Week 
(Visit window ±3 days)
V1
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V15
V16
V17
V18
Procedures
SV
BL 
W0
W2
W4
W6
W8
W10
W12
W16
W20
W24
W28
W32
W36
W40
W44
W48
/WD
W64
(Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4). 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
27 
n 
27
at
l
T
l
Period
tho
Period
ho
V14
au
V14
uth
th
th
g a t
W32
ting
W32
W
g
W
g
et g
ke
application and any extensions or variations thereof.
V15
f
V15
e
W36
ere
W36
W4
e
W4
eo
th re
th
th
the

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 31 of 136
5.8
Schematic diagram
Figure 5‒1: Schematic diagram
CZP=certolizumab pegol; N=number of subjects; Q2W=every two weeks; Q4W=every 4 weeks; sc=subcutaneous(ly); SFU=Safety Follow-up, W=week
a Subjects not responding to treatment during the Treatment Period will be withdrawn from the study as per Investigator’s discretion and will not enter the 
Treatment Extension Period.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
27 
n 
27
at
l
T
l
mber of sub
men
mber of sub
reatment du
me
reatment du
od.
u
od.
nt cannot be used to support any marketing aut
applicatio
bjects; Q2W
cat
bjects; Q2W
uring the T
lica
uring the T
tion and any extensions or variations thereof.

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 32 of 136
5.9
Rationale for study design and selection of dose
AS0013 is a Phase 2a, multicenter, randomized, subject-blind and investigator-blind study to 
evaluate the efficacy and safety of bimekizumab and CZP in adult subjects with active AS. 
AS0013 includes a 12–week Treatment Period, a 36-week Treatment Extension Period, and a 
20-week SFU Period. Rationales for the study design, selected population, and bimekizumab 
doses are provided below.
Study design
AS0013 was designed to evaluate the efficacy, safety and the process of osteoproliferation using 
PET imaging techniques at Screening and after 12 and 48 weeks of treatment. The scientific 
rationale suggesting a role for IL-17A treatment in bone formation as compared to TNFα 
treatment is provided in detail in Section 2.4.
While the primary evaluation will be conducted after 12 weeks, a 36-week Treatment Extension 
Period has been added in order to maintain the treatment blind after subjects have reached 
Week 12 (ie, the evaluation of the primary efficacy variable) and to allow continued access to 
IMP for subjects responding to treatment. This extension also allows further evaluation of the 
inhibition of the osteoproliferative effect of bimekizumab and CZP at Week 48 and to compare 
this to Baseline and Week 12.
Population
AS0013 was designed to evaluate the potential benefit of bimekizumab to prevent bone 
formation in subjects at risk of new bone formation (disease progression) and comparing the 
outcome to treatment with CZP. Inclusion criteria will ensure that all subjects have active AS. 
Some exclusion criteria are intended to eliminate subjects who may present an unacceptable 
safety risk were they to participate in this investigational study program. Active AS is defined by 
a BASDAI score ≥4 and a spinal pain score ≥4 (from BASDAI Question 2). The full list of 
inclusion and exclusion criteria is provided in Section 6.
Dose selection
The following dose regimens of bimekizumab and CZP will be evaluated during the Treatment 
Period:

Bimekizumab 160mg sc Q2W from Week 0 through Week 10 

CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200mg sc Q2W in 
Weeks 6 to 10.
Exposure levels up to 8-fold greater than 160mg Q2W have been previously studied in the 
development of bimekizumab. In the single ascending dose study UP0008, a single dose of 
bimekizumab 640mg was tested. In the multiple dose study PA0007, a bimekizumab 560mg 
loading dose followed by 2 subsequent 320mg doses every 3 weeks was tested. At exposure 
levels achieved at these doses, the compound had no significant safety concerns. Additionally, in 
the above clinical studies (UP0008 and PA0007), bimekizumab was administered iv and the 
current study proposes to administer the compound sc. The exposure of the drug is expected to 
be lower than after iv administration due to lower bioavailability following sc administration 
and, therefore, the dose regimens are expected to be safe. No safety concerns have been reported 
in ongoing clinical studies evaluating cumulative monthly doses of bimekizumab 320mg in other 
PUBLIC COPY 
mab 
Y
mab 
ntial ben
C C
ntial ben
ne forma
LIC 
ne forma
lusion cr
BLI
lusion cr
ded to el
UB
ded to el
pate in th
PU
pate in th
l pa
P
l pa
ment cannot be used to support any marketing authorization 
tion using
tho
tion using
cientific
auth
cientific
o TNFα
g au
o TNFα
Treatme
etin
Treatme
bjects hav
rke
bjects hav
allow con
mark
allow con
ows furthe
ma
ows furthe
CZP at W
ny m
CZP at W
efit of bim
ppo
efit of bim
ion (disea
upp
ion (disea
teria will 
sup
teria will 
minate su
to s
minate su
is inves
d to
is investig
o
tig
n score ≥4
ed 
n score ≥4
provided
use
provided
mens of bim
t be
mens of bim
160mg sc
ann
160mg sc
mg sc Q2W
t ca
mg sc Q2W
6 to
nt
to 10.
nt 
10.
ure levels 
me
ure levels 
This docu
elopment 
cum
elopment 
bimekizum
ocu
bimekizum
loading
do
loading
level
s d
level
th
s
th
plication and any extensions or variations thereof.
nt Extens
her
nt Extens
ve reached
s th
ve reached
ntinued ac
ns 
ntinued ac
er evaluat
ion
er evaluat
Week 48 a
atio
Week 48 a
mekizuma
or 
mekizuma
ase progre
ns o
ase progre
l ensure th
ons
l ensure th
ubjects wh
sio
ubjects wh
igational s
ens
igational s
≥4 (from B
xten
≥4 (from B
d in
ex
d in Sectio
ext
Sectio
imekizum
d any
imekizum
c Q2W fr
an
c Q2W fr
W at Wee
ion 
W at Wee
s up to 8
lica
s up to 8
app
-f
t of bimek
ppli
t of bimek
mab 640m
app
mab 640m
se fol
ap
se fol

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 33 of 136
populations including PA0008 in subjects with active PsA, AS0008 in subjects with active AS, 
and several ongoing studies in subjects with PSO. 
Simulations were performed using a model to predict the dose response of ASAS20/40 at 
Week 12, ie, for a different endpoint than the primary efficacy endpoint being proposed in this 
study (Diderichsen and Cox, 2016). These simulations indicated that increasing doses above 
bimekizumab 320mg Q4W may not provide additional benefit in terms of efficacy. 
The dose selected in the current study is bimekizumab 160mg Q2W instead of 320mg Q4W. 
Given that the PK of bimekizumab has been established to be linear in the exposure range 
(UP0008 and PA0007), the proposed dose of bimekizumab 160mg Q2W is expected to provide 
similar overall exposure and hence response compared to a dose of 320mg Q4W. Table 5‒2
shows a comparable AUCtau between bimekizumab 320Q4W and 160mg Q2W calculated over a 
period of similar time (14 days). In conclusion, the existing data suggest that at the proposed 
dose level, bimekizumab is well tolerated and the analysis suggests that maximum benefit is 
achieved at this exposure level.
Table 5‒2:
Exposure to bimekizumab by dose
Parameter
Bimekizumab dose
160mg Q2W sc
320mg Q4W sc
640mg SD iv from 
UP0008
AUCtau or AUC0-inf (µg*day/mL)
442a,b
445a,b
3787c,d
Cmax (µg/mL)
33a
38a
260c
iv=intravenous; Q2W=every 2 weeks; Q4W=every 4 weeks; sc=subcutaneous, SD=single dose
a Median model predicted 
b Calculated over a period of 14 days 
c Median observed in UP0008 
d AUC0-inf
The dose and regimen proposed for CZP is one of the currently approved dose regimens in 
axSpA (CZP 400mg loading dose + CZP 200mg maintenance dose Q2W) and has been widely 
tested in the clinic, and is in line with the dosing guidance from the labeling. The proposed dose 
of CZP has been tested in Phase 3 studies in subjects with axSpA. The results of these studies 
have shown a favorable risk-benefit profile for the treatment of subjects with axSpA.
6
SELECTION AND WITHDRAWAL OF SUBJECTS
6.1
Inclusion criteria
To be eligible to participate in this study, all of the following criteria must be met:
1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written 
Informed Consent form is signed and dated by the subject. 
2. Subject is considered reliable and capable of adhering to the protocol (eg, able to understand 
and complete diaries), visit schedule, and medication intake according to the judgment of the 
Investigator.
IC COPY
Bi
Y 
Bi
Y
W sc
OP
W sc
PY
PY
PY
PY
442
C C
442a,b
C C
a,b
C
BLIC
33
IC
33
PUBLIC
Q4W=ev
UB
Q4W=ev
ys
P
ys
BL
pport any marketing authorization 
W.
o
W.
ge
th
ge
to provide
uth
to provide
Table
au
Table 5
u
5‒
u
‒2
calculated
g a
calculated
at the pro
ting
at the pro
maximum b
ketin
maximum b
ekizumab
ny 
ekizumab
y m
320mg Q
t a
320mg Q
any
o
pp
cument cannot be used to supp
pp
pp
pp
pp
ry 4 weeks
o s
ry 4 weeks
s
oposed fo
ot b
oposed fo
oading do
not 
oading do
and is in 
nno
and is in 
n tested in
can
n tested in
favorable
t ca
favorable
This do
SE
nt
SE
To be elig
docu
To be elig
1.
s d
1. A
o
A
s or variations thereof.
d over a 
eof
d over a 
oposed 
ereo
oposed 
benefit is
ther
benefit is
b dose
iat
b dose
tio
Q4W sc
var
Q4W sc
ria
445
or
445a,b
r
a,b
r
ons 
3
ation and any extensions
; sc=subcut
sion
; sc=subcut
on
or CZP is 
d any
or CZP is 
ose + CZP
nd a
ose + CZP
line with
and
line with
n Phase 3 
n a
n Phase 3 
e risk
ion
e risk-
n
-ben
n
ben
applica
ELECTI
cati
ELECTI
Inclus
plic
Inclus
gible to p
app
ible to p
ut
a
t

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 34 of 136
3. Subject is male or female and at least 18 years of age.
4. Subject has a documented diagnosis of adult-onset AS as defined by documented radiologic 
evidence (X-ray) fulfilling the Modified New York criteria for AS (1984) of at least 
3 months’ symptom duration and age of onset <45 years. 
5. Subject has moderate to severe active disease at the Screening Visit as defined by each of the 
following:

BASDAI score ≥4

Spinal pain score ≥4 on a 0 to 10 numeric rating scale (NRS) (from BASDAI Item 2)
6. Subject must have had an inadequate response to, have a contraindication to, or has been 
intolerant to at least 2 NSAIDs (inadequate response to an NSAID is defined as lack of 
response to at least 14 days of continuous NSAID therapy at the highest tolerated dose of the 
administered NSAID).
7. Subject may not have been exposed to more than 1 TNF antagonist prior to the Baseline Visit 
and may not be a primary failure to any TNF antagonist therapy (defined as no response 
within the first 12 weeks of treatment with the TNF antagonist.
8. Subject has hs-CRP levels above the ULN at the Screening Visit. One re-test of hs-CRP is 
permitted during the Screening Period upon discretion of the Investigator. 
9. Female subjects must be postmenopausal (at least 1 year; to be confirmed hormonally as part 
of the screening process, if less than 2 years since last menstrual period), permanently 
sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy) or, if of childbearing 
potential (and engaged in sexual activity that could result in procreation), must be willing to 
use a highly effective method of contraception up till 20 weeks after last administration of 
IMP, and have a negative pregnancy test at Visit 1 (Screening) and immediately prior to first 
dose. The following methods are considered highly effective when used consistently and 
correctly.

combined (estrogen and progestogen) hormonal contraception associated with inhibition 
of ovulation (oral, intravaginal or transdermal)

progestogen-only hormonal contraception associated with inhibition of ovulation (oral, 
injectable, implantable)

intrauterine device (IUD)

intrauterine hormone-releasing system (IUS)

bilateral tubal occlusion

vasectomized partner (where postvasectomy testing had demonstrated sperm clearance)

sexual abstinence if it is in accordance with a subject’s preferred and common lifestyle. 
Subjects who use abstinence as a form of birth control must agree to abstain from 
heterosexual intercourse until 20 weeks after the final dose of IMP (anticipated 5 
half-lifes of bimekizumab). Study personnel must confirm the continued use of 
abstinence is still in accordance with the subject’s lifestyle at regular intervals during the 
study.
PUBLIC COPY 
F an
Y
F an
the Scree
OPY
the Scree
n discret
COP
n discret
sal (at le
C C
sal (at le
n 2 years
LIC 
n 2 years
ysterecto
BLIC
ysterecto
ual activi
UBL
ual activi
od of co
PU
od of co
egna
P
egna
not be used to support any marketing authorization 
Item 2)
uth
Item 2)
or has bee
g au
or has bee
ed as lack
ng 
ed as lack
tolerated
eting
tolerated
ist prior to
ark
ist prior to
py (define
ma
py (define
nist.
y
nist.
ning Visit
any
ning Visit
on of the 
rt a
on of the 
ast 1 year
por
ast 1 year
since last 
upp
since last 
my, bilater
sup
my, bilater
ty that cou
to s
ty that cou
ntraception
d to
ntraception
ncy
ed
ncy test at
ed 
test at
are consid
use
are consid
n and prog
t be
n and prog
al, intrava
ot b
al, intrava
This document cann
only hor
nno
only hor
e, implant
can
e, implant
uterine de
nt c
uterine de
ntrauterin
men
ntrauterin

bilate
um
bilate

oc

v
nd any extensions or variations thereof.
en
o
en
k o
re
k of
e
f
d dose of t
here
d dose of t
to the Bas
ns t
to the Bas
ed as no r
ions
ed as no r
it. One re
aria
it. One re
In
v
Investiga
var
vestiga
r; to be co
or 
r; to be co
t menstrua
s o
t menstrua
eral salpi
ons
eral salpin
uld result
sion
uld result
on up till 2
nsi
on up till 2
at Visit 1 (
ten
at Visit 1 (
dered high
exte
dered high
gestogen)
any
gestogen)
aginal or t
d a
aginal or t
plication an
rmonal co
and
rmonal co
table)
n a
table)
evice (IUD
tion
evice (IUD
ne hormo
cat
ne hormo
app
ral tubal 
pli
ral tubal 
ap
sectomi
ap
sectomi

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 35 of 136
Male subjects with a partner of childbearing potential must be willing to use a condom when 
sexually active, up until 20 weeks after the last administration of IMP (anticipated 5 half-
lives).
6.2
Exclusion criteria
Subjects are not permitted to enroll in the study if any of the following criteria is met:
1. Female subject who is breastfeeding, pregnant, or planning to become pregnant during the 
study or within 20 weeks following final dose of study drug. Male subject who is planning a 
partner pregnancy during the study or within 20 weeks following the final dose.
2. Subject who has previously received bimekizumab or CZP.
3. Subject has participated in another study of a medication under investigation within the last 3 
months or at least 5 half-lives of the IMP, whichever is greater, or is currently participating in 
another study of a medication under investigation.
4. Subject has a known hypersensitivity to any excipients of bimekizumab or CZP.
5. Subject has received previous treatment with a polyethylene glycolylated (PEGylated) 
compound that resulted in a severe hypersensitivity reaction or an anaphylactic reaction
6. Subject has a total ankylosis of the spine or a diagnosis of any other inflammatory arthritis 
eg, RA, systemic lupus erythematosus, sardoidosis, psoriatic arthritis, or reactive arthritis. 
Subjects with a diagnosis of Crohn’s disease or ulcerative colitis are allowed as long as they 
have no active symptomatic disease at Screening or Baseline.
7. Subject has a secondary, noninflammatory condition (eg, osteoarthritis, fibromyalgia) that in 
the Investigator’s opinion is symptomatic enough to interfere with evaluation of the effect of 
study drug on the subject’s primary diagnosis of active AS.
8. Subject has received previous or current biological treatment other than TNFα inhibitor 
treatment.
9. Subjects must not have used medications in the manner as detailed by the exclusion criteria 
in Table 7‒2.
10. Subject has: 

a history of chronic or recurrent infections (eg, more than 3 episodes requiring systemic 
antibiotics or antivirals during the preceding year). Minor illnesses like common cold or 
transient, localized infections that may have been treated with a short course of antibiotic 
therapy (up to 7 days) need not count in this assessment.

a serious or life-threatening infection within the 6 months prior to the Baseline Visit 
(including herpes zoster) or hospitalization for any infection in the last 6 months.

any current sign or symptom that may indicate an active infection (except for common 
cold), or has had an infection requiring systemic antibiotics within 2 weeks prior to 
Baseline.

a high risk of infection in the Investigator’s opinion (eg, subjects with leg ulcers, 
indwelling urinary catheter, prior prosthetic joint infection at any time, subjects who are 
permanently bedridden or wheelchair assisted).
PUBLIC COPY
ity rea
PY 
ity rea
a diagno
OPY
a diagno
rdoidosi
CO
rdoidosi
isease or
C C
isease or
at Scree
LIC 
at Scree
lammato
UBL
lammato
symptom
PUB
symptom
primar
PU
primar
nt cannot be used to support any marketing authorization 
e
r
e
ning a 
horiz
ning a 
on within 
ng 
on within 
rently par
ting
rently par
zumab or
ark
zumab or
glycolyla
y m
glycolyla
on or an a
ny 
on or an a
is of any o
t an
is of any o
, psoriatic
ort 
, psoriatic
ulcerative
por
ulcerative
ning or Ba
upp
ning or Ba
ry conditi
su
ry conditi
atic enou
to s
atic enou
y diagnosi
d to
y diagnosi
or current
sed
or current
used med
be 
used med
y of chron
can
y of chron
otics or a
t ca
otics or a
This documen
nsient, loc
ent 
nsient, loc
therapy (u
men
therapy (u

a ser
um
a ser
(in
u
(in

tion and any extensions or variations thereof.
the last 3
reo
the last 3
rticipating
here
rticipating
r CZP.
ns t
r CZP.
ated (
tion
ated (PEG
on
PEG
anaphylac
iatio
anaphylac
other infl
vari
other infl
c a
r
c arthritis
r va
rthritis
e colitis a
or v
e colitis a
aseline.
s o
aseline.
ion (eg, o
ions
ion (eg, o
ugh to inte
nsio
ugh to inte
is of activ
ens
is of activ
t biologic
exte
t biologic
dications 
any
dications 
nic or recu
n a
nic or recu
antivirals 
tion
antivirals 
applicat
ocalized in
atio
ocalized in
(up to 7 d
lica
(up to 7 d
ious or li
ppl
ious or li
ncluding 
app
cluding 

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 36 of 136
11. Subject has a history of or current clinically active infection with Histoplasma, Coccidiodes, 
Paracoccidioides, Pneumocystis, nontuberculous mycobacteria (NTMB), Blastomyces, or 
Aspergillus or current active Candidiasis (local or systemic)
12. Subject has acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) 
infection. Subjects who have evidence of, or test positive for, hepatitis B or hepatitis C are 
excluded as follows: 

A positive test for the hepatitis B virus (HBV) is defined as: 1) positive for hepatitis B 
surface antigen (HBsAg+), or 2) positive for anti-hepatitis B core antibody (HBcAb+). 

A positive test for the hepatitis C virus (HCV) is defined as: 1) positive for hepatitis C 
antibody (anti-HCV Ab), and 2) positive via a confirmatory test for HCV (for example, 
HCV polymerase chain reaction).
13. Subjects with known TB infection, at high risk of acquiring TB infection, with latent TB 
infection (LTBI), or current or history of NTMB infection (refer to Section 12.7.5 for details 
on determining full TB exclusion criteria). 
14. Subject has a primary immunosuppressive condition, including taking immunosuppressive 
therapy following an organ transplant or has had a splenectomy.
15. Subjects with concurrent malignancy or a history of malignancy (including surgically 
resected uterine/cervical carcinoma-in-situ) during the past 5 years will be excluded with the 
following exceptions that may be included:
a. ≤3 excised or ablated basal cell carcinomas of the skin
b. One squamous cell carcinoma of the skin (stage T1 maximum) successfully excised or 
ablated only (other treatments, ie, chemotherapy, do not apply) with no signs of 
recurrence or metastases for more than 2 years prior to Screening
c. Actinic keratosis(-es)
d. Squamous cell carcinoma-in-situ of the skin successfully excised or ablated more than 
6 months prior to Screening
16. Subject has a history of a lymphoproliferative disorder including lymphoma or current signs 
and symptoms suggestive of lymphoproliferative disease.
17. Subject has a history of demyelinating disease (including myelitis) or neurologic symptoms 
suggestive of demyelinating disease.
18. Subject has a current or recent history, as determined by the Investigator, of severe, 
progressive, and/or uncontrolled renal, hepatic hematological, endocrine, pulmonary, cardiac 
(eg, congestive heart failure New York Heart Association [NYHA] Grade 3 and 4), 
gastrointestinal (GI) (note: subjects with active peptic ulcer disease are excluded; subjects 
with a history of peptic ulcer disease are allowed), or neurological disease.
19. Subjects has a history of uncompensated heart failure, fluid overload, or myocardial 
infarction, or evidence of new-onset ischemic heart disease or in the opinion of the 
Investigator other serious cardiac disease, within 12 weeks prior to Baseline.
PUBLIC COPY
a sple
PY 
a sple
story of 
OP
story of 
u) durin
CO
u) durin
uded:
C C
uded:
l carcino
LIC
l carcino
oma of th
UBL
oma of th
tments, i
PU
tments, i
for 
P
for 
ent cannot be used to support any marketing authorization 
 B
o
 B
Ab+). 
thor
Ab+). 
hepatitis C
auth
hepatitis C
(for exam
g au
(for exam
on, with l
ketin
on, with l
Section 
rke
Section 1
ing taking
y m
ing taking
ctomy.
ny
ctomy.
malignanc
t an
malignanc
g the past 
ort 
g the past 
mas of the
upp
mas of the
e skin (sta
to s
e skin (sta
e, chemoth
d to
e, chemoth
more than 
ed 
more than 
oma
be
oma-
e
-in
e u
in-si
u
si
Screening
t be
Screening
ory of a ly
not
ory of a ly
suggestiv
ann
suggestiv
s a history
t ca
s a history
ve of dem
nt c
ve of dem
This docume
ject has a
men
ject has a
progressiv
um
progressiv
(eg, con
ocu
(eg, con
gastr
oc
gastr
w
1
s
1
ation and any extensions or variations thereof.
C
f
C
mple,
of
mple,
latent TB
ther
latent TB
2.7.5
th
2.7.5 for
h
for
g immuno
tion
g immuno
cy (includ
vari
cy (includ
5 years w
r va
5 years w
e skin
ns
e skin
tage T1 m
sion
tage T1 m
therapy, d
nsi
therapy, d
n 2 years p
ten
n 2 years p
itu of the 
ny e
itu of the 
g
ymphopro
nd 
ymphopro
ve of lymp
and
ve of lymp
y of demy
on a
y of demy
myelinatin
tion
myelinatin
applic
a current o
ica
a current o
ve, and/or
plic
ve, and/or
ngestive h
app
ngestive h
intestin
ap
intestin
st

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 37 of 136
20. Subjects with presence of significant uncontrolled neuropsychiatric disorder, active suicidal 
ideation, or positive suicide behavior using the “Baseline” version of the Columbia-Suicide 
Severity Rating Scale (C-SSRS) and the Hospital Anxiety and Depression Scale (HADS) 
with either of the following criteria:

Subject has a lifetime history of suicide attempt (including an actual attempt, interrupted 
attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by 
a positive response (“Yes”) to either question 4 or question 5 of the “Screening/Baseline” 
version of the C-SSRS at screening.

HADS Depression score ≥10 or Anxiety score ≥15.
21. Subject has >2x upper limit of normal (ULN) of any of the following: alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), *alkaline phosphatase (ALP), or 
>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to 
identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).
*An isolated elevation between 2xULN and <3xULN of ALP is acceptable in the absence of 
an identified exclusionary medical condition.
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated 
once for confirmation during the Screening Period. Upon retesting, subjects whose ALT, 
AST, or ALP remain above the thresholds defined above, should not be randomized. 
For randomized subjects with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, 
a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
understood and recorded in the electronic Case Report form (eCRF).
If a subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at 
Screening, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing 
clinically relevant increase. In case of a clinically relevant increase, inclusion of the subject 
must be discussed with the Medical Monitor.
22. Subjects with clinically significant laboratory abnormalities (eg, creatinine >1.5xULN, 
neutropenia <1.5x109/L, hemoglobin <8.5g/dL, lymphocytes <1.0 x109/L, white blood cell 
(WBC) count <3.0x109, platelets <100 x109/L). Individual screening tests for which the 
results are in error, borderline, or indeterminate for inclusion in the study, can be repeated 
once for confirmation during the Screening Period if they are within 25% of the exclusion 
limit. Upon retesting, subjects whose results remain outside this threshold should not be 
randomized. 
23. Subject has an estimated glomerular filtration rate (GFR) as measured by Chronic Kidney 
Disease Epidemiology Collaboration <60mL/min/1.73m2
24. Subject has a 12-lead ECG with changes considered to be clinically significant upon medical 
review (eg, QT corrected for heart rate [QTc] using Fridericia’s correction [QTcF] >450ms, 
bundle branch block, evidence of myocardial ischemia).
PUBLIC COPY 
25% abo
OPY
25% abo
g Period
COP
g Period
ds defin
C CO
ds defin
eline res
LIC 
eline res
cause of 
BLI
cause of 
he electro
UB
he electro
T, AST
PU
T, AST
P
annot be used to support any marketing authorization 
y 
z
y 
line”
riz
line”
g
sphatase (
ng 
sphatase (
drome). If
eting
drome). If
tionate bil
ket
tionate bil
ubin <35%
ark
ubin <35%
is accept
ma
is accept
ve the exc
t any
ve the exc
Upon rete
ort a
Upon rete
ed above, 
por
ed above, 
ult >ULN
upp
ult >ULN
any clinica
sup
any clinica
nic Case R
to s
nic Case R
or ALP t
d t
or ALP t
ossible, pr
sed
ossible, pr
In case of 
use
In case of 
e Medica
e u
e Medica
ly signific
t be
ly signific
10
n
109
o
9/L, hem
not 
/L, hem
This document ca
3.0x10
nno
3.0x109
no
9
o
error, bo
can
error, bo
onfirmati
t ca
onfirmati
Upon retes
ent 
Upon retes
omized.
men
omized.
Subject h
cum
Subject h
Diseas
ocu
Diseas
24.
do
24. Su
o
Su
nd any extensions or variations thereof.
(ALP), or
reo
(ALP), or
f subject h
here
f subject h
ilirubin to
the
ilirubin to
%).
s
%).
table in th
tion
table in th
lusion lim
aria
lusion lim
testing, su
va
testing, su
should n
or v
should n
N for AL
ns o
N for ALT
o
T
ally mean
ons
ally mean
Report fo
sio
Report fo
that does 
tens
that does 
rior to do
xte
rior to do
f a clinica
ex
f a clinica
l Monitor
y e
l Monitor
icant labo
d any
icant labo
moglobin
nd a
moglobin
application an
platelets <
and
platelets <
orderline, 
n a
orderline, 
ion during
ion 
ion during
esting, sub
atio
esting, sub
has an est
ppli
has an est
se Epidem
app
e Epidem
has
a
has

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 38 of 136
25. Subjects has received any live (includes attenuated) vaccination within the 8 weeks prior to 
Baseline (12 months prior to Baseline for the TB Bacille Calmette-Guérin [BCG] vaccine) 
(eg, inactivated influenza and pneumococcal vaccines are allowed but nasal influenza 
vaccination is not permitted). Live vaccines are not allowed during the study or for 20 weeks 
after the final dose of IMP. 
Live vaccines include, but are not limited to the following: 

Anthrax vaccine

Intranasal influenza vaccine

Measles-mumps-rubella (MMR) vaccine

Polio live oral vaccine (OPV)

Smallpox vaccine

Tuberculosis BCG vaccine (within 12 months prior to Baseline)

Typhoid live oral vaccine

Varicella vaccine

Yellow fever vaccine
26. Subject has a history of chronic alcohol or drug abuse within the previous 6 months.
27. Subjects has any other condition which, in the Investigator's judgment, would make the 
subject unsuitable for inclusion in the study.
28. Subject is Investigator site personnel directly affiliated with this study and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
biological or legally adopted.
29. Subject is a UCB employee or is an employee of a third-party organization involved in the 
study.
6.3
Withdrawal criteria
Subjects are free to withdraw from the study at any time, without prejudice to their continued 
care.
Subjects should be withdrawn from the study and encouraged to come for the SFU Visit 
(20 weeks after the last received dose of IMP) if any of the following events occur:
1. Subject withdraws his/her consent.
2. The sponsor or a regulatory agency requests withdrawal of the subject.
3. There is confirmation of a pregnancy during the study, as evidenced by a positive pregnancy 
test.
4. Subject develops an illness that would interfere with his/her continued participation.
PUBLIC COPY 
or drug 
C CO
or drug 
hich, in t
LIC 
hich, in t
n the stu
BLI
n the stu
ersonnel
PUB
ersonnel
is defi
PU
is defi
cument cannot be used to support any marketing authorization 
e)
a
e)
abuse with
port
abuse with
he Investig
upp
he Investig
dy.
s
dy.
directly a
to s
directly a
ned as a sp
d to
ned as a sp
or is an e
us
or is an e
awal cri
ot b
awal cri
withdraw
nno
withdraw
uld be wit
nt c
uld be wit
s after the 
ent
s after the 
ubject wit
me
ubject wit
This docu
The spo
ocu
The spo
3.
d
3. The
o
The
pplication and any extensions or variations thereof.
hin the pr
or v
hin the pr
gator's jud
s o
gator's jud
affiliated w
nsio
affiliated w
pouse, pa
ens
pouse, pa
employee
y ex
employee
teria
d an
teria
w from the
and
w from the
ithdr
tio
ithdrawn f
on
awn f
e last rece
atio
e last rece
thdraws h
plica
thdraws h
ap
onsor or a
app
onsor or a
s con
a
s con

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 39 of 136
5. Subject considered as having either a suspected new LTBI or who develops active TB or 
NTMB infection during the study (including but not limited to, conversion demonstrated by 
interferon-gamma release assay [IGRA] or other diagnostic means) must be immediately 
discontinued from IMP, and an Early Withdrawal Visit must be scheduled as soon as 
possible, but not later than the next regular visit.
Confirmed active TB is a serious adverse event (SAE) and must be captured on an SAE 
Report Form and provided to the Sponsor in accordance with SAE reporting requirements. 
As with all SAEs, periodic follow-up reports should be completed as per protocol 
requirements until such time as the TB infection resolves. 
Additional information on TB policies are provided Section 12.7.5.
6. Subject is noncompliant with the study procedures or medications in the opinion of the 
Investigator.
7. Subject uses prohibited concomitant medications as defined in this protocol (see 
Section 7.8.2) that may present a risk to the safety of the subject in the opinion of the 
Investigator and/or the Medical Monitor.
8. Subject develops laboratory abnormalities (with or without clinical symptoms) of ALT or 
AST as defined in Section Section 6.3.1; neutropenia <0.5x109/L; lymphopenia <0.5x109/L. 
Any laboratory value or change judged to be clinically significant by the Investigator should 
prompt consideration of whether the subject should continue on IMP. For clarification, 
laboratory values that are markedly abnormal as per Table 19‒2 and Table 19‒3 will be 
flagged to the Investigator and to the medical monitor but do not trigger mandatory 
withdrawal unless listed above (Refer to Section 6.3.1 for withdrawal criteria in relation to 
potential drug-induced liver injury [PDILI].)
9. Subject has active suicidal ideation as indicated by a positive response (“Yes”) to 
Questions 4 or 5 or to the suicidal behavior questions of the “Since Last Visit” version of the 
self-rated C-SSRS. The subject should be referred immediately to a Mental Healthcare 
Professional and must be withdrawn from the study.
10. Subjects with a Hospital Anxiety and Depression Scale—Depression (HADS-D) score ≥15 
must be withdrawn. Any subject who develops a HADS-D score of ≥10 during the study 
should be referred immediately to a Mental Healthcare Professional for further evaluation 
and potential withdrawal by the Investigator.
11. Subjects with newly diagnosed IBD or with IBD flares during the study must:

Be referred, as appropriate, to a health care professional treating IBD, such as a 
gastroenterologist

Discontinue IMP and be followed-up until resolution of active IBD symptoms
If IBD flares increase in severity or frequency during the study, the Investigator should use 
clinical judgement in deciding whether the subject should continue in the study and contact 
the Medical Monitor and UCB study physician to confirm the subject’s suitability for 
continued participation in the study.
PUBLIC COPY
h or
PY
h or with
PY 
with
utropenia
OPY
utropenia
be clini
CO
be clini
ubject sh
C C
ubject sh
abnorm
LIC 
abnorm
B
the med
BLI
the med
e (Refer 
UB
e (Refer 
r injury 
PU
r injury 
P
sed to support any marketing authorization 
s.
r
s.
opinion of
ting
opinion of
s protocol
arke
s protocol
t in the op
mar
t in the op
out clinica
any
out clinica
<0.5x10
t an
<0.5x109
n
9
cally signi
ort 
cally signi
ould conti
po
ould conti
l as per 
upp
l as per T
p
T
ical moni
sup
ical moni
to 
to
to Section
o s
Section
PDILI].)
d to
PDILI].)
tion as ind
sed
tion as ind
This document cannot be us
icidal beh
use
icidal beh
ubject sho
be u
ubject sho
be withdr
t be
be withdr
spital An
not 
spital An
awn. Any 
nno
awn. Any 
ferred imm
can
ferred imm
tial withdr
t ca
tial withdr
cts with n
ent
cts with n
Be refe
ume
Be refe
gastr
um
gastr

o

xtensions or variations thereof.
f the
ere
f the
l (see 
s th
l (see 
pinion of 
ons
pinion of 
al sympto
riat
al sympto
/L; lymp
vari
/L; lymp
ificant by
r va
ificant by
inue on IM
or 
inue on IM
Table
s o
Table 19
o
19‒
o
‒
itor but do
ons
itor but do
n 6.3.1
sio
6.3.1 for
on
for
dicated by
xte
dicated by
application and any e
havior qu
ext
havior qu
ou
n
ould be re
ny e
ld be re
rawn from
any
rawn from
nxiety and
nd a
nxiety and
subject w
and
subject w
mediately
n a
mediately
drawal by 
ion 
drawal by 
newly dia
catio
newly dia
erred, as a
plic
erred, as a
troenterolo
ppl
troenterolo
scontin
ap
scontin

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 40 of 136
In an attempt to prevent missing data during the study, efforts will be made to collect data from 
subjects who withdraw early from the study (NRC, 2010). If a subject withdraws from study 
treatment for any of the above criteria prior to Week 48, they will be asked to return for the study 
termination assessments as laid down at the Week 48/WD Visit and for the SFU Visit (20 weeks 
after final dose administration). All subjects who withdraw from the study due to an AE must be 
followed until resolution of the event or until the event is considered stable. All subjects who 
withdraw from the study due to development of a laboratory abnormality must be closely 
monitored. If a subject at any time has had an ALT and/or AST >5xULN, additional monitoring 
of hepatic markers will be performed every week or 2 weeks until resolution of the event, the 
event is considered stable, or they have reached the end of the SFU Period.
Investigators should attempt to obtain information on subjects in the case of withdrawal or 
discontinuation. For subjects considered as lost to follow up, the Investigator should make an 
effort (at least 1 phone call and 1 written message to the subject), and document his/her effort 
(date and summary of the phone call and copy of the written message in the source documents), 
to complete the final evaluation. All results of these evaluations and observations, together with a 
narrative description of the reason(s) for removing the subject, must be recorded in the source 
documents. The eCRF must document the primary reason for withdrawal or discontinuation.
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a subject in advance.
6.3.1
Potential drug-induced liver injury IMP discontinuation criteria
Subjects with potential drug-induced liver injury (PDILI) must be assessed to determine if IMP 
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary should also be discontinued. 
The PDILI criteria below require immediate discontinuation of IMP: 
Subjects with either of the following:

ALT or AST ≥5ULN

ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 

Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
Investigator. 

Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, 
fatigue, nausea, vomiting, right upper quadrant pain or tenderness).
Evaluation of PDILI must be initiated as described in Section 12.6.1. 
If subjects are unable to comply with the applicable monitoring schedule, IMP must be 
discontinued immediately.
PUBLIC COPY 
son
Y
son
whenev
OPY
whenev
liver inj
C CO
liver inj
ver injur
LIC
ver injur
l concom
BLI
l concom
lso be di
UB
lso be di
re imm
PU
re imm
This document cannot be used to support any marketing authorization 
oring
oriz
oring
t, the
tho
t, the
drawal or
g au
drawal or
should ma
ing 
should ma
ment his/h
eting
ment his/h
the sourc
ket
the sourc
observatio
ark
observatio
st be reco
ma
st be reco
withdrawal
y m
withdrawal
r possible
any
r possible
ury IMP 
por
ury IMP 
y (PDILI)
upp
y (PDILI)
mitant med
sup
mitant med
scontinued
to s
scontinued
mediate dis
ed t
mediate dis
ng:
us
ng:
N and coe
t be
N and coe
LT or AST
no
LT or AST
persensiti
ann
persensiti
rant pain 
can
rant pain 
ve cause),
nt c
ve cause),
ILI criteri
men
ILI criteri
stigato
ume
stigator.
m
r.
Subjec
ocu
Subjec
<2x
o
<2x
f
pplication and any extensions or variations thereof.
r r 
ake an
reo
ake an
/her effort
here
/her effort
ce docum
the
ce docum
ons, toget
ns t
ons, toget
orded in th
ons
orded in th
al or disco
atio
al or disco
e, to discu
aria
e, to discu
discont
or v
discont
) must be 
ns o
) must be 
dications 
ons
dications 
d. 
s
d. 
scontinua
tens
scontinua
existing to
d any
existing to
T ≥3xULN
nd 
T ≥3xULN
ivity. Hep
an
ivity. Hep
or tender
on a
or tender
), rash, or 
tion
), rash, or 
ion below
icat
ion below
ap
cts with A
app
cts with A
LN, an
ap
LN, an

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 41 of 136
Investigators should attempt to obtain information on subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study 
until investigation and monitoring are complete. All results of these evaluations and 
observations, as well as the reason(s) for IMP discontinuation and subject withdrawal (if 
applicable), must be recorded in the source documents. The eCRF must document the primary 
reason for IMP discontinuation.
6.4
Study stopping rules
During the study, planned dosing and procedures may be discontinued or suspended for all 
subjects in any part of the study and appropriate follow-up procedures established. Where it is 
possible to do so without threatening the safety of subjects, such discontinuation/suspension 
should be discussed with the UCB Study Physician prior to its implementation.
Possible reasons for discontinuation or suspension of the study include (but are not limited to):

A pattern of AEs occurs that contraindicates the further dosing of enrolled/additional 
subjects, including (but not limited to):

More than 1 subject meets any individual Withdrawal Criteria #5, #9, ro #10, or (as 
provided in Section 6.3), regardless of whether they met the same or different criteria.

Once a second subject meets any of those criteria, referral to the DMC may not be 
delayed while awaiting the outcome of either case.
If the above criteria are reached, the DMC will meet as soon as possible to determine whether 
discontinuation or suspension of the study should occur and to determine what investigations, 
analyses, procedural amendments, or other actions should occur, before making any 
recommendation regarding the possibility of recommencing the study. Further details on the role 
of the DMC are provided in Section 12.5. 

If the Sponsor or designees judges it necessary for medical, safety, regulatory, or any other 
reasons consistent with applicable laws, regulations, and Good Clinical Practice (GCP).
6.5
Retesting/rescreening
In the event of an isolated laboratory value outside the laboratory’s normal range, the evaluation 
may be repeated on 1 occasion during the Screening Period. If a value from the repeated test is 
within the screening-specified ranges, the subject maybe enrolled. 
Subjects whose Screening Period expires may be rescreened following discussion with the 
Sponsor.
Subjects who withdraw from the study may be replaced, up to a maximum of 10 subjects. 
BLIC COPY
dr
Y
dr
her they
PY 
her they
se criteri
OP
se criteri
of either 
CO
of either 
C will m
IC C
C will m
tudy 
BLIC
tudy sho
LIC
sho
PUB
or other
UBL
or other
possibili
PUB
possibili
ction
PU
ction
support any marketing authorization 
all
th
all
here it is
uth
here it is
uspension
au
uspension
are not li
eting
are not li
nrolled/ad
rke
nrolled/ad
riteria #
y m
riteria #5
m
5
met the sa
ny 
met the sa
a, referral 
rt a
a, referral 
case.
ort
case.
eet as soo
ppo
eet as soo
uld occur 
sup
uld occur 
t cannot be used to s
actions sh
o su
actions sh
y of recom
d to 
y of recom
2.5
d
2.5.
d
.
dges it ne
use
dges it ne
plicable la
e us
plicable la
g/rescre
t be
g/rescre
ated labor
not 
ated labor
n 1 occasio
nno
n 1 occasio
ning
ca
ning-
an
-spec
an
spec
ment
ose Scree
nt c
ose Scree
This docum
ects who w
ume
ects who w
ons or variations thereof.
n 
o
n 
imited to)
here
imited to)
dditional
s th
dditional
, #
ti
, #9
tio
9, ro
tio
, ro #
n
#
ame or dif
riati
ame or dif
to the DM
var
to the DM
on as poss
s o
on as poss
r and to de
ns 
r and to de
and any extensio
hould occ
ion
hould occ
mmencing
nsio
mmencing
ecessary f
ext
ecessary f
aws
y
aws, regu
y e
, regu
eening
any
eening
ratory val
nd a
ratory val
ion during
and
ion during
on 
cified rang
n a
cified rang
licatio
ening Peri
tion
ening Peri
appl
withdraw
plic
withdraw

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 42 of 136
7
STUDY TREATMENT(S)
7.1
Description of investigational medicinal product(s)
The IMPs used in this study are bimekizumab and CZP.
Bimekizumab will be supplied as a vial or in a pre-filled syringe (PFS) form as described below: 

Vial: a clear to opalescent, colorless to slightly brown, sterile, preservative-free solution in 
2mL Type I, colorless glass vials (1.0mL extractable volume) closed with a rubber stopper 
and sealed with an aluminum cap overseal. Each single-use dose vial will contain 160mg/mL 
bimekizumab in 
mM sodium acetate,
mM glycine, and 
 (w/v) polysorbate 80 at 
pH 

PFS: 1mL PFS at a concentration of 160mg/mL (
mM sodium acetate, 
mM glycine, 
 polysorbate 80 at pH 
) for sc injection.
Certolizumab pegol will be supplied as a sterile, clear, colorless-to-slightly yellow solution at 
pH
 in 1mL single-use glass PFS for sc injection. Each syringe contains an extractable volume 
of 1.0mL at a concentration of CZP 200mg/mL in 
mM sodium acetate buffer and 
mM 
sodium chloride as a tonicity agent. The syringes are stored at 2 to 8ºC, not frozen, and protected 
from light.
Placebo will be supplied as 0.9% sodium chloride aqueous solution (physiological saline, 
preservative free) of pharmacopoeia (United States Pharmacopoeia/European Pharmacopoeia) 
quality appropriate for injection.
Further details of the IMPs and their specifications are provided in the IMP Handling Manual.
7.2
Treatment(s) to be administered
The IMP is to be administered in the clinic by trained study site staff as 2 sc injections. Suitable 
areas for sc injections are the lateral abdominal wall and upper outer thigh. During each dosing 
visit, each of the 2 injections should be administered at a separate injection site. Injection sites 
should be rotated and injections should not be given into areas where the skin is tender, bruised, 
red, or hard.
The IMP (bimekizumab or CZP) will be administered at time points indicated in Table 5‒1.
At Baseline, eligible subjects will be randomized in a 2:1 ratio to the following bimekizumab or 
CZP treatment arms and will receive IMP as shown in Table 7‒1.
PUBLIC COPY 
store
Y
store
ride aqu
COP
ride aqu
d States 
C CO
d States 
r specific
BLI
r specific
to be a
PUB
to be a
n th
P
n th
y marketing authorization 
per 
ori
per 
60mg/mL 
thor
60mg/mL 
rbate 80 a
uth
rbate 80 a
mM gly
ing 
mM gly
htly yello
rke
htly yello
ontains an
mar
ontains an
m acetate b
ma
m acetate b
This document cannot be used to support any
2 to 8ºC, 
ny m
2 to 8ºC, 
ous soluti
ort a
ous soluti
Pharmaco
por
Pharmaco
ations are
sup
ations are
administ
d to 
administ
clinic by
ed 
clinic by
ral abdom
use
ral abdom
hould be a
e us
hould be a
ions s
be
ions shou
e 
hou
mab or CZ
nno
mab or CZ
gible subje
can
gible subje
t arms an
t ca
t arms an
in
tions thereof.
lycine,
reo
lycine,
ow solutio
s th
ow solutio
n extracta
ns 
n extracta
buffer and
tion
buffer and
application and any extensions or variat
, not froze
atio
, not froze
tion (phys
va
tion (phys
opoeia/Eu
or v
opoeia/Eu
e provided
ons
e provided
tered
nsio
tered
y trained s
xten
y trained s
minal wall
ext
minal wall
administe
y e
administe
uld not be
any 
uld not be
ZP) will b
and
ZP) will b
ects will b
n a
ects will b
nd will rec
ion 
nd will rec

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 43 of 136
Table 7‒1:
Treatments administered
IMP
Study period
Treatment Period 
Treatment Extension Period 
Bimekizumab
160mg sc Q2Wa
320mg sc Q4W
CZP
Loading doses of 400mg sc Q2W at Weeks 0, 2, 
and 4 followed by CZP 200mg sc Q2W
400mg sc Q4W
CZP=certolizumab pegol; IMP=investigational medicinal product, Q2W=every 2 weeks; Q4W=every 4 weeks; 
sc=subcutaneous
a In addition, subjects will receive 1 placebo injection at Baseline, Week 2, and Week 4 in order to maintain the 
blind vs the CZP loading dose at these visits.
The minimum time between doses should be no less than 10 days during the Treatment Period 
and no less than 22 days during the Treatment Extension Period. 
An IMP Handling Manual will be provided to each site containing instructions regarding drug 
preparation and dosing.
7.3
Packaging
Bimekizumab and CZP will be packaged and labeled according to Good Manufacturing Practice 
(GMP) guidelines and applicable laws or regulations. They will be suitably packaged in such a 
way as to protect the product from deterioration during transport and storage. Further 
information regarding storage and transport conditions are provided in the IMP Handling 
Manual.
7.4
Labeling
Clinical drug supplies will be labeled in accordance with the current International Council for 
Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and GMP and will include any 
locally required statements. If necessary, labels will be translated into the local language.
7.5
Handling and storage requirements
Investigational Medicinal Product must be stored under refrigerated conditions (2ºC to 8ºC) 
protected from light. The IMP must not be frozen.
The Investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
Investigational medicinal product stored by the Investigator is to be kept in a secured area with 
limited access according to the storage conditions mentioned on the label.
Appropriate storage conditions must be ensured either by controlling the temperature (eg, room, 
refrigeration unit) or by completion of a temperature log in accordance with local requirements 
on a regular basis (eg, once a week), showing actual and minimum/maximum temperatures 
reached over the time interval.
In case an out-of-range temperature is noted, it must be immediately reported as per instructions 
contained in the IMP Handling Manual.
PUBLIC COPY 
d labeled
CO
d labeled
regulatio
C C
regulatio
erioratio
LIC
erioratio
C
ransport 
BLI
ransport 
ment cannot be used to support any marketing authorization 
riz
4 weeks;
tho
4 weeks;
to maintain
au
to maintain
ho
g the Trea
ket
g the Trea
g instruct
ma
g instruct
according
ort 
according
ns. They w
ppo
ns. They w
during tr
upp
during tr
conditions
sup
conditions
eled in ac
use
eled in ac
es on Goo
e us
es on Goo
If necess
be 
If necess
ng and 
ot b
ng and 
dicinal Pr
nn
dicinal Pr
ight. The 
can
ight. The 
gator (or d
nt c
gator (or d
ational me
en
ational me
This docum
d access a
me
d access a
ppropriate
ocu
ppropriate
refrigera
doc
refrigera
on a r
s do
on a r
rea
s 
rea
ication and any extensions or variations thereof.
n the
f
n the
atment Pe
the
atment Pe
tions rega
tion
tions rega
g to Good
r va
g to Good
will be su
or 
will be su
ransport a
ns o
ransport a
s are prov
ions
s are prov
ccordance
ext
ccordance
od Clinica
y e
od Clinica
sary, labe
any
sary, labe
 storage
d a
 storage
roduct mu
and
roduct mu
e IMP mu
n a
e IMP mu
designee)
tion
designee)
edicinal p
cati
edicinal p
appli
according
plica
according
te storage 
app
te storage 
on unit
ap
on unit
ba
b

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 44 of 136
7.6
Drug accountability 
A Drug Accountability form will be used to record IMP dispensing and return information on a 
by-subject basis and will serve as source documentation during the course of the study. Details of 
any IMP lost, damaged (due to breakage or wastage), not used, partially used, disposed of at the 
study site, or returned to the sponsor or designee must also be recorded on the appropriate forms. 
All supplies and pharmacy documentation must be made available throughout the study for UCB 
(or designee) to review.
In order to maintain the blind, all IMP documentation (eg, shipping receipts, drug accountability 
logs, and interactive response technology [IRT] randomization materials) must be maintained 
and accessed by unblinded, trained site personnel only. Designated, unblinded site personnel 
must be appropriately trained and licensed (per country guidelines) to administer injections.
The packaging identifies each kit by a unique number. Unblinded study staff will be responsible 
for preparation (breaking tamper proof sticker on kit, etc) of the clinical trial material, including 
recording the administration information on source document.
The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of IMP until returned or destroyed.
The Investigator may assign some of the Investigator’s duties for drug accountability at the study 
site to an appropriate pharmacist/designee.
The Investigator must ensure that the IMP is used only in accordance with the protocol.
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers)/partially used, unused, damaged, and/or expired IMP must be reconciled and 
destroyed at the site according to local laws, regulations, and UCB standard operating procedures 
(SOPs). Investigational medicinal product intended for the study cannot be used for any other 
purpose than that described in this protocol.
7.7
Procedures for monitoring subject compliance
During theTreatment Period and the Treatment Extension Period, IMP will be administered in 
the clinic and compliance will be determined at the visit by study personnel. Drug accountability 
must be recorded on the Drug Accountability Form.
7.8
Concomitant medication(s)/treatment(s)
All concomitant medications, including over the counter products, herbal, traditional remedies, 
vitamin/mineral supplements, other dietary supplements, “nutraceuticals,” and hormones must be 
recorded in the subject’s source documentation (eg, clinical chart) and on the electronic Case 
Report Form (eCRF). This record should include the name of the drug, the dose, the route and 
date(s) of administration, and the indication for use.
The Investigator should examine the acceptability of all concomitant procedures, medications, 
topical preparations and dietary supplements not explicitly prohibited in this study, and if 
necessary, discuss with the Medical Monitor.
In order to ensure that appropriate concomitant therapy is administered, subjects will be 
instructed to consult with the Investigator prior to taking any medication (either 
PUBLIC COPY 
ator’s du
OPY
ator’s du
is us
C C
is used 
C
ed 
of the cli
BLIC
of the cli
damaged
UBL
damaged
o local la
PUB
o local la
nal pro
PU
nal pro
P
This document cannot be used to support any marketing authorization 
B
z
B
ntability 
thor
ntability 
intained 
uth
intained 
personne
au
personne
er injectio
ng a
er injectio
ff will
etin
ff will be 
ng
be 
trial mate
ket
trial mate
d, unused,
ma
d, unused,
ties for dr
t any
ties for dr
only in acc
ppo
only in acc
nical phas
supp
nical phas
, and/or e
o su
, and/or e
ws, regula
to 
ws, regula
duct inten
d to
duct inten
protocol.
sed
protocol.
for mon
e us
for mon
d and the
t be
d and the
ce will be
ot b
ce will be
the Drug 
no
the Drug 
oncomi
an
oncomi
tant medi
nt c
tant medi
mineral su
ent
mineral su
ed in the s
me
ed in the s
port Form 
cum
port Form 
date(s) of 
ocu
date(s) of 
The In
s do
The In
top
s 
top
application and any extensions or variations thereof.
el
of
el
ons.
eo
ons.
responsib
here
responsib
erial, inclu
the
erial, inclu
,
i
, and part
ion
and part
rug accou
aria
rug accou
ccordance
or 
ccordance
se of the s
ns 
se of the s
expired IM
ion
expired IM
ations, an
nsio
ations, an
nded for th
tens
nded for th
nitoring 
y ex
nitoring 
e Treatme
any
e Treatme
e determin
d a
e determin
Accounta
nd 
Accounta
itant
n a
itant me
a
me
ications, i
tion
ications, i
upplement
cati
upplement
subject’s 
lica
subject’s 
m (eCRF). 
ppli
m (eCRF). 
administr
app
administr
gato
a
gato

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 45 of 136
self-administered non-prescription drugs or prescription therapy prescribed by another 
physician).
7.8.1
Permitted concomitant treatments (medications and therapies)
The following concomitant medications are permitted during the study:
Subjects may use NSAIDs under the following conditions:

Subjects who are already receiving an established NSAID regimen and have been on a stable 
dose for at least 2 weeks prior to Baseline may continue their use during the study. However, 
initiation of, or increase in dosage of NSAIDs during the study (especially in subjects with a 
history of GI intolerance to NSAIDs or a history of GI ulceration) should be done with 
caution and must not occur until after the Week 12 Visit.
Subjects may use corticosteroids under the following conditions:

Oral (maximum allowed ≤10mg daily total prednisone equivalent)—subjects are permitted to 
decrease their oral corticosteroid therapy dose equivalent and/or alter their regimen only after 
Week 12.
Subjects may use MTX, sulfasalazine (SSZ), or hydroxychloroquine (HCQ) under the following 
conditions:

No change in dose or dose regimen of these agents is allowed during the study except for 
reasons of intolerance/AEs. No increase of the dose is permitted. No change is permitted in 
the route of administration for MTX (intramuscular [im], sc, or oral). It is strongly 
recommended that subjects taking MTX are also taking folic acid supplements. No 
combinations of DMARDs are permitted during the study.
7.8.2
Prohibited concomitant treatments (medications and therapies)
The following concomitant medications are prohibited during the study:
Table 7‒2:
Prohibited or restricted medications and required wash-out periods 
prior to Baseline
Drug class
Dose
Exclusion criteria
Analgesics, including opioid analgesics 
(acetaminophen/paracetamol, etc)
Any dose 
Any ad hoc use in the 24 hours prior to any 
study visit. 
Stable doses of analgesics permitted.
NSAIDs/COX-2 inhibitors
Any dose regimen
Any change in dose/dose regimen in the 
14 days prior to the Baseline Visit
Oral corticosteroids
Any dose regimen
Any change in dose/dose regimen in the 
14 days prior to the Baseline Visit
Intramuscular (im)/intravenous (iv)/
intra-articular (ia) corticosteroids/bursal 
corticosteroids 
Any dose 
Use in the 28 days prior to the Baseline 
Visit. 
PUBLIC COPY
roxych
PY 
roxych
se agent
CO
se agent
e of the 
C C
e of the 
X (intram
LIC 
X (intram
g MTX 
BLIC
g MTX 
e permit
UBL
e permit
ncom
PU
ncom
ent cannot be used to support any marketing authorization 
table
oriz
table
owever,
hor
owever,
ects with a
utho
ects with a
ne with 
aut
ne with 
subjects 
rke
subjects 
alter their
ark
alter their
roquine (H
ny 
roquine (H
 is allowe
ort 
 is allowe
dose is pe
po
dose is pe
uscular [im
upp
uscular [im
are also tak
sup
are also tak
ed during 
to s
ed during 
tant trea
d to
tant trea
ations are
sed
ations are
or restri
be u
or restri
Baseline
t be
Baseline
ot
ng opioid an
ann
ng opioid an
paracetamo
ca
paracetamo
nn
This documen
Ds/COX
me
Ds/COX-
e
-2 
e
2 
en
Oral cor
doc
Oral cor
oc
s d
s
cation and any extensions or variations thereof.
s are perm
the
s are perm
r regimen
ns t
r regimen
HCQ) und
iatio
HCQ) und
ed during
r va
ed during
ermitted. N
or 
ermitted. N
im], sc, or
s o
im], sc, or
aking folic
ons
aking folic
g the study
sion
g the study
atments 
ens
atments 
e prohibite
exte
e prohibite
ricted me
ny e
ricted me
e
Do
Do
d a
d
nalgesics
an
nalgesics
ol, etc)
on
ol, etc)
an
applica
inhibitors
lica
inhibitors
ca
osteroid
ap
osteroid
ap

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 46 of 136
Table 7‒2:
Prohibited or restricted medications and required wash-out periods 
prior to Baseline
Drug class
Dose
Exclusion criteria
Intra-articular hyaluronic acid 
Any dose 
Any use in the 6 months prior to the 
Baseline Visit. 
DMARDs:
-azathioprine
-cyclosporine,
-cyclophosphamide,
-mycophenolic acid,
-mycophenylate mofetil
-any other small molecule DMARDs 
(eg tofacitinib, apremilast)
Any dose
Use within 12 weeks prior to the Baseline 
Visit.
MTX, SSZ, and HCQ
Maximum allowed: 
SSZ ≤3g daily 
HCQ ≤400mg daily 
MTX ≤25mg weekly
Use initiated and/or any change in the dose 
regimen in the 28 days prior to the Baseline 
Visit. No change is permitted in the route of 
administration for MTX (im, sc, or oral) in 
the 28 days prior to the Baseline Visit.
DMARDs:
-leflunomide 
Any dose 
Use in the 6 months prior to the Baseline 
Visit unless a cholestyramine washout has 
been performed; in which case, use up to 
28 days prior to the Baseline Visit is 
acceptable. 
TNF inhibitors
-infliximab (IFX)
-adalimumab (ADA)
-etanercept (ETN)
-golimumab (GOL)
-certolizumab pegol (CZP)
Any dose
For IFX, ADA, and GOL, any use within 
the 12 weeks prior to the Baseline Visit
For ETN, use within the 28 days prior to 
the Baseline Visit.
For CZP, any previous use
This applies to biosimilar versions of any 
TNF inhibitors.
Any non-TNF biologic medications
Any dose
Any exposure history.
ADA=adalimumab; ia=intra-articular; COX-2=cyclooxygenase 2; CZP=certolizumab pegol; 
DMARD=disease-modifying antirheumatic drug; ETN=etanercept; GOL=golimumab; 
HCQ=hydroxychloroquine; IFX=infliximab; im=intramuscular; iv=intravenous; MTX=methotrexate; 
NSAID=nonsteroidal anti-inflammatory drug; sc=subcutaneous; SSZ=sulfasalazine; TNF=tumor necrosis factor 
Subjects who are receiving an established antidepressant regimen should be on a stable dose of 
anti-depressant for 12 weeks prior to Baseline.
PUBLIC COPY 
PY
Any dos
BLI
Any dos
LIC
U
not be used to support any marketing authorization 
za
ne
ri
ne
za
za
za
nd/or any c
rke
nd/or any c
the 28 days
ark
the 28 days
 change is 
mar
 change is 
istration fo
m
istration fo
28 days pr
ny m
28 days pr
et
Use in the
any
Use in the
Visit u
rt a
Visit u
been
rt
been
2
ny
ort
up
us
anno
ic medicati
ann
ic medicati
no
cument can
ab; ia=intra
ca
ab; ia=intra
sease
t c
sease-
t c
-modi
c
modi
droxychloro
ent 
droxychloro
=nonstero
men
=nonstero
This do
an
Subjects w
doc
Subjects w
anti
do
anti-de
o
de
and any extensions or variations thereof.
change in th
the
change in th
s prior to th
s t
s prior to th
permitted i
ons
permitted i
or MTX (im
tion
or MTX (im
rior to the B
atio
rior to the B
he
e 6 months
aria
e 6 months
unless a cho
var
unless a cho
n performe
r v
n performe
8 days p
or 
days prio
rio
acceptab
s o
acceptab
ia
For 
ns
For 
thth
ns
d
on
ions
a
ions
nd
pplication a
-articular;
n a
articular;
ifying antir
tion
ifying antir
oquine; IFX
atio
oquine; IFX
idal anti
cat
idal anti-in
t
in
ap
a
who are r
app
who are r
sant
a
sant

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 47 of 136
Subjects who take prohibited medications, except topical therapies, may be withdrawn from 
study treatment, but followed until the Safety Follow-Up Visit (20 weeks after the final dose of 
IMP). The decision to withdraw a subject for taking prohibited medications should be made in 
consultation with the Medical Monitor. As noted above, subjects who use prohibited topical 
medications will be allowed to stay in the study but will be counseled to not use them further.
Vaccines
Administration of live, attenuated vaccines is not allowed during the conduct of the study or for 
20 weeks after the final dose of study drug. Subjects receiving BCG vaccinations within 
12 months prior to study drug administration are excluded (see Exclusion Criterion #25,
Section 6.2).
7.8.3
Rescue medication
There are no absolute restrictions on the use of concomitant medications to “rescue” subjects 
whose AS deteriorates during the course of the study. While the objectives of the study should be 
protected as much as possible through observance of the restrictions detailed in Table 7‒2, the 
wellbeing of the subject will always take priority, and subjects should be managed as deemed 
appropriate by the Investigator. If use of any prohibited medications is anticipated, this should be 
discussed with the Sponsor's Study Physician first, wherever possible.
7.9
Blinding
Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in order to maintain the blind vs the 
CZP loading dose at these visits. 
Investigational medicinal product injections will be prepared at the investigational sites by 
unblinded, dedicated study personnel. The unblinded personnel will not be involved in the study 
in any way other than assuring the medication is taken from the correct kit and prepared 
according to the pharmacy manual instructions, and administering the drug to the subjects.
During the study, the Sponsor will provide blinded and unblinded site monitors for the purposes 
of verifying safety, efficacy, and study drug administration and documentation records. Blinded 
study monitors and study site personnel, blinded to treatment assignment, will not discuss or 
have access to any study drug-related information.
Further details are provided in the study manuals and site blinding plan. 
7.9.1
Procedures for maintaining and breaking the treatment blind
The IMP handling manual describes the handling of bimekizumab and CZP. Appropriate training 
will be given to the site personnel to avoid any unblinding. In case the Investigator becomes 
unblinded for any subject, another assessor will perform the remaining evaluations for that 
subject.
PUBLIC COPY
ed m
Y
ed m
wherev
PY 
wherev
MPs (bim
C C
MPs (bim
ects rand
LIC 
ects rand
and We
BLI
and We
uct inje
PU
uct inje
P
ot be used to support any marketing authorization 
r
o
r for 
riz
for 
5
u
5,
ut
,
o “rescue”
ketin
o “rescue”
ves of
rke
ves of the
e
the
detailed i
mark
detailed i
ould be m
ma
ould be m
ations is a
y m
ations is a
r possible
any
r possible
mekizumab
ppo
mekizumab
omized to
upp
omized to
ek 4 (Visit
sup
ek 4 (Visit
ctions wil
d to
ctions wil
el. The un
sed
el. The un
he medica
use
he medica
anual inst
be u
anual inst
onsor will 
t be
onsor will 
This document canno
ficacy, and
not 
ficacy, and
study site
nno
study site
ny study d
can
ny study d
ils are pro
nt c
ils are pro
Pr
n
Pr
IMP hand
um
IMP hand
will be giv
ocu
will be giv
unblind
doc
unblind
subje
s d
subje
d any extensions or variations thereof.
” subjects
her
” subjects
e study sh
th
e study sh
in
n
in Table
ns t
Table 7
managed a
ions
managed a
anticipate
atio
anticipate
e.e.
ab and CZ
or 
ab and CZ
o bimekiz
ns o
o bimekiz
it 4) in ord
ons
it 4) in ord
ll be prep
tens
ll be prep
nblinded 
xte
nblinded 
ation is ta
ex
ation is ta
tructions, 
ny e
tructions, 
l provide b
any
l provide b
application and
nd study d
nd a
nd study d
e personn
and
e personn
drug
n a
drug-
a
-relat
a
relat
ovided in 
tion
ovided in 
rocedure
icat
rocedure
ndling man
pplic
ndling man
ven to the
app
ven to the
for an
ap
for an

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 48 of 136
All Sponsor and Investigator site personnel involved in the study will be blinded to the 
randomized IMP (bimekizumab or CZP) assignment with the following exceptions:

Sponsor Clinical Study Supplies manager and qualified personnel

Sponsor Patient Safety (PS) staff reporting SAEs to the regulatory authorities

Site pharmacist involved in IMP preparation and dispensing

Unblinded monitor who reviews the IMP related documentation and drug accountability

Bioanalytical staff analyzing blood samples for PK and immunogenicity, and biomarkers

Any Sponsor staff and/or designee who is responsible for data analyses for the unblinded 
DMC and interim analyses. These individuals will be separate from the main blinded study 
team.

Unblinded team at PAREXEL for the purpose of sending unblinded output for the planned 
interim analyses
If necessary, the results of any planned analysis may be shared with key Sponsor’s personnel in 
order to facilitate additional Clinical Planning or Portfolio Management decisions. Only 
unblinded summary results will be provided, and individual subject data will be kept blinded. All 
individuals seeing unblinded summary data will be documented in the Trial Master File (TMF).
7.9.1.1
Maintenance of study treatment blind
All subject treatment details (bimekizumab or CZP) will be allocated and maintained by the 
interactive response technology (IRT) system.
7.9.1.2
Breaking the treatment blind in an emergency situation
In the event of an emergency, it will be possible to determine to which treatment arm and dose 
the subject has been allocated by contacting the IRT. All sites will be provided with details of 
how to contact the system for code breaking at the start of the study. The Medical Monitor or 
equivalent should be consulted prior to unblinding, whenever possible.
The Exploratory Project Manager (EPM) will be informed immediately via the IRT when a code 
is broken, but will remain blinded to specific treatment information. Any unblinding of the IMP 
performed by the Investigator must be recorded in the source documents and on the Study 
Termination eCRF page.
7.10
Randomization and numbering of subjects
An IRT will be used for assigning eligible subjects to a treatment regimen (as applicable) based 
on a predetermined production randomization and/or packaging schedule provided by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. To enroll a subject at Visit 1, the Investigator or designee will contact the IRT and 
provide brief details about the subject to be enrolled. Each subject will receive a 5-digit number 
assigned at screening that serves as the subject identifier throughout the study. The subject 
number will be required in all communication between the Investigator or designee and the IRT 
regarding a particular subject. Subject numbers and kit numbers will be tracked via the IRT. 
PUBLIC COPY
folio
Y
folio
ndividua
PY 
ndividua
l be docu
OP
l be docu
eatmen
C CO
eatmen
mab or C
LIC 
mab or C
T) system
BLI
T) system
reatmen
PUB
reatmen
will
P
will
ment cannot be used to support any marketing authorization 
y
o
y
arkers
tho
arkers
unblinded
au
unblinded
n blinded 
g a
n blinded 
output for
ket
output for
ith key Sp
ma
ith key Sp
nagement
ny m
nagement
 subject d
any
 subject d
mented in
rt a
mented in
 blind
port
 blind
ZP) will b
upp
ZP) will b
t blind in
to s
t blind in
be possibl
ed 
be possibl
contacting
sed
contacting
ode break
us
ode break
ted prior t
be u
ted prior t
Manager
ot b
Manager
main blind
not
main blind
Investigat
ann
Investigat
CRF page.
can
CRF page.
Rand
nt c
Rand
T will be u
me
T will be u
This docu
a predeterm
um
a predeterm
designee). 
ocu
designee). 
genera
do
generat
c
t
sche
s d
sche
pr
s
pr
lication and any extensions or variations thereof.
d 
f
d 
d study 
eof
d study 
r the plan
the
r the plan
ponsor’s p
ion
ponsor’s p
t decision
atio
t decision
data will b
riat
data will b
n the Tria
var
n the Tria
be allocat
s o
be allocat
n an em
nsio
n an em
ble to dete
ten
ble to dete
g the IRT
exte
g the IRT
king at the
y ex
king at the
to unblind
ny 
to unblind
r (EPM) w
d an
r (EPM) w
nded to sp
nd 
nded to sp
tor must b
an
tor must b
o
domiza
atio
domiza
used for 
lica
used for 
app
rmined pr
pplic
rmined pr
. The rand
app
The rand
ndividu
ap
ndividu

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 49 of 136
To randomize a subject at Visit 2, the Investigator or designee will contact the IRT and provide 
brief details about the subject to be randomized. The IRT will automatically inform the 
Investigator or designee of the subject’s randomization number. The IRT will allocate kit 
numbers to the subject based on the subject number during the course of the study. The 
randomization number must be incorporated into the eCRF.
8
STUDY PROCEDURES BY VISIT 
The schedule of study assessments (Table 5‒1) provides a general overview of study 
assessments. A list of procedures to be completed at each visit is described below.

Visit windows of ±3 days on either side of the scheduled dosing are permitted; however, the 
Investigator should try to keep the subjects on the original dosing schedule. The window of 
±3 days is relative to Baseline and applicable for all subsequent visits. Changes to the dosing 
schedule outside of the 3-day window must be discussed with the Medical Monitor.

For the SFU Visit (20 weeks after the final dose of IMP), the visit should occur no more than 
3 days prior to the scheduled visit date and within 7 days after the scheduled visit date 
(-3 days to +7 days).
8.1
Screening Visit (Visit 1)
Prior to any study specific activities, subjects will be asked to read, sign, and date an ICF that has 
been approved by the Sponsor and an IEC/IRB, and that complies with regulatory requirements. 
Subjects will be given adequate time to consider any information concerning the study given to 
them by the Investigator or designee. As part of the informed consent procedure, subjects will be 
given the opportunity to ask the Investigator any questions regarding potential risks and benefits 
of participation in the study.
Two additional ICFs for substudies will be required:

Where local regulations permit, subjects will also be given the option to participate in the 
pharmacogenetic and pharmacogenomic substudy. Subjects agreeing to participate in the 
substudy will be required to complete a separate ICF. The ICF must be signed prior to 
collecting any samples for the substudy. The substudy will only be conducted where ethically 
accepted and authorized by the regulatory agencies. Refusal to participate in the substudy 
will not affect a subject’s ability to participate in the main AS0013 study.

Subjects will also be given the option to participate in the PET-MRI or PET-CT substudy at 
selected sites. Subjects who decide to participate in the substudy will need to complete a 
separate ICF following the same procedure and given the same considerations as the main 
ICF. Their willingness to participate in the substudy will be independent from their consent 
to participate in the main AS0013 study.
The following procedures or assessments will be performed at the Screening Visit:

Obtain written informed consent. 

Collect demographic and Baseline characteristics data (including lifestyle and child bearing 
potential as applicable).

Collect AS history. 
PUBLIC COPY 
will be as
COP
will be as
RB, and 
CO
RB, and 
onsider a
C C
onsider a
As part o
LIC
As part o
e
B
estigator
BL
stigator
dies w
PU
dies w
ment cannot be used to support any marketing authorization 
however, t
aut
however, t
The windo
g a
The windo
anges to th
ing 
anges to th
cal Monit
eting
cal Monit
should oc
rke
should oc
he schedu
mar
he schedu
ked to read
rt a
ked to read
hat compl
ort
hat compl
ny inform
ppo
ny inform
f the infor
upp
f the infor
any quest
sup
any quest
will be requ
ed t
will be requ
it, subject
use
it, subject
macogeno
e us
macogeno
ed to comp
be 
ed to comp
es for the
ot b
es for the
orized by
not
orized by
a subject’
ann
a subject’
will also be
t ca
will also be
d sites. Su
nt c
d sites. Su
rate ICF f
men
rate ICF f
This docum
CF. Their 
ume
CF. Their 
to partic
cum
to partic
The foll
doc
The foll

s 

ication and any extensions or variations thereof.
the
f
the
ow of 
of
ow of 
the dosing
reo
the dosing
itor.
he
itor.
ccur no m
s th
ccur no m
uled visit 
ns 
uled visit 
ad, sign, an
var
ad, sign, an
plies with
r v
plies with
mation con
or
mation con
rmed cons
ns o
rmed cons
stions rega
ions
stions rega
quired:
ten
quired:
cts will als
ext
cts will als
omic sub
y e
omic sub
mplete a se
any
mplete a se
e substudy
d an
e substudy
y the regu
nd 
y the regu
’s ability 
an
’s ability 
e given th
on 
e given th
ubjects wh
atio
ubjects wh
following
cat
following
appli
willingne
plic
willingne
cipate in t
ppl
cipate in t
wing pr
ap
wing pr

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 50 of 136

Assess if all inclusion criteria and no exclusion criteria are met.

Collect significant past medical history and concomitant diseases.

Record prior and concomitant medications. 

Assess adverse events.

C-SSRS.

HADS.

Determine the BASDAI. 

Determine the Bath Ankylosing Spondylitis Functional Index (BASFI).

Total and nocturnal spinal pain (NRS).

Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB, weight and height.

Measure vital signs (temperature, pulse, and blood pressure).

Perform a 12-lead ECG.

Administer the tuberculosis questionnaire.

Perform an IGRA tuberculosis test (QuantiFERON TB test).

Perform a serum pregnancy test.

Collect samples for hematology/biochemistry/urinalysis.

Collect samples for hs-CRP.

Collect samples for HIV, hepatitis B and C, and HLA-B27 serology. 

Perform a sacroiliac joint X-ray (if subjects have a previous X-ray documenting AS meeting 
eligibility criteria, they are eligible for study entry after reconfirming their eligibility by 
central reading. If no X-ray is available one must be performed at the Screening Visit. If the 
previous X-ray is more than 1 year old, and central read criteria for randomization are not 
met, another X-ray may be performed if permitted by local guidelines).

Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 
2 weeks prior to Baseline.

Obtain a chest radiograph or computer tomography (CT) scan, unless one has been obtained 
within 3 months prior to the Screening Visit.

Register the subject using the interactive response technology (IRT).
Individual screening tests for which the results are borderline for inclusion in the study may be 
repeated if necessary without complete rescreening of all tests.
PUBLIC COPY 
antiFER
C CO
antiFER
y/bioche
UBL
y/bioche
P.
P
P.
P
t cannot be used to support any marketing authorization 
d sympto
ket
d sympto
ON TB tes
por
ON TB tes
mistry/urin
o su
mistry/urin
itis B and
sed
itis B and
e
-ray (if s
e us
ray (if s
are eligibl
be 
are eligibl
X
ot
X-
t
-ray is a
ot b
ray is a
more than
not 
more than
ray may b
nno
ray may b
PET
c
PET-
ca
-
This document
MRI
ca
MRI
prior to B
nt c
prior to B
ain a ches
men
ain a ches
within 3 m
um
within 3 m
Regist
ocu
Regist
Indivi
s do
Indivi
rep
s 
rep
n and any extensions or variations thereof.
oms of act
the
oms of act
st).
or
st).
inalysis.
ion
inalysis.
d C, and H
xte
d C, and H
subjects h
y ex
subjects h
le for stud
ny 
le for stud
available
d an
available
n 1 year o
nd a
n 1 year o
be perfor
and
be perfor
application
I or PET
on a
I or PET
Baseline.
tion
Baseline.
st radiogr
ica
st radiogr
months pr
plic
months pr
ter the su
app
er the su
cre
a

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 51 of 136
8.2
Baseline (Visit 2, Week 0)
The following procedures or assessments will be performed/recorded prior to administration of 
the IMP:

Verify if all inclusion criteria and no exclusion criteria are met.

Verify significant past medical history and concomitant diseases.

Record prior and concomitant medications. 

Assess adverse events.

C-SSRS.

HADS.

Determine the BASDAI. 

Determine the BASFI.

Perform the Patient’s Global Assessment of Disease Activity (PGADA).

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
then at 30 minutes and 1 hour after dosing.

Perform a 12-lead ECG.

Perform a urine pregnancy test.

Collect samples for: 

Hematology/biochemistry/urinalysis.

Bimekizumab and CZP plasma concentrations.

Anti-bimekizumab and anti-CZP antibody detection.

hs-CRP.

If the respective ICF has been provided collect blood samples for: 

Cytokines, complement, and biomarker analyses 

Pharmacogenetic variables.

Nonhereditary pharmacogenomic variables.

Collect urine samples for biomarker research if the respective ICF has been provided.

Contact the IRT for randomization.

Administer IMP after all other visit assessments are completed.

Record visit in the IRT.
PUBLIC COPY 
 and blo
C CO
 and blo
osing.
IC C
osing.
est.
PU
est.
ment cannot be used to support any marketing authorization 
(PGADA
ma
(PGADA
od pressur
por
od pressur
y/urinalys
use
y/urinalys
ZP plasm
be 
ZP plasm
ab and an
ot b
ab and an
ctive ICF
ca
ctive ICF
tokines, c
ent 
tokines, c
This docume
Pharmac
me
Pharmac

c

Non
um
Non

d

Col
o
Col

s 

cation and any extensions or variations thereof.
A).
io
A).
re) prior t
or v
re) prior t
ysis.
e
ysis.
ma concen
ny 
ma concen
nti
d
nti-
d
-CZP a
d a
CZP a
F has been
on a
F has been
compleme
atio
compleme
applic
cogenetic
lica
cogenetic
nhereditar
pp
nhereditar
t urine
ap
t urine

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 52 of 136
8.3
Week 2 (Visit 3)
The following procedures or assessments will be performed/recorded:

Record concomitant medications. 

Assess adverse events.

C-SSRS.

Determine the BASDAI. 

Determine the BASFI.

Perform the PGADA.

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Measure vital signs (temperature, pulse, and blood pressure).

Collect samples for hematology/biochemistry/urinalysis.

Administer IMP.

Record visit in the IRT.
8.4
Week 4 (Visit 4)

Record concomitant medications. 

Assess adverse events.

C-SSRS.

HADS.

Determine the BASDAI. 

Determine the BASFI.

Perform the PGADA.

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Measure vital signs (temperature, pulse, and blood pressure).

Perform a 12-lead ECG.

Perform a urine pregnancy test.
PUBLIC COPY 
y
Y
y
B
ent cannot be used to support any marketing authorization 
FI.
o
FI.
ADA.
nno
ADA.
PhGADA
can
PhGADA
nd noctur
nt 
nd noctur
This docum
easure vita
me
easure vita
Perform
cum
Perform

d

Perf
oc
Perf
cation and any extensions or variations thereof.
A.
n
A.
rnal spina
atio
rnal spina
applic
tal signs (t
lica
tal signs (t
m a 12
ppl
m a 12-
pp
-lea
pl
lea
m a 
ap
m a ur
ap
ur

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 53 of 136

Collect samples for:

Hematology/biochemistry/urinalysis.

Bimekizumab and CZP plasma concentrations.

Anti-bimekizumab and anti-CZP antibody detection.

hs-CRP.

If the respective ICF has been provided collect blood samples for:

Cytokines, complement, and biomarker analyses.

Nonhereditary pharmacogenomic variables.

Collect urine samples for biomarker research if the respective ICF has been provided.

Administer IMP.

Record visit in the IRT.
8.5
Week 6 (Visit 5)

Record concomitant medications. 

Assess adverse events.

C-SSRS.

Determine the BASDAI. 

Determine the BASFI.

Perform the PGADA.

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Measure vital signs (temperature, pulse, and blood pressure).

Collect samples for hematology/biochemistry/urinalysis.

Administer IMP.

Record visit in the IRT.
8.6
Week 8 (Visit 6)

Record concomitant medications. 

Assess adverse events.

C-SSRS.

HADS.

Determine the BASDAI. 

Determine the BASFI.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
en provid
ting
en provid
al pain (N
be 
al pain (N
(temperat
ot b
(temperat
for hema
nno
for hema
IMP.
ca
IMP.
visit in th
nt 
visit in th
Record
ocu
Record

d

As
o
As

s

pplication and any extensions or variations thereof.
ded.
er
ded.
NRS).
ny
NRS).
ture, puls
d a
ture, puls
atology/b
and
atology/b
he IRT.
atio
he IRT.
Week 8
plic
Week 8
ap
d concom
app
d concom
adv
a
adv

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 54 of 136

Perform the PGADA.

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Measure vital signs (temperature, pulse, and blood pressure).

Perform a 12-lead ECG.

Perform a urine pregnancy test.

Collect samples for: 

Hematology/biochemistry/urinalysis.

hs-CRP.

Administer IMP.

Record visit in the IRT.
8.7
Week 10 (Visit 7)

Record concomitant medications. 

Assess adverse events.

C-SSRS.

Determine the BASDAI. 

Determine the BASFI.

Perform the PGADA.

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Measure vital signs (temperature, pulse, and blood pressure).

Collect samples for hematology/biochemistry/urinalysis.

Administer IMP.

Record visit in the IRT.
8.8
Week 12 (Visit 8)

Record concomitant medications. 

Assess adverse events.

C-SSRS.

HADS.

Determine the BASDAI. 

Determine the BASFI.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
al pain (N
be 
al pain (N
(temperat
ot b
(temperat
for hema
nno
for hema
IMP.
ca
IMP.
visit in th
nt 
visit in th
Record
ocu
Record

d

As
o
As

s

application and any extensions or variations thereof.
NRS).
ny
NRS).
ture, puls
d a
ture, puls
atology/b
and
atology/b
he IRT.
atio
he IRT.
Week 1
plic
Week 1
d concom
app
d concom
adv
a
adv

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 55 of 136

Perform the PGADA.

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB and weight.

Measure vital signs (temperature, pulse, and blood pressure).

Perform a 12-lead ECG.

Administer the tuberculosis questionnaire.

Perform a urine pregnancy test.

Collect samples for:

Hematology/biochemistry/urinalysis.

Bimekizumab and CZP plasma concentrations.

Anti-bimekizumab and anti-CZP antibody detection.

hs-CRP.

If the respective ICF has been provided collect blood samples for:

Cytokines, complement, and biomarker analyses.

Pharmacogenetic variables.

Nonhereditary pharmacogenomic variables.

Collect urine samples for biomarker research if the respective ICF has been provided.

Perform a PET-MRI or PET-CT scan in at least 25 subjects at selected sites within 2 weeks 
after Week 12 Visit if PET-positive lesions were observed in the previous scan.

Administer IMP.

Record visit in the IRT.
8.9
Week 16 (Visit 9), Week 20 (Visit 10), Week 28 (Visit 12), Week 32 
(Visit 13), Week 40 (Visit 15), and Week 44 (Visit 16)

Record concomitant medications. 

Assess adverse events.

C-SSRS.

HADS.

Determine the BASDAI. 

Determine the BASFI.

Perform the PGADA.
PUBLIC COPY
etection
PY 
etection
collect b
C CO
collect b
omarker 
LIC
omarker 
ogenom
PU
ogenom
P
ument cannot be used to support any marketing authorization 
lood samp
por
lood samp
analyses.
upp
analyses.
ic variable
d to
ic variable
arker rese
sed
arker rese
T-CT scan
e us
CT scan
ET
b
ET-
be
-positiv
be 
positiv
he IRT.
nno
he IRT.
Week 1
t ca
Week 1
(Vis
nt 
(Vis
cord conc
me
cord conc
This docu
Assess 
cu
Assess 

d

C
o
C-S

s

plication and any extensions or variations thereof.
mples for:
or v
mples for:
les.
en
les.
earch if th
xte
earch if th
an in at lea
y ex
an in at lea
ive lesion
ny 
ive lesion
16 (Visi
ion 
16 (Visi
sit 13), W
atio
sit 13), W
comitant 
lica
comitant 
app
adverse e
pp
adverse e
S.
a
S.

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 56 of 136

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Measure vital signs (temperature, pulse, and blood pressure).

Perform a 12-lead ECG.

Blood sample for hs-CRP.

Perform a urine pregnancy test.

Administer IMP.

Record visit in the IRT.
8.10
Week 24 (Visit 11) and Week 36 (Visit 14)

Record prior and concomitant medications. 

Assess adverse events.

C-SSRS.

HADS.

Determine the BASDAI. 

Determine the BASFI.

Perform the PGADA.

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB.

Measure vital signs (temperature, pulse, and blood pressure).

Perform a 12-lead ECG.

Administer the tuberculosis questionnaire.

Perform a urine pregnancy test.

Collect samples for:

Hematology/biochemistry/urinalysis.

Bimekizumab and CZP plasma concentrations.

Anti-bimekizumab and anti-CZP antibody detection.

hs-CRP.
PUBLIC COPY 
ain (
P
ain (
ent cannot be used to support any marketing authorization 
NRS).
ed
NRS).
ion, inclu
use
ion, inclu
to TB.
be u
to TB.
emperatu
t be
emperatu
d ECG.
no
d ECG.
he tubercu
can
he tubercu
a urine pr
nt c
a urine pr
This docume
ect sampl
men
ect sampl

Hema
um
Hema

oc

B
application and any extensions or variations thereof.
uding an e
ex
uding an e
ure, pulse,
d any
ure, pulse,
ulosis que
n a
ulosis que
pregnancy
tion
pregnancy
les for:
icat
les for:
atolo
pli
atology/b
pli
gy/b
a
mekizum
ap
mekizum

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 57 of 136

If the respective ICF has been provided collect blood samples for:

Cytokines, complement, and biomarker analyses.

Administer IMP.

Record visit in the IRT.
8.11
Week 48 (Visit 17)/Early Withdrawal Visit

Record prior and concomitant medications. 

Assess adverse events.

C-SSRS.

HADS.

Determine the BASDAI. 

Determine the BASFI.

Perform the PGADA.

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Measure vital signs (temperature, pulse, and blood pressure).

Perform a 12-lead ECG.

Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB and weight.

Perform a 12-lead ECG.

Administer the tuberculosis questionnaire.

Perform an IGRA tuberculosis test (QuantiFERON TB test).

Perform a urine pregnancy test.

Collect samples for:

Hematology/biochemistry/urinalysis.

Bimekizumab and CZP plasma concentrations.

Anti-bimekizumab and anti-CZP antibody detection.

hs-CRP.

If the respective ICF has been provided collect blood samples for:

Cytokines, complement, and biomarker analyses.

Pharmacogenetic variables.

Nonhereditary pharmacogenomic variables.
PUBLIC COPY 
lse, and b
IC C
lse, and b
tion, incl
PUB
tion, incl
 TB an
PU
 TB an
This document cannot be used to support any marketing authorization 
lood pres
ppo
lood pres
uding an e
to 
uding an e
d weight.
ed t
d weight.
is questio
be u
is questio
berculosis 
t be
berculosis 
pregnancy
no
pregnancy
ples for:
can
ples for:
atology/b
nt c
atology/b
Bimekizu
men
Bimekizu

Anti
um
Anti b

oc

h

s d

I
application and any extensions or variations thereof.
ssure).
s or
ssure).
evaluation
nsio
evaluation
t
onnaire.
ny e
onnaire.
s test (Qua
d any
s test (Qua
y test.
nd
y test.
biochemis
tion
biochemis
umab and 
icat
umab and 
bimekizu
pli
bimekizu
ap
-CRP.
ap
CRP.

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 58 of 136

Collect urine samples for biomarker research if the respective ICF has been provided.

Obtain a X-ray or CT scan of the chest if the QuantiFERON TB test returned a positive 
result. 

Perform a PET-MRI or PET-CT scan in at least 25 subjects at selected sites within 2 weeks 
after the Week 48/WD Visit if PET-positive lesions were observed in the previous scan. At 
the WD Visit, the PET-MRI or PET-CT must be done only, if the previous imaging 
evaluation occurred more than 12 weeks ago and if PET-positive lesions were observed in 
the previous scan.

Record visit in the IRT.
8.12
Safety Follow-Up Visit (Week 64, Visit 18, 20 weeks after the 
final dose of IMP)

Record concomitant medications. 

Assess adverse events.

Measure vital signs (temperature, pulse, and blood pressure).

Perform a 12-lead ECG.

Administer the tuberculosis questionnaire.

Perform a urine pregnancy test.

Collect samples for:

Hematology/biochemistry/urinalysis.

Bimekizumab and CZP plasma concentrations.

Anti-bimekizumab and anti-CZP antibody detection.

hs-CRP.

If the respective ICF has been provided collect blood samples for:

Cytokines, complement, and biomarker analyses.

Nonhereditary pharmacogenomic variables.

Record visit in the IRT.
8.13
Early Withdrawal Visit
Subjects withdrawing early from the study (see Section 6.3) should undergo the same 
assessments scheduled for the Week 48 Visit (see Section 8.11) as soon as possible after 
withdrawal (as an Early Withdrawal Visit) and then enter the SFU Period, completing study 
participation with the SFU Visit 20 weeks after their final dose of study medication.
8.14
Unscheduled Visit
At the Investigator’s discretion, an Unscheduled Visit may be completed at any time during the 
study but prior to the SFU Visit, if deemed necessary for the subject’s safety and well-being. 
PUBLIC COPY 
d pre
Y
d pre
e.
C
e.
ry/urinal
PUB
ry/urinal
las
P
las
nt cannot be used to support any marketing authorization 
d in
or
d in
ks after 
ing 
ks after 
e).
ny
e).
ysis.
d to
ysis.
ma concen
ed 
ma concen
nti
u
nti-
u
-CZP a
us
CZP a
F has been
ot b
F has been
compleme
nn
compleme
reditary ph
t ca
reditary ph
This documen
visit in t
ent 
visit in t
Subjects w
ocu
Subjects w
assessm
do
assessm
with
s d
with
p
s
p
ation and any extensions or variations thereof.
the 
reo
the 
ntrations.
xten
ntrations.
antibody 
ex
antibody 
en pr
d
en provide
d a
ovide
ment, and b
and
ment, and b
pharmacog
on a
pharmacog
applicat
he IRT.
atio
he IRT.
Early W
plic
Early W
withdrawi
app
withdrawi
ts sch
ap
ts sch

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 59 of 136
If an Unscheduled Visit is conducted due to safety or efficacy reasons, a C-SSRS assessment will 
be performed with the subject during the visit. If an Unscheduled Visit is conducted for reasons 
other than safety or efficacy concerns (eg, repeated collection of a laboratory specimen due to 
collection or analysis issues), an C-SSRS will not be required at these visits. 
At this visit, any of the following assessments may be performed, depending on the reason for 
the visit:

Vital signs (temperature, pulse, and blood pressure).

C-SSRS. 

Other patient-reported outcomes (HADS, BASDAI, BASFI, PhGADA, PGADA, total and 
nocturnal spinal pain) as required. 

Administer the tuberculosis questionnaire.

Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB and weight.

Record 12-lead ECG.

If medically indicated, obtain blood sample(s) for:

Standard safety laboratory tests (hematology, serum chemistry).

The blood sample may also be used for PK/PD assessments, if needed.

Obtain urine sample for standard safety laboratory tests (including urine pregnancy test).

Record concomitant medication.

Record AEs.
9
ASSESSMENT OF EFFICACY
The timing for all assessments described below is specified in the Schedule of Assessments 
(Table 5‒1).
9.1
ASDAS
The ASDAS is comprised of a number of assessments which are scored by the subject and 
Investigator and multiplied by a validated formula (van der Heijde et al, 2009) as listed:

0.121 x Total spinal pain (BASDAI Question 2 result, Section 9.3)

0.058 x Duration of morning stiffness (BASDAI Question 6 result, Section 9.3) 

0.110 x PGADA (Section 9.6)

0.073 x Peripheral pain/swelling (BASDAI Question 3 result, Section 9.4)

0.579 x (natural logarithm of the CRP [mg/L] + 1)
Spinal pain, PGADA, duration of morning stiffness, and peripheral pain/swelling are all assessed 
on a numerical scale (0 to 10 units) (Lukas et al, 2009). The results of these calculations are 
summed to calculate the ASDAS.
PUBLIC COPY 
for:
PY
for:
tology, s
COP
tology, s
d for PK
C C
d for PK
safe
BLI
safety la
LIC
ty la
on.
U
on.
annot be used to support any marketing authorization 
A, total an
au
A, total an
and sympt
rke
and sympt
erum chem
ort a
erum chem
/PD asses
ppo
/PD asses
boratory te
sup
boratory te
T OF EF
use
T OF EF
ts describe
be u
ts describe
AS
n
AS
mprised o
ann
mprised o
This document c
d multipli
ca
d multipli
x Total sp
ent 
x Total sp
058 x Dur
me
058 x Dur
0.110 x
ocu
0.110 x

d

0.0
o
0.0

s

n and any extensions or variations thereof.
and 
of
and 
toms of a
s th
toms of a
mistry).
va
mistry).
ssments, i
or 
ssments, i
ests (inclu
ns 
ests (inclu
FFICA
exte
FFICAC
e
C
bed below
ny e
bed below
of a numb
an
of a numb
application
lied by a v
on a
lied by a v
pinal pain
atio
pinal pain
ration of m
lica
ration of m
x PGADA
app
x PGADA
a
Peri
ap
Peri

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 60 of 136
The following definitions apply to ASDAS Disease Activity categories:

ASDAS-Inactive Disease: ASDAS <1.3

ASDAS-Moderate Disease activity: ASDAS ≥1.3, <2.1

ASDAS-High Disease activity: ASDAS ≥2.1; ≤3.5

ASDAS-Very High Disease activity: ASDAS >3.5
9.2
ASAS20, ASAS40, and ASAS partial remission
The ASAS20 response is defined as an improvement of at least 20% and absolute improvement 
of at least 1 unit on a 0 to 10 NRS in at least 3 of the 4 following domains:

PGADA (see Section 9.6)

Pain assessment (the total spinal pain NRS score; Section 9.8)

Function (represented by BASFI, Section 9.5)

Inflammation (the mean of the BASDAI Questions 5 and 6 results, [see Section 9.4] 
concerning morning stiffness intensity and duration)
and absence of deterioration in the potential remaining domain [deterioration is defined as a 
relative worsening of at least 20% and an absolute worsening of at least 1 unit].
The ASAS40 response is defined as an improvement of at least 40%, and absolute improvement 
of at least 2 units on a 0 to 10 NRS in at least 3 of the 4 domains above and no worsening at all 
in the remaining domain.
The ASAS partial remission response is defined as a score of ≤2 units on a 0 to 10 unit NRS 
scale in all 4 domains listed above for ASAS20.
9.3
BASDAI
The most common instrument used to measure the disease activity of AS from the subject’s 
perspective is the BASDAI (Garrett et al, 1994). The BASDAI is a validated self-reported 
instrument which consists of six 10 unit horizontal NRSs to measure severity of fatigue, spinal 
and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and 
duration, respectively) over the last week (van Tubergen et al, 2015). The BASDAI score ranges 
from 0 to 10, with lower scores indicating lower disease activity. Question 2 of the BASDAI 
asks 
 Question 3 of 
the BASDAI asks 
 Question 6 of the BASDAI asks 
 
The BASDAI is calculated as follows: 
𝐵𝐴𝑆𝐷𝐴𝐼=
Q1 + Q2 + Q3 + Q4 + (𝑄5 + 𝑄6
2
)
5
PUBLIC COPY 
on)
Y
on)
ining do
OPY
ining do
lute wor
COP
lute wor
proveme
C C
proveme
t least 3 
LIC 
t least 3 
ponse is 
PUB
ponse is 
ove for
PU
ove for
cument cannot be used to support any marketing authorization 
provemen
uth
provemen
sults, [see
ma
sults, [see
main [dete
any
main [dete
sening of
rt a
sening of
nt of at lea
po
nt of at lea
of the 4 do
upp
of the 4 do
defined as
to 
defined as
ASAS20.
d to
ASAS20.
t used to m
e u
t used to m
I (Garrett 
be
I (Garrett 
sts of six 1
ot b
sts of six 1
pain and sw
not
pain and sw
vel
a
vely) over
ann
y) over
with lower 
can
with lower 
SDAI ask
me
SDAI ask
nt c
ent
cum
doc
docu
This do
do
s d
pplication and any extensions or variations thereof.
e
i
e Section
ons
Section
erioration
aria
erioration
at least 1
va
at least 1
east 40%, 
or 
east 40%, 
omains ab
s o
omains ab
s a score o
nsio
s a score o
.
measure t
y e
measure t
et al, 1
any
et al, 199
y
99
10 unit ho
d an
10 unit ho
swelling, 
nd 
swelling, 
r the last w
an
r the last w
r scores in
on a
r scores in
ks
li
ks
tion
cati
lica
ppli
ap
app
ap

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 61 of 136
Fatigue item of the BASDAI
Fatigue as a major symptom of AS can effectively be measured with single-item questions such 
as the BASDAI item (van Tubergen et al, 2002b). This item has shown moderate to good 
reliability and responsiveness (van Tubergen et al, 2002b). The same minimal clinically 
important difference (MCID) will be used for the fatigue item of the BASDAI as for the 
BASDAI score, ie, a change of 1 unit on the NRS.
9.4
Inflammation – BASDAI (mean of Questions 5 and 6)
Question 5 of the BASDAI (described completely in Section 9.3) measures intensity of morning 
stiffness. The subject considers the previous week and responds to the question, 
The response is indicated on a 10-point NRS in which 0=None and 10=Very severe. Question 6 
of the BASDAI measures duration of morning stiffness. The subject considers the previous week 
and responds to the question, 
The response is indicated on a 10-point NRS in which 0=0 hours, 5=1 hour, and 10=2 
or more hours. The ratings for each question are summed and divided by 2 to provide the mean 
of Questions 5 and 6. This is used in the definition of the ASAS response variables defined in 
Section 9.2.
9.5
Function – BASFI
The BASFI is a validated disease-specific instrument for assessing physical function (van der 
Heijde et al, 2005; Calin et al, 1994). The BASFI comprises 10 items relating to the past week. 
The NRS version will be used for the answering options of each item on a scale of 0 (“Easy”) to 
10 (“Impossible”) (van Tubergen et al, 2015 and van Tubergen et al, 2002a). The BASFI is the 
mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating 
better physical function. The MCID used to interpret scores is 7mm on a 0 to 100mm visual 
analog scale (VAS) or 17.5% of the Baseline score (Pavy et al, 2005); an MCID of 1 unit will be 
used for the NRS version. This is used in the definition of the ASAS response variables defined 
in Section 9.2.
9.6
Patient global assessment (PGADA)
Subjects will provide their global assessment of their disease activity in response to the question 
“How active was your spondylitis on average during the last week?” using a NRS where 0 is 
“not active” and 10 is “very active” (van Tubergen et al, 2015).
This is used in the calculation of ASDAS (Section 9.1) and the definition of the ASAS response 
variables defined in Section 9.2.
9.7
PhGADA
The Investigator will assess the overall status of the subject with respect to their AS signs and 
symptoms and functional capacity using an NRS in which 0=very good, asymptomatic and no 
limitations of normal activities and 10=very poor, very severe symptoms which are intolerable 
and inability to carry out normal activities. This assessment by the Investigator should be made 
blind to the PGADA.
The subject should be asked to consider both joint and skin components in their response to this 
question.
PUBLIC COPY 
he
Y
he
nstrume
C CO
nstrume
e BASF
IC C
e BASF
answeri
BLIC
answeri
et al, 201
UBL
et al, 201
the tota
PUB
the tota
MCID u
PU
MCID u
uthorization 
f morning
tho
f morning
keting au
evere. Qu
ng 
evere. Qu
ers the pr
eting
ers the pr
This document cannot be used to support any marke
hours, 5=
ark
hours, 5=
ded by 2 t
ma
ded by 2 t
 response
y m
 response
nt for asse
por
nt for asse
comprise
ppo
comprise
ng options
sup
ng options
5 and van
o su
5 and van
score ran
d to 
score ran
sed to int
ed t
sed to int
e Baseline
sed
e Baseline
is used in
us
is used in
global a
ot b
global a
e their glo
nno
e their glo
your spon
ann
your spon
d 10 is
ca
d 10 is “v
a
“v
ed in the c
ent 
ed in the c
s defined
men
s defined
The Inve
doc
The Inve
symp
s d
symp
lim
s 
lim
aut
g au
ket
hereof.
uestion 6
reo
uestion 6
revious w
here
revious w
application and any extensions or variations th
=1 hour, a
s t
=1 hour, a
to provide
ons
to provide
e variable
tion
e variable
essing phy
or v
essing phy
es 10 item
s o
es 10 item
s of each 
ons 
s of each 
n Tuberge
sion
n Tuberge
nges from
nsio
nges from
terpret sco
ten
terpret sco
ne score
exte
ne score (P
e
(P
n the defin
ex
n the defin
assessm
d an
assessm
obal asses
and
obal asses
ndylitis o
n an
ndylitis o
very activ
on 
very activ
calculatio
atio
calculatio
d in
ic
d in Sectio
ca
Sectio
PhGA
ppli
PhGA
tigator 
ap
tigator 
nd
f
of
the

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 62 of 136
9.8
Total and nocturnal spinal pain
The pain experienced by AS subjects is adequately measured by 2 separate questions: 1) total 
pain in the spine due to AS (ie, “How much pain of your spine due to spondylitis do you have?”); 
and 2) pain in the spine at night due to AS (ie, “How much pain of your spine due to spondylitis 
do you have at night?”) (Sieper et al, 2009; van der Heijde et al, 2005; Committee for Proprietary 
Medicinal Product [CPMP]/EWP/556/95). When responding to each question, the subject is to 
consider the average amount of pain in the preceding week. The total pain score is used in the 
definition of the ASAS response variables defined in Section 9.2.
9.9
hs-CRP
Blood will be collected for measurement of hs-CRP. After Screening, the hs-CRP data will not 
be sent to the Investigator to protect the blinded nature of the treatment assignments. The hs-CRP 
will be used in the calculation of ASDAS (Section 9.1).
9.10
Hospital Anxiety and Depression Scale
The HADS was chosen for its well-established psychometric properties and its use in clinical 
research on biological therapy in subjects with chronic plaque psoriasis (Langley et al, 2010; 
Dauden et al, 2009). The HADS scores for anxiety and for depression range from 0 to 21 with 
higher scores indicating worse state. A score below 8 is considered to be normal whereas a score 
of 15 and above is considered severe (Snaith and Zigmond, 1994).
9.11
PET-MRI or PET-CT scan
High bone turnover assessed by nuclear medicine methods may detect osteoproliferative 
processes regardless of the inflammatory or noninflammatory origin.
While exact localization of regions of radionuclide uptake is difficult with conventional 
scintigraphy,18F-fluoride PET-CT or PET-MRI has a much better spatial resolution and 
sensitivity (Strobel et al, 2010; Even-Sapir et al, 2007). In the present study, UCB will assess the 
regions of high bone turnover as detected by 18F PET-MRI or 18F PET-CT within the spine and 
the sacroiliac joints. 
The 18F-fluoride PET-MRIs of the whole spine will be performed by using a whole-body 
PET/MRI system. Alternatively, subjects will be examined in supine position on a combined 
PET-CT system permitting the acquisition of co-registered CT and PET images in the same 
session. The PET-MRI or PET-CT scan will be performed at time points provided in Table 5‒1
in at least 25 subjects at selected sites.
10
ASSESSMENT OF PHARMACOKINETIC/ 
PHARMACODYNAMIC/PHARMACOGENOMIC/ 
PHARMACOGENETIC VARIABLE(S)
Plasma concentrations of bimekizumab and CZP are the PK variables. 
10.1
Pharmacokinetic variables
Blood samples for measurement of PK variables will be collected at the time points specified in 
the Table 5‒1. At dosing visits, blood samples will be drawn prior to dosing, and will be drawn 
at the same time of the sampling for clinical laboratory tests. The time and date of collection will 
PUBLIC COPY
p
Y
p
and for
PY 
and for
ow 8 is c
OPY
ow 8 is c
and Zigm
COP
and Zigm
can
C C
can
ear medi
BLIC
ear medi
matory o
UBL
matory o
ions of 
PU
ions of 
CT
P
CT
nnot be used to support any marketing authorization 
he 
he 
P data wil
g au
P data wil
m
in
ments. Th
ng 
ents. Th
erties and 
ma
erties and 
soriasis (L
y m
soriasis (L
epression 
ny 
epression 
onsidered 
t an
onsidered 
ond, 1994
ort a
ond, 1994
ine metho
sup
ine metho
r noninflam
o su
r noninflam
adionuclid
d to
adionuclid
r PET
ed
r PET-
d
-MR
d 
MR
ven
us
ven-
s
-Sapir 
use
Sapir 
as detecte
e us
as detecte
MRIs of t
ot b
MRIs of t
lternative
nno
lternative
This document can
permitting
ann
permitting
ET
c
ET-
c
-MRI o
ca
MRI o
5 subjects
nt c
subjects
A
n
A
Plasm
s do
Plasm
1
s
1
and any extensions or variations thereof.
l not 
of
l not 
he hs
reo
he hs-
eo
-CR
eo
CR
d its use in
ons
d its use in
(Langley e
tion
(Langley e
n range fro
riati
n range fro
d to be nor
aria
d to be nor
4).
v
4).
ods may d
ons 
ods may d
ammatory
sion
ammatory
ide uptake
ens
ide uptake
MRI has a m
xten
MRI has a m
r et al, 200
ext
r et al, 200
ed by 18F
y e
ed by 18F
the whole
d a
the whole
ely, subjec
and
ely, subjec
ation a
g the acqu
an
g the acqu
or PET
on 
or PET-C
a
C
s at select
tion
s at select
applic
ASSESS
ica
ASSESS
PHAR
plic
PHAR
PH
pp
PH
cen
a

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 63 of 136
be recorded in the eCRF. Instructions pertaining to sample collection, processing, storage, 
labeling, and shipping are provided in the laboratory manual for this study. Detailed information 
on sample analysis will be provided in a bioanalytical report.
10.2
Pharmacodynamic variables
Blood samples for measurement of PD variables will be collected at the time points specified in 
Table 5‒1. Flow cytometry by fluorescence-activated cell sorting (FACS) analysis might 
include, but is not limited to: cluster of differentiation (CD)3, CD19, CD4, CD8, and CD69. 
Candidate biomarkers might include, but are not limited to: IL-17A/IL17-F pathway signaling, 
TNF signaling pathway, bone metabolism and AS (eg, IL-17A, IL-17F, IL-23, IL-6, TNF, DC-
STAMP, and circulating osteoclast precursors). At dosing visits, blood samples will be drawn 
prior to dosing, and will be drawn at the same time of the sampling for clinical laboratory tests. 
The time and date of collection will be recorded in the eCRF. Instructions pertaining to sample 
collection, processing, storage, labeling, and shipping are provided in the laboratory manual for 
this study. Detailed information on sample analysis will be provided in a bioanalytical report.
10.3
Nonhereditary pharmacogenomic variables
Where local regulation permit, blood samples will be drawn for exploratory RNA, proteins and 
metabolites biomarker analysis at the time points specified in Table 5‒1. Where local regulation 
permit, urine samples will be drawn for exploratory proteins and metabolites biomarker analysis 
at the time points specified in the schedule of study assessments. Collection of these samples will 
enable evaluation of biomarkers relative to disease biology and progression, drug treatment, bone 
metabolism and inflammatory and immune response processes. Instructions pertaining to sample 
collection, processing, storage, labeling, and shipping are provided in the laboratory manual for 
this study. The nature and format of these tentative analyses will be determined at a later stage. 
The samples will be stored at the secure long-term storage facility selected by UCB for up to 
20 years. 
10.4
Pharmacogenetic variables
For individuals consenting to the pharmacogenetic substudy, blood samples will be drawn for 
exploratory genetic/epigenetic, analyses at the time points specified in Table 5‒1. Collection of 
these samples will enable evaluation of genetics/epigenetics biomarkers relative to disease 
biology and progression, drug treatment, bone metabolism and inflammatory and immune 
response processes. The nature and format of these tentative analyses will be determined when 
the results of the main study are made available. A separate ICF will be required for those 
subjects who agree to participate in the pharmacogenetics substudy. The substudy will be 
conducted only where ethically accepted and authorized by the regulatory agencies. Refusal to 
participate in the substudy will not affect a subject’s ability to participate in the main study. The 
samples will be stored at -80°C at the central biorepository for up to 20 years. 
11
ASSESSMENT OF IMMUNOLOGICAL VARIABLE(S)
The immunological variables comprise detection of anti-bimekizumab and anti-CZP antibodies 
related to immunogenicity, serum complement concentrations, mononuclear cell subtypes 
(analyzed by flow cytometry/fluorescence-activated cell sorting), and other exploratory 
biomarkers.
PUBLIC COPY 
draw
Y
draw
pecified
OPY
pecified
atory pro
COP
atory pro
f study a
CO
f study a
o diseas
C C
o diseas
mune res
LIC
mune res
ling, and
BL
ling, and
t of these
PUB
t of these
he secu
PU
he secu
used to support any marketing authorization 
9.
o
9.
naling,
thor
naling,
TNF, DC
uth
TNF, DC
ll be draw
au
ll be draw
laboratory
g a
laboratory
rtaining t
ting
rtaining t
laboratory
keti
laboratory
 a bioanal
rke
 a bioanal
bles
ma
bles
or explora
ny m
or explora
in
a
in Table
any
Table 5
y
5
eins and m
rt a
eins and m
ssessment
ort
ssessment
biology a
ppo
biology a
ponse proc
upp
ponse proc
shipping 
sup
shipping 
tentative 
to s
tentative 
e long
d to
e long-
t
-ter
to
ter
cument cannot be u
netic va
us
netic va
to the pha
be 
to the pha
enetic, an
ot b
enetic, an
able evalu
not
able evalu
ess
a
ession, dru
ann
ion, dru
ses. The n
can
ses. The n
f the main
nt c
f the main
who agree 
ent
who agree 
ted only w
me
ted only w
icipate in 
um
icipate in 
This doc
amples w
ocu
amples w
11
do
11
Th
s
Th
extensions or variations thereof.
wn 
of
wn 
y tests.
eof
y tests.
to sample
ere
to sample
ry manual
ther
ry manual
alytical rep
s th
alytical rep
atory RNA
atio
atory RNA
5‒
r
‒1
ri
1. Whe
ria
. Whe
metabolit
var
metabolit
ts. Collec
r va
ts. Collec
and progr
or 
and progr
cesses. 
ns o
cesses. In
o
In
g are provi
ions
g are provi
e analyses
sio
e analyses
rm storag
ens
rm storag
pplication and any e
ariables
y ex
ariables
armacoge
any
armacoge
nalyses at 
d an
nalyses at 
uation of 
nd 
uation of 
ug treatm
an
ug treatm
nature an
n a
nature an
n study ar
tion
n study ar
e to partic
atio
e to partic
where eth
lica
where eth
n the subst
pplic
n the subst
ap
will be stor
app
will be stor
A

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 64 of 136
The Investigator or designee will obtain blood samples for these measurements at the time points 
specified in Table 5‒1. When these samples are required at a visit during which the subject is 
dosed with IMP, the blood samples will be drawn prior to dosing. Samples should be drawn at 
the same time of the sampling for clinical laboratory tests. The time and date of collection will be 
recorded in the eCRF. Instructions pertaining to sample collection, processing, storage, labeling, 
and shipping are provided in the laboratory manual for this study. The presence of antibodies to 
bimekizumab or CZP will be determined using a validated bioanalytical method. Detailed 
information on sample analysis will be provided in a bioanalytical report.
12
ASSESSMENT OF SAFETY
12.1
Adverse events
12.1.1
Definitions
12.1.1.1
Adverse event
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
In order to ensure complete safety data collection, all AEs occurring during the study (ie, after 
the signing of the Informed Consent form), including any pretreatment and posttreatment periods 
required by the protocol, must be reported in the eCRF even if no IMP was taken but specific 
study procedures were conducted. This includes all AEs not present prior to the initial visit and 
all AEs that recurred or worsened after the initial visit.
Signs or symptoms of the condition/disease for which the IMP is being studied should be 
recorded as AEs only if their nature changes considerably or their frequency or intensity 
increases in a clinically significant manner as compared to the clinical profile known to the 
Investigator from the subject’s history or the Baseline Period. 
12.1.1.2
Serious adverse event
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
determined. An SAE must meet 1 or more of the following criteria:

Death

Life-threatening
(Life-threatening does not include a reaction that might have caused death had it occurred in 
a more severe form.)

Significant or persistent disability/incapacity

Congenital anomaly/birth defect (including that occurring in a fetus)

Important medical event that, based upon appropriate medical judgment, may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other 
outcomes listed in the definition of serious
PUBLIC COPY
e 
Y
e 
m, or d
PY 
m, or d
ther or n
OPY
ther or n
llection,
C C
llection,
rm), inc
LIC
rm), inc
ported in
BLI
ported in
d. This in
UB
d. This in
ed after
PU
ed after
This document cannot be used to support any marketing authorization 
nt or clini
ark
nt or clini
sarily hav
ma
sarily hav
favorable 
y m
favorable 
ease temp
ny 
ease temp
ot related 
t any
ot related 
all AEs oc
ppo
all AEs oc
uding any
upp
uding any
the eCRF
sup
the eCRF
cludes all 
to s
cludes all 
the initia
d to
the initia
n/disease 
sed
n/disease 
ture chang
us
ture chang
ficant man
be u
ficant man
ect’s histo
t be
ect’s histo
s adver
not 
s adver
ned that a
ann
ned that a
n SAE mu
ca
n SAE mu
e
m
e-
m
-threaten
me
threaten
(Life
cum
(Life-
u
-th
m
th
a mo
oc
a mo

s d

S
application and any extensions or variations thereof.
nical inves
s th
nical inves
ve a causa
ons
ve a causa
e and unin
tion
e and unin
porally as
riati
porally as
d to the me
aria
d to the me
occurring 
or 
occurring 
y pretreatm
ns o
y pretreatm
F even if n
ons
F even if n
l AEs not 
sio
l AEs not 
l visit.
ens
l visit.
for which
xte
for which
nges consi
ex
nges consi
anner as c
ny e
anner as c
ory or the
any
ory or the
rse even
nd a
rse even
a subject 
an
a subject 
ust meet 1
on a
ust meet 1
ening
lic
ening
hreatening
pp
hreatening
e severe
ap
e severe

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 65 of 136
(Important medical events may include, but are not limited to, potential Hy’s Law [see 
Section 12.1.1.3], allergic bronchospasm requiring intensive treatment in an emergency room 
or at home, blood dyscrasias that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse.)

Initial inpatient hospitalization or prolongation of hospitalization
(A patient admitted to a hospital, even if he/she is released on the same day, meets the 
criteria for the initial inpatient hospitalization. An emergency room visit that results in 
admission to the hospital would also qualify for the initial inpatient hospitalization criteria. 
However, emergency room visits that do not result in admission to the hospital would not 
qualify for this criteria and, instead, should be evaluated for 1 of the other criteria in the 
definition of serious [eg, life-threatening adverse experience, important medical event].
Hospitalizations for reasons not associated with the occurrence of an AE [eg, preplanned 
surgery or elective surgery for a pre-existing condition that has not worsened or manifested 
in an unusual or uncharacteristic manner] do not qualify for reporting. For example, if a 
subject has a condition recorded on his/her medical history and later has a preplanned surgery 
for this condition, it is not appropriate to record the surgery or hospitalization as an SAE, 
since there is no AE upon which to assess the serious criteria. Please note that, if the 
pre-existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify as an AE and, if necessary, the seriousness of the event would need to 
be determined.)
12.1.1.2.1
Anticipated serious adverse events
The following Anticipated SAEs are anticipated to occur in the population studied in this 
protocol at some frequency that is independent of drug exposure. 
This list does not change the Investigator’s obligation to report all SAEs (including Anticipated 
SAEs) as detailed in Section 12.1.2.3.
Table 12‒1: Anticipated serious adverse events for the population of subjects 
with AS
MedDRA system organ class
MedDRA preferred term
Skin and subcutaneous tissue disorders
Psoriasis
Eye disorders
Uveitis
Musculoskeletal and connective tissue disorders
Dactylitis
Tendonitis
Atlantoaxial instability
Gastrointestinal disorders
Colitis ulcerative
Crohn's disease
PUBLIC COPY
 s
Y
 s
rious c
PY 
rious c
fested in 
OPY
fested in 
ecessary
COP
ecessary
advers
LIC
advers
re anticip
UBL
re anticip
is indep
PUB
is indep
P
esti
P
esti
ot be used to support any marketing authorization 
riteria.
thor
riteria.
ould not 
uth
ould not 
ria in the 
au
ria in the 
dical even
g a
dical even
E [eg,
etin
E [eg, pre
ng
pre
worsened o
ket
worsened o
ting. For e
ark
ting. For e
d later has 
ma
d later has 
or hospita
y m
or hospita
eria. Plea
ny 
eria. Plea
an unusua
t any
an unusua
the seriou
ort a
the seriou
e events
upp
e events
ated to oc
o su
ated to oc
endent of 
to 
endent of 
gator’s ob
ed 
gator’s ob
2.3
s
2.3.
s
.
ed seriou
be u
ed seriou
This document cannot
organ cla
nno
organ cla
ot
taneous t
can
taneous t
nn
ders
nt
ders
ca
loskeleta
men
loskeleta
n
d
 do
Gast
do
Gast
do
s d
d any extensions or variations thereof.
o
nt].
e
nt].
eplanned 
here
eplanned 
or manife
the
or manife
example,
s th
example,
s a preplan
ons
s a preplan
alization 
tion
alization 
ase note th
riati
ase note th
al or unch
aria
al or unch
usness of 
va
usness of 
ccur in th
ion
ccur in th
f drug exp
nsio
f drug exp
bligation t
xten
bligation t
us adver
ny 
us adver
application and 
ass
an
ass
d a
tissue dis
n a
tissue dis
an
on
al and con
icat
al and con
ati
ap
stin
a
ti
ap

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 66 of 136
Table 12‒1: Anticipated serious adverse events for the population of subjects 
with AS
MedDRA system organ class
MedDRA preferred term
Cardiac disorders
Aortic valve incompetence
Atrial tachycardia
Atrioventricular block
Bundle branch block
Cardiomyopathy
Vascular disorders
Aortitis
Respiratory, thoracic and mediastinal disorders
Pulmonary fibrosis
Nervous system disorders
Cauda equina syndrome
Injury, poisoning and procedural complications
Spinal cord injury
Spinal fracture
Cervical Vertebral fracture
Lumbar Vertebral fracture
Thoracic Vertebral fracture
Immune system disorders
Amyloidosis
Psychiatric disorders
Depression
AS=ankylosing spondylitis; MedDRA=Medical Dictionary for Regulatory Activities; SAE=serious adverse 
event
Note: Exception: Listed events will not be regarded as anticipated SAEs if they are life threatening or if they 
result in the death of the study subject.
12.1.1.3
Adverse events of special interest
An AE of special interest is any AE that a regulatory authority has mandated be reported on an 
expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound. Potential Hy’s Law, defined as ≥3xULN ALT or 
AST with coexisting ≥2xULN total bilirubin in the absence of ≥2xULN ALP, with no alternative 
explanation for the biochemical abnormality, must ALWAYS be reported to UCB as an AE of 
special interest (AESI) (ie, without waiting for any additional etiologic investigations to have 
been concluded). Follow-up information should then be reported if an alternative etiology is 
identified during investigation and monitoring of the subject.
In addition, events that are considered as Adverse Events of Interest for CZP include:

Serious infections including opportunistic infections

Malignancies including lymphoma

Congestive heart failure

Demyelinating-like disorders

Aplastic anaemia, pancytopenia, thrombocytopenia, neutropenia and leucopenia
LIC COPY
pin
Y
pin
Cervic
PY 
Cervic
Lu
OP
Lu
OP
C C
PUBLI
LIC
A=Medic
PUB
A=Medic
ot b
P
ot b
UB
o support any marketing authorization 
iz
au
ng
drome
rke
drome
et
jury
ma
jury
ture
y
ture
l Vertebr
any
l Vertebr
mbar Vert
t a
mbar Vert
Thoracic 
ort
Thoracic 
ark
Amyl
pp
Amyl
po
up
be used to sup
D
up
up
up
up
l Dictionary
to 
l Dictionary
e regarded a
ed
e regarded a
t.
u
t.
o s
nts of sp
e u
nts of sp
ot b
i
t
i
ment canno
s any AE
t be
s any AE
dless of th
not 
dless of th
UCB prod
nno
UCB prod
ting ≥2xU
can
ting ≥2xU
or the bioc
t ca
or the bioc
rest (AES
nt c
rest (AES
ncluded). 
men
ncluded). 
This docum
ified durin
ume
ified durin
n addition
ocu
n addition

d

Se
o
Se

s

ns or variations thereof.f
eo
he
ral fractur
riat
ral fractur
ebral frac
var
ebral frac
Vertebra
r v
Vertebra
s
yloidosis
s o
yloidosis
or
ny extensions
Depressio
ion
Depressio
ns
y for Regul
nsio
y for Regul
as anticipat
xten
as anticipat
sio
pecial in
y e
pecial in
lication and a
E that a re
any
E that a re
he seriousn
d a
he seriousn
duct/comp
and
duct/comp
ULN total
n an
ULN total
chemical 
ion 
chemical 
SI) (ie, wi
atio
SI) (ie, wi
Follow
icat
Follow-
appl
u
ing invest
plic
ing invest
n, events 
app
n, events 
infe
a
infe

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 67 of 136

Serious bleeding events

Lupus and lupus-like illness

Serious skin reactions (e.g. Stevens Johnson syndrome, toxic epidermal necrolysis, and 
erythema multiforme)
12.1.1.4
Adverse events for special monitoring
UCB has identified AEs for special monitoring (AESM). An AESM is an AE or safety topic for 
which special monitoring, additional data collection activities, and/or enhanced signal detection 
activities (within UCB), are considered appropriate. Identified AESM can be of particular 
concern based on findings from the IMP clinical program to date, potential risks generally 
associated with biologic immunomodulators, or comorbidities and risk factors prevalent in the 
study population.
Adverse events for special monitoring for this study include: infections (serious, opportunistic, 
fungal, and TB, see Section 12.7.5), neutropenia, hypersensitivity, suicidal ideation and behavior 
(assessed using the C-SSRS), depression, (assessed using the HADS, see Section 9.10), major 
cardiovascular events, liver function test changes/enzyme elevations (ALT, AST, and bilirubin; 
see Section 12.6.1), malignancies, and inflammatory bowel diseases (with gastroenterology 
referral as appropriate).
12.1.2
Procedures for reporting and recording adverse events 
The subject will be given the opportunity to report AEs spontaneously. A general prompt will 
also be given at each study visit to detect AEs. For example:
“Did you notice anything unusual about your health (since your last visit)?”
In addition, the Investigator should review any self-assessment procedures (eg, diary cards) 
employed in the study.
12.1.2.1
Description of adverse events
When recording an AE, the Investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The eCRF 
and source documents should be consistent. Any discrepancies between the subject’s own words 
on his/her own records (eg, diary card) and the corresponding medical terminology should be 
clarified in the source documentation.
When recording the intensity of an AE in the eCRF (ie, mild, moderate, or severe), the 
Investigator should use the following criteria:

Mild: the subject is aware of the sign or symptom (syndrome), but it does not interfere with 
his/her usual activities and/or is of no clinical consequence

Moderate: the AE interferes with the usual activities of the subject or it is of some clinical 
consequence

Severe: the subject is unable to work normally or to carry out his/her usual activities, or the 
AE is of definite clinical consequency
Details for completion of the Adverse Event eCRF (including judgment of relationship to IMP) 
are described in the eCRF Completion Guidelines.
PUBLIC COPY
m
Y
m
y bowe
PY 
y bowe
and rec
CO
and rec
y to repo
IC C
y to repo
ect AEs
BLIC
ect AEs
ng unusu
UBL
ng unusu
ould re
PU
ould re
annot be used to support any marketing authorization 
c for 
oriz
c for 
etection 
thor
etection 
cular 
uth
cular 
enerally 
au
enerally 
revalent i
g a
revalent i
serious, o
ket
serious, o
cidal idea
arke
cidal idea
S, see
mar
S, see Se
ar
Se
tions (AL
y m
tions (AL
iseases (w
ny 
iseases (w
ording a
ort 
ording a
t AEs
ppo
t AEs spo
po
spo
For exam
supp
For exam
al about y
to s
al about y
view any s
d to
view any s
f adverse
us
f adverse
Investiga
be 
Investiga
ology, rat
ot b
ology, rat
s should b
not
s should b
ords (eg,
ann
ords (eg,
This document ca
ource do
can
ource do
rding the i
nt c
rding the i
ator shoul
men
ator shoul
Mild: the 
um
Mild: the 
his/her
ocu
his/her

d

Mo
o
Mo
and any extensions or variations thereof.
in the 
eof
in the 
opportuni
the
opportuni
ation and 
s th
ation and 
ction
ons
ction 9.1
s
9.1
LT, AST, 
tion
LT, AST, 
with gastr
iati
with gastr
adverse 
r va
adverse 
ontaneous
s or
ontaneous
mple:
ns
mple:
your heal
sion
your heal
self
en
self-
en
-f-f
en
f-f asses
ens
asses
se events
y ex
se events
ator shou
any
ator shou
ther than 
d an
ther than 
be consist
nd 
be consist
diary car
an
diary car
application 
cumentat
n a
cumentat
intensity 
atio
intensity 
ld use the
cat
ld use the
subject is
plic
subject is
r usual act
app
r usual act
t
a
te: t
a
e: t

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 68 of 136
12.1.2.2
Rule for repetition of an adverse event 
An increase in the intensity of an AE should lead to the repetition of the AE being reported with:

The outcome date of the first AE that is not related to the natural course of the disease being 
the same as the start date of the repeated AE, and the outcome of “worsening”

The AE verbatim term being the same for the first and repeated AE, so that the repeated AE 
can be easily identified as the worsening of the first one
12.1.2.3
Additional procedures for reporting serious adverse events 
If an SAE is reported, UCB must be informed within 24 hours of receipt of this information by 
the site (see contact information for SAE reporting listed in the Serious Adverse Event Reporting 
section at the front of the protocol). The Investigator must forward to UCB (or its representative) 
a duly completed “Investigator SAE Report Form for Development Drug” (SAE Report form) 
provided by UCB, even if the data are incomplete, or if it is obvious that more data will be 
needed in order to draw any conclusions. Information recorded on this form will be entered into 
the global safety database.
An Investigator SAE Report form will be provided to the Investigator. The Investigator SAE 
Report form must be completed in English. 
It is important for the Investigator, when completing the SAE Report form, to include the 
assessment as to a causal relationship between the SAE and the IMP administration. This insight 
from the Investigator is very important for UCB to consider in assessing the safety of the IMP 
and in determining whether the SAE requires reporting to the regulatory authorities in an 
expedited manner.
Additional information (eg, autopsy or laboratory reports) received by the Investigator must be 
provided within 24 hours. All documents in the local language must be accompanied by a 
translation in English, or the relevant information included in the same document must be 
summarized in the Investigator SAE Report form.
The Investigator is specifically requested to collect and report to UCB (or its representative) any 
SAEs (even if the Investigator is certain that they are in no way associated with the IMP), up to 
30 days from the end of the study for each subject, and to also inform participating subjects of 
the need to inform the Investigator of any SAE within this period. Serious AEs that the 
Investigator thinks may be associated with the IMP must be reported to UCB regardless of the 
time between the event and the end of the study.
Upon receipt of the SAE Report form, UCB will perform an assessment of expectedness of the 
reported SAE. The assessment of the expectedness of the SAE is based on the IB.
12.1.3
Follow up of adverse events
An AE should be followed until it has resolved, has a stable sequelae, the Investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. This 
follow-up requirement applies to AEs, SAEs, and AEs of special interest; further details 
regarding follow up of PDILI events is provided in Section 12.6.1.4. 
If an AE is ongoing at the end of the study for a subject, follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the Investigator no longer deems that it is 
PUBLIC COPY 
the 
Y
the 
leting th
COP
leting th
en the S
C CO
en the S
or UCB t
IC C
or UCB t
equires r
BLIC
equires r
opsy or 
PU
opsy or 
ocum
P
ocum
ment cannot be used to support any marketing authorization 
rmation by
auth
rmation by
Event Rep
au
Event Rep
its repres
ng a
its repres
SAE Rep
ting
SAE Rep
more data
ket
more data
s form wil
arke
s form wil
stigator. T
y m
stigator. T
e SAE Rep
rt a
e SAE Rep
AE and th
port
AE and th
o consider
ppo
o consider
eporting t
supp
eporting t
aboratory
d to
aboratory
ents in th
ed 
ents in th
ant inform
use
ant inform
SAE Rep
e us
SAE Rep
ally reque
be
ally reque
tigator is c
ot b
tigator is c
of the stu
not
of the stu
the Inves
ann
the Inves
nks may b
can
nks may b
n the even
nt c
n the even
ceipt of th
men
ceipt of th
This docum
ted SAE. 
ume
ted SAE. 
2.1.3
ocu
2.1.3
An AE
do
An AE
dete
s d
dete
f
s
f
ication and any extensions or variations thereof.
by 
f
y
porting
of.
porting
sentative)
reo
sentative)
port form)
here
port form)
ta will be 
the
ta will be 
ill be ente
s th
ill be ente
The Inves
atio
The Inves
eport form
var
eport form
he IMP ad
or v
he IMP ad
er in asses
s or
er in asses
to the reg
ns 
to the reg
y reports) 
nsi
y reports) 
he local la
ten
he local la
mation in
exte
mation in
port form
y ex
port form
uested to c
any
uested to c
certain th
d an
certain th
udy for ea
nd 
udy for ea
stigator o
an
stigator o
be associ
on a
be associ
nt and the
tion
nt and the
he SAE R
icat
he SAE R
appl
 The asse
plic
 The asse
Foll
pp
Foll
uld b
a
uld b

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 69 of 136
clinically significant, or until the subject is lost to follow up. If no follow up is provided, the 
Investigator must provide a justification. The follow up will usually be continued for 20 weeks 
after the subject has discontinued his/her IMP.
Information on SAEs obtained after clinical database lock will be captured through the Patient 
Safety (PS) database without limitation of time.
12.2
Pregnancy
If an Investigator is notified that a subject has become pregnant after the first intake of any IMP, 
the Investigator must immediately notify UCB’s PS department by providing the completed 
Pregnancy Report and Outcome form (for contact details see SAE reporting information at the 
beginning of this protocol). The subject should be withdrawn from the study as soon as 
pregnancy is known (by positive pregnancy test), and the following should be completed:

The subject should return for an early discontinuation visit.

The subject should immediately stop the intake of the IMP 

A Safety Follow-Up Visit should be scheduled 20 weeks after the subject has discontinued 
his/her IMP.
The Investigator must inform the subject of information currently known about potential risks 
and about available treatment alternatives.
The pregnancy will be documented on the Pregnancy Report and Outcome form provided to the 
Investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outcome form in which the Investigator has to 
report on the health of the mother and of the child. Every reasonable attempt should be made to 
follow the health of the child for 30 days after birth for any significant medical issues. In certain 
circumstances, UCB may request that follow up is continued for a period longer than 30 days. If 
the subject is lost to follow up and/or refuses to give information, written documentation of 
attempts to contact the subject needs to be provided by the Investigator and filed at the site. 
UCB’s PS department is the primary contact for any questions related to the data collection for 
the pregnancy, eventual birth, and follow up.
In cases where the partner of a male subject enrolled in a clinical study becomes pregnant, the 
Investigator or designee is asked to contact the subject to request consent of the partner via the 
Partner Pregnancy Consent form that has been approved by the responsible IRB/IEC and should 
be available in the Investigator site file. In case of questions about the consent process, the 
Investigator may contact the UCB/Contract Research Organization (CRO) contract monitor for 
the study. The Investigator will complete the Pregnancy Report and Outcome form and send it to 
UCB’s PS department (for contact details see SAE reporting information at the beginning of this 
protocol) only after the partner has agreed that additional information can be captured and has 
provided the signed Partner Pregnancy Consent form. UCB’s PS department is also the primary 
contact for any questions related to the data collection for the partner pregnancy, eventual birth, 
and follow up.
A pregnancy becomes an SAE in the following circumstances: miscarriage, abortion (elective or 
spontaneous), unintended pregnancy after hormonal contraceptive failure (if the hormonal 
contraceptive was correctly used), ectopic pregnancy, fetal demise, or any congenital 
PUBLIC COPY 
mation c
OPY
mation c
Pregnan
C C
Pregnan
egnancy 
LIC 
egnancy 
port and
BLI
port and
and of t
UB
and of t
or 30 da
PU
or 30 da
st th
P
st th
nnot be used to support any marketing authorization 
y IMP,
horiz
y IMP,
leted 
tho
leted 
ation at th
auth
ation at th
oon as
g au
oon as
complete
ng 
complete
r the subje
ma
r the subje
urrently 
t any
urrently kn
y
kn
cy Report
ppo
cy Report
and the ev
upp
and the ev
Outcome 
sup
Outcome 
he child. E
to s
he child. E
ys after bir
d to
ys after bir
at follow u
ed 
at follow u
d/or refuse
use
d/or refuse
nee
e u
needs to b
e us
ds to b
e primary 
be 
e primary 
birth, and 
ot b
birth, and 
artner of a
nno
artner of a
This document can
signee is a
ann
signee is a
ncy Cons
ca
ncy Cons
in the In
nt c
in the In
tor may c
ent
tor may c
udy. The I
me
udy. The I
CB’s PS de
cum
CB’s PS de
protocol) 
docu
protocol) 
provide
do
provide
cont
s d
cont
a
s
a
and any extensions or variations thereof.
he
f
he
ed:
r
ed:
ect has di
ion
ect has di
known abo
aria
known abo
t and Out
or 
t and Out
ventual bi
ns o
ventual bi
e form in w
ons
e form in w
Every rea
sio
Every rea
irth for an
ens
irth for an
up is cont
xten
up is cont
ses to give
exte
ses to give
be provid
y ex
be provid
y contact f
any 
y contact f
d follow u
d an
d follow u
a male su
nd 
a male su
application a
asked to 
an
asked to 
sent form 
on a
sent form 
vestigator
tion
vestigator
contact th
cati
contact th
Investigat
plica
Investigat
departmen
ppli
departmen
only afte
app
only afte
he sig
a
he sig

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 70 of 136
anomaly/birth defect of the baby. Those SAEs must be additionally reported using the 
Investigator SAE Report form.
12.3
Suspected transmission of an infectious agent
For the purposes of reporting, any suspected transmission of an infectious agent via a medicinal 
product should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the eCRF, and followed as any other SAE. Any organism, virus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infectious agent.
12.4
Overdose of investigational medicinal product
Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the eCRF. Any SAE or nonserious AE associated with excessive dosing must be 
followed as any other SAE or nonserious AE. These events are only considered AEs or SAEs if 
there are associated clinical signs and symptoms or if the act of taking the excess medicine itself 
is an AE or SAE (eg, suicide attempt).
12.5
Safety signal detection
Selected data from this study will be reviewed periodically to detect as early as possible any 
safety concern(s) related to the IMP so that Investigators, clinical study subjects, regulatory 
authorities, and IRBs/IECs will be informed appropriately and as early as possible.
The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.
As appropriate for the stage of development and accumulated experience with the IMP, 
medically qualified personnel at UCB may identify additional safety measures (eg, AEs, vital 
signs, laboratory or ECG results) for which data will be periodically reviewed during the course 
of the study.
In addition, an independent DMC will periodically review and monitor the safety data from this 
study and advise UCB. The DMC membership includes clinicians knowledgeable about the 
disease or the treatment. All members have experience and expertise in clinical trials. Board 
members may not participate in the study as principal or co-Investigators, or as study subject 
care physicians. The duration of membership for the DMC will be inclusive of planned analyses 
for AS0013. The DMC may also be asked to provide a review of final study results, as deemed 
appropriate. The DMC procedures will ensure that data remain blind to the study team and 
Investigators at all times throughout the conduct of the study. The detailed role, scope, 
responsibilities, and complete procedures, as well as the identity of the DMC members, will be 
described in a separate charter document. A Cardiovascular and a Neuropsychiatric Adjudication 
Committee will be in place for this study. Specific procedures will be outlined in the charter, 
which will be developed by the committee members.
12.6
Laboratory measurements
Clinical laboratory assessments consist of serum chemistry, hematology, and urinalysis, and 
pregnancy tests (serum or urine) (Table 12‒2). A centralized laboratory will be used to supply all 
laboratory test supplies and analyze all blood and urine samples for hematology, biochemistry 
and urinalysis measurements. Any unscheduled laboratory testing should also be collected using 
PUBLIC COPY
odically
PY 
odically
estigator
OP
estigator
appropri
CO
appropri
ied desig
IC C
ied desig
econcilia
BLIC
econcilia
velopme
UB
velopme
at UCB 
PU
at UCB 
) fo
P
) fo
ment cannot be used to support any marketing authorization 
us 
iz
us 
nic or 
oriz
nic or 
e) should 
g a
e) should 
dosing m
ting
dosing m
dered AE
ketin
dered AE
the excess
rke
the excess
to detect a
any
to detect a
, clinical 
rt a
, clinical 
ately and 
ort 
ately and 
nee/equiv
ppo
nee/equiv
ions in co
sup
ions in co
nt and acc
to s
nt and acc
may identi
d to
may identi
which da
ed 
which da
DMC will 
be u
DMC will 
e DMC m
t be
e DMC m
. All mem
ot b
. All mem
rticipate i
nno
rticipate i
The duratio
ann
The duratio
he DMC m
ca
he DMC m
The DM
nt c
The DM
tors at all
ent
tors at all
This docum
nsibilities,
me
nsibilities,
cr
c
cribed in 
cum
ibed in 
Committe
docu
Committe
which 
do
which 
12
s 
12
cation and any extensions or variations thereof.
d be
eo
d be
must be 
ereo
must be 
Es or SAE
ther
Es or SAE
ss medicin
s th
ss medicin
as early a
riat
as early a
study sub
var
study sub
as early a
r va
as early a
valent wil
s or
valent wil
ollaborati
ns 
ollaborati
cumulated
sio
cumulated
tify additi
ens
tify additi
ata will be
xten
ata will be
periodica
ny e
periodica
membersh
any
membersh
mbers hav
d a
mbers hav
in the stu
nd 
in the stu
ion of mem
an
ion of mem
may also 
on a
may also 
MC pr
tio
MC proced
ion
oced
l times thr
cati
l times thr
applic
s, and com
plica
s, and com
a separat
ppli
a separat
ee will be
app
e will be
be d
a
be d

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 71 of 136
the central laboratory. Testing to rule out hepatitis B, hepatitis C, and HIV (see Exclusion 
Criterion #12, Section 6.2 ) will be performed at Screening in addition to those measurements 
listed in Table 12‒2.
Specific details regarding the handling and processing of serum chemistry, hematology, and 
urinalysis samples are provided in the study laboratory manuals.
The following laboratory parameters will be measured:
Table 12‒2: Laboratory measurements
Hematology
Chemistry
Urinalysis
Serology
Basophils
Bicarbonate
Albumin
HIV
Eosinophils 
Calcium
Bacteria
HLA-B27
Lymphocytes 
Chloride
Crystals
Hepatitis B
Atypical lymphocytes 
hs-CRPa
Glucose
Hepatitis C
Monocytes 
Magnesium
pH
Neutrophils 
Potassium
RBC
Hematocrit
Sodium
WBC
Hemoglobin 
Glucose
Urine dipstick for 
pregnancy testingb
MCH 
BUN
MCHC 
Creatinine
MCV 
AST
Platelet count 
ALT
RBC count 
ALP
WBC count 
GGT
Total bilirubinc
LDH
Uric acid
Total cholesterol
Serum FSH testingd
Serum pregnancy testingb
PUBLIC COPY 
Y
PY
OP
cose
C C
cose
C
BU
BL
BU
LI
C
U
C
UB
P
d to support any marketing authorization 
rology
aut
rology
th
HIV
g a
HIV
au
HLA
ng
HLA
ng
et
ke
se
m
se
rk
pH
y
pH
ma
RBC
any
RBC
ny
W
a
W
t a
o
Ur
o
Ur
or
ppo
up
eatinine
d to
eatinine
o
ent cannot be used 
AST
ed
AST
d
A
se
e
t b
t b
t b
t b
t b
no
an
t c
This docume
um
doc
s d
ensions or variations thereof.f
A-
e
-B27
ere
B27
eo
Hepatitis 
the
Hepatitis 
he
Hepa
ns 
Hepa
s t
on
tio
at
WBC
va
WBC
ar
rine dipstic
or 
rine dipstic
pregnancy
ns o
pregnancy
r v
ns
sio
sio
sio
cation and any extensio
sio
sio
en
ALT
e
ALT
ex
ALP
any
ALP
y
G
a
G
a
T
nd
n a
n
tio
applica
ca
pl
ap

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 72 of 136
Table 12‒2: Laboratory measurements
Hematology
Chemistry
Urinalysis
Serology
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; FSH=follicle-stimulating hormone; GGT=gamma glutamyltransferase; HIV=human 
immunodeficiency virus; HLA-B27=human leukocyte antigen B27; hs-CRP=high sensitivity C-reactive 
protein; IMP=investigational medicinal product; LDH=lactate dehydrogenase; MCH=mean corpuscular 
hemoglobin; MCHC=mean corpuscular hemoglobin concentration; MCV=mean corpuscular volume; 
RBC=red blood cell; ULN=upper limit of normal; WBC=white blood cell
a hs-CRP will be tested at specified visits per Table 5‒1.
b A serum pregnancy test will be conducted at Screening – all other pregnancy tests will be performed on urine. 
Pregnancy results must be negative prior to administering IMP.
c If total bilirubin is >ULN, a direct bilirubin estimation (%) will be performed.
d A serum FSH test will be performed at Screening for all female subjects whose last menstrual cycle occurred 
between 12 and 24 months prior to the Screening Visit. 
12.6.1
Evaluation of PDILI
The PDILI IMP discontinuation criteria for this study are provided in Section 6.3.1, with the 
accompanying required follow-up investigation and monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study site and sponsor within 24 hours of learning 
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
reported as an AE of special interest (see Section 12.1.1.3), and, if applicable, also reported as an 
SAE (see Section 12.1.1.2). 
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in 
Table 12‒4 (specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section 12.6.1.1). The local 
hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section 12.6.1.4). 
The results of all monitoring, including laboratory testing and other testing, should be made
available to the study site and sponsor.
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but
appropriate medical action must not be delayed waiting for the repeat result.
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapidly available results and a conservative approach must be taken if the results from the 
2 laboratory tests are significantly different. Data from the local and central laboratory are to be 
recorded on the applicable eCRF pages.
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, the Investigator should also 
consider dose reduction for medically necessary concomitant medication and consider changing
any medically required concomitant medication known to be hepatotoxic to a suitable 
alternative.
PUBLIC COPY 
monit
Y
monit
dy site an
OPY
dy site an
s the crit
COP
s the crit
tion
CO
tion 12
CO
12
iagnosti
BLIC
iagnosti
nt on lab
UBL
nt on lab
ologist (i
PUB
ologist (i
ly con
PU
ly con
t cannot be used to support any marketing authorization 
on urine. 
uth
on urine. 
al cycle oc
ing 
al cycle oc
ed in 
m
ed in Sect
ma
Sect
ng detailed
ny m
ng detailed
d sponsor
any
d sponsor
erion for p
rt a
erion for p
.1.3
or
.1.3), and
ort
), and
testing an
sup
testing an
oratory re
o su
oratory re
applicabl
d to 
applicabl
sulted by 
ed t
sulted by 
isease. Th
sed
isease. Th
nvestigati
us
nvestigati
use of the 
be u
use of the 
nitoring, in
not
nitoring, in
dy site an
ann
dy site an
resulting
t ca
resulting
This document
medical a
nt c
medical a
are done l
men
are done l
ral laborat
um
ral laborat
most rapidl
ocu
most rapidl
2
d
2 labor
doc
labora
c
a
recor
s d
recor
W
s
W
ion and any extensions or variations thereof.
curred 
reo
curred 
ion
io
ion 6.3.1
on
6.3.1
d below. A
atio
d below. A
r within 2
aria
r within 2
potential 
var
potential 
d, if appli
r v
d, if appli
and con
ons
and contin
s 
tin
esults and
sion
esults and
ble; discus
nsio
ble; discus
the treati
ten
the treati
his would
exte
his would
ion and m
y ex
ion and m
 liver inju
ny e
 liver inju
ncluding 
nd 
ncluding 
nd sponso
and
nd sponso
g in abnor
on 
g in abnor
applicati
action mu
tio
action mu
locally fo
lica
locally fo
atory when
plic
atory when
dly availab
app
dly availab
ory tests
ap
ry tests
th

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 73 of 136
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may be 
fatal, and must not occur.
Table 12‒3 summarizes the approach to investigate PDILI.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 74 of 136
Table 12‒3: Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN
≥2xULNb
NA
Hepatology consult.c
Medical Monitor 
must be notified 
within 24 hours 
(eg, by laboratory 
alert) and subject 
discussed with 
Medical Monitor 
ASAP.
Immediate IMP 
discontinuationd.
Essential: Must have 
repeat liver chemistry 
values and additional 
testing completed 
ASAP (see 
Section 12.6.1.3); 
recommended to 
occur at the site with 
HCP.
Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within baseline 
values.e
Monitoring of liver chemistry 
values at least twice per week 
for 2 weeks.e

Immediate IMP 
≥3xULN
NA
Yes
≥5xULN
NA
NA
Need for hepatology 
consult to be 
discussed. (required 
if ALT or AST 
≥8xULN). Medical 
Monitor must be 
notified within 
24hours (eg, by 
laboratory alert) and 
subject discussed 
with Medical Monitor 
ASAP.
PUBLIC COPY 
C
logy 
LIC
logy 
(required
UB
(required
or AST
PU
or AST
)
P
) M
P
M
C
to support any marketing authorization 
27 
n 
27
at
Follow up
tho
Follow up
ho
Evalu
au
Evalu
ut
g a
l: Must hav
keti
l: Must hav
t liver chem
rke
t liver chem
ues and add
ark
ues and add
testing com
mar
testing com
ASAP (s
ma
ASAP (s
Sectio
y m
Sectio
rec
y
rec
tin
y
This document cannot be used to
l
T
l
dical 
ed
dical 
st be 
se
st be 
within
us
within
urs (eg, by 
be u
urs (eg, by 
oratory ale
t be
oratory ale
subject dis
ot b
subject dis
with M
not
with M
ASA
nn
ASA
an
to
extensions or variations thereof.
uation
f
uation
e e 
mistry 
th
mistry 
ditional
s t
ditional
mpleted 
ons
mpleted 
see
ti
see
n
a
n 12.6.1.3
atio
12.6.1.3)
ommended 
iat
ommended 
occur at the
aria
occur at the
HCP.
var
HCP.
Moni
he
Moni
va
h
va
er
th
r v
and any e
ert) and 
any
ert) and 
scussed 
d a
scussed 
edical Mo
nd 
edical Mo
AP.
a
AP.
application a
e

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 75 of 136
Table 12‒3: Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN 
(and ≥2x 
baseline) 
and 
<5xULN 
(and ≥2x 
baseline)
<2xULN
No
Discussion with 
Medical Monitor 
required.
Consider need for 
hepatology consult if 
there is no evidence 
of resolution (see 
Follow-up 
requirements) c
Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section 12.6.1.2).
IMP discontinuation 
required if any of 
the following occur:

Subject cannot 
comply with 
monitoring 
schedule. 

Liver chemistry 
values continue 
to increase 

Liver chemistry 
values remain 
≥3xULN (and 
≥2xbaseline) 
after 2 weeks of 
monitoring 
without 
evidence of 
resolution
Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48hours at 
the site with HCP 
(see Section 
12.6.1.3).
discontinuation required if 
liver chemistry values 
continue to increase. After 2 
weeks of monitoring liver 
chemistry values: 

Discontinue IMP if levels 
remain ≥3xULN (and ≥2x 
baseline) without evidence 
of resolutione
Continue to monitor until values 
normalize, stabilize, or return to 
within baseline valuese.
C COPY 
2.6
Y
2.6
discontin
PY
discontin
quired if
OP
quired if
the follo
CO
the follo

C C

PUBLIC
y marketing authorization 
27 
n 
27
at
Follow up
tho
Follow up
ho
Evalu
au
Evalu
ut
g a
tial: Every
keti
tial: Every
empt must 
rke
empt must 
made to ha
ar
made to ha
repeat l
ma
repeat l
chem
y m
chem
an
y
an
tin
to support any
uation 
any
uation 
any of 
t a
any of 
wing occur
ort 
wing occur
Subject ca
ppo
Subject ca
comply
supp
comply
mon
su
mon
This document cannot be used to
l
T
l
cu
n
to
y
thereof.
uation
f
uation
didi
er
r variations th
y
t
y
be 
s t
be 
ave
n
ave
liver 
io
liver 
mistry valu
atio
mistry valu
nd addition
riat
nd addition
testing c
ari
testing c
within
va
within
the
v
the
extensions or v
ur:
r
ur:
annot 
s o
annot 
y with
ns
y with
nitoring
ion
nitoring
schedule. 
sio
schedule. 

t

Liver 
ten
Liver 
va
te
va
application and any e
pp
at
e
r v
th

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 76 of 136
Table 12‒3: Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal 
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause). 
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor. 
c Details provided in Section 12.6.1.1. The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist. 
d Details are provided in Section 12.6.1.2.1.
e Unless an alternative monitoring schedule is agreed by the Investigator and UCB responsible physician. Determination of stabilization is at the discretion of the 
Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
PUBLIC COPY 
sulted
Y
sulted
oenterolo
PY
oenterolo
UCB resp
CO
UCB resp
B respons
C CO
B respons
ting authorization 
27 
n 
27
at
Follow up
tho
Follow up
ho
Evalu
au
Evalu
ut
g a
This document cannot be used to support any marketin
l
T
l
ransferase; 
ketin
ransferase; 
LN=upper 
rke
LN=upper 
ersensitivity
ark
ersensitivity
be discusse
m
be discusse
he treating p
ny m
he treating p
ist. 
a
ist. 
nsible phy
ort a
nsible phy
ble physicia
por
ble physicia
tin
ereof.
uation
f
uation
application and any extensions or variations ther
HCP=heal
her
HCP=heal
limit of nor
the
limit of nor
y symptom
s t
y symptom
ed with the 
tion
ed with the 
physician f
atio
physician f
sician. Det
va
sician. Det
an, as neede
or v
an, as neede
er

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 77 of 136
12.6.1.1
Consultation with Medical Monitor and local hepatologist 
Potential drug-induced liver injury events require notification of the Medical Monitor within 
24hours (eg, by laboratory alert), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discussed with the local hepatologist. The 
local hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. If determined necessary, this discussion should be followed by a full 
hepatology assessment (see Section 12.6.1.3) and SAE report (if applicable).
12.6.1.2
Immediate action: Determination of IMP discontinuation
All PDILI events require immediate action, testing, and monitoring. 
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) to 
immediate discontinuation (see Section 6.3.1 and Table 12‒3 for details).
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The Investigator should also consider dose 
reduction for medically necessary concomitant medication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative. 
12.6.1.2.1
IMP restart/rechallenge
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may be 
fatal, and must not occur.
12.6.1.3
Testing: Identification/exclusion of alternative etiology
The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility that they may have been caused by the IMP are included but not 
limited to those listed in Table 12‒4 (laboratory measurements) and Table 12‒5 (additional 
information). Results of the laboratory measurements and information collected are to be 
submitted to the sponsor on the corresponding eCRF. If the medical history of the subject 
indicates a requirement for other assessments not included below, these additional assessments 
should be completed and submitted, as applicable.
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.
The following measurements are to be assessed:
Table 12‒4: PDILI laboratory measurements
Virology-
related
Hepatitis A IgM antibody
HBsAg
Hepatitis E IgM antibody
HBcAb-IgM
Hepatitis C RNA
PUBLIC COPY
cation
PY 
cation
patotoxic
OPY
patotoxic
causing 
C C
causing 
cation/e
UBL
cation/e
nal info
PU
nal info
ha
P
ha
This document cannot be used to support any marketing authorization 
f hepatitis
ting
f hepatitis
diate inves
ketin
diate inves
s).
rk
s).
suppleme
mar
suppleme
or should 
y m
or should 
d conside
ny 
d conside
to a suita
any
to a suita
drug
pp
rug-
p
-indu
ppo
indu
xclusion
o s
xclusion
rmation re
d to
rmation re
they may
sed
they may
‒4
u
4 (labor
use
(labor
boratory m
e us
boratory m
n the corre
be 
n the corre
for other a
ot b
for other a
and subm
not
and subm
s should b
ann
s should b
mple must
t ca
mple must
wing meas
ent 
wing meas
e
u
e 12
um
12‒
m
‒4
m
4:
Virology
doc
Virology
related
do
related
cu
s
application and any extensions or variations thereof.
s or 
ere
s or 
stigation)
her
stigation)
ments that 
ons 
ments that 
d also con
tion
d also con
er changin
iatio
er changin
able altern
aria
able altern
uced liver 
s or
uced liver 
n of alte
sion
n of alte
equired fo
ens
equired fo
y have bee
xten
y have bee
ratory me
ext
ratory me
measurem
y e
measurem
esponding
any
esponding
assessmen
d an
assessmen
mitted, as a
nd 
mitted, as a
be stored,
n an
be stored,
t also be s
on 
t also be s
surements
atio
surements
PDILI l
plic
PDILI l
He
pp
He
pp
pp
pp
pp

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 78 of 136
Table 12‒4: PDILI laboratory measurements
Cytomegalovirus IgM antibody
Epstein-Barr viral capsid antigen IgM antibody (if unavailable, obtain heterophile 
antibody or monospot testing)
Immunology
Anti-nuclear antibody (qualitative and quantitative)
Anti-smooth muscle antibody (qualitative and quantitative)
Type 1 anti-liver kidney microsomal antibodies (qualitative and quantitative)
Hematology
Eosinophil count
Urinalysis
Toxicology screen
Chemistry
Amylase
Sodium, potassium, chloride, glucose, BUN, creatinine
Total bilirubin, ALP, AST, ALT, GGT, total cholesterol, albumin
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
Additional
Prothrombin time/INRa
Serum pregnancy test
PK sample
ALT=alanine aminotransferase; AST=aspartate aminotransferase; CPK=creatine phosphokinase; HBcAb-
IgM=hepatitis B core antibody-IgM; HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; 
INR=international normalized ratio; LDH=lactate dehydrogenase; PDILI=potential drug-induced liver injury; 
PK=pharmacokinetic; RNA=ribonucleic acid; ULN=upper limit of normal
a Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).
The following additional information is to be collected:
PY 
ionate
Y
ionate
BLIC COPY
ossible m
OPY
ossible m
PY
OP
C
LIC
PUBL
spartate am
UB
spartate am
; HBsAg
PU
; HBsAg
LDH
P
LDH
BL
marketing authorization 
za
iza
za
z
ho
ut
a
ing
ke
ol, albumin
ma
ol, albumin
ar
ny m
lirubin to 
ny m
lirubin to 
support any m
uscle injury
t any
uscle injury
ny
t a
po
upp
nnot be used to s
inotransfer
to s
inotransfer
hepatitis B 
d to
hepatitis B 
lactate dehy
ed t
lactate dehy
acid; ULN
sed
acid; ULN
>8xULN, 
use
>8xULN, 
ms include 
e u
ms include 
mptoms inc
be 
mptoms inc
This document ca
s
ditional in
ann
ditional in
ions thereof.
of
re
the
n
o
n
s
iatio
obtain % d
atio
obtain % d
ons or varia io
y causing 
aria
y causing 
ia
va
or
s
and any extension
rase; CPK=
sio
rase; CPK=
surface an
nsi
surface an
ydrogenase
ten
ydrogenase
N=upper lim
xte
N=upper lim
elevations 
ex
elevations 
fatigue, na
y e
fatigue, na
lud
n
lude eosino
ny
e eosino
application a
on
nformatio
n an
nformatio

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 79 of 136
Table 12‒5: PDILI information to be collected
New or updated information
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.
Pertinent medical history, including the following:

History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”)

Adverse reactions to drugs

Allergies

Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha-1 antitrypsin 
deficiency)

Recent travel 

Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by itself, 
should not be used as an explanation for significant AST and/or ALT elevations.)
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
Alcohol and illicit drug use
Results of liver imaging or liver biopsy, if done
Results of any specialist or hepatology consult, if done
Any postmortem/pathology reports
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug-induced liver injury
12.6.1.4
Follow-up evaluation
Potential drug-induced liver injury events require follow-up monitoring as described in 
Table 12‒3. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to baseline. Determination of stabilization is at the discretion of the Investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
12.7
Other safety measurements
12.7.1
Vital signs
The Investigator or designee should measure all vital signs (systolic and diastolic blood 
pressure (BP), temperature [oral, axillary, or otic], pulse rate) after the subject has been sitting 
for at least 5 minutes, and the subject should remain seated during the measurements. Body 
temperature should be obtained prior to dosing with IMP at study visits when IMP is 
administered. At Baseline/Day 1, pulse and BP should be collected prior to IMP administration 
and then at 30 minutes and 1 hour after dosing. At all other visits pulse and BP should be 
collected prior to IMP administration.
PUBLIC COPY 
atitis 
Y
atitis 
eased app
PY
eased app
oxemia w
CO
oxemia w
CO
C C
, if done
BL
, if done
LIC
ogy cons
PUB
ogy cons
UB
PU
annot be used to support any marketing authorization 
tty 
o
tty 
a
n
a-
n
-1 antitry
ng 
1 antitry
sease to th
ark
sease to th
ALT elev
ma
ALT elev
za
ypersensiti
ny m
ypersensiti
etite, abdo
any
etite, abdo
m
ith compro
port
ith compro
rt
po
up
ult, if done
to 
ult, if done
o s
d t
spartate am
use
spartate am
se
p evalua
t be
p evalua
ed liver inj
not
ed liver inj
toring sho
ann
toring sho
This document ca
ne. Determ
can
ne. Determ
with the h
nt c
with the h
Ot
n
Ot
7.1
u
7.1
The Inve
doc
The Inve
pressu
s do
pressu
for 
s d
for 
t
and any extensions or variations thereof.
ypsin 
reo
ypsin 
he liver, by
ns t
he liver, by
vations.)
ons
vations.)
ivi
at
ivity (eg, f
atio
ty (eg, f
ominal pai
ria
ominal pai
io
omised ca
or v
omised ca
va
or
ns
io
ns
minotransfer
ext
minotransfer
xte
ation
an
ation
njury even
nd 
njury even
ould cont
an
ould cont
application
i
mination 
on a
mination 
hepatolog
tion
hepatolog
ther saf
cat
ther saf
Vital s
pplic
Vital s
tigator o
app
tigator o
P),
a
P)

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 80 of 136
12.7.2
Body weight and height
Height is collected at the Screening Visit only. Body weight will be measured by the Investigator 
or designee at the time points listed in Table 5‒1. The Investigator or designee will measure the 
height of the subject with shoes removed in meters and the weight of the subject in kilograms. 
The same scale should be utilized throughout the study where possible.
12.7.3
Physical examination
The physical examination should be conducted by the Investigator or designee at the time points 
listed in Table 5‒1 and will include general appearance; ear, nose, and throat; eyes, hair, and 
skin; respiratory; cardiovascular; GI; musculoskeletal; hepatic; neurological (including limb 
reflexes); and mental status. Findings considered clinically significant changes since the physical 
examination at the Screening Visit will be recorded as AEs.
12.7.4
12-lead electrocardiogram
The Investigator or designee will perform the ECG at time points specified in Table 5‒1. The 
ECGs will be read locally. The RR, PR, QRS, QT, and QT intervals corrected for heart rate using 
Fridericia’s formula (QTcF) including changes from Baseline ECG variables will be evaluated.
12.7.5
Tuberculosis and TB risk factor assessment and management
All subjects will be assessed for TB at the Screening Visit and at the time points specified in 
Table 5‒1 through physical examination for signs and symptoms of TB, chest X-ray or CT 
(Section 12.7.5.2), laboratory testing (Section 12.7.5.1), and subject questionnaire 
(Section 12.7.5.3). 
At the Screening Visit, all subjects will have an IGRA test (QuantiFERON TB test is 
recommended), a chest X-ray or CT (unless already performed within 3 months of screening) 
and an examination for signs and symptoms of TB. In addition, each subject will complete a TB 
questionnaire with questions directed at symptoms of TB and potential exposure to TB. 
Exclusion Criteria at Screening
Subjects with known TB infection, at high risk of acquiring TB infection, with LTBI, or current 
or history of NTMB infection.
a.
Known TB infection whether present or past is defined as:

Active TB infection or clinical signs and symptoms suspicious for TB (pulmonary or 
extra-pulmonary)

History of active TB infection involving any organ system or findings in other organ 
systems consistent with TB infection, unless adequately treated and proven to be fully 
recovered upon consult with a TB specialist.

Any evidence by radiography or other imaging modalities consistent with previously 
active TB infection that is not reported in the subject’s medical history
PUBLIC COPY
or asse
PY 
or asse
ening Vi
COP
ening Vi
signs an
CO
signs an
tion
C C
tion 12.
C C
12.
s will ha
UBL
s will ha
r CT (un
PUB
r CT (un
nd sym
P
nd sym
be used to support any marketing authorization 
points 
horiz
points 
r, and 
tho
r, and 
ng limb
auth
ng limb
nc
g
nce the ph
g au
e the ph
ified in
arke
ified in T
e
T
s correcte
mar
s correcte
CG variab
y m
CG variab
sment a
any
sment a
sit and at t
rt a
sit and at t
d symptom
port
d symptom
.5.1
pp
.5.1), and
ppo
), and
ve an IGR
o s
ve an IGR
less alread
d to 
less alread
mptoms of
ed t
mptoms of
ted at sym
sed
ted at sym
g
e
g
This document cannot be
nfection, 
t be
nfection, 
fection.
ot 
fection.
ection whe
nno
ection whe
TB infect
t ca
TB infect
a-
n
-pulmona
nt c
pulmona
History o
men
History o
system
um
system
reco
u
reco

o

ny extensions or variations thereof.
hysical
of.
hysical
Table
s th
Table 5
th
5‒
t
‒1
h
1
ed for hea
ons 
ed for hea
bles will b
tion
bles will b
and man
riat
and man
the time p
var
the time p
ms of TB
or v
ms of TB
d subject 
s or
d subject 
RA test (Q
sion
RA test (Q
ady perfor
nsi
ady perfor
f TB. In a
ten
f TB. In a
mptoms o
exte
mptoms o
application and a
at high ri
any
at high ri
hether pres
and
hether pres
tion or cli
on a
tion or cli
nary)
tio
nary)
of active T
lica
of active T
ms consist
plic
ms consist
overed up
app
overed up
y evi
a
y evi

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 81 of 136
b. High risk of acquiring TB infection is defined as:

Known exposure to another person with active TB infection within the 3 months prior to 
Screening

Time spent in a healthcare delivery setting or institution where individuals infected with 
TB are housed and where the risk of transmission of infection is high
c.
Latent TB infection is defined as:

The absence of signs, symptoms (ie, evidence of organ-specific involvement), or physical 
findings suggestive of TB infection with a positive IGRA test (or 2 indeterminate IGRA 
test results) and a chest X-ray (or other imaging) without evidence of TB infection. If the 
result of the IGRA test is indeterminate, the particular IGRA test previously performed 
may be repeated once; if positive or indeterminate on retest, the subject may not be 
randomized to IMP without further evaluation, treatment and discussion with Study 
Physician, if Latent TB infection is identified. The retest must be done during the 
protocol-defined Screening window.
Note: If available, respiratory or other specimens must also be smear and culture negative for 
TB (Centers for Disease Control [CDC] diagnosis of latent tuberculosis [LTB] infection) 
http://www.cdc.gov/TB/topic /testing/default.htm)
d. Current or history of NTMB infection despite prior or current therapy.
Signs and Symptoms
The Investigator should consider all potential sites of infection when assessing for TB during the 
physical examination, and other evaluations, and based on the subject’s medical or social history. 
The most common primary focus of TB is the lung. Other sites may include gastrointestinal 
system, bone/joints, lymph glands and meninges, etc. However, in immune compromised
patients and/or patients treated with TNF inhibitors, extra-pulmonary manifestations of TB are 
common compared to normal population.
Some common symptoms that the subject may present are dependent on the primary focus of 
infection and may include cough, blood in sputum, night sweats, lymphadenitis, joint 
pain/swelling, spinal deformity, headache/confusion, abdominal pain (mimicking inflammatory 
bowel disease), etc. Unusual presentations should always be considered.
Latent tuberculosis infection is defined in the “Exclusion Criteria” above. If the result of the 
IGRA is indeterminate, the particular IGRA previously performed may be repeated once; if 
positive or indeterminate on retest, the subject may not be randomized to IMP without further 
evaluation by a TB specialist. If LTBI or active TB is identified, subject must undergo 
appropriate study specified withdrawal procedures. The retest must be done during the protocol-
defined Screening window. Laboratory diagnosis should be undertaken via mycobacteria culture 
media (or if available by preferred nucleic acid amplification test such as the Xpert 
mycobacterium tuberculosis [MTB] rifampin [RIF] test) and result must be negative for TB 
inducing pathogens.
PUBLIC COPY
u
Y
u
is of la
PY 
is of la
htm)
OPY
htm)
spite prio
CO
spite prio
potentia
BLIC
potentia
valuatio
UBL
valuatio
us of T
PU
us of T
s
P
s
nnot be used to support any marketing authorization 
physical
hor
physical
nate IGRA
uth
nate IGRA
nfection. I
au
nfection. I
usly perfo
g a
usly perfo
ct may no
ting
ct may no
ussion wit
ketin
ussion wit
be 
be done du
rke
done du
be smear 
y m
be smear 
nt tubercu
ny 
nt tubercu
r or curre
ort 
r or curre
sites of in
sup
sites of in
ns, and bas
to s
ns, and bas
B is the lu
d to
B is the lu
and menin
sed
and menin
with TNF i
use
with TNF i
populatio
be u
populatio
s that the s
t be
s that the s
ude cough
not 
ude cough
al deformi
nno
al deformi
This document ca
etc. Unusu
can
etc. Unusu
ulosis inf
t c
ulosis inf
ndetermin
ent
ndetermin
e or indet
me
e or indet
uation by
um
uation by
ppropriat
ocu
ppropriat
defined
doc
defined
medi
s d
medi
m
s
m
and any extensions or variations thereof.
If the 
of.
If the 
ormed 
eof
ormed 
ot be
ere
ot be
th Study 
ther
th Study 
uring the
s th
uring the
and cultu
tion
and cultu
ulosis [LT
iati
ulosis [LT
ent therap
r va
ent therap
nfection w
ons
nfection w
ased on th
sion
ased on th
ung. Othe
ens
ung. Othe
nges, etc. 
xte
nges, etc. 
inhibitors
ext
inhibitors
on.
y
on.
subject m
any
subject m
h, b
d
h, blood i
d a
lood i
ity, heada
and
ity, heada
application 
ual presen
n an
ual presen
fection is
tion
fection is
nate, the p
atio
nate, the p
terminate
lica
terminate
y a T
ppli
y a TB spe
plic
B spe
te study sp
app
e study sp
reenin
ap
reenin

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 82 of 136
Test Conversion
Tuberculosis test conversion is defined as a positive IGRA result for the current test, when 
previous IGRA test results were negative. All subjects with TB test conversion must immediately 
stop IMP administration. In case of a TB test conversion, the subject must be considered as 
having either a suspected new latent or an active TB infection and be promptly referred to an 
appropriate specialist (eg, pulmonologist, infectious disease specialist) for further evaluation. If 
test conversion indicates LTBI, active TB, or NTMB then, per UCB TB working instructions, 
TB test conversion (confirmed) should be classified adequately, either as due to LTBI, active TB 
infection, or NTMB, respectively. Additional assessments (eg, blood tests or IGRA, chest 
X-rays, or other imaging) should be performed where medically relevant and documented. Such 
conversions should be reported to the UCB PS function.
Latent TB
In case the evaluation by the appropriate specialist indicates a new LTBI during the study, a 
prophylactic TB treatment should be initiated and the subject must be withdrawn.
Every related action should be discussed in advance with the Medical Monitor. 
Once withdrawn from study treatment, subjects should return for the WD Visit, complete all 
WD Visit assessments, and complete a SFU Visit (20 weeks after the final dose of IMP).
Active TB or NTMB infection 
Subjects who develop active TB or NTMB infection during the study must be withdrawn from 
the study. The subject must be immediately discontinued from IMP and an WD Visit must be 
scheduled as soon as possible, but no later than the next scheduled visit. The subject should be 
encouraged to keep the SFU Visit as specified by the protocol. Treatment should be started 
immediately.
Note that subjects with history of NTMB or active NTMB infection are excluded from the study 
regardless of prior or current therapy for this condition. 
12.7.5.1
Tuberculosis assessment by IGRA
During conduct of the study, the TB assessment by IGRA (QuantiFERON TB test is 
recommended) will be performed at Screening and should be repeated at the SFU Visit for all 
subjects. The test results will be reported as positive, negative, or indeterminate. UCB also 
recommends that a TB specialist be consulted where TB (latent or active) is suspected or if there 
are doubts regarding test results. If latent or active TB is identified, subject must undergo 
appropriate study-specified withdrawal procedures. The retest during Screening must be done 
during the protocol-defined Screening window.
12.7.5.2
Chest X-ray for tuberculosis
A plain posteroanterior chest X-ray must be performed during the Screening Period unless one 
has been performed within 3 months prior to the Screening Visit. The chest X-ray (or, if done, 
Computed Axial Tomography of the Chest) must be clear of signs of TB infection (previous or 
current) before first IMP administration. All chest imaging (particularly X-rays) should be 
available for review by the Investigator before randomization of the subject. The chest X-ray 
should be repeated only if the TB test was confirmed positive or any further evidence is 
suggestive of potential lung TB infection (eg, exposure). Radiographic findings suggestive of 
PUBLIC COPY
uld retu
PY 
uld retu
(20 wee
OPY
(20 wee
B infect
C C
B infect
iately di
LIC
iately di
no later t
UBL
no later t
it as spe
PUB
it as spe
ment cannot be used to support any marketing authorization 
s,
r
s,
tive TB
hori
tive TB
est 
th
est 
mented. Su
aut
mented. Su
during th
ket
during th
withdraw
ark
withdraw
dical Mon
ma
dical Mon
for the W
ny 
for the W
ks after th
any
ks after th
on during
ppo
on during
continued
upp
continued
han the ne
o su
han the ne
ified by t
to s
ified by t
NTMB or
sed
NTMB or
erapy for 
us
erapy for 
sis asse
be 
sis asse
study, the
ot 
study, the
be perform
nno
be perform
results w
ann
results w
hat a
ca
hat a TB s
ca
TB s
regarding 
nt c
regarding 
ate study
men
ate study
This docum
g the prot
ume
g the prot
2.7.5.2
ocu
2.7.5.2
A plain
do
A plain
has 
s d
has 
C
s
C
ation and any extensions or variations thereof.
uch
f
uch
he study, 
the
he study, 
wn.
s
wn.
nitor.
ion
nitor.
WD Visit,
iati
WD Visit,
he f
ari
he final do
aria
inal do
fif
ari
fif
g the study
s or
g the study
d from IM
ns 
d from IM
ext schedu
ion
ext schedu
the protoc
nsio
the protoc
r active N
exte
r active N
r this cond
y ex
r this cond
essment
any
essment
e TB asses
d a
e TB asses
rmed at Sc
and
rmed at Sc
will be rep
n an
will be rep
specialist
on 
specialist
g test resu
atio
g test resu
applica
y specified
cat
specified
tocol
plic
tocol-
ic
-defi
c
defi
Che
pp
Che
tero
a
tero

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 83 of 136
inactive TB or active TB may include but are not limited to: apical fibrosis, pleural thickening, 
pulmonary nodules, fibrotic scars, calcified granulomas, upper lobe infiltrates, cavitations and 
pleural effusions, calcified lung nodules, calcified hilar lymph nodes, and pericardial 
calcification.
The chest imaging must be negative for any old or recent TB infection as determined by a 
qualified radiologist and/or pulmonary physician. Any new clinically significant findings post 
Baseline on chest X-ray must be documented in the source documents and the eCRF as an AE.
12.7.5.3
Tuberculosis questionnaire 
The questionnaire “Evaluation of signs and symptoms of tuberculosis” should be used as a 
source document. The questionnaire will be completed at the Screening Visit, Weeks 12, 24, 
and 36, and the SFU Visit. The questionnaire will assist with the identification of subjects who 
may require therapy for TB. A subject who answers “Yes” to the question “Has the subject been 
in close contact with an individual with active TB, or an individual who has recently been treated 
for TB?” at Screening is excluded. A “Yes” response to any of the other questions within the 
questionnaire at Screening should trigger further careful assessment to determine if subject has 
LTB or active TB (see Exclusion Criterion #13, Section 6.2). A “Yes” response to any of the 
questions during the study should trigger further assessments to determine if the subject has 
either LTB or active TB infection. 
Subjects with a latent or active TB infection must be withdrawn from the study.
12.7.5.4
Tuberculosis management
LTB infection and active TB identified during study
During the study, subjects who develop evidence of LTB infection or active TB must 
immediately stop further administration of IMP and will be referred to an appropriate TB 
specialist (pulmonologist or infectious disease specialist) for further evaluation. Evidence of 
LTB infection is defined as subject’s IGRA test converts to positive or indeterminate (and 
confirmed indeterminate on repeat), or the subject’s questionnaire or history and physical 
indicates that TB infection or exposure may have occurred. Evidence of active TB includes, in 
addition to the aforementioned tests, signs and symptoms of organ involvement. In either 
situation, the subject should be carefully assessed by a TB specialist for active TB. Subjects 
diagnosed with active TB or LTB infection should be withdrawn from the study and receive 
appropriate TB or prophylaxis therapy. 
Any presumptive diagnosis or diagnosis of a TB infection is a reportable event. Confirmed active 
TB must be reported as an SAE. The Investigator is to complete and submit the TB follow-up 
Form provided.
The subject should be transferred to the care of his/her physician and managed according to the 
best available standard of care. Subjects identified as having converted to active TB during the 
study must be withdrawn and scheduled to return for the WD Visit as soon as possible but no 
later than the next scheduled study visit and complete all WD Visit assessments. 
The subject should be encouraged to complete a SFU Visit (20 weeks after the final dose of 
IMP).
PUBLIC COPY
n
essmen
PY 
essmen
must be 
CO
must be 
ment
IC C
ment
ed durin
BLIC
ed durin
BL
develop e
PUB
develop e
nistratio
PU
nistratio
ti
P
ti
t be used to support any marketing authorization 
E.
ri
E.
ed as a 
auth
ed as a 
eeks
g a
eeks 12, 2
au
12, 2
of subjec
ng 
of subjec
Has the s
eting
Has the s
has recent
ket
has recent
her questio
arke
her questio
nt to determ
mar
nt to determ
“Yes” res
y m
“Yes” res
to determ
ny 
to determ
withdrawn
ort 
withdrawn
g study
sup
g study
su
vidence o
to s
vidence o
n of IMP 
d to
n of IMP 
ous diseas
sed
ous diseas
ect’s IGRA
use
ect’s IGRA
epeat), or 
be u
epeat), or 
or exposu
t be
or exposu
ment cannot
ntioned te
ot b
ntioned te
should be
no
should be
tive TB o
ann
tive TB o
or prophy
can
or prophy
mptive dia
nt 
mptive dia
t be repor
men
t be repor
This docum
m provided
ume
m provided
The subjec
ocu
The subjec
best ava
doc
best ava
study
s d
study
la
s
la
any extensions or variations thereof.
24, 
of
24, 
cts who
reo
cts who
subject be
here
subject be
ntly been t
the
ntly been t
ons withi
s th
ons withi
rmine if su
ons
rmine if su
esponse to
tion
esponse to
mine if th
iati
mine if th
n from th
r va
n from th
of LTB in
nsio
of LTB in
P and will 
ens
P and will 
se special
xte
se special
RA test con
ext
RA test con
r the subje
ny e
r the subje
ure may h
any
ure may h
pplication and 
ests, signs
d a
ests, signs
e carefull
nd 
e carefull
or LTB in
an
or LTB in
hylaxis the
on a
hylaxis the
agnosis o
atio
agnosis o
rted as an
icat
rted as an
ap
d.
p
d.
ct should 
app
ct should 
ble sta
ap
ble sta

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 84 of 136
If infection with NTMB is identified during the study, the same procedure as for active TB 
acquired during the study must be followed.
12.7.6
Pregnancy testing
A serum human chorionic gonadotropin (hCG) pregnancy test for all women of childbearing 
potential will be performed at the Screening Visit. This recommendation also applies to women 
of childbearing potential with infrequent or irregular menstrual cycles and women during 
menopause. Natural menopause is recognized to have occurred after 12 consecutive months of 
amenorrhea, for which there is no other obvious pathological or physiological cause 
(International Menopause Society, 2015).
Pregnancy testing will performed on urine at all other visits. Pregnancy test results (serum and 
urine) must be negative prior to administering IMP.
12.7.7
Assessment of suicidal ideation and behavior
Suicidal ideation and behavior will be assessed by trained study personnel using the C-SSRS. 
This scale will be used to assess suicidal ideation and behavior that may occur during the study. 
The visits at which the C-SSRS assessments will be performed are specified in the schedule of 
study assessments (Table 5‒1).
The C-SSRS is a standardized and validated instrument developed for the assessment of the 
severity and frequency of suicidal ideation and behavior (Posner et al, 2011; Mundt et al, 2010). 
Subjects respond to standardized clinical questions that are presented in a uniform fashion. The 
C-SSRS defines 5 subtypes of suicidal ideation and behavior in addition to self-injurious 
behavior with no suicidal intent. The C-SSRS takes approximately 3 to 10 minutes to complete. 
Refer to Section 6.3 for C-SSRS-related withdrawal criteria.
13
OTHER STUDY MEASUREMENTS
13.1
Demographic and Baseline characteristics
The Investigator or designee will collect demographic information for all subjects according to 
local rules and regulations. This will include age, gender, race, and ethnicity. Information will 
also be collected on Baseline characteristics for subjects including lifestyle, child bearing 
potential, as applicable, height, weight, and body mass index (BMI). Demographic and baseline 
characteristics information will be recorded in the eCRF.
13.2
Medical history
The Investigator or designee will obtain a complete medical history of AS as part of the 
screening assessment and include all clinically relevant past or coexisting medical conditions, 
responses to AS treatment as available, and surgeries. Findings will be recorded in the eCRF.
13.3
Ankylosing spondylitis history
The Investigator or designee will obtain a detailed history of AS, including the date of onset and 
past treatments for AS. Specific information related to AS history will be recorded in the eCRF.
13.4
Prior and concomitant medications
As part of the medical history, the Investigator or designee will determine prior and concomitant 
medications and record these in the eCRF. 
PUBLIC COPY 
Y
rument d
OPY
rument d
d behav
CO
d behav
uestions
C C
uestions
ideation 
LIC 
ideation 
C
BL
C-
BL
-SSR
BLIC
SSR
related 
PUB
related 
DY 
P
DY 
sed to support any marketing authorization 
s of 
ori
s of 
ts (serum 
g au
ts (serum 
nnel using
arke
nnel using
may occu
mar
may occu
are specifi
y m
are specifi
eveloped 
t an
eveloped 
or (Posne
ort 
or (Posne
that are p
po
that are p
and behav
upp
and behav
 takes app
sup
 takes app
withdrawa
to s
withdrawa
MEASU
ed t
MEASU
This document cannot be u
and Ba
use
and Ba
e will colle
be 
e will colle
s. This wi
t be
s. This wi
aseline ch
not 
aseline ch
able, heigh
nno
able, heigh
formation
an
formation
Medic
nt c
Medic
estigator o
men
estigator o
ning asse
ume
ning asse
sponses to
cum
sponses to
13.3
doc
13.3
The
s 
The
xtensions or variations thereof.
and 
of
and 
g the C
s th
g the C-S
h
S
ur during
ons 
ur during
fied in the
tion
fied in the
d for the a
vari
d for the a
er et al, 20
r va
er et al, 20
present
or
presented 
r 
ed 
vior in add
s o
vior in add
proximate
ons
proximate
al criteria
sio
al criteria
UREM
ten
UREME
application and any e
aseline c
ext
aseline c
lect demo
ny 
lect demo
will includ
any
will includ
haracterist
nd a
haracterist
gh
a
ght, weigh
and
t, weigh
n will be 
n a
n will be 
cal hist
tion
cal hist
or design
icat
or design
essment an
plic
essment an
o AS trea
pp
o AS trea
A
p
A

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 85 of 136
14
STUDY MANAGEMENT AND ADMINISTRATION 
14.1
Adherence to protocol
The Investigator should not deviate from the protocol. However, the Investigator should take any 
measure necessary in deviation from or not defined by the protocol in order to protect clinical 
study subjects from any immediate hazard to their health and safety. In this case, this action 
should be taken immediately, without prior notification of the regulatory authority, IRB/IEC, or 
sponsor.
After implementation of such measure, the Investigator must notify the EPM of the sponsor 
within 24 hours and follow any local regulatory requirements.
14.2
Monitoring
Monitoring of the study will be delegated by UCB to a CRO. The CRO will monitor the study to 
meet the CRO’s monitoring Standard Operating Procedures (SOPs), ICH-GCP guideline, and 
applicable regulatory requirements, and to ensure that study initiation, conduct, and closure are 
adequate. 
The Investigator and his/her staff are expected to cooperate with UCB (or designee) and to be 
available during the monitoring visits to answer questions sufficiently and to provide any 
missing information. The Investigator(s)/institution(s) will permit direct access to source 
data/documents for study-related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s).
The Investigator will allow UCB (or designee) to periodically review all eCRFs and 
corresponding source documents (eg, hospital and laboratory records for each study participant). 
Monitoring visits will provide UCB (or designee) with the opportunity to evaluate the progress 
of the study, verify the accuracy and completeness of eCRFs, ensure that all protocol 
requirements, applicable authorities regulations, and Investigator’s obligations are being 
fulfilled, and resolve any inconsistencies in the study records.
14.2.1
Definition of source data 
All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typing, printing, 
optical disc). They should not be obscured by correction fluid or have temporary attachments 
(such as removable self-stick notes). Photocopies and/or printouts of eCRFs are not considered 
acceptable source documents. 
Source documents are original records in which raw data are first recorded. These may include 
hospital/clinic/general practitioner records, charts, diaries, X-rays, laboratory results, printouts, 
pharmacy records, care records, ECG or other printouts, completed scales, quality of life 
questionnaires, or video, for example. Source documents should be kept in a secure, limited 
access area.
Source documents that are computer-generated and stored electronically must be printed for 
review by the monitor (eg, ECG reports). Once printed, these copies should be signed and dated 
by the Investigator and become a permanent part of the subject’s source documents. The 
Investigator will facilitate the process for enabling the monitor to compare the content of the 
printout and the data stored in the computer to ensure all data are consistent.
PUBLIC COPY 
perat
Y
perat
uestions 
OPY
uestions 
tion(s) w
COP
tion(s) w
, aud
CO
, audits,
CO
its,
designee
BLIC
designee
eg,
UB
eg, hosp
UBL
hosp
UCB (or 
PUB
UCB (or 
y and 
PU
y and 
nnot be used to support any marketing authorization 
or 
iz
or 
onsor 
utho
onsor 
l monitor
eting
l monitor
H-
k
-GCP gu
ket
GCP gu
n, conduct
ark
n, conduct
th UCB
ny m
th UCB (
m
(
ufficientl
any
ufficientl
ill permit
rt a
ill permit
IRB/IEC r
ort
IRB/IEC r
) to period
sup
) to period
tal and lab
o su
tal and lab
designee) 
d to 
designee) 
completen
ed t
completen
s regulati
sed
s regulati
sistencies 
us
sistencies 
of sourc
be 
of sourc
must be ac
ot b
must be ac
d be made
nno
d be made
This document can
y should n
ann
y should n
vable self
t ca
vable self
source doc
nt c
source doc
document
men
document
ital/clinic
um
ital/clinic
harmacy r
ocu
harmacy r
question
doc
question
acces
s d
acces
S
s
S
and any extensions or variations thereof.
r the study
here
r the study
uideline, a
the
uideline, a
t, and clos
ns t
t, and clos
(or design
atio
(or design
ly and to p
aria
ly and to p
t direct ac
var
t direct ac
review, a
r va
review, a
dically rev
ons 
dically rev
aboratory 
sion
aboratory 
) with the 
nsio
) with the 
ness of eC
ten
ness of eC
ions, and 
exte
ions, and 
s in the stu
y ex
s in the stu
ce data 
ny 
ce data 
ccurate, c
d a
ccurate, c
e using so
and
e using so
application a
not be ob
an
not be ob
stick not
on a
stick not
ocuments.
tion
ocuments.
nts are orig
ica
nts are orig
c/general 
plic
c/general 
records, c
app
records, c
aires, o
ap
aires, o

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 86 of 136
14.2.2
Source data verification
Source data verification ensures accuracy and credibility of the data obtained. During monitoring 
visits, reported data are reviewed with regard to being accurate, complete, and verifiable from 
source documents (eg, subject files, recordings from automated instruments, tracings [ECG], 
X-ray films, laboratory notes). All data reported on the eCRF should be supported by source 
documents, unless otherwise specified in Section 14.2.1.
14.3
Data handling
14.3.1
Case Report Form completion
The study will use electronic data capture (EDC); the Investigator will be responsible for prompt 
reporting of accurate, complete, and legible data in the eCRFs and in all required reports.
Any change or correction to the eCRF after saving must be accompanied by a reason for the 
change.
Corrections made after the Investigator’s review and approval (by means of a 
password/electronic signature) will be reapproved by the Investigator.
The Investigator should maintain a list of personnel authorized to enter data into the electronic 
eCRF. Access to the EDC will be given after training has been received. A training certificate 
will be provided and filed.
Serious AE reporting will be done using the SAE Report Form (see Section 12.1.2.3) while also 
entering the event in the appropriate eCRF section. The safety database and the clinical database 
will be reconciled during the study and discrepancies will be corrected as needed.
Detailed instructions will be provided in the eCRF Completion Guidelines.
14.3.2
Database entry and reconciliation
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to check for discrepancies and to ensure consistency of 
the data. The data will be entered into the eCRFs once and will be subsequently verified if the 
study is performed using electronic data capture.
An electronic audit trail system will be maintained within the CDMS to track all data changes in 
the database once the data have been saved initially into the system or electronically loaded. 
Regular backups of the electronic data will be performed.
14.3.3
Subject Screening and Enrollment log/Subject Identification Code list
The subject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
log.
The Investigator will keep a Subject Identification Code list. This list remains with the 
Investigator and is used for unambiguous identification of each subject.
The subject’s consent and enrollment in the study must be recorded in the subject’s medical 
record. These data should identify the study and document the dates of the subject’s 
participation.
PUBLIC COPY
author
PY 
author
ning has 
OPY
ning has 
e SAE R
C C
e SAE R
RF secti
LIC 
RF secti
nd discre
BLIC
nd discre
vided in 
PUB
vided in 
ry an
PU
ry an
This document cannot be used to support any marketing authorization 
ble for pro
aut
ble for pro
d reports.
g a
d reports.
a reason 
ting
a reason 
eans of a 
ark
eans of a 
ator.
m
ator.
d to enter
ny 
d to enter
been recei
any
been recei
eport Form
por
eport Form
on. The sa
upp
on. The sa
pancies w
sup
pancies w
he eCRF 
to s
he eCRF 
d rec
ed t
d reconc
d t
onc
ronic data
use
ronic data
manageme
e us
manageme
manual rev
be 
manual rev
e entered 
ot b
e entered 
ing electr
not
ing electr
dit trail sys
ann
dit trail sys
nce the da
t ca
nce the da
ckups of th
nt c
ckups of th
S
n
S
sub
cu
subject’s
um
ject’s
bjb
um
bjb
log.
do
log.
The In
s do
The In
Inv
s 
Inv
plication and any extensions or variations thereof.
ompt
f.
ompt
n for the 
here
n for the 
r data into
iatio
r data into
ived. A tr
aria
ived. A tr
rm (see
or v
rm (see Se
v
Se
afety data
s o
afety data
will be cor
ons
will be cor
Complet
sio
Complet
ciliation
ten
ciliation
a will be e
ext
a will be e
ment system
y e
ment system
view to c
ny
view to c
into the e
d an
into the e
ronic data
nd 
ronic data
ystem will
an
ystem will
ata have b
on 
ata have b
the electro
tio
the electro
Subject S
lica
Subject S
app
s screenin
ppli
s screenin
gat
a
t

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 87 of 136
14.4
Termination of the study
UCB reserves the right to temporarily suspend or prematurely discontinue this study either at a 
single site, multiple sites, or at all sites at any time for reasons including, but not limited to, 
safety or ethical issues, inaccurate or incomplete data recording, noncompliance, or 
unsatisfactory enrollment with respect to quality or quantity.
If the study is prematurely terminated or suspended, UCB (or its representative) will inform the 
Investigators/institutions and the regulatory authority(ies) of the termination or suspension and 
the reason(s) for the termination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the 
termination or suspension by the sponsor or by the Investigator/institution, as specified by the 
applicable regulatory requirement(s). In addition, arrangements will be made for the return of all 
unused IMP and other material in accordance with UCB procedures for the study.
14.5
Archiving and data retention
The Investigator will maintain adequate records for the study, including eCRFs, medical records, 
laboratory results, Informed Consent documents, drug dispensing and disposition records, safety 
reports, information regarding participants who discontinued, and other pertinent data.
All essential documents are to be retained by the Investigator until at least 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IMP. These documents should be retained 
for a longer period, however, if required by the applicable regulatory requirement(s) or by an 
agreement with UCB (CPMP/ICH/135/95, 2002 [Section 4.9.5]). The Investigator will contact 
UCB for authorization prior to the destruction of any study records or in the event of accidental 
loss or destruction of any study records. The Investigator will also notify UCB should he/she 
relocate or move the study-related files to a location other than that specified in the sponsor’s 
trial master file.
14.6
Audit and inspection
The Investigator will permit study-related audits mandated by UCB, after reasonable notice, and 
inspections by domestic or foreign regulatory authorities.
The main purposes of an audit or inspection are to confirm that the rights and wellbeing of the 
subjects enrolled have been protected, that enrolled subjects (ie, signing consent and undergoing 
study procedures) are appropriate for the study, and that all data relevant for the evaluation of the 
IMP have been processed and reported in compliance with the planned arrangements, the 
protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
requirements.
The Investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory authority is announced, the Investigator will immediately 
inform UCB (or designee).
PUBLIC COPY 
ntinu
Y
ntinu
Investig
OPY
Investig
region a
COP
region a
ICH reg
C CO
ICH reg
opment o
IC C
opment o
red by th
BLIC
red by th
/135/95,
UBL
/135/95,
the destr
PUB
the destr
recor
PU
recor
t be used to support any marketing authorization 
he 
i
he 
and 
ori
and 
y
t
y
r the 
uth
r the 
ified
au
ified by th
au
by th
r the retur
g a
r the retur
tudy.
ting
tudy.
ding eCRF
mark
ding eCRF
g and disp
ma
g and disp
and other 
ny m
and other 
ator until a
t any
ator until a
nd until th
ort a
nd until th
on, or at l
por
on, or at l
f the IMP
ppo
f the IMP
e applicab
sup
e applicab
2002 [Sec
o su
2002 [Sec
uction of a
d to 
uction of a
ds. The In
ed t
ds. The In
files to a 
sed
files to a 
inspect
be 
inspect
ment canno
ermit stud
ot b
ermit stud
stic or for
nno
stic or for
ses of an 
can
ses of an 
lled have 
t ca
lled have 
edures) ar
ent 
edures) ar
ve been p
men
ve been p
This docum
ocol, inve
um
ocol, inve
equiremen
ocu
equiremen
The Inv
do
The Inv
data
s d
data
in
s
in
nd any extensions or variations thereof.
the
of
the
urn of all
eof
urn of all
Fs, medic
ns 
Fs, medic
position re
tion
position re
r pertinen
atio
r pertinen
at least 2 
aria
at least 2 
here are n
va
here are n
least 2 ye
or v
least 2 ye
P. These d
s o
P. These d
ble regula
ons 
ble regula
ction
sion
ction 4.
on
4.9.
n
9.
any study
nsio
any study
nvestigato
ten
nvestigato
location 
exte
location 
ction
any
ction
lication an
dy
d
dy-
d
-related
d a
related
oreign regu
and
oreign regu
audit or i
n a
audit or i
 been pro
tion
 been pro
are approp
atio
are approp
processed
lica
processed
app
estigation
plic
estigation
nts.
ap
nts.
gato
a
gato

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 88 of 136
14.7
Good Clinical Practice
Noncompliance with the protocol, ICH-GCP, or local regulatory requirements by the 
Investigator, institution, institution staff, or designees of the sponsor will lead to prompt action 
by UCB to secure compliance. Continued noncompliance may result in the termination of the 
site’s involvement in the study.
15
STATISTICS
A description of statistical methods follows and will be described in more detail in the SAP. 
Deviations from the original SAP will be documented in the clinical study report (CSR).
15.1
Definition of analysis sets
The Enrolled Set (ES) will consist of all subjects who have given informed consent.
The Randomized Set (RS) will consist of all randomized subjects.
The Safety Set (SS) will consist of all subjects who receive at least 1 dose of the IMP.
The Full Analysis Set (FAS) will consist of all randomized subjects who receive at least 1 dose 
of the IMP and have a valid measurement of the primary efficacy variable at Baseline and at 
least 1 post-baseline efficacy assessment. 
The Per-Protocol Set (PPS) will consist of all subjects in the FAS who have no important 
protocol deviation affecting the primary efficacy variable. The subjects with important protocol 
deviations will be predefined and evaluated during a data evaluation meeting prior to unblinding 
of the data.
The Pharmacokinetics Per-Protocol Set (PK-PPS) will consist of all randomized subjects who 
receive at least 1 dose of the IMP and have at least 1 quantifiable post-dose plasma 
concentration. 
The PET Per-Protocol Set (PET-PPS) will consist of all randomized subjects who receive at least 
1 dose of the IMP and have evaluable PET-CT or PET-MRI scan data at Baseline and at 
at least 1 of the post-Baseline assessments.
Further details of each analysis set along with specifications of analyses by analysis set will be 
provided in the SAP.
15.2
General statistical considerations
Statistical evaluation will be performed by PAREXEL and supervised by the Exploratory 
Statistics and Global Statistical Sciences Departments of UCB.
All analyses will be performed using SAS® Version 9.2 or later (SAS Institute, Cary, NC, USA) 
or R Version 2.10.1 (R Development Core Team) or later, or OpenBUGS Version 3.0.6 or later.
Descriptive statistics will be used to provide an overview of the Baseline, efficacy and safety 
results. For categorical parameters, the number and percentage of subjects in each category will 
be presented by treatment group. The denominator for the percentages will be based on the 
number of subjects appropriate for the purpose of analysis. Unless otherwise noted, all 
percentages will be expressed to 1 decimal place. For continuous parameters, descriptive 
statistics will include n, mean, standard deviation (SD), median, minimum, and maximum. Two-
PUBLIC COPY 
ary e
Y
ary e
subjects 
COP
subjects 
icacy va
C CO
icacy va
ted durin
IC C
ted durin
ol Set (P
UB
ol Set (P
MP and h
PU
MP and h
ent cannot be used to support any marketing authorization 
AP. 
ho
AP. 
R).
ut
R).
nsent.
ing
nsent.
dose of th
ark
dose of th
cts who re
ma
cts who re
acy variab
y m
acy variab
n the FAS
rt a
n the FAS
iable. The
port
iable. The
g a data ev
ppo
g a data ev
K
to
K-
o
-PPS) w
to s
PPS) w
ave at lea
d to
ave at lea
PPS) will
use
PPS) will
valuable P
e u
valuable P
ne assess
be
ne assess
analysis s
not 
analysis s
P.
P.
General
can
General
evaluation
nt c
evaluation
This docume
s and Glo
men
s and Glo
analyses w
um
analyses w
r R Versi
ocu
r R Versi
Descri
do
Descri
resu
s d
resu
b
s
b
ation and any extensions or variations thereof.
he IMP.
s th
he IMP.
eceive at l
ions
eceive at l
ble at Bas
atio
ble at Bas
S who hav
va
S who hav
e subjects
or v
e subjects
evaluation
s or
evaluation
will consis
sion
will consis
ast 1 quan
ns
ast 1 quan
ll consist 
ext
ll consist 
PET
y
PET-
y
-CT o
y e
CT o
ments.
any
ments.
set along
nd a
set along
l statist
n a
l statist
n will be p
atio
n will be p
applica
obal Statis
icat
obal Statis
will be pe
pplic
will be pe
ion 2.10.1
app
on 2.10.1
stat
a
stat

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 89 of 136
sided 95% confidence intervals, geometric means, and coefficient of variation (CV) will be 
presented for selected variables as appropriate.
Baseline for each assessment is defined as either the value obtained at Baseline (Visit 2) or the 
last available value obtained prior to treatment administration at the Screening Visit (Visit 1) 
(details to be specified in the SAP).
Formal statistical testing will be conducted for this study for the primary efficacy variable. Other 
efficacy variables will be summarized descriptively by treatment group. Additional exploratory 
analyses will be conducted as deemed appropriate. 
15.3
Subject disposition 
The number of subjects who were screened, subjects included in each analysis set, and subjects 
who completed/prematurely discontinued the study, as well as the primary reason for 
discontinuation, will be presented by treatment group, and overall using frequency counts and 
percentages.
15.4
Subject characteristics
The following subject characteristics will summarized and listed as appropriate:

Demographics (including gender, age, race, and ethnicity)

Baseline characteristics (including lifestyle, childbearing potential, height, weight, and BMI) 

Medical/procedure history

Prior and concomitant medications/medical procedures 

Baseline disease characteristics
15.5
Planned efficacy analyses
The primary efficacy analyses will be based on the PPS.
15.5.1
Analysis of the primary efficacy variable
The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
Week 12 in the bimekizumab treatment group versus the CZP treatment group. Summary 
statistics will be presented by treatment group for ASDAS at each time point together with the 
changes from Baseline. 
The statistical analysis of the primary efficacy variable will be conducted following a Bayesian 
paradigm. An informative prior will be used for the model intercept coefficient which in the 
primary model is equal to the mean change from Baseline in ASDAS in the CZP group when 
centered Baseline is observed at its mean of zero (βCZP ~ Normal [-1.78, var=0.0605]). Vague 
priors will be used for all other model coefficients. All priors will be fully documented in the 
SAP and in the interim analysis SAP.
The Bayesian analysis will employ a linear regression model including treatment group and 
Baseline ASDAS (mean centered).
The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
bimekizumab groups and of the difference in mean changes from Baseline between the treatment 
PUBLIC COPY 
d and
Y
d and
nd 
OP
nd ethni
OPY
ethni
le, child
CO
le, child
ns/medi
BLI
ns/medi
ics
PU
ics
c
P
c
t be used to support any marketing authorization 
her 
iz
her 
tory 
ori
tory 
et, and su
g a
et, and su
ason for 
ting
ason for 
equency c
ketin
equency c
ed as appr
y m
ed as appr
ity)
a
ity)
bearing po
ort 
bearing po
al proced
sup
al proced
y analys
sed
y analys
will be ba
us
will be ba
of the pri
be 
of the pri
ocument canno
nalysis w
ot 
nalysis w
ekizumab
nno
ekizumab
presented 
ann
presented 
Baseline. 
t ca
Baseline. 
tical analy
ent 
tical analy
gm. An inf
men
gm. An inf
mary mode
um
mary mode
entered B
ocu
entered B
This do
priors w
doc
priors w
SAP 
s d
SAP 
T
s
T
d any extensions or variations thereof.
ubjects
eof
ubjects
counts an
ther
counts an
ropriate:
atio
ropriate:
otential, h
r va
otential, h
dures 
on
dures 
ses
xte
ses
ased on th
y ex
ased on th
imary ef
any
imary ef
application and 
will be the 
d a
will be the 
b treatmen
and
b treatmen
d by treatm
n an
d by treatm
ysis of the
atio
ysis of the
nformative
lica
nformative
el is equa
plic
el is equa
Baseline is
app
Baseline is
l be
ap
be use
ap
use
h

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 90 of 136
groups (CZP - bimekizumab) will be summarized with means, standard deviations, 95% credible
intervals and 95% Highest Posterior Density intervals. The posterior probability that the 
difference between treatment groups in the mean change from Baseline in ASDAS is greater than 
zero will also be presented. The posterior probability that bimekizumab achieves a lower 
ASDAS score at Week 12 compared to CZP will be derived from this distribution.
The study will be considered a success if the posterior probability of the difference in the mean 
change from Baseline in ASDAS between the CZP and bimekizumab treatment groups (CZP -
bimekizumab) being greater than zero is at least 97.5% (ie, the lower bound of the 95% credible 
interval of the difference between treatment groups in the mean change from Baseline in ASDAS 
is zero or greater).
If further information (independent to this study) regarding the CZP treatment group response 
comes to light subsequent to writing this protocol then this prior may be updated prior to study 
unblinding, and details of this will be supplied in the SAP and the CSR. Note that the prior will 
not be updated based upon accrued study data at any time point.
15.5.2
Supportive analysis of the primary efficacy variable
A sensitivity analysis on the choice of the prior distribution for the CZP treatment arm will be 
conducted by repeating the primary analysis assuming vague priors for all parameters of the 
model. 
Additional sensitivity analyses will assess the primary efficacy for alternative analysis sets.
Further analyses may be performed for the primary efficacy variable adjusting for other Baseline 
covariates (to be defined in the SAP). Results from any additional analyses will not be used as a 
substitute for the planned analyses, but may be used as supplemental information for the CSR.
15.5.3
Analysis of the secondary efficacy variables
The secondary efficacy variables are listed in Section 4.1.2.
All secondary efficacy variables will be summarized descriptively by treatment group and time 
point. Estimated effects relating to the categorical variables ASDAS-MI and ASDAS-ID will be 
derived from the primary Bayesian analysis. Further details of the analysis methods for 
secondary efficacy variables will be included in the SAP.
15.5.4
Analysis of the other efficacy variables
The other efficacy variables are listed in Section 4.1.3.
The other efficacy variables will be listed and summarized descriptively by treatment group and 
time point. Any formal statistical analyses of the other efficacy variables will be described in 
more detail in the SAP.
Details of the summaries and analyses of efficacy data assessed during the Treatment Extension 
Period, will be provided in the SAP.
15.6
Pharmacokinetic analyses
Bimekizumab and CZP trough plasma concentrations will be listed and summarized by treatment 
group at each time point for all subjects in the PK-PPS using descriptive statistics. 
PUBLIC COPY
butio
Y
butio
ming vag
PY 
ming vag
he prima
C CO
he prima
the prim
LIC 
the prim
). Result
BLIC
). Result
s, but ma
UBL
s, but ma
e sec
PU
e sec
cannot be used to support any marketing authorization 
-
i
-
redible
hori
redible
in ASDA
tho
in ASDA
group resp
g a
group resp
ated prior
ting
ated prior
Note that th
ketin
Note that th
variable
mar
variable
r the CZP 
y m
r the CZP 
e priors fo
any
e priors fo
ry efficacy
port
ry efficacy
ary efficac
upp
ary efficac
from any
sup
from any
y be used
to s
y be used
ondary e
d to
ondary e
are listed i
sed
are listed i
es will be
e u
es will be
ating to th
be 
ating to th
y Bayesia
ot b
y Bayesia
ariables w
not
ariables w
nalysis o
ann
nalysis o
This document 
ficacy vari
t ca
ficacy vari
r efficacy
en
r efficacy
point. Any
me
point. Any
re detail i
cum
re detail i
Details o
doc
Details o
Perio
s do
Perio
1
s
1
on and any extensions or variations thereof.
ponse
eof
ponse
r to study 
ereo
r to study 
th
th
the prior w
ther
e prior w
o
P treatmen
atio
P treatmen
for all par
riat
for all par
y for alter
or v
y for alter
acy variab
s o
acy variab
y addition
ons
y addition
d as suppl
sion
d as suppl
efficacy 
ens
efficacy 
in
e
in Section
xte
Section
e summar
y e
e summar
he categor
any
he categor
an analysi
d an
an analysi
will be inc
nd 
will be inc
of the o
n an
of the ot
applicatio
riables are
tion
riables are
y variable
cati
y variable
y formal s
plica
y formal s
in the SA
ppl
in the SA
f the sum
ap
the sum
be
b

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 91 of 136
15.7
Immunological analyses
Immunological variables will be analyzed for all subjects in the PK-PPS.
Anti-bimekizumab and anti-CZP antibody data will be summarized at each scheduled visit, and 
the rate of ADA positive subjects for each treatment group will be calculated and presented.
15.8
Planned safety and other analyses
15.8.1
Safety analyses
All safety variables will be analyzed for all subjects in the SS.
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA®, version 19.0). The incidence of treatment-emergent adverse events (TEAEs) will be 
summarized descriptively by MedDRA system organ class, preferred term, and treatment group. 
Additional tables will summarize TEAEs by intensity and relationship to IMP, TEAEs leading to 
withdrawal from the study, serious TEAEs, and deaths. All AE information will be listed.
Laboratory values, ECGs, vital signs, physical examination, and extent of exposure will be 
presented descriptively by treatment group. The C-SSRS data will be listed only.
15.9
Handling of protocol deviations
After all data have been verified/coded/entered into a database, a data review will be performed. 
The purpose of this review will be to check all protocol deviations, define the PPS, and check the 
quality of the data. The review will also help decide how to manage problems in the subjects’ 
data (eg, missing values, withdrawals, dropouts, and protocol deviations). 
Accepted deviations from theoretical time points will be described in the appropriate documents 
and included in the Study Master File. After the pre-analysis review, resolution of all issues, and 
documentation of all decisions, the database will be locked.
15.10
Handling of dropouts or missing data
Appropriate missing data imputation methods will be used according to the variable being 
analyzed. Details will be included in the SAP.
15.11
Planned interim analysis and data monitoring
This study will include 3 informal unblinded interim analyses; the first after approximately 
45 subjects have completed 4 weeks of the study, the second when the last randomized subject 
not participating in the PET-MRI or PET-CT substudy has completed the Week 12 Visit at the 
end of the Treatment Period or has withdrawn prematurely from the study, and the third when 
the last randomized subject has completed the Week 12 Visit at the end of the Treatment Period 
or this subject’s participation has ended prematurely. 
The purpose of these interim analyses is for Sponsor key personnel to review results from the 
primary efficacy analysis and a subset of the analyses of secondary efficacy and safety outcomes 
to facilitate additional Clinical Planning or Portfolio Management decisions; consequently, none 
of the interim analyses will lead to any formal decision to alter or terminate the study. 
Interim analyses will be conducted by an unblinded study team and will follow internal SOPs for 
the formal process to control the unblinding of the study for interim analysis purposes. This 
process will ensure that no unnecessary or unintentional unblinding occurs. The unblinded team 
PUBLIC COPY 
Y
ons
PY
ons
into a d
COP
into a d
all proto
CO
all proto
help
IC
help dec
C C
dec
dropout
BLIC
dropout
cal time
UBL
cal time
er File
PU
er File A
U
A
the d
P
the d
nnot be used to support any marketing authorization 
Activities
aut
Activities
(TEAEs)
g a
(TEAEs)
nd treatme
ting
nd treatme
MP, TEA
ketin
MP, TEA
tion will b
rke
tion will b
tent of ex
mar
tent of ex
ill be liste
y m
ill be liste
atabase, a 
rt a
atabase, a 
col deviat
port
col deviat
de how to
ppo
de how to
s, and pro
supp
s, and pro
points wil
to s
points wil
After the p
d to
After the p
atabase w
ed 
atabase w
ropouts
use
ropouts
putation m
be u
putation m
ncluded i
t be
ncluded i
ned inte
not
ned inte
This document ca
nclude 3 in
an
nclude 3 in
ve compl
t ca
ve compl
ating in th
nt c
ating in th
he Treatm
men
he Treatm
st random
ume
st random
this subje
cum
this subje
The pur
doc
The pur
prim
s d
prim
to
s
to
and any extensions or variations thereof.
) will be
eof.
) will be
ment group
ereo
ment group
AEs leadin
her
AEs leadin
be listed.
the
be listed.
xposure w
ons 
xposure w
ed only.
tion
ed only.
a data revi
var
a data revi
tions, defi
or v
tions, defi
o manage 
s or
o manage 
otocol dev
ns 
otocol dev
ill be desc
sion
ill be desc
pre
n
pre-
ns
-analy
nsi
analy
will be loc
ten
will be loc
s or mis
ext
s or mis
methods w
ny 
methods w
in the SA
any
in the SA
erim ana
nd 
erim ana
application a
informal u
n an
informal u
leted 4 we
on 
leted 4 we
the PET
atio
the PET-
o
-M
ment Perio
icat
ment Perio
mized sub
plic
mized sub
ect’s parti
ppl
ect’s parti
se of t
ap
se of t

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 92 of 136
will not disclose any unblinded information to the blinded study team and the storage of all 
unblinded documentation will be held securely and separately from the rest of the study 
documentation and outputs up until the end of the study.
All analyses and unblinding instructions will be prespecified in the interim SAP.
15.12
Determination of sample size
A sufficient number of subjects will be enrolled in order to ensure at least 60 subjects are 
available at Week 12 to compare the change from Baseline in ASDAS between bimekizumab 
and CZP and at least 25 subjects will be enrolled into the PET-CT/MRI substudy.
Subjects will be randomized in a 2:1 ratio to receive bimekizumab or CZP respectively. 
The sample size was calculated to provide at least 80% power to detect a difference between 
treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group mean 
change from Baseline for CZP and bimekizumab being -1.78 and -2.67 respectively) with a 
common standard deviation of 1.17 using frequentist methods for the comparison of the 
treatment group mean change from Baseline in ASDAS at Week 12 with Baseline ASDAS as a 
covariate (Overall and Starbuck, 1979). The correlation between Baseline and Week 12 raw 
ASDAS was assumed to be 0.35. Note that the informative prior for the model intercept to be 
used in the Bayesian modelling of the primary efficacy variable, given by βCZP ~ Normal (-
1.78,var=0.0605), contributes an effective sample size of approximately 20 CZP subjects. A 
prior data conflict test will be performed and a vague prior will be used for the model intercept 
coefficient if this test indicates prior data conflict.
16
ETHICS AND REGULATORY REQUIREMENTS
16.1
Informed consent
Subject’s informed consent must be obtained and documented in accordance with local 
regulations, ICH-GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the subject in both oral and written form by the Investigator (or 
designee). Each subject will have the opportunity to discuss the study and its alternatives with 
the Investigator.
Prior to participation in the study, the Informed Consent form should be signed and personally 
dated by the subject and by the person who conducted the informed consent discussion 
(Investigator or designee). The subject must receive a copy of the signed and dated Informed 
Consent form. As part of the consent process, each subject must consent to direct access to 
his/her medical records for study-related monitoring, auditing, IRB/IEC review, and regulatory 
inspection.
If the Informed Consent form is amended during the study, the Investigator (or the sponsor, if 
applicable) must follow all applicable regulatory requirements pertaining to the approval of the 
amended Informed Consent form by the IRB/IEC and use of the amended form.
All studies conducted at centers in the United States must include the use of a Health Insurance 
Portability and Accountability Act Authorization form.
PUBLIC COPY
mati
PY
mative
Y 
ve
ficacy va
OPY
ficacy va
mple size 
COP
mple size 
d a vagu
C CO
d a vagu
a conflic
IC C
a conflic
EGULA
BLI
EGULA
sent
PUB
sent
t be
P
t be
ment cannot be used to support any marketing authorization 
mab
o
mab
vely.
au
vely.
ence betw
ng 
ence betw
of 0.89 (g
ting
of 0.89 (g
espectivel
ket
espectivel
compariso
arke
compariso
2 with Ba
mar
2 with Ba
n Baseline
y m
n Baseline
rior for th
ny 
rior for th
riable, giv
t any
riable, giv
of approx
rt a
of approx
e prior wi
por
e prior wi
ATOR
sup
ATORY 
up
Y 
obtained 
ed 
obtained 
nts, and th
use
nts, and th
f Helsinki
e us
f Helsinki
d consent
t be
d consent
abl
o
able to the
ot b
e to the
ect will h
nno
ect will h
cipation in
t ca
cipation in
he subject
ent 
he subject
gator or d
men
gator or d
This docum
sent form.
um
sent form.
s/her med
ocu
s/her med
inspectio
doc
inspectio
If th
s d
If th
a
s
a
lication and any extensions or variations thereof.
ween 
eo
ween 
group mea
here
group mea
ely) with a
the
ely) with a
son of the
s th
son of the
aseline AS
ons
aseline AS
e and We
tion
e and We
he model 
iati
he model 
ven by βC
aria
ven by βC
ximately 2
va
ximately 2
ill be used
or v
ill be used
REQU
ons
REQU
and docu
xten
and docu
he ethical
ext
he ethical
ki.
y
ki.
t, informa
any
t, informa
e subject 
d a
e subject 
have the o
and
have the o
n the stud
tion
n the stud
t and by t
atio
t and by t
designee)
ica
designee)
appl
m. As part 
plic
m. As part 
dical reco
app
dical reco
n
a

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 93 of 136
Separate ICFs will be required for subjects participating in the pharmacogenetic and 
pharmacogenomic substudy and in the PET-MRI or PET-CT substudy conducted at selected 
sites.
The subject may withdraw his/her consent to participate in the study at any time. A subject is 
considered as enrolled in the study when he/she has signed the Informed Consent Form. An 
eCRF must not be started, nor may any study specific procedure be performed for a given 
subject, without having obtained his/her written consent to participate in the study.
16.2
Subject identification cards
Upon signing the Informed Consent form, the subject will be provided with a subject 
identification card in the language of the subject. The Investigator will fill in the subject 
identifying information and medical emergency contact information. The Investigator will 
instruct the subject to keep the card with him/her at all times.
16.3
Institutional Review Boards and Independent Ethics 
Committees
The study will be conducted under the auspices of an IRB/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki.
The Investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies with 
the requirements of the current ICH-GCP version or applicable country-specific regulations will 
be responsible for the initial and continuing review and approval of the clinical study. Prior to 
initiation of the study, the Investigator/UCB will forward copies of the protocol, Informed 
Consent form, IB, Investigator’s curriculum vitae (if applicable), advertisement (if applicable), 
and all other subject-related documents to be used for the study to the IRB/IEC for its review and 
approval.
Before initiating a study, the Investigator will have written and dated full approval from the 
responsible IRB/IEC for the protocol.
The Investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, and any protocol deviations, 
to eliminate immediate hazards to subjects.
The Investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the subjects. For 
minor changes to a previously approved protocol during the period covered by the original 
approval, it may be possible for the Investigator to obtain an expedited review by the IRB/IEC as 
allowed.
As part of the IRB/IEC requirements for continuing review of approved studies, the Investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropriate to the degree of subject risk involved, but no less than 
once per year. The Investigator should provide a final report to the IRB/IEC following study 
completion.
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active Investigators in accordance with applicable regulatory requirements. 
PUBLIC COPY
RB
Y
RB
ples th
PY 
ples th
propriate
CO
propriate
version 
C C
version 
nuing rev
LIC
nuing rev
tor/UCB
BLI
tor/UCB
curriculu
UB
curriculu
cument
PU
cument
This document cannot be used to support any marketing authorization 
t 
a
t 
subject 
g au
subject 
stigator w
ng 
stigator w
nt Ethics
rke
nt Ethics
as defined
y m
as defined
have their
ny 
have their
ly constitu
ort 
ly constitu
or applicab
ppo
or applicab
iew and ap
upp
iew and ap
will forwa
sup
will forwa
m vitae (i
to s
m vitae (i
 to be use
d to
 to be use
vestigator 
us
vestigator 
protocol.
be u
protocol.
o promptl
ot b
o promptl
ms in
no
ms involvin
not
volvin
diate hazar
nno
diate hazar
or will not
ca
or will not
xcept whe
nt c
xcept whe
anges to a
ent
anges to a
val, it may
me
val, it may
wed.
cum
wed.
As part o
doc
As part o
will b
s do
will b
req
s 
req
application and any extensions or variations thereof.
will
re
will
cs
s
cs
ed in local
tion
ed in local
ir origin in
riati
ir origin in
tute
r
tuted IRB/
r va
d IRB/
able count
or 
able count
approval o
ns o
approval o
ward copie
ions
ward copie
if applica
sio
if applica
ed for the
ens
ed for the
r will have
ex
r will have
ly report t
d an
ly report t
ing risks t
nd a
ing risks t
ards to sub
and
ards to sub
ot make an
on a
ot make an
ere necess
tion
ere necess
a previou
cati
a previou
ay be poss
plica
ay be poss
f the I
ap
the IRB
p
RB
on
a

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 94 of 136
The appropriate IRB/IEC will also be informed by the Investigator or the sponsor, as specified 
by the applicable regulatory requirements in each concerned country. Where applicable, 
Investigators are to provide the sponsor (or its representative) with evidence of such IRB/IEC 
notification.
16.4
Subject privacy
UCB staff (or designee) will affirm and uphold the subject’s confidentiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by the subject number 
assigned at Screening.
The Investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of the 
subject’s primary medical records that directly concerns this study (including, but not limited to, 
laboratory test result reports, ECG reports, admission/discharge summaries for hospital 
admissions occurring during a subject’s study participation, and autopsy reports for deaths 
occurring during the study).
16.5
Protocol amendments
Protocol changes may affect the legal and ethical status of the study and may also affect the 
statistical evaluations of sample size and the likelihood of the study fulfilling its primary 
objective.
Significant changes to the protocol will only be made as an amendment to the protocol and must 
be approved by UCB, the IRB/IEC, and the regulatory authorities (if required), prior to being 
implemented.
17
FINANCE, INSURANCE, AND PUBLICATION
Insurance coverage will be handled according to local requirements.
Finance, insurance, and publication rights are addressed in the Investigator and/or CRO 
agreements, as applicable.
18
REFERENCES
Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of 
active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody 
infliximab. Arthritis Rheum. 2000;43:1346-52.
Braun J. Axial spondyloarthritis: thoughts about nomenclature and treatment targets. Clin Exp 
Rheumatol. 2012;30:S132-5.
Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379-90.
Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 
2010 update of the ASAS/EULAR recommendations for the management of ankylosing 
spondylitis. Ann Rheum Dis. 2011;70:896-904.
Braun J, van der Heijde D. Imaging and scoring in ankylosing spondylitis. Best Pract Res Clin 
Rheumatol. 2002;16:573-604.
PUBLIC COPY
atus of 
PY 
atus of 
lihood o
OPY
lihood o
nly be m
C C
nly be m
d the reg
LIC
d the reg
NSURA
PUB
NSURA
led
P
led
This document cannot be used to support any marketing authorization 
er 
o
er 
the releva
auth
the releva
at portion
g au
at portion
but not li
ng 
but not li
for hospi
eting
for hospi
reports fo
ket
reports fo
e study an
ny 
e study an
the study
t any
the study
de as an a
ppo
de as an a
ulatory au
upp
ulatory au
NCE,
d to
NCE, A
according
ed 
according
ion rights
use
ion rights
ENCES
t b
ENCES
Cornely D
nno
Cornely D
spondyli
ann
spondyli
thritis Rhe
t ca
thritis Rhe
Axial spon
ent 
Axial spon
atol. 2012
men
atol. 2012
aun J, Siep
cum
aun J, Siep
Braun J, 
doc
Braun J, 
2
s d
2010 
do
010 
spo
s 
spo
application and any extensions or variations thereof.
van
f
van
n of th
of
n of the
f.
e
imited to,
reo
imited to,
ital
he
ital
for deaths
the
for deaths
nd may al
iati
nd may al
y fulfilling
aria
y fulfilling
amendme
or 
amendme
uthorities 
ns o
uthorities 
AND PU
nsio
AND PU
g to local 
xten
g to local 
s are addr
ex
s are addr
S
d
S
D, Golder
and
D, Golder
itis with th
an
itis with th
heum. 200
on a
heum. 200
ndyloarthr
atio
ndyloarthr
2;30:S132
ica
2;30:S132
per J. Ank
ppli
per J. Ank
van den 
ap
an den 
of
a
f

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 95 of 136
Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, et al. Efficacy of 
sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis 
and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis. 
2006;65:1147-53.
Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to 
defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing 
Spondylitis Functional Index. J Rheumatol. 1994;2:2281-5.
Chabaud M, Lubberts E, Joosten L, van den Berg W, Miossec P. IL-17 derived from juxta-
articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis 
Res. 2001;3:168–77. 
CPMP/ICH/135/95. Note for guidance on good clinical practice. July 2002. 
CPMP/EWP/556/95. Guideline on clinical investigation of medicinal products other than 
NSAIDs for treatment of rheumatoid arthritis. Mar 2015. 
Dauden E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson D, et al. Improvements 
in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or 
paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol 
Venereol. 2009;23(12):1374-82.
Diderichsen PM, Cox E (Quantitative Solutions BV, Breda, NL). Comparative effectiveness 
modeling of treatment in ankylosing spondylitis. Final Report. UCB Celltech; 2016 Feb. Project 
report No.: UCB-MBMA-AS-164.
Davis JC, Mease PJ. Insights into the pathology and treatment of spondyloarthritis: from the 
bench to the clinic. Semin Arthritis Rheum. 2008;38(2):83-100. 
Even-Sapir E, Mishani E, Flusser G, Metser U: 18F-Fluoride positron emission tomography and 
positron emission tomography/computed tomography. Semin Nucl Med. 2007;37:462–9.
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to 
defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease 
Activity Index. J Rheumatol. 1994;21:2286-91.
Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, et al. No efficacy of 
subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann 
Rheum Dis. 2007;66:419-21.
Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active 
ankylosing spondylitis. Ann Rheum Dis. 2005;64:124-6.
Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh KC, et al. Estimates of the 
prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis 
Rheum. 2008;58:15-25.
International Menopause Society. Cornwall, UK: Menopause Terminology; c2015. 
http://www.imsociety.org/menopause_terminology.php. Accessed 25 Jan 2016.
Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of 
certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing 
PUBLIC COPY
YSTEL
PY 
YSTEL
ns BV, B
CO
ns BV, B
dylitis. F
C C
dylitis. F
he patho
UBL
he patho
itis Rheu
PUB
itis Rheu
er G,
P
er G,
nnot be used to support any marketing authorization 
ta
th
ta-
h
-
Arthritis
uth
Arthritis
ucts other
ketin
ucts other
rtson D, e
mar
rtson D, e
ients rece
y m
ients rece
udy. J Eu
ny 
udy. J Eu
Breda, NL
ort 
Breda, NL
nal Repor
po
nal Repor
ogy and tr
o su
ogy and tr
m. 2008;3
to s
m. 2008;3
Metser U
ed t
Metser U
mputed to
sed
mputed to
dy LG, W
e u
dy LG, W
nkylosing
be 
nkylosing
matol. 1994
ot b
matol. 1994
C, Song IH
nno
C, Song IH
ument ca
thotrexate
ann
thotrexate
007;66:41
t ca
007;66:41
Rudwalei
ent 
Rudwalei
sing spond
men
sing spond
This docu
lmick CG
cum
lmick CG
prevalenc
docu
prevalenc
Rheum
do
Rheum
Int
s 
Int
and any extensions or variations thereof.
er than
her
er than
et al.
ons
et al. Imp
ns
Imp
eiving con
tion
eiving con
ur Ac
iati
ur Acad D
ati
ad D
L). Compa
r va
L). Compa
rt. UCB C
or 
rt. UCB C
treatment 
ion
treatment 
38(2):83
nsio
38(2):83
U: 18F
ten
U: 18F-
en
-Flu
n
Flu
omograph
exte
omograph
Whitelock
y e
Whitelock
g spondyl
any
g spondyl
4;21:228
d an
4;21:228
IH, Brand
and
IH, Brand
plication a
e in activ
n an
e in activ
19
o
19-
o
-21.
on
21.
eit M, Bra
atio
eit M, Bra
ndylitis. A
lica
ndylitis. A
app
G, Felson 
ppl
G, Felson 
e of arthr
app
e of arthr
08;5
a
08;5

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 96 of 136
spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann 
Rheum Dis. 2014;73:39-47.
Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, et al. Ustekinumab 
significantly improves symptoms of anxiety, depression, and skin-related quality of life in 
patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-
controlled phase III trial. J Am Acad Dermatol. 2010;63(3):457-65. 
Lories RJU, Luyten FP, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone 
formation in spondyloarthritis. Arthritis Res Ther. 2009;11:221.
Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an 
ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann 
Rheum Dis. 2009;68:18-24.
Mease PJ, Fleischmann R, Wollenhaupt J, Deodhar A, Gladman D, Hoepken B, et al. Long-term 
safety and efficacy of certolizumab pegol in patients with psoriatic arthritis with and without 
prior anti-tumor necrosis factor exposure: 96-week outcomes from the RAPID-PsA trial. 
Presented at the European League Against Rheumatism (EULAR) 2014 Congress. Abstract 
#OP0077.
Miossec P. Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and 
implication for clinical practice. RMD Open. 2017;3(1):e000284). 
Mundt JC, Greist JH, Gelenberg AJ, Katzelnick DJ, Jefferson JW, Modell JG. Feasibility and 
Validation of a Computer-Automated Columbia-Suicide severity Rating Scale Using Interactive 
Voice Response Technology. J Psychiatr Res. 2010;44(16):1224-8.
Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of 
rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis 
Rheum. 2010;62:1576-82.
Nam, JM. A simple approximation for calculating sample sizes for detecting linear trend in 
proportions. Biometrics. 1987;43(3):701-5.
National Research Council Panel on Handling Missing Data in Clinical Trials. The prevention 
and treatment of missing data in clinical trials. Washington DC: National Academies Press. 
2010. Ogdie A, Weiss P. The Epidemiology of Psoriatic Arthritis. Rheum Dis Clin North Am. 
2015;41(4):545-68.
Ono T, Okamoto K, Nakashima T, Nitta T, Hori S, Iwakura Y, et al. IL-17-producing γδ T cells 
enhance bone regeneration. Nat Commun. 2016;11;7:10928.
Osta B, Lavocat F, Eljaafari A, et al. Effects of interleukin-17A on osteogenic differentiation of 
isolated human mesenchymal stem cells. Front Immunol. 2014;5:425.
Overall J, Starbuck R. Sample size estimation for randomized pre-post designs. Journal of 
Psychiatric Research. 1979;15(1):51-5. 
Pavy S, Brophy S, Calin A. Establishment of the minimum clinically important difference for the 
bath ankylosing spondylitis indices: a prospective study. J Rheumatol. 2005;32:80-5.
Poddubnyy D. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet 
Dis. 2013;5:45-54.
PUBLIC COPY 
e pathog
OPY
e pathog
2017;3(1
COP
2017;3(1
elnick D
C C
elnick D
olumbia
LIC 
olumbia
hiatr Res
BLI
hiatr Res
remers H
PUB
remers H
sults fr
PU
sults fr
t be used to support any marketing authorization 
f an
aut
f an
ndylitis. 
g au
ndylitis. A
u
A
ken B, et a
ketin
ken B, et a
ritis with 
rke
ritis with 
he RAPID
ark
he RAPID
) 2014 Co
ma
) 2014 Co
nesis of in
any
nesis of in
:e000284
rt a
:e000284
, Jefferson
po
, Jefferson
Suicide s
upp
Suicide s
. 2010;44
sup
. 2010;44
M, Thern
to s
M, Thern
m Olmste
d to
m Olmste
tion for ca
us
tion for ca
87;43(3):7
be u
87;43(3):7
This document cannot
cil Panel 
ot b
cil Panel 
ing data i
not
ing data i
eiss P. Th
ann
eiss P. Th
68.
ca
68.
amoto K, 
nt c
amoto K, 
bone rege
men
bone rege
a B, Lavoc
um
a B, Lavoc
solated hu
ocu
solated hu
Overal
do
Overal
Psy
s d
Psy
any extensions or variations thereof.
Ann
of
Ann
al. 
h
al. Long
her
Long
and with
th
and with
D
n
D-PsA tria
ns t
PsA tria
ongress. A
ions
ongress. A
inflammat
aria
inflammat
4).
v
4).
n JW, Mo
or 
n JW, Mo
severity R
s o
severity R
4(16):1224
ons
4(16):1224
neau T
nsio
neau TM, 
io
M, 
ed County
ens
ed County
alculating
y ex
alculating
701
n
701
application and a
-
ny
-5.
ny
5.
on Hand
d an
on Hand
in clinica
nd 
in clinica
he Epidem
an
he Epidem
Nakashim
atio
Nakashim
generation
cat
generation
ocat F, Elj
plic
ocat F, Elj
uman mes
app
uman mes
Starb
a
Starb

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 97 of 136
Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, et al. Effect of 
non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial 
spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 
2012;71:1616-22.
Ramiro S, van der Heijde D, van Tubergen A, Stolwijk C, Dougados M, van den Bosch F, et al. 
Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 
12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014;73:1455-61.
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The 
Columbia-Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From 
Three Multisite Studies With Adolescents and Adults. Am J Psychiatry. 2011;168(12):1266-77.
Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondyloarthritis in the United States: 
estimates from a cross-sectional survey. Arthritis Care Res (Hoboken). 2012;64:905-10.
Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral 
spondyloarthritis. Curr Opin Rheumatol. 2010;22:375-80.
Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker-Hermann E, Zeidler H, et al. The early 
disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception 
Cohort. Arthritis Rheum. 2009a;60:717-27.
Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The 
Assessment of SpondyloArthritis International Society classification criteria for peripheral 
spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25-31.
Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development 
of Assessment of SpondyloArthritis international Society classification criteria for axial 
spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty 
appraisal. Ann Rheum Dis. 2009b;68:770-6.
Shah et al. unpublished data/abstract submitted European League Against Rheumatism; 14–17 
June 2017. 
Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment 
of SpondyloArthritis International Society (ASAS) handbook: a guide to assess 
spondyloarthritis. Ann Rheum Dis. 2009;68(Supple 2):ii1-44.
Sieper J, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F, et al. Rapid 
improvements in patient-reported outcomes with certolizumab pegol in patients with axial 
spondyloarthritis, including ankylosing spondylitis: 24-Week results of RAPID-axSpA trial. 
European League Against Rheumatism (EULAR) 2013b, Congress 2013; Abstract # THU0360.
Sieper J, Rudwaleit M, van der Heijde D. Long-term safety and efficacy of certolizumab pegol in 
patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial 
spondyloarthritis: 96-week outcomes of the RAPID-axSpA trial. Presented at the European 
League Against Rheumatism (EULAR) 2014 Congress. Abstract #SAT0351.
Snaith RP, Zigmond AS. The hospital anxiety and depression scale, with the irritability-
depression-anxiety scale and the Leeds situational anxiety scale manual. 1994.
PUBLIC COPY
he Ger
PY 
he Ger
Akkoc N
CO
Akkoc N
onal Soc
C C
onal Soc
itis in ge
LIC 
itis in ge
Heijde D
UBL
Heijde D
ritis inte
PUB
ritis inte
ificatio
PU
ificatio
b
P
b
nnot be used to support any marketing authorization 
ndings Fro
uth
ndings Fro
12):1266
au
12):1266
the Unite
ng 
the Unite
2;64:905
eting
2;64:905
and periph
rke
and periph
nn E, Zeid
y m
nn E, Zeid
an Spondy
ny 
an Spondy
N, Brandt J
ort 
N, Brandt J
iety classi
po
iety classi
neral.
upp
neral. Ann
pp
Ann
, Listing J
o su
, Listing J
national S
to s
national S
n of paper
d to
n of paper
68:770
sed
68:770-
d
-6.
d
6.
ststract sub
us
ract sub
Baraliakos
ot b
Baraliakos
Internatio
not
Internatio
ocument can
Ann Rheu
ann
Ann Rheu
z A, van T
t ca
z A, van T
nts in pat
nt c
nts in pat
oarthritis, 
men
oarthritis, 
pean Leag
ume
pean Leag
ieper J, R
ocu
ieper J, R
This do
patients
doc
patients
spon
s d
spon
Le
s
Le
nd any extensions or variations thereof.
o
-
f
-77.
f
77.
ed States:
reo
ed States:
10.
e
10.
heral 
th
heral 
dler H, et
tion
dler H, et
yloarthrit
iati
yloarthrit
J, Chou C
r va
J, Chou C
ification c
or 
ification c
n Rheum 
s o
n Rheum 
J, Brandt 
ion
J, Brandt 
Society cl
nsio
Society cl
r patients 
ens
r patients 
bmitted Eu
y ex
bmitted Eu
os X, Bran
d an
os X, Bran
onal Socie
nd 
onal Socie
application a
um Dis. 2
an
um Dis. 2
Tubergen
on 
Tubergen
tient
atio
tient-
tio
-repo
io
repo
, including
cat
, including
gue Again
plic
gue Again
Rudwaleit
app
Rudwaleit
a
ith axi
ap
ith axi

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 98 of 136
Strobel K, Fischer DR, Tamborrini G, Kyburz D, Stumpe KD, Hesselmann RG, Johayem A, von 
Schulthess GK, Michel BA, Ciurea A. 18F-fluoride PET/CT for detection of sacroiliitis in 
ankylosing spondylitis. Eur J Nucl Med Mol Imaging. 2010; 37:1760–65.
van der Heijde D, Dougados M, Davis J, Weisman MH, Maksymowych W, Braun J, et al. 
Assessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of 
America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis 
Rheum. 2005;52:386-94.
van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al. 
Radiographic findings following two years of infliximab therapy in patients with ankylosing 
spondylitis. Arthritis Rheum. 2008;58:3063-70.
van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, et al. Adalimumab 
effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: 
long-term results from the ATLAS trial. Ann Rheum Dis. 2009;68:922-9.
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing 
spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 
1984;27:361-68.
van Tubergen A, Black PM, Coteur G. Are patient-reported outcome instruments for ankylosing 
spondylitis fit for purpose for the axial spondyloarthritis patient? A Qualitative and Psychometric 
Analysis. Rheum. 2015;54:1842-51.
van Tubergen A, Debats I, Ryser L, Londoño J, Burgos-Vargas R, Cardiel MH, et al. Use of a 
numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. 
Arthritis Rheum. 2002a;47:242-8.
van Tubergen A, Coenen J, Landewé R, Spoorenberg A, Chorus A, Boonen A, et al. Assessment 
of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum. 
2002b;47:8-16.
Wein MN, Jones DC, Shim JH, et al. Control of bone resorption in mice by Schnurri-3. Proc Natl 
Acad Sci. 2012;109:8173–8. 
PUBLIC COPY 
nt
O
nt-
P
-reporte
OPY
reporte
loarthrit
COP
loarthrit
ndoño J,
LIC 
ndoño J,
modality
BLI
modality
ndewé 
PU
ndewé 
i
P
i
This document cannot be used to support any marketing authorization 
, et al
tho
, et al.
o
.
ylosing
uth
ylosing
Adalimum
ng 
Adalimum
p to 2 yea
eting
p to 2 yea
.
k
.
criteria fo
mark
criteria fo
Arthritis
ma
Arthritis
d outcom
any
d outcom
s patient? 
rt a
s patient? 
Burgos
upp
Burgos-
p
-V
p
V
in ankylo
sup
in ankylo
R, Spoore
d to
R, Spoore
ng spondy
sed
ng spondy
JH, et al. 
be u
JH, et al. 
–
t
–8.
t b
8.
application and any extensions or variations thereof.
mab 
reo
mab 
ars:
he
ars:
for ankylo
ns t
for ankylo
s Rheum.
ons
s Rheum.
me instrum
aria
me instrum
? A Qualit
va
? A Qualit
Vargas R, 
s o
Vargas R, 
osing spon
ons
osing spon
enberg A, 
ens
enberg A, 
ylitis: a ps
xte
ylitis: a ps
Control o
ny 
Control o

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 99 of 136
19
APPENDICES
19.1
Modified New York (mNY) Classification Criteria for AS
Table 19‒1: Modified New York (mNY) Classification Criteria for AS
Diagnosis
1. Clinical criteria:
a.
Low back pain and stiffness for more than 3 months which improves with exercise, but is 
not relieved by rest 
b.
Limitation of motion of the lumbar spine in both the sagittal and frontal planes.
c.
Limitation of chest expansion relative to normal values corrected for age and sex.
2. Radiologic criterion:
Sacroiliitis grade ≥2 bilaterally or grade 3 to 4 unilaterally
Grading
1. Definite ankylosing spondylitis if the radiologic criterion is associated with at least 1 
clinical criterion
AS=ankylosing spondylitis; mNY=modified New York Criteria
Note: A second grading of “probably ankylosing spondylitis” is part of the modified NY criteria, but it is not 
applicable for this study. It is included here for completeness. The grading will be probable ankylosing 
spondylitis if 3 clinical criteria are present and the radiologic criterion is present without any signs or 
symptoms satisfying the clinical criteria (other causes of sacroiliitis should be considered).
COPY 
logic cri
OPY
logic cri
Y
PUBLIC C
w York C
C C
w York C
ing spond
LIC 
ing spond
ere for 
BLIC
ere for co
IC
co
esent and 
UBL
esent and 
iteria (oth
PUB
iteria (oth
C
ort any marketing authorization 
but is
tho
but is
al planes.
g a
al planes.
for age an
ting
for age an
z
riz
eti
m
erion is as
t any
erion is as
ny
This document cannot be used to suppor
iteria
po
iteria
ylitis” is pa
pp
ylitis” is pa
mpleteness. 
sup
mpleteness. 
he radiolog
su
he radiolog
r causes of
to s
r causes of
or
r variations thereof.
nd sex.
ere
nd sex.
f.
he
on
associated
aria
associated
at
application and any extensions or 
rt of the mo
s o
rt of the mo
The gradin
ns 
The gradin
ic criterion
ion
ic criterion
f sacroiliitis
sio
f sacroiliitis
r v

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 100 of 136
19.2
Markedly abnormal laboratory values
Table 19‒2: Definitions of markedly abnormal hematology values
Parameter (SI units)
Markedly Abnormal Definition
Low
High
Hemoglobin (g/dL)
<LLN 
AND 
>2.0 decrease from baseline
N/A
Hemoglobin (g/dL)
<8.0
N/A
Leukocytes (total x 1000)
<2.0
N/A
Lymphocytes (x 1000)
<0.5
N/A
Neutrophils (x 1000)
<1.0
N/A
Platelets (x 1000)
<50
N/A
LLN=lower limit of normal; N/A = Not Applicable: SI=standard international
Data source: modified from Appendix Rheumatology Common Toxicity Criteria v.2.0 presented in 
Woodworth et al, 2007
a Withdrawal criteria for neutrophils is <0.5 (Section 6.3)
Table 19‒3: Definitions of markedly abnormal biochemistry values
Parameter (SI units)
Markedly Abnormal Definition
Low 
High
Alkaline Phosphatase
N/A
>3 x ULN
ALT
N/A
>3 x ULN
AST
N/A
>3 x ULN
Calcium (mg/dL)
<7.0
>12.5
Creatinine (mg/dL)
N/A
>1.8 x ULN
Glucose (mg/dL)
<40
>250
Potassium (mmol/L)
<3.0
>6.4
Sodium (mmol/L)
<125
N/A
Total bilirubin
N/A
≥2 x ULN
Uric acid
N/A
≥3 x ULN
ALT=alanine aminotransferase; AST=aspartate aminotransferase; N/A=Not applicable; SI=standard international; 
ULN=upper limit of normal
PUBLIC COPY
inte
Y
inte
n Toxici
PY 
n Toxici
)
C
)
kedly ab
BLIC
kedly ab
BL
U
This document cannot be used to support any marketing authorization 
a
za
/A
a
/A
ut
N/A
ng
N/A
a
N/A
n
N/A
ing
ke
ar
m
nal
y
nal
Criteria v.2
ny
Criteria v.2
m
normal b
sup
normal b
s
to
ed
us
us
us
us
us
be
/dL)
no
/dL)
ot
e (mg/dL)
ann
e (mg/dL)
nn
cose (mg/d
t ca
cose (mg/d
ca
otassium (
ent
otassium (
nt
Sodiu
me
Sodiu
me
um
oc
s
ALT
s 
ALT
s d
s d
application and any extensions or variations thereof.
of
A
h
A
re
N/A
s th
N/A
the
N/A
ns
N/A
s 
2.0 present
riat
2.0 present
io
biochem
ons 
biochem
Marked
sio
Marked
on
Low 
ten
Low 
ns
N/
t
N/
te
ex
ny
d a
d
n
dL)
io
dL)
n
(mmol/L)
cati
(mmol/L)
tio
um (mmol/
plic
um (mmol/
ca
Total bili
app
Total bili
pl
Ur
a
Ur
ap

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 101 of 136
19.3
Protocol Amendment 1
Rationale for the amendment
The purpose of this protocol amendment is the following: 

Sections summarizing the use of concomitant DMARDs have been updated for internal 
consistency.

hs-CRP was added to the assessments at Screening.
In addition, minor clarifications were made and typographical errors were corrected.
Modifications and changes
Global changes
No global changes have been made.
Specific changes
Change #1 
Section 1, Summary, paragraph 8

Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in 
order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 
Has been changed to:

Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in 
order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 
PUBLIC COPY 
 Week 0
LIC 
 Week 0
seline (V
BLI
seline (V
the certo
UB
the certo
e used to support any marketing authorization 
through W
upp
through W
isit 2), W
sup
isit 2), W
lizumab p
to s
lizumab p
W from We
use
W from We
at Baselin
e us
at Baselin
This document cannot be
nd vs the 
be 
nd vs the 
y extensions or variations thereof.
Week
ns o
Week 10.
o
10.
Week 2 (V
ons
Week 2 (V
pegol (CZ
sio
pegol (CZ
eek 0 thro
exte
eek 0 thro
ine (Visit 
y ex
ine (Visit 
application and any
e certolizu
ny 
e certolizu

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 102 of 136
Change #2
Table 5-1, Schedule of assessments, Screening
Study Period
S
C
r
Treatment Period
Treatment Extension Period
SF
Ua
Visitb/Week 
(Visit window 
±3 days)
V
1
V
2
V
3
V
4
V
5
V
6
V7
V8
V9
V1
0
V1
1
V1
2
V1
3
V1
4
V1
5
V1
6
V1
7
V1
8
Procedures
S
V
B
L 
W
0
W
2
W
4
W
6
W
8
W
10
W
12
W
16
W
20
W
24
W
28
W
32
W
36
W
40
W
44
W
48
/
W
D
W
64
Blood sample 
for hs-CRPk
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Has been changed to:
Study Period
S
C
r
Treatment Period
Treatment Extension Period
SF
Ua
Visitb/Week 
(Visit window 
±3 days)
V
1
V
2
V
3
V
4
V
5
V
6
V7
V8
V9
V1
0
V1
1
V1
2
V1
3
V1
4
V1
5
V1
6
V1
7
V1
8
Procedures
S
V
B
L 
W
0
W
2
W
4
W
6
W
8
W
10
W
12
W
16
W
20
W
24
W
28
W
32
W
36
W
40
W
44
W
48
/
W
D
W
64
Blood sample 
for hs-CRPk
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Change #3
Table 5-1, Schedule of assessments, footnote g
g The physical examination includes the evaluation of signs and symptoms of active TB, risk for exposure to TB, 
height (Screening only) and weight (Baseline, Week 12 and Week 48/WD only).
Has been changed to:
g The physical examination includes the evaluation of signs and symptoms of active TB, risk for exposure to TB, 
height (Screening only) and weight (Screening, Week 12 and Week 48/WD only).
PUBLIC COPY 
Y
CO
7
C
7
V8
C C
V8
CO
CO
CO
BL C CO
PUBL
W
U
W
6
PU
6
W
UB
W
8
U
8
BL
BL
BL
PUBL
to support any marketing authorization 
at
V1
iza
V1
8
riz
8
at
at
thor zat
W
u
W
44
au
44
W
th
W
48
48
th
tho
eti g
utho
X
X
ke
X
et
et
arket
Treatment
any
Treatment
y
V9
p
V9
V1
po
V1
0
p
0
or
supp
cannot be used to su
r
W
10
d t
10
W
o s
W
12
o
12
W
su
su
su
u ed to su
u
X
u
X
u
t be
b
u
This document 
Schedu
t ca
Schedu
cal examin
ent
cal examin
Screening o
me
Screening o
as been 
cum
as been 
g
d
g The phy
doc
The phy
height 
s do
height 
ns or variations thereof.
8
/
o
/
W
reo
W
D
re
D
6
f
6
her of
X
t
X
X
h
X
he
ns the
Extension
ria
Extension
at
V1
o
V1
1
s o
1
V1
r 
V1
r v
ons
n and any extensions or v
W
s
W
16
ns
16
W
io
W
20
i
20
on
e te si n
X
e
X
e
X
e
an
applicatio
e
ule of as
tion
ule of as
nation inclu
cati
nation inclu
only) and w
lica
only) and w
n change
ppl
n change
a
cal exam
ap
cal exam
ing
a
ing

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 103 of 136
Change #4
Section 7.8.1 Permitted concomitant treatments (medications and 
therapies)
The following concomitant medications are permitted during the study:
Subjects may use NSAIDs under the following conditions:

Subjects who are already receiving an established NSAID regimen and have been on a stable 
dose for at least 2 weeks prior to Baseline may continue their use during the study. However, 
initiation of, or increase in dosage of NSAIDs during the study (especially in subjects with a 
history of GI intolerance to NSAIDs or a history of GI ulceration) should be done with 
caution and must not occur until after the Week 12 Visit.
Subjects may use corticosteroids under the following conditions:

Oral (maximum allowed ≤10mg daily total prednisone equivalent)—subjects are permitted to 
decrease their oral corticosteroid therapy dose equivalent and/or alter their regimen only after 
Week 12
Subjects may use sulfasalazine and/or hydroxychloroquine under the following conditions:

Sulfasalazine (maximum SSZ ≤3g daily) and/or hydroxychloroquine (≤400mg daily) are 
allowed. No change in dose or dose regimen is allowed during the study except for reasons of 
intolerance, where the DMARD dose may be reduced or discontinued.
Subjects may use MTX under the following conditions:

No change in dose or dose regimen of MTX is allowed during the study except for reasons of 
intolerance/AEs. No increase of the MTX dose is permitted. No change is permitted in the 
route of administration for MTX (intramuscular [im], sc, or oral). It is strongly recommended 
that subjects taking MTX are also taking folic acid supplements. No combinations of 
DMARDs are permitted during the study.
Has been changed to: 
The following concomitant medications are permitted during the study:
Subjects may use NSAIDs under the following conditions:

Subjects who are already receiving an established NSAID regimen and have been on a stable 
dose for at least 2 weeks prior to Baseline may continue their use during the study. However, 
initiation of, or increase in dosage of NSAIDs during the study (especially in subjects with a 
history of GI intolerance to NSAIDs or a history of GI ulceration) should be done with 
caution and must not occur until after the Week 12 Visit.
Subjects may use corticosteroids under the following conditions:

Oral (maximum allowed ≤10mg daily total prednisone equivalent)—subjects are permitted to 
decrease their oral corticosteroid therapy dose equivalent and/or alter their regimen only after 
Week 12
Subjects may use MTX, sulfasalazine (SSZ), or hydroxychloroquine (HCQ) under the following 
conditions:
PUBLIC COPY
oquine
PY 
oquine
d/or hyd
OP
d/or hyd
men is al
CO
men is al
may be r
C C
may be r
owing c
BLIC
owing c
gimen of
UB
gimen of
se of th
PU
se of th
MTX
P
MTX
document cannot be used to support any marketing authorization 
stable
oriz
stable
However,
thor
However,
ects with 
uth
ects with 
one with 
au
one with 
—
r
—subjects
rke
subjects
alter thei
mar
alter thei
nder the f
ny 
nder the f
roxychloro
rt a
roxychloro
owed dur
ort 
owed dur
educed or
ppo
educed or
onditions:
sup
onditions:
MTX is a
to s
MTX is a
MTX do
d to
MTX do
(intramu
ed 
(intramu
also takin
use
also takin
uring the s
e us
uring the s
o: 
t
o: 
mitant med
not 
mitant med
NSAIDs 
ann
NSAIDs 
who are al
t ca
who are al
or at least 
ent 
or at least 
ation of, o
men
ation of, o
istory of 
um
istory of 
caution 
cu
caution 
This do
Subject
do
Subject

s 

application and any extensions or variations thereof.
ts are perm
s th
ts are perm
ir regimen
ns 
ir regimen
following
iati
following
roquine (≤
var
roquine (≤
ring the st
r va
ring the st
r discontin
or 
r discontin
allowed d
sio
allowed d
ose is perm
ens
ose is perm
uscular [im
xten
uscular [im
ng folic ac
ext
ng folic ac
study.
y e
study.
dications 
nd a
dications 
under the
an
under the
already rec
ion 
already rec
2 weeks 
atio
2 weeks 
or increas
icat
or increas
GI intole
plic
GI intole
and mus
pp
and mus
may us
ap
may us

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 104 of 136

No change in dose or dose regimen of these agents is allowed during the study except for 
reasons of intolerance/AEs. No increase of the dose is permitted. No change is permitted in 
the route of administration for MTX (intramuscular [im], sc, or oral). It is strongly 
recommended that subjects taking MTX are also taking folic acid supplements. No 
combinations of DMARDs are permitted during the study.
Change #5 
Table 7-2, Prohibited or restricted medications and required wash-out 
periods prior to Baseline (MTX, SSZ, and HCQ)
Drug class
Dose
Exclusion criteria
…
MTX
Any dose regimen
Use within 12 weeks prior to the Baseline 
Visit 
SSZ
Any dose
Use within 12 weeks prior to the Baseline 
Visit 
HCQ
Any dose
Use within 12 weeks prior to the Baseline 
Visit 
…
ADA=adalimumab; COX-2=cyclooxygenase 2; CZP=certolizumab pegol; DMARD=disease modifying 
antirheumatic drug; ETN=etanercept; GOL=golimumab; HCQ=hydroxychloroquine; IFX=infliximab; 
ia=intra-articular; im=intramuscular; iv=intravenous; MTX=methotrexate; NSAID=nonsteroidal 
anti-inflammatory drug; sc=subcutaneous; SSZ=sulfasalazine; TNF=tumor necrosis factor 
Has been changed to:
Drug class
Dose
Exclusion criteria
…
MTX
Any dose regimen
Use within 12 weeks prior to the Baseline 
Visit 
SSZ
Any dose
Use within 12 weeks prior to the Baseline 
Visit 
MTX, SSZ, and HCQ
Maximum allowed: 
SSZ ≤3g daily 
HCQ ≤400mg daily 
MTX ≤25mg weekly
Use initiated and/or any change in the 
dose regimen in the 28 days prior to the 
Baseline Visit. No change is permitted in 
the route of administration for MTX (im, 
sc, or oral) in the 28 days prior to the 
Baseline Visit.
HCQ
Any dose
Use within 12 weeks prior to the Baseline 
Visit 
…
PUBLIC COPY 
Y
OP
C C
ase 2; 
BL
ase 2; CZ
LI
CZ
GOL=go
UB
GOL=go
r; iv=intr
PUB
r; iv=intr
taneous
PU
taneous
LIC
This document cannot be used to support any marketing authorization 
ut 
th
ut 
a
ing
in 12 week
ma
in 12 week
ar
Use within 1
ny 
Use within 1
Visit 
an
Visit 
y m
t
Use w
rt 
Use w
V
r
V
t a
ort
po
=certolizum
sup
=certolizum
mumab; H
o s
mumab; H
venous; MT
d to
venous; MT
SSZ=sulfa
d t
SSZ=sulfa
up
D
u
D
u
be
ot
an
Z, and HC
en
Z, and HC
nt 
s d
s d
H
s d
s d
s d
application and any extensions or variations thereof.
of
re
ks prior to t
ons
ks prior to t
s
12 weeks p
iat
12 weeks p
tio
within 12 w
r va
within 12 w
isit 
o
isit 
a
o
n
mab pegol; 
ons
mab pegol; 
CQ=hydro
sion
CQ=hydro
TX=metho
nsi
TX=metho
t
salazine; T
tens
salazine; T
ns
Dose
ny
Dose
e
ny
d
An
An
d a
d
a
CQ
c
CQ
tio

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 105 of 136
Drug class
Dose
Exclusion criteria
ADA=adalimumab; COX-2=cyclooxygenase 2; CZP=certolizumab pegol; DMARD=disease modifying 
antirheumatic drug; ETN=etanercept; GOL=golimumab; HCQ=hydroxychloroquine; IFX=infliximab; 
ia=intra-articular; im=intramuscular; iv=intravenous; MTX=methotrexate; NSAID=nonsteroidal 
anti-inflammatory drug; sc=subcutaneous; SSZ=sulfasalazine; TNF=tumor necrosis factor 
Change #6
Section 8.1, Screening Visit (Visit 1)
The following bullet has been added:

Collect samples for hs-CRP.
Change #7
Section 8.1, Screening Visit (Visit 1)

Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
then at 30 minutes and 1 hour after dosing.
Has been changed to:

Measure vital signs (temperature, pulse, and blood pressure).
Change #8
Section 8.2, Baseline (Visit 2, Week 0)

Measure vital signs (temperature, pulse, and blood pressure).
Has been changed to:

Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
then at 30 minutes and 1 hour after dosing.
Change #9
Section 12.7.5, Tuberculosis and TB risk factor assessment and 
management), latent TB
Latent TB
In case the evaluation by the appropriate specialist indicates a new LTBI during the study, a 
prophylactic TB treatment should be initiated and the IMP can be continued no sooner than 4 
weeks after start of prophylactic TB treatment, if it is deemed likely by the Investigator that 
prophylactic TB treatment is continued to completion.
If prophylaxis is not initiated, the subject must be withdrawn.
Has been changed to:
PUBLIC COPY 
d pres
PY
d pres
se, and b
C C
se, and b
sit 2
PU
sit 2
This document cannot be used to support any marketing authorization 
re) prior to
ny m
re) prior to
lood press
ppo
lood press
Week 0
ed t
Week 0
ture, pulse
use
ture, pulse
(temperatu
ot b
(temperatu
s and 1 ho
not
s and 1 ho
9
n
9
n 12.7.5
men
n 12.7.5
agemen
ume
agemen
atent TB
ocu
atent TB
oc
In case
do
In case
prop
s d
prop
s
application and any extensions or variations thereof.
to IMP ad
iatio
to IMP ad
sure).
s or
sure).
0)
t
0)
se, and blo
ext
se, and blo
ture, pulse
d an
ture, pulse
our after d
nd 
our after d
5, Tuber
cat
5, Tuber
nt), late
plic
nt), late
eval
a
eval

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 106 of 136
Latent TB
In case the evaluation by the appropriate specialist indicates a new LTBI during the study, a 
prophylactic TB treatment should be initiated and the subject must be withdrawn.
Change #10
Section 12.7.5.4, Tuberculosis management, LTB infection and active TB 
identified during study, paragraph 2
If a TB specialist excludes an active TB infection the subject can proceed with the IMP no earlier 
than 4 weeks after the start of an appropriate prophylactic therapy.
Has been deleted.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
no earlier 
hor
no earlier 
application and any extensions or variations thereof.

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 107 of 136
19.4
Protocol Amendment 2
Rationale for the amendment
The purpose of this amendment is to revise the withdrawal criteria section to provide instructions 
for the management of subjects with newly diagnosed IBD or with IBD flares during the study.
In the statistical analysis section of the protocol, text describing the planned analysis of the 
primary efficacy variable was updated, and text describing the planned interim analyses and 
sample size re-estimation was revised. The rationale for this is that the observed pattern of 
subject recruitment is not as expected at the time of study planning. Consequently, an insufficient 
number of subjects will have completed the Week 12 visit and be evaluable for response at the 
time of the first interim analysis. The risk of performing an analysis with a very small amount of 
data is that the estimates obtained from the analysis will be unstable and the risk of committing a 
Type II error will be inflated. To mitigate these risks it was decided to remove the formal futility 
and sample size re-estimation aspects from the first interim analysis.
In addition, it was further clarifed that PET-MRI or PET-CT scans for subjects at selected sites 
participating in the substudy will be performed at Screening and during the study at Week 12 and 
Week 48/Early Withdrawal Visit if PET positive lesions were observed in the previous scan.
Modifications and changes
Global changes
No global changes have been made.
Specific changes
Change #1
STUDY CONTACT INFORMATION
The Sponsor study physician and Clinical Trial Biostatistician have been 
changed:
Sponsor Study Physician
Name:
Address:
UCB Celltech, 208 Bath Rd, Slough, Berkshire, SL1 3WE, UK
Phone:
Fax:
PUBLIC COPY 
ons w
Y
ons w
RMA
P
RMA
t cannot be used to support any marketing authorization 
h
nsufficien
tho
nsufficien
onse at th
auth
onse at th
mall amo
g au
mall amo
sk of
ng
sk of com
g 
com
ove the fo
eting
ove the fo
or 
or subject
mark
subject
during the
ma
during the
observed 
ny m
observed 
TION
ed
TION
cian and
use
cian and
ysician
ot b
ysician
no
nn
s:s:
an
This document c
one:
ent
one:
t c
Fax:
me
Fax:
en
um
n
nd any extensions or variations thereof.
he
f
he
ount of 
of.
ount of 
mmitting a
reo
mmitting a
ormal futil
here
ormal futil
ts at selec
ns 
ts at selec
e study at
ion
e study at
d in the pr
atio
d in the pr
nd Clinic
ext
nd Clinic
nd
cation a
UCB C
on 
UCB C
a
io
applicatioioioio
tio
ca
pl
an
io

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 108 of 136
Clinical Trial Biostatistician
Name:
Address:
UCB Celltech, 208 Bath Rd, Slough, Berkshire, SL1 3WE, UK
Phone:
Fax:
Change #2 
Section 5.1, Study description
A new paragraph has been added at the end of this section:
In approximately 25 subjects at selected sites, a PET-MRI or PET-CT scan will be performed at 
Screening and during the study at Week 12 and Week 48/Early Withdrawal Visit if PET positive 
lesions were observed in the previous scan.
Change #3 
Section 5.1.2, Treatment Period (Week 0 to Week 12), bullet #1
Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
treatments: 

Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in 
order to maintain the blind vs the CZP loading dose at these visits. 

CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200mg sc Q2W in 
Weeks 6 to 10.
Study treatments will be prepared and administered by appropriately trained unblinded site 
personnel. 
A formal unblinded interim analysis will be conducted when approximately 45 subjects have 
completed the Week 4 Visit during the Treatment Period. In addition, an informal unblinded 
interim analysis of the primary efficacy variable is planned when the last randomized subject has 
completed the Week 12 Visit or the subject has discontinued prematurely from the study. Further 
details on the interim analyses planned for this study are included in Section 15.11 and in the 
interim Statistical Analysis Plan (SAP).
Has been changed to: 
Eligible subjects will be randomized in a 2:1 ratio to to receive the following blinded study 
treatments: 

Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in 
order to maintain the blind vs the CZP loading dose at these visits. 
PUBLIC COPY 
Week 0 
C CO
Week 0 
a 2:1 rat
LIC 
a 2:1 rat
W from W
PUB
W from W
at Bas
PU
at Bas
t
P
t
ument cannot be used to support any marketing authorization 
can will b
rke
can will b
hdrawal V
mark
hdrawal V
to Week
port
to Week
o to recei
upp
o to recei
Week 0 thr
to 
Week 0 thr
line (Visi
d to
line (Visi
he CZP lo
sed
he CZP lo
eks 0, 2, a
e us
eks 0, 2, a
e prepared
ot b
e prepared
ded interim
can
ded interim
Week 4 V
t ca
Week 4 V
alysis of th
nt c
alysis of th
ed the We
men
ed the We
ls on the i
ume
ls on the i
This docu
terim Stat
cum
terim Stat
Has b
doc
Has b
Elig
s 
Elig
plication and any extensions or variations thereof.
be perform
th
be perform
Visit if
ns t
Visit if PE
t
PE
k 12), bu
or v
k 12), bu
ive the fo
s o
ive the fo
hrough W
nsio
hrough W
it 2), Wee
tens
it 2), Wee
oading do
xte
oading do
and 4 (loa
y ex
and 4 (loa
d and adm
d an
d and adm
m analysi
n an
m analysi
Visit duri
ion 
Visit duri
he primar
atio
he primar
eek 12 Vi
icat
eek 12 Vi
interim an
plic
interim an
app
tistical An
ppl
tistical An
n cha
ap
n cha

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 109 of 136

CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200mg sc Q2W in 
Weeks 6 to 10.
Study treatments will be prepared and administered by appropriately trained unblinded site 
personnel. 
Change #4 
Section 5.3, Imaging evaluation, paragraph 1
In a subpopulation of AS0013, a PET-MRI or PET-CT scan of the entire spine will be performed 
at selected sites in approximately 25 subjects at Screening, Week 12, and at Week 48/Early 
Withdrawal Visit. 
Has been changed to: 
In a subpopulation of AS0013, a PET-MRI or PET-CT scan of the entire spine will be performed 
at selected sites in approximately 25 subjects at Screening, and during the study at Week 12 and 
Week 48/Early Withdrawal Visit if PET positive lesions were observed in the previous scan. 
Change #5 
Section 5.7, Schedule of assessments, Table 5-1, footnote c
A separate Informed Consent Form is required for subjects participating in the 2 sub-studies: 
1) with biomarker, pharmacogenomic and nonhereditary pharmacogenomic blood-samples and 
2) PET-MRI or PET-CT scans.
Has been changed to: 
A separate Informed Consent Form is required for subjects participating in the 2 sub-studies: 
1) with biomarker, pharmacogenetic and nonhereditary pharmacogenomic blood-samples and 
2) PET-MRI or PET-CT scans.
Change #6 
Section 5.7, Schedule of assessments, Table 5-1, footnote o
A PET-MRI or Pet-CT scan should be done up to 2 weeks before Baseline and within 2 weeks 
after the W12 and W48/WD Visit. If a subject withdraws from the study early, the PET-MRI or 
PET-CT scan must be repeated at the WD visit only, if the prior examination was done more 
than 12 weeks prior to the WD visit.
Has been changed to: 
A PET-MRI or PET-CT scan should be done up to 2 weeks before Baseline and within 2 weeks 
after the W12 and W48/WD Visit if PET-positive lesions are observed in the previous scan. If 
a subject withdraws from the study early, the PET-MRI or PET-CT scan must be repeated at the 
WD visit only, if the prior examination was done more than 12 weeks prior to the WD visit and 
the previous PET-scan showed positive lesions.
PUBLIC COPY 
s
Y
s
ments, 
C C
ments, 
required
BLIC
required
mi
UB
mic and n
UBL
c and n
This document cannot be used to support any marketing authorization 
be perform
auth
be perform
k 48/Early
g au
k 48/Early
tire spine 
arke
tire spine 
ing the stu
mar
ing the stu
bserved in
y m
bserved in
Table 5
ppo
Table 5
for subje
supp
for subje
onheredit
o su
onheredit
rm is requ
use
rm is requ
genetic an
be u
genetic an
ans.
be
ans.
7, Sched
t ca
7, Sched
RI or Pet
ent
RI or Pet
e W12 an
me
e W12 an
-CT scan
cum
CT scan
han 12 we
ocu
han 12 we
Has b
s do
Has b
A
s
A
application and any extensions or variations thereof.
me
f
me
y y 
will be p
s th
will be p
tudy at W
ons
tudy at W
n the prev
tion
n the prev
1, footn
or 
1, footn
ects partic
ns 
ects partic
tary pharm
ion
tary pharm
quired for 
ex
quired for 
nd nonher
ny e
nd nonher
dule of a
ion 
dule of a
-CT scan
catio
CT scan
nd W48/W
lica
nd W48/W
n must be
ppli
n must be
eeks prio
app
eeks prio
ch
a
ch

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 110 of 136
Change #7
Section 5.7, Table 5-1 Schedule of assessments, footnote p
CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200mg sc Q2W in 
Weeks 6 to 10 and 400mg Q4W from Week 12 to Week 44. Bimekizumab will be administered 
at a dose of 160mg sc Q2W from Week 0 through Week 10 and 320mg sc Q4W from Week 12 
to Week 44. The IMP will be administered at the end of the visit after all assessments have been 
completed. Subjects randomized to bimekizumab will receive 1 placebo injection at Baseline 
(Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3). 
Has been changed to: 
CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200mg sc Q2W in 
Weeks 6 to 10 and 400mg Q4W from Week 12 to Week 44. Bimekizumab will be administered 
at a dose of 160mg sc Q2W from Week 0 through Week 10 and 320mg sc Q4W from Week 12 
to Week 44. The IMP will be administered at the end of the visit after all assessments have been 
completed. Subjects randomized to bimekizumab will receive 1 placebo injection at Baseline 
(Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4).
Change #8
Section 6.3, Withdrawal criteria
The following was added to the withdrawal criteria:
11. Subjects with newly diagnosed IBD or with IBD flares during the study must:

Be referred, as appropriate, to a health care professional treating IBD, such as a 
gastroenterologist

Discontinue IMP and be followed-up until resolution of active IBD symptoms
If IBD flares increase in severity or frequency during the study, the Investigator should use 
clinical judgement in deciding whether the subject should continue in the study and contact 
the Medical Monitor and UCB study physician to confirm the subject's suitability for 
continued participation in the study.
Change #9
Section 7.2, Treatments to be administered, paragraph 1
The IMP is to be administered in the clinic by trained study site staff as 2 sc injections. Suitable 
areas for sc injections are the lateral abdominal wall, upper outer thigh, and upper arm. During 
each dosing visit, each of the 2 injections should be administered at a separate injection site. 
Injection sites should be rotated and injections should not be given into areas where the skin is 
tender, bruised, red, or hard.
PUBLIC COPY 
re
Y
re
a
L
a
thdrawa
UBL
thdrawa
osed IBD
PU
osed IBD
P
ument cannot be used to support any marketing authorization 
z
12
ri
12
e been
hori
e been
aseline
tho
aseline
200m
etin
200mg sc
ng
g sc
ab will be
ket
ab will be
mg sc Q4W
ark
mg sc Q4W
ter all
ma
ter all ass
a
ass
placebo i
y m
placebo i
criteria:
o su
criteria:
 or with I
d to
 or with I
to a healt
sed
to a healt
d be follow
be 
d be follow
e in severi
ot b
e in severi
t in decid
no
t in decid
onitor and
ann
onitor and
articipatio
ca
articipatio
ge #9
me
ge #9
This doc
ection 7
cum
ection 7
The IM
do
The IM
areas
s d
areas
ea
s
ea
plication and any extensions or variations thereof.
c Q2W in
here
c Q2W in
e adminis
the
e adminis
W from W
s t
W from W
sessments
ons
sessments
injection 
tion
injection 
IBD flare
ens
IBD flare
th care pr
xte
th care pr
wed
ny
wed-
ny
-up u
y 
up u
rity or freq
d a
rity or freq
ding wheth
nd 
ding wheth
d UCB stu
an
d UCB stu
on in the s
on a
on in the s
app
7.2, Trea
ppl
7.2, Trea
s to be
ap
s to be

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 111 of 136
Has been changed to: 
The IMP is to be administered in the clinic by trained study site staff as 2 sc injections. Suitable 
areas for sc injections are the lateral abdominal wall and upper outer thigh. During each dosing 
visit, each of the 2 injections should be administered at a separate injection site. Injection sites 
should be rotated and injections should not be given into areas where the skin is tender, bruised, 
red, or hard.
Change #10 
Section 7.9, Blinding, paragraph 1
Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in order to maintain the blind vs the 
CZP loading dose at these visits. 
Has been changed to: 
Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in order to maintain the blind vs the 
CZP loading dose at these visits. 
Change #11 
Section 7.9.1, Procedures for maintaining and breaking the treatment blind, 
last 2 paragraphs

Any Sponsor staff and/or designee who is responsible for data analyses for the unblinded 
DMC and interim analysis. These individuals will be separate from the main blinded study 
team.

Unblinded programming team at PAREXEL for the purpose of sending unblinded data cuts
Has been changed to: 

Any Sponsor staff and/or designee who is responsible for data analyses for the unblinded 
DMC and interim analyses. These individuals will be separate from the main blinded study 
team.

Unblinded team at PAREXEL for the purpose of sending unblinded output for the planned 
interim analyses
Change #12
Section 8.8, Week 12 (Visit 8), bullet #18

Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 
2 weeks after Week 12 Visit.
PUBLIC COPY
ekizum
PY 
ekizum
mized to
OPY
mized to
k 4 (Visi
COP
k 4 (Visi
es for m
PU
es for m
ot be used to support any marketing authorization 
al precaut
ng 
al precaut
ll receive 
eting
ll receive 
intain the
ket
intain the
b and CZP
ny 
b and CZP
bim
t a
bimekizu
any
ekizu
4) in ord
ort a
) in ord
maintain
d to
maintain
signee wh
us
signee wh
is. These i
be u
is. These i
This document canno
mming te
not
mming te
nged to
ann
nged to
nsor staff 
t ca
nsor staff 
and interi
ent 
and interi
m.
m
m.
Unblinde
cum
Unblinde
interim
ocu
interim
C
s
C
d any extensions or variations thereof.
tions will
reo
tions will
e placebo 
here
e placebo 
e blind vs
the
e blind vs
P), specia
iati
P), specia
umab will
aria
umab will
der to mai
va
der to mai
ning and
ens
ning and
ho is resp
ex
ho is resp
individua
ny e
individua
pplication and
eam at PA
nd 
eam at PA
o: 
n
o: 
f and/or de
tion
f and/or de
im analy
atio
im analys
o
s
ed team a
ppl
ed team a
ap
m analyse
app
m analyse

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 112 of 136
Has been changed to: 

Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 
2 weeks after Week 12 Visit if PET positive lesions were observed in the previous scan.
Change #13
Section 8.11, Week 48 (Visit 17)/Early Withdrawal Visit, bullet #21

Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 
2 weeks after the Week 48/WD Visit. At the WD Visit, the PET-MRI or PET-CT must be 
done only, if the previous imaging evaluation occurred more than 12 weeks ago
Has been changed to: 

Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 
2 weeks after the Week 48/WD Visit if PET positive lesions were observed in the previous 
scan. At the WD Visit, the PET-MRI or PET-CT must be done only, if the previous imaging 
evaluation occurred more than 12 weeks ago and if PET positive lesions were observed in 
the previous scan.
Change #14 
Section 9.7, PhGADA, paragraph 1
The Investigator will assess the overall status of the subject with respect to their AS signs and 
symptoms and functional capacity (considering both joint and skin components) using an NRS in 
which 0=very good, asymptomatic and no limitations of normal activities and 10=very poor, 
very severe symptoms which are intolerable and inability to carry out normal activities. This 
assessment by the Investigator should be made blind to the PGADA.
Has been changed to: 
The Investigator will assess the overall status of the subject with respect to their AS signs and 
symptoms and functional capacity using an NRS in which 0=very good, asymptomatic and no 
limitations of normal activities and 10=very poor, very severe symptoms which are intolerable 
and inability to carry out normal activities. This assessment by the Investigator should be made 
blind to the PGADA.
Change #15
Section 10, ASSESSMENT OF PHARMACOKINETIC/ 
PHARMACODYNAMIC/PHARMACOGENOMIC VARIABLE(S) 
Has been changed to: 
Section 10, ASSESSMENT OF PHARMACOKINETIC/ 
PHARMACODYNAMIC/PHARMACOGENOMIC/PHARMACOGENETIC
VARIABLE(S) 
PUBLIC COPY 
f P
Y
f P
ph 1
LIC
ph 1
erall stat
UBL
erall stat
ity (cons
PUB
ity (cons
atic an
PU
atic an
cannot be used to support any marketing authorization 
within
tho
within
T must be
aut
T must be
go
g
go
t selected
ket
t selected
e observe
ark
e observe
e only, if t
ma
e only, if t
ositive les
y m
ositive les
us of t
o su
us of the s
su
he s
idering bo
d to 
idering bo
d no limit
ed t
d no limit
ntolerable
sed
ntolerable
hould be 
us
hould be 
ssess the o
ot b
ssess the o
ional capa
nno
ional capa
mal activi
ann
mal activi
This document c
o carry ou
t ca
o carry ou
PGADA.
nt c
PGADA.
hange #1
cum
hange #1
Sectio
doc
Sectio
PHA
s d
PHA
H
s
H
n and any extensions or variations thereof.
e 
f
e 
d sites wit
the
d sites wit
ved in the
ns t
ved in the
the previo
ons
the previo
sions wer
atio
sions wer
subject w
sion
subject w
oth joint a
nsio
oth joint a
itations of
ten
itations of
e and inab
exte
e and inab
 made bli
ex
 made bli
overall sta
d a
overall sta
acity usin
and
acity usin
vities and 
n an
vities and 
application
ut normal 
on 
ut normal 
.
#15
pp
#15
10,
ap
10, AS
p
AS
C

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 113 of 136
Change #16
Section 12.6.1.3, Table 12-4 PDILI laboratory measurements
Chemistry
Amylase
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
Has been changed to: 
Chemistry
Amylase
ALT, AST
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
And the following was added to the list of abbreviations: 
AST=aspartate aminotransferase;
Change #17
Section 15.5.1, Analysis of the primary efficacy variable 
The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
Week 12 in the bimekizumab treatment group versus the CZP treatment group. Summary 
statistics will be presented by treatment group for ASDAS at each time point together with the 
changes from Baseline. 
The statistical analysis of the primary efficacy variable will be conducted following a Bayesian 
paradigm. Informative priors will be assumed for the mean change from Baseline in ASDAS in 
the CZP treatment arm and for the effect of Baseline ASDAS. These will be derived from an 
internal UCB study (AS0001). A vague prior will be applied to the mean change from Baseline 
in ASDAS in the bimekizumab treatment group. All priors will be fully documented in the SAP 
and in the interim analysis SAP.
The Bayesian analysis will employ a linear regression model including treatment group and 
adjusting for Baseline ASDAS.
The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
bimekizumab groups and of the difference in mean changes from Baseline between the treatment 
groups (CZP - bimekizumab) will be summarized with means, standard deviations, 95% credible 
intervals and 95% Highest Posterior Density intervals. The posterior probability that the 
difference between treatment groups in the mean change from Baseline in ASDAS is greater than 
zero will also be presented. The posterior probability that bimekizumab achieves a lower 
ASDAS score at Week 12 compared to CZP will be derived from this distribution.
PUBLIC COPY 
tion
Y
tion
he prim
BLIC
he prim
ll be the
PUB
ll be the
reatmen
PU
reatmen
atm
P
atm
upport any marketing authorization 
a
za
evation
hori
evation
riz
ho z
au
ng
btain % d
ket
btain % d
eti
causing tr
mar
causing tr
rk
ma
ent cannot be used to su
ary effic
sup
ary effic
compariso
to s
compariso
t group ve
d to
t group ve
ment group
sed
ment group
 primary 
be u
 primary 
ors will b
t be
ors will b
and for th
ot 
and for th
(AS0001)
nno
(AS0001)
bimekizu
ann
bimekizu
rim analy
t ca
rim analy
sian analy
ent 
sian analy
This docum
ng for Bas
men
ng for Bas
e posterio
cum
e posterio
bimekizu
docu
bimekizu
groups
do
groups
inte
s d
inte
d
s
d
s or variations thereof.f
eo
direct biliru
the
direct biliru
he
transamina
ns 
transamina
s t
on
cation and any extension
cacy va
ons
cacy va
on of the 
sio
on of the 
versus the 
ens
versus the 
p for ASD
xten
p for ASD
efficacy v
ny e
efficacy v
be assume
any
be assume
he effect 
d a
he effect 
). A vagu
and
). A vagu
umab trea
n an
umab trea
ysis SAP.
on 
ysis SAP.
ysis will e
atio
ysis will e
applic
aseline AS
lica
aseline AS
or distribu
ppl
or distribu
mab grou
app
mab grou
P
a
P -
a
- b

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 114 of 136
The study will be considered a success if this posterior probability is at least 97.5% (ie, the lower
bound of the 95% credible interval of the difference between treatment groups in the mean 
change from Baseline in ASDAS is greater than zero). 
If further information (independent to this study) regarding the CZP treatment group response 
comes to light subsequent to writing this protocol then this prior may be updated prior to study 
unblinding, and details of this will be supplied in the SAP and the CSR. Note that the prior will 
not be updated based upon accrued study data at any time point.
Has been changed to: 
The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
Week 12 in the bimekizumab treatment group versus the CZP treatment group. Summary 
statistics will be presented by treatment group for ASDAS at each time point together with the 
changes from Baseline. 
The statistical analysis of the primary efficacy variable will be conducted following a Bayesian 
paradigm. An informative prior will be used for the model intercept coefficient which in the 
primary model is equal to the mean change from Baseline in ASDAS in the CZP group when 
centered Baseline is observed at its mean of zero (βCZP ~ Normal [-1.78, var=0.0605)). Vague 
priors will be used for all other model coefficients. All priors will be fully documented in the 
SAP and in the interim analysis SAP.
The Bayesian analysis will employ a linear regression model including treatment group and 
Baseline ASDAS (mean centered).
The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
bimekizumab groups and of the difference in mean changes from Baseline between the treatment 
groups (CZP - bimekizumab) will be summarized with means, standard deviations, 95% credible 
intervals and 95% Highest Posterior Density intervals. The posterior probability that the 
difference between treatment groups in the mean change from Baseline in ASDAS is greater than 
zero will also be presented. The posterior probability that bimekizumab achieves a lower 
ASDAS score at Week 12 compared to CZP will be derived from this distribution.
The study will be considered a success if the posterior probability of the difference in the mean 
change from Baseline in ASDAS between the CZP and bimekizumab treatment groups (CZP -
bimekizumab) being greater than zero is at least 97.5% (ie, the lower bound of the 95% credible 
interval of the difference between treatment groups in the mean change from Baseline in ASDAS 
is zero or greater).
If further information (independent to this study) regarding the CZP treatment group response 
comes to light subsequent to writing this protocol then this prior may be updated prior to study 
unblinding, and details of this will be supplied in the SAP and the CSR. Note that the prior will 
not be updated based upon accrued study data at any time point.
PUBLIC COPY 
ZP ~
Y
ZP ~
 All prio
PY
 All prio
regressi
C CO
regressi
an chan
BLI
an chan
ifferenc
UB
ifferenc
will be su
PU
will be su
rior
P
rior
ent cannot be used to support any marketing authorization 
n ASDAS
auth
n ASDAS
ummary 
g au
ummary 
ogether w
ng 
ogether w
ed follow
rke
ed follow
coefficien
mark
coefficien
DAS in the
ma
DAS in the
mal [
ny m
mal [-
y
-1.7
m
1.7
rs will be 
any
rs will be 
on model i
por
on model i
ges from B
sup
ges from B
in mean 
to s
in mean 
ummarized
d to
ummarized
Density i
ed 
Density i
ups in the 
use
ups in the 
e posterio
e us
e posterio
ompared 
be 
ompared 
dered a su
ot b
dered a su
e in ASD
nno
e in ASD
ing greate
ann
ing greate
difference
ca
difference
eater).
nt c
eater).
ocume
er informa
men
er informa
es to light
um
es to light
nblinding,
ocu
nblinding,
This do
not be up
doc
not be up
ation and any extensions or variations thereof.
S at
f
S at
with the
reo
with the
wing a Bay
s th
wing a Bay
nt which 
ns 
nt which 
he CZP gr
ion
he CZP gr
78, var=0.
atio
78, var=0.
e fully doc
ria
e fully doc
including
or v
including
Baseline i
ons
Baseline i
changes f
sio
changes f
ed with me
ens
ed with me
intervals. 
xten
intervals. 
e mean ch
ext
e mean ch
or probab
y ex
or probab
to CZP w
any 
to CZP w
uccess if t
d a
uccess if t
DAS betwe
nd 
DAS betwe
er than ze
an
er than ze
e between
on a
e between
applic
ation (ind
icat
ation (ind
t subseque
plic
t subseque
, and deta
app
, and deta
a
dated ba
ap
dated ba

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 115 of 136
Change #18
Section 15.11, Planned interim analysis and data monitoring 
A formal unblinded interim analysis will be conducted after approximately 45 subjects have 
completed 4 weeks of the study. During this interim analysis, the sample size assumptions will 
be checked and the final sample size may be modified. 
The study may be stopped for futility. Futility rules and operating characteristics will be detailed 
in the interim SAP. The futility rule will be chosen such that the overall power of the study 
remains high.
An informal unblinded interim analysis will be performed when the last randomized subject for 
this study has completed the Week 12 Visit at the end of the Treatment Period or this subject’s 
participation has ended prematurely. The purpose of this informal interim analysis is for the 
Sponsor key personnel to review results from the primary efficacy analysis and a subset of the 
analyses of secondary efficacy and safety outcomes to facilitate additional Clinical Planning or 
Portfolio Management decisions.
All analyses and unblinding instructions will be prespecified in the interim SAP.
Has been changed to: 
This study will include two unblinded interim analyses, the first after approximately 45 subjects 
have completed 4 weeks of the study and the second when the last randomized subject for this 
study has completed the Week 12 Visit at the end of the Treatment Period or this subject’s 
participation has ended prematurely. The purpose of these interim analyses is for Sponsor key 
personnel to review results from the primary efficacy analysis and a subset of the analyses of 
secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
Management decisions; consequently, neither analysis and will lead to any formal decision to 
alter or terminate the trial. Interim analyses will be conducted by an unblinded study team and 
will follow internal SOPs for the formal process to control the unblinding of the study for interim 
analysis purposes. This process will ensure that no unnecessary or unintentional unblinding 
occurs. The unblinded team will not disclose any unblinded information to the blinded study 
team and the storage of all unblinded documentation will be held securely and separately from 
the rest of the study documentation and outputs up until the end of the study.
All analyses and unblinding instructions will be prespecified in the interim SAP.
Change #19
Section 15.12, Determination of sample size, paragraph 3
The sample size was calculated to provide at least 80% power to detect a difference between 
treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group means 
for CZP and bimekizumab change from baseline being -1.78 and -2.67 respectively) with a 
common standard deviation of 1.17 using frequentist methods for the comparison of group 
means with baseline as covariate (Overall and Starbuck, 1979). The correlation between Baseline 
and Week 12 raw ASDAS was assumed to be 0.35. UCB considers this sample size conservative 
PUBLIC COPY 
ci
Y
ci
analyses
COP
analyses
C
e second
C CO
e second
at the end
IC C
at the end
The purp
BLIC
The purp
e primar
UBL
e primar
utcomes
PUB
utcomes
uently
PU
uently
This document cannot be used to support any marketing authorization 
ailed 
riz
ailed 
y 
h
y 
ed subject
au
ed subject
or this sub
g a
or this sub
alysis is f
ting
alysis is f
s and a su
ketin
s and a su
nal Clinic
rke
nal Clinic
the interim
y m
the interim
the first a
rt a
the first a
when the
por
when the
of the Tr
ppo
of the Tr
ose of the
sup
ose of the
y efficacy
o su
y efficacy
to facilita
to 
to facilita
 neither a
ed t
 neither a
analyses w
sed
analyses w
e formal p
us
e formal p
ess will en
be u
ess will en
m will no
t be
m will no
f all unblin
ot b
f all unblin
document
nno
document
d unblindi
can
d unblindi
ge #19
men
ge #19
ction 15
cum
ction 15
The sam
doc
The sam
treatm
s do
treatm
for
s 
for
application and any extensions or variations thereof.
t for 
of
t for 
bject’s
eof
bject’s
for the
ereo
for the
ubset of th
ther
ubset of th
cal Plann
s th
cal Plann
m SAP.
tion
m SAP.
after appr
va
after appr
e last rand
or v
e last rand
reatment P
s or
reatment P
ese interim
ns 
ese interim
y analysis
ion
y analysis
ate additio
nsio
ate additio
analysis a
tens
analysis a
will be co
xte
will be co
process to
ex
process to
nsure that
ny e
nsure that
ot disclose
any
ot disclose
inded docu
d a
inded docu
nta
a
ntation and
and
tion and
ing instru
n a
ing instru
5.12, De
ppli
5.12, De
le size w
ap
e size w
ou
a

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 116 of 136
as the Bayesian analysis with the informative priors described in Section 15.5.1 will improve the 
probability of study success for an effective drug.
Has been changed to: 
The sample size was calculated to provide at least 80% power to detect a difference between 
treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group mean 
change from Baseline for CZP and bimekizumab being -1.78 and -2.67 respectively) with a 
common standard deviation of 1.17 using frequentist methods for the comparison of the 
treatment group mean change from Baseline in ASDAS at Week 12 with Baseline ASDAS as a 
covariate (Overall and Starbuck, 1979). The correlation between Baseline and Week 12 raw 
ASDAS was assumed to be 0.35. Note that the informative prior for the model intercept to be 
used in the Bayesian modelling of the primary efficacy variable, given by βCZP ~ Normal (-
1.78,var=0.0605), contributes an effective sample size of approximately 20 CZP subjects. A 
prior data conflict test will be performed and a vague prior will be used for the model intercept 
coefficient if this test indicates prior data conflict.
PUBLIC COPY 
authorization 
AS as a 
thor
AS as a 
12 raw 
uth
12 raw 
ercept to
au
ercept to b
ng
P ~ Norma
g a
P ~ Norma
tin
CZP subje
ting
CZP subje
This document cannot be used to support any marke
or the mod
keti
or the mod
hereof.
be
f
be
mal (
eo
mal (-
eo
-
ects. A
ere
ects. A
application and any extensions or variations th
del interc
ther
del interc

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 117 of 136
19.5
Protocol Amendment 3
Rationale for the amendment
The major purpose of this protocol amendment is the following: 

Secondary and other study objectives and variables have been updated to evaluate the effect 
of bimekizumab or CZP on changes in bone formation as an “other” exploratory variable. 
It is convention that clinical study research is divided into 2 broad areas of evaluations: 
1) prospectively declared analyses and 2) hypothesis-generating or exploratory analyses. 
Prospectively declared evaluations are partitioned into primary analyses (where type I error is 
conserved) and secondary analyses that are prospectively declared in order to offer 
unambiguous interpretation. Owing to the novelty of PET-CT/MRI assessments within this 
disease indication, it is not possible to prospectively define the analyses as we are continuing 
to develop UCB’s understanding of the specific data and endpoints yielded from the imaging 
software, the distribution and covariance of these endpoints and the hypothesized difference 
owing to treatment. As a result, the analyses of the PET-CT/MRI data in this study will 
primarily be descriptive and exploratory and this is now updated in the study objectives, ie, 
the evaluation of the effect of bimekizumab or CZP on changes in bone formation is now an 
other exploratory objective or variable instead of a secondary objective or variable.

A clarification regarding the sample size is required in this protocol amendment. The planned 
sample size of 60 subjects provides sufficient power to detect meaningful treatment 
differences in the primary efficacy variable whilst also providing at least 25 subjects for the 
PET-CT/MRI substudy. However, due to complexities in the initiation of sites capable of 
performing PET-CT or PET-MRI scans, more than the planned 35 non-PET-CT/MRI 
substudy subjects were screened and randomized before it was possible to close enrolment at 
the sites not participating in the substudy. Owing to the novelty of the PET-CT/MRI 
outcomes within this disease area, it is considered important to ensure at least 25 evaluable 
subjects are included in the assessment of this exploratory objective to maximize the 
possibility of identifying the salient factors or variables that might differ between the 
treatment groups and, therefore, the total sample size is increased to at least 72 subjects. This 
sample size increase will not negatively impact the power to detect a difference in the 
primary efficacy variable at Week 12 (ie, it will remain >80%), but will ensure that the target 
number of subjects are included in the exploratory analysis of changes in bone formation at 
Week 12 and Week 48. Since the analyses of PET-CT/MRI data are exploratory and 
treatment effect sizes are unknown, formal power calculations were not performed. Clinical 
expertise does, however, indicate that a sample size of at least 25 subjects in the substudy 
will characterize broad differences between treatment groups.

Objectives related to PK and immunogenicity were downgraded from “secondary” objectives 
to “other” objectives for consistency with the classification of the corresponding variables.

Nonhereditary pharmacogenomic variables and pharmacogenetic variables are considered 
exploratory in nature and have been labelled as “other”.

A PFS as described in Section 7.1 is available for administration in addition to the vial and 
corresponding text has been added. The PFS use is expected to improve the subject 
experience.
PUBLIC COPY 
ZP on
Y
ZP on
of a seco
OPY
of a seco
s require
COP
s require
ficient p
C CO
ficient p
ariable w
IC 
ariable w
r, due to 
BLIC
r, due to 
MRI scan
UBL
MRI scan
ened and
PUB
ened and
 the s
PU
 the s
cannot be used to support any marketing authorization 
yses.
ho
yses.
ype I error
uth
ype I error
offer 
a
offer 
ents withi
g a
ents withi
as we are c
ting
as we are c
elded from
ketin
elded from
 hypothes
rke
 hypothes
I data in t
mark
I data in t
ted in the
ma
ted in the
anges in b
ny m
anges in b
ndary obj
any
ndary obj
d in this p
ort a
d in this p
wer to de
por
wer to de
whilst also 
pp
whilst also 
complexit
sup
complexit
, more tha
o su
, more tha
randomiz
d to 
randomiz
ubstudy. O
ed t
ubstudy. O
rea, it is c
sed
rea, it is c
assessmen
us
assessmen
the salien
be u
the salien
therefore
t be
therefore
e will not
ot 
e will not
y variable 
nno
y variable 
bjects are
an
bjects are
This document c
nd Week 
t ca
nd Week 
nt effect s
nt c
nt effect s
rtise does
men
rtise does
ill charac
me
ill charac
Object
ocu
Object
to “
oc
to “

s 

n and any extensions or variations thereof.
in this 
eof
in this 
continuin
ereo
continuin
m the ima
ther
m the ima
sized diff
s th
sized diff
this study
ns 
this study
e study ob
tion
e study ob
bone form
atio
bone form
jective or
aria
jective or
protocol a
va
protocol a
etect mean
or v
etect mean
o providin
s o
o providin
ties in the
ons 
ties in the
han the pla
sion
han the pla
zed befor
nsio
zed befor
Owing to 
ten
Owing to 
considered
exte
considered
ent of this 
y ex
ent of this 
nt factors 
ny e
nt factors 
e, the total
any
e, the total
t negative
d a
t negative
e at Week 
and
e at Week 
e included
n an
e included
application
48. Sinc
on 
48. Sinc
sizes are u
atio
sizes are u
s, howeve
icat
s, howeve
terize bro
plic
terize bro
tives relat
app
ives relat
her” ob
ap
her” ob

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 118 of 136

The section describing AEs of special monitoring have been updated to reflect the 
development process and to maintain consistency with other protocols. 

A third informal unblinded interim analysis when the last randomized subject has completed 
the Week 12 Visit at the end of the Treatment Period or this subject’s participation has ended 
prematurely, has been added to facilitate additional Clinical Planning or Portfolio 
Management decisions. 

Study contact details have been updated.
In addition, a few minor updates including consistency changes for PDILI-related text and a few 
clarifications and corrections of typographical errors have been made. The occurrence of 
abbreviations was updated.
Modifications and changes
Global changes
The specification of the IGRA TB test has been changed from “QuantiFERON TB GOLD test” 
to “QuantiFERON TB test”.
Specific changes
Change #1
Sponsor Study Physician
Name:
Address:
UCB Celltech, 208 Bath Rd, Slough, Berkshire, SL1 3WE, UK
Phone:
Fax:
Has been changed to: 
Name:
Address:
UCB Celltech, 208 Bath Rd, Slough, Berkshire, SL1 3WE, UK
Phone:
Fax:
Change #2
Section 1, Summary, paragraphs 3, 4, and 5
The primary objective of the study is to evaluate the efficacy of bimekizumab administered 
subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of 
subjects with active AS. The primary efficacy variable is the change from Baseline in 
PUBLIC COPY 
BL
Cellte
P
Cellte
PU
PUB
sed to support any marketing authorization 
and a few
tho
and a few
ce of 
aut
ce of 
ntiFERON
mark
ntiFERON
s
ch, 208 B
ed t
ch, 208 B
to
ed
e us
u
This document cannot be
be
 to: 
ot
 to: 
no
nn
s:s:
an
one:
ent
one:
t c
Fax:
me
Fax:
en
um
Cha
s d
Cha
S
s
S
use
be u
n
nd any extensions or variations thereof.
N TB GO
ns 
N TB GO
on
Bath Rd, S
ten
Bath Rd, S
ns
xte
e
ny
nd
e
ny
application a
UCB C
on 
UCB C
a
ioioioio
tio
ca
pl
2
an
io

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 119 of 136
Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12. The secondary objectives 
of the study are to evaluate the effect of bimekizumab or CZP on changes in osteoblastic activity, 
to assess the safety and tolerability of bimekizumab, and to assess the pharmacokinetics (PK) 
and immunogenicity of bimekizumab. The secondary efficacy variables include the 
determination of ASDAS inactive disease (ASDAS-ID) at Week 12, ASDAS major 
improvement (ASDAS-MI) at Week 12, and osteoblastic activity as detected by 
positron-emission tomography-magnetic resonance imaging (PET-MRI) or positron-emission 
tomography computed tomography (PET-CT) at Week 12 and Week 48. Primary safety variables 
include the incidence of adverse events (AEs), serious adverse events (SAEs), and withdrawal 
due to AEs.
Other objectives of the study are to obtain additional biomarkers and clinical and imaging data as 
applicable and to assess the efficacy and safety of bimekizumab or CZP during the Treatment 
Extension Period.
Multiple sites in North America, Europe, and the Asian-Pacific (APAC) region will randomize 
approximately 60 subjects in a 2:1 ratio to receive either bimekizumab or CZP. 
Has been changed to: 
The primary objective of the study is to evaluate the efficacy of bimekizumab administered 
subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of 
subjects with active AS. The primary efficacy variable is the change from Baseline in 
Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12. The secondary objective 
of the study is to assess the safety and tolerability of bimekizumab. The secondary efficacy 
variables include the determination of ASDAS inactive disease (ASDAS-ID) and ASDAS major 
improvement (ASDAS-MI) at Week 12. Primary safety variables include the incidence of 
adverse events (AEs), serious adverse events (SAEs), and AEs leading to withdrawal from 
investigational medicinal product (IMP).
Other exploratory objectives of the study are to evaluate the effect of bimekizumab or CZP 
on changes in bone formation, to assess the pharmacokinetics (PK) and immunogenicity of 
bimekizumab, to obtain additional biomarkers and clinical and imaging data as applicable, and 
to assess the efficacy and safety of bimekizumab or CZP during the Treatment Period and the 
Treatment Extension Period.
Multiple sites in North America, Europe, and the Asian-Pacific (APAC) region will randomize at 
least 60 subjects in a 2:1 ratio to receive either bimekizumab or CZP. 
Change #3
Section 3.2, Secondary objectives
The secondary objectives of the study are as follows:

To evaluate the effect of bimekizumab or CZP on changes in osteoblastic activity 

To assess the safety and tolerability of bimekizumab

To assess the PK and immunogenicity of bimekizumab
PUBLIC COPY 
he effica
PY
he effica
2 weeks
OP
2 weeks
y variab
CO
y variab
Score
C C
Score (A
C
(A
tolerabil
LIC
tolerabil
of ASDA
BLI
of ASDA
eek 12. 
PUB
eek 12. 
adverse 
PU
adverse 
uct
P
uct
used to support any marketing authorization 
riables
oriz
riables
drawal
thor
drawal
imaging 
g au
imaging 
g the Trea
ing 
g the Trea
C) region w
rke
C) region w
mab or CZP
mark
mab or CZP
y of bime
any
y of bime
compared
rt a
compared
e is the ch
ort 
e is the ch
SDAS) at
ppo
SDAS) at
ty of bime
upp
ty of bime
AS inactiv
sup
AS inactiv
Primary sa
to s
Primary sa
events (SA
d to
events (SA
(IMP).
sed
(IMP).
f the study
us
f the study
ument cannot be
on, to ass
be u
on, to ass
additional
t be
additional
nd safety 
ot 
nd safety 
n Period.
nno
n Period.
North Am
can
North Am
ects in a 2
t ca
ects in a 2
ge #3
men
ge #3
This docu
ction 3.2
cum
ction 3.2
The seco
doc
The seco

s d

T
y extensions or variations thereof.
data as
of.
data as
atment 
reo
atment 
will rando
s th
will rando
ZP.
n
ZP.
ek
r
ekizumab
ria
izumab
d to CZP 
var
d to CZP 
hange fro
r va
hange fro
t Week
or
t Week 12
12
mekizumab
ns o
mekizumab
ve disease
ions
ve disease
afety vari
sio
fety vari
AEs), and
ens
AEs), and
y are
ex
y are to
ex
to e
plication and any
sess the p
ny e
sess the p
l biomark
any
l biomark
of bimek
d a
of bimek
America, E
n a
America, E
2:1 ratio t
tion
2:1 ratio t
app
2, Second
ppli
2, Second
ndary ob
ap
dary ob

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 120 of 136
Has been changed to: 
Section 3.2, Secondary objective
The secondary objective of the study is as follows:

To assess the safety and tolerability of bimekizumab
Change #4
Section 3.3, Other objectives
The other objectives of the study are as follows:

To assess additional biomarker, clinical, and imaging data as available

To assess the efficacy and safety of bimekizumab or CZP during the Treatment Extension 
Period
Has been changed to: 
Section 3.3, Other exploratory objectives
The other exploratory objectives of the study are as follows:

To evaluate the effect of bimekizumab or CZP on changes in bone formation 

To assess the PK and immunogenicity of bimekizumab

To assess additional biomarker, clinical, and imaging data as available

To assess the efficacy and safety of bimekizumab or CZP during the Treatment Extension 
Period
Change #5
Section 4.1.2, Secondary efficacy variables
The secondary efficacy variables for this study are as follows:

ASDAS-ID at Week 12

ASDAS-MI at Week 12

Osteoblastic activity as detected by PET-MRI or PET-CT at Week 12 and Week 48 
Has been changed to: 
The secondary efficacy variables for this study are as follows:

ASDAS-ID at Week 12

ASDAS-MI at Week 12
PUBLIC COPY
as follow
PY 
as follow
r CZP o
COP
r CZP o
ty of bim
C C
ty of bim
inical, an
BLIC
inical, an
ety of bi
UB
ety of bi
This document cannot be used to support any marketing authorization 
eatment E
eting
eatment E
s:
a
s:
n change
rt a
n change
mekizuma
ppo
mekizuma
d imaging
supp
d imaging
mekizuma
to s
mekizuma
ry effica
be u
ry effica
ariables fo
t be
ariables fo
eek 12
not
eek 12
at Week 1
an
at Week 1
stic activi
nt c
stic activi
been cha
me
been cha
e seconda
cum
e seconda

d

ASD
oc
ASD

s 

application and any extensions or variations thereof.
Extension
here
Extension
es in bone
va
es in bone
ab
ab
ng data as 
ns 
ng data as 
ab or CZP
sio
ab or CZP
acy vari
ny e
acy vari
for this stu
any
for this stu
12
n
12
vity as det
tion
vity as det
anged t
lica
anged t
ary effica
ppl
ary effica
AS
a
AS-
a
-ID a
ap
ID a

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 121 of 136
Change #6
Section 4.1.3, Other efficacy variables
Assessment time points for the other efficacy variables are specified in Table 5‒1. Other efficacy 
variables are as follows:

Change from Baseline in ASDAS

ASAS20 response

ASAS40 response

Time to ASAS20 response

Time to ASAS40 response

ASAS partial remission

Change from Baseline in BASDAI
Has been changed to: 
Section 4.1.3, Other efficacy variables
Assessment time points for the other efficacy variables are specified in Table 5‒1. The following 
efficacy variables are exploratory and are assessed over the Treatment Period and 
Treatment Extension Period, as applicable:

Change from Baseline in ASDAS

ASAS20 response

ASAS40 response

Time to ASAS20 response

Time to ASAS40 response

ASAS partial remission

Change from Baseline in BASDAI

Changes in bone formation as measured by standardized uptake value by area under 
the curve (SUVAUC) and derived from PET-MRI or PET-CT at Baseline, Week 12, and 
Week 48 
Change #7, Primary safety variables
The primary safety variables for this study are as follows:

Incidence of AEs and SAEs

Withdrawal due to AEs
Has been changed to: 
The primary safety variables for this study are as follows:
PUBLIC COPY 
ariables a
OP
ariables a
assessed
CO
assessed
able:
C C
able:
ment cannot be used to support any marketing authorization 
re specifi
rt a
re specifi
 ov
o
 over the
ort 
er the
e
b
e
on
ot
on
seline in B
nno
seline in B
bone form
can
bone form
 (SUV
t ca
 (SUV
This docum
AU
c
AU
48
n
48
nge #7,
ume
nge #7,
The prima
ocu
The prima

d

In
o
In

s

n and any extensions or variations thereof.
ied in
var
ied in Tab
ar
Tab
e Treatm
r va
e Treatm
BASDAI
nd 
BASDAI
ma
n
mation a
n a
tion a
application
C
i
C) and de
ion
) and de
, Primar
plic
, Primar
ary safety
app
ry safety
ce
a
ce
a

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 122 of 136

Incidence of AEs and SAEs

Adverse events leading to withdrawal from IMP
Change #8, Section header
4.5
Nonhereditary pharmacogenomic variables
Has been changed to: 
4.5
Other nonhereditary pharmacogenomic variables
Change #9, Section header
4.6
Pharmacogenetic variables
Has been changed to: 
4.6
Other pharmacogenetic variables 
Change #10
Section 5.1, Study description, paragraph 3
Approximately 60 subjects will be randomized to 1 of 2 treatment arms in a 2:1 ratio and will 
receive either bimekizumab or CZP up to Week 44 (final dose of IMP). 
Has been changed to: 
At least 60 subjects will be randomized to 1 of 2 treatment arms in a 2:1 ratio and will receive 
either bimekizumab or CZP up to Week 44 (final dose of IMP). 
Change #11
Section 5.5, Planned number of subjects and site(s)
It is anticipated that approximately 120 subjects will be screened in order to enroll approximately 
60 subjects at multiple sites.
Has been changed to: 
It is anticipated that approximately 120 subjects will be screened in order to enroll at least
60 subjects in the main study and at least 25 subjects in the PET-CT or PET-MRI substudy 
at multiple sites.
PUBLIC COPY 
ph 3
PY
ph 3
d to 1 of 
COP
d to 1 of 
Week
C C
Week 44 
CO
44 
mized to 
UBL
mized to 
to Week
PUB
to Week
t cannot be used to support any marketing authorization 
2 treatmen
rt a
2 treatmen
final dose
por
final dose
 of 2 trea
o su
 of 2 trea
44 (final d
to 
44 (final d
mber of 
e us
mber of 
ximately 1
t be
ximately 1
sites.
ot
sites.
ged to: 
nno
ged to: 
that appr
can
that appr
This document 
n the ma
nt c
n the ma
e sites.
ent
e sites.
on and any extensions or variations thereof.
nt arms in
va
nt arms in
e of IMP)
or v
e of IMP)
atment arm
ion
atment arm
dose of IM
nsio
dose of IM
f subjec
y ex
f subjec
120 subje
any
120 subje
roximatel
on a
roximatel
applicatio
ain study 
tion
ain study 

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 123 of 136
Change #12
Section 6.3.1, Potential drug-induced liver injury IMP discontinuation 
criteria, paragraph 2
The PDILI criteria below require immediate and permanent discontinuation of IMP: 
Subjects with either of the following:

ALT or AST ≥5ULN

ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness. Hypersensitivity symptoms include fever (without clear alternative cause), 
rash, or eosinophilia (ie, >5%).
Has been changed to: 
The PDILI criteria below require immediate discontinuation of IMP: 
Subjects with either of the following:

ALT or AST ≥5ULN

ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 

Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).
Change #13
Section 7.1, Description of investigational medicinal product(s), 
paragraphs 1 and 2
The IMPs used in this study are bimekizumab and CZP.
Bimekizumab will be supplied as a clear to opalescent, colorless to slightly brown, sterile, 
preservative-free solution in 2mL Type I, colorless glass vials (1.0mL extractable volume) closed 
with a rubber stopper and sealed with an aluminum cap overseal. Each single-use dose vial will 
contain 160mg/mL bimekizumab in 
mM sodium acetate,
mM glycine and 
 (w/v) 
polysorbate 80 at pH 
.
PUBLIC COPY 
otal biliru
C CO
otal biliru
N who ex
LIC 
N who ex
patitis sy
BLI
patitis sy
ness. Hy
UB
ness. Hy
eosinop
PU
eosinop
ment cannot be used to support any marketing authorization 
of hepati
au
of hepati
pper quadr
g a
pper quadr
alternative
ting
alternative
MP: 
m
MP: 
bin ≥2xU
port
bin ≥2xU
hibit temp
upp
hibit temp
mptoms in
sup
mptoms in
persensitiv
to s
persensitiv
hilia (ie, >
d to
hilia (ie, >
n of inve
be u
n of inve
study are
not 
study are
l be suppl
ann
l be suppl
ee solutio
ca
ee solutio
er stopper 
nt c
er stopper 
60mg/mL
ent
60mg/mL
This docum
orbate 80 a
me
orbate 80 a
cation and any extensions or variations thereof.
itis or 
of.
itis or 
drant 
eof
drant 
e cause),
ereo
e cause),
ULN
or
ULN
mporally as
ns o
mporally as
nclude fat
ons
nclude fat
iv
s
ivity symp
sio
ity symp
>5%).
ens
>5%).
vestigati
ny e
vestigati
e bimekiz
nd a
e bimekiz
lied as a c
an
lied as a c
on in 2mL
on a
on in 2mL
r and seale
tion
r and seale
L bimekiz
cati
L bimekiz
applic
at pH 
lica
at pH 
ca

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 124 of 136
Has been changed to: 
The IMPs used in this study are bimekizumab and CZP.
Bimekizumab will be supplied as a vial or in a pre-filled syringe (PFS) form as described 
below: 

Vial: a clear to opalescent, colorless to slightly brown, sterile, preservative-free solution in 
2mL Type I, colorless glass vials (1.0mL extractable volume) closed with a rubber stopper 
and sealed with an aluminum cap overseal. Each single-use dose vial will contain 160mg/mL 
bimekizumab in 
mM sodium acetate, 
mM glycine, and 
 (w/v) polysorbate 80 at 
pH 

PFS: 1mL PFS at a concentration of 160mg/mL 
mM sodium acetate, 
mM 
glycine, 
 polysorbate 80 at pH 
) for sc injection.
Change #14
Section 8.8, Week 12 (Visit 8), PET-MRI/PET-CT scan bullet

Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 
2 weeks after Week 12 Visit if PET positive lesions were observed in the previous scan.
Has been changed to: 

Perform a PET-MRI or PET-CT scan in at least 25 subjects at selected sites within 2 weeks 
after Week 12 Visit if PET-positive lesions were observed in the previous scan.
Change #15
Section 8.11, Week 48 (Visit 17), PET-MRI/PET-CT scan bullet

Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 2 
weeks after the Week 48/WD Visit if PET positive lesions were observed in the previous 
scan. At the WD Visit, the PET-MRI or PET-CT must be done only, if the previous imaging 
evaluation occurred more than 12 weeks ago and if PET positive lesions were observed in the 
previous scan.
Has been changed to: 

Perform a PET-MRI or PET-CT scan in at least 25 subjects at selected sites within 2 weeks 
after the Week 48/WD Visit if PET-positive lesions were observed in the previous scan. At 
the WD Visit, the PET-MRI or PET-CT must be done only, if the previous imaging 
evaluation occurred more than 12 weeks ago and if PET-positive lesions were observed in 
the previous scan.
Change #16
Section 9.11, PET-MRI or PET-CT scan, last paragraph
The 18F-fluoride PET-MRIs of the whole spines will be performed by using a whole-body 
PET/MRI system. Alternatively, subjects will be examined in supine position on a combined 
PET-CT system permitting the acquisition of co-registered CT and PET images in the same 
PUBLIC COPY 
mately
Y
mately
sions we
PY
sions we
n 
C
n at lea
C C
at lea
e lesions
LIC
e lesions
t 17),
PU
t 17),
used to support any marketing authorization 
er 
ri
er 
mg/mL 
hori
mg/mL 
bate 80 at 
tho
bate 80 at 
, 
mM
g a
, 
mM
bullet
mar
bullet
subjects a
ny m
subjects a
re observe
any
re observe
t 25 subje
ppo
25 subje
were obse
upp
were obse
PET
ed t
PET-
d
-MR
t
MR
CT scan in
use
CT scan in
This document cannot be u
WD Visit i
e us
WD Visit i
he PET
be 
he PET-M
more than
ot b
more than
nged to
ann
nged to
PET
t c
PET-
c
-MR
ca
MR
e Week 4
ent 
e Week 4
WD Visit
men
WD Visit
evaluation
um
evaluation
the prev
ocu
the prev
Chan
s do
Chan
S
s
S
ng
extensions or variations thereof.
at selecte
atio
at selecte
ed in the p
ria
ed in the p
ects at se
or 
ects at se
erved in t
ns o
erved in t
RI/PET
ens
RI/PET
n approxi
ext
n approxi
application and any 
if PET po
y e
if PET po
MRI or PE
ny 
MRI or PE
n 12 week
d an
n 12 week
o: 
o: 
RI or PET
ion
RI or PET
48/WD V
atio
48/WD V
t, the PET
ica
t, the PET
n occurred
plic
n occurred
evious sca
app
evious sca
16
a
16

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 125 of 136
session. The PET-MRI or PET-CT scan will be performed at time points provided in Table 5‒1
in approximately 25 subjects at selected sites.
Has been changed to: 
The 18F-fluoride PET-MRIs of the whole spine will be performed by using a whole-body 
PET/MRI system. Alternatively, subjects will be examined in supine position on a combined 
PET-CT system permitting the acquisition of co-registered CT and PET images in the same 
session. The PET-MRI or PET-CT scan will be performed at time points provided in Table 5‒1
in at least 25 subjects at selected sites.
Change #17
Section 12.1.14, Adverse events for special monitoring, section header and 
paragraph 2
12.1.1.4
Adverse events for special monitoring
Adverse events for special monitoring for this study include: serious infections (including 
opportunistic infections and TB, see Section 12.7.5), cytopenias, hypersensitivities, suicide 
ideation or behavior (assessed using the C-SSRS), depression and anxiety (assessed using the 
HADS, see Section 9.10), major cardiovascular events and liver function test changes/enzyme 
elevations (ALT, AST, and bilirubin; see Section 12.6.1), malignancies, and inflammatory bowel 
diseases.
Has been changed to: 
12.1.1.4
Adverse events for special monitoring
Adverse events for special monitoring for this study include: infections (serious, opportunistic, 
fungal, and TB, see Section 12.7.5), neutropenia, hypersensitivity, suicidal ideation and
behavior (assessed using the C-SSRS), depression, (assessed using the HADS, see Section 9.10), 
major cardiovascular events, liver function test changes/enzyme elevations (ALT, AST, and 
bilirubin; see Section 12.6.1), malignancies, and inflammatory bowel diseases (with 
gastroenterology referral as appropriate).
BLIC COPY
yt
Y
yt
epressi
PY 
epressi
vents an
OPY
vents an
on
CO
on 12.6
COP
12.6
PUB
ecial mo
UBL
ecial mo
nitoring 
PU
nitoring 
7.5
P
7.5)
P
)
support any marketing authorization 
5
o
5‒
r
‒1
ori
1
on head
ng 
on head
us infectio
mar
us infectio
, hypersen
y m
, hypersen
n and anxi
ny 
n and anxi
d liver fun
t any
d liver fun
), malign
ort a
), malign
sed to s
nitoring
o su
nitoring
for this stu
d to
for this stu
neutrope
ed 
neutrope
This document cannot be us
SRS), dep
use
SRS), dep
ver functi
e us
ver functi
), malign
be 
), malign
al as app
ot b
al as app
sions or variations thereof.
der and
reo
der and
ons (inclu
ons
ons (inclu
ensitivities
tion
ensitivities
xiety (asse
iati
xiety (asse
nction tes
aria
nction tes
nancies, a
va
nancies, a
xten
udy inclu
ens
udy inclu
enia,
xten
enia, hyp
en
hyp
application and any ex
pression, (
exte
pression, (
ion test ch
y ex
ion test ch
nancies, an
ny 
nancies, an
propriate
d an
propriate

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 126 of 136
Change #18
Section 12.6.1, Evaluation of PDILI, Table 12-3
Table 12‒3:
Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN
≥2xULNb
NA
Hepatology consult.b
Medical Monitor 
must be notified 
within 24 hours 
(eg, by laboratory 
alert) and subject 
discussed with 
Medical Monitor 
ASAP.
Immediate, 
permanent IMP 
discontinuation.
Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see 
Section 12.6.1.3); 
recommended to 
occur at the site 
with HCP.
Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within baseline 
values.b
Monitoring of liver chemistry 
values at least twice per week 
for 2 weeks.d

Immediate IMP 
discontinuation required if 
liver chemistry values
≥3xULN
NA
Yes
≥5xULN
NA
NA
Need for hepatology 
consult to be 
discussed. (required 
if ALT or AST 
≥8xULN) Medical 
Monitor must be 
notified within 
24hours (eg, by 
laboratory alert) and 
subject discussed 
with Medical Monitor 
ASAP.
Immediate, 
permanent IMP 
discontinuation
UBLIC COPY 
or 
BL
or 
ent IM
Y
ent IM
ntinuatio
PY
ntinuatio
C
PU
r hepato
PU
r hepato
be
P
be
UB
nnot be used to support any marketing authorization 
27 
n 
27
at
F
g a
g
k
g
ting
.
a
.
Essenti
ma
Essenti
have
y m
have
c
y
c
ma
y
to
ogy 
d t
ogy 
(required 
use
(required 
r AST
us
r AST
ULN) Medi
be u
ULN) Medi
onitor mus
t be
onitor mus
notified w
ot 
notified w
24hour
nno
24hour
labo
nn
labo
s
n
s
Im
o
Im
to
to
to 
This document can
l
T
l
en
n
to
sions or variations thereof.
Follow up
reo
Follow up
of
Evalu
her
Evalu
re
th
ial: Must
ion
ial: Must
e repeat liv
atio
e repeat liv
chemistry v
ria
chemistry v
and add
ar
and add
testin
va
testin
AS
v
AS
ns
r v
extensi
mmediate,
ens
mmediate,
permanen
xten
permanen
discon
exte
discon
si
application and any e
ical
ny
ical
st be 
an
st be 
within
d a
within
rs (eg, by 
nd
rs (eg, by 
oratory ale
an
oratory ale
subject dis
on a
subject dis
with
tion
with Me
n
Me
ASA
atio
ASA
cat
a
e

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 127 of 136
Table 12‒3:
Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN 
(and ≥2x 
baseline) 
and 
<5xULN 
(and ≥2x 
baseline)
<2xULN
No
Discussion with 
Medical Monitor 
required.
Consider need for 
hepatology consult if 
there is no evidence 
of resolution (see 
Follow-up 
requirements) c
Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section 12.6.1.2).
IMP discontinuation 
required if any of 
the following occur:

Subject cannot 
comply with 
monitoring 
schedule. 

Liver chemistry 
values continue 
to increase 

Liver chemistry 
values remain 
≥3xULN (and 
≥2xbaseline) 
after 2 weeks of 
monitoring 
without 
evidence of 
resolution 
Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48hours at 
the site with HCP 
(see Section 
12.6.1.3).
continue to increase. After 2 
weeks of monitoring liver 
chemistry values:

Discontinue IMP if levels 
remain ≥3xULN (and ≥2x 
baseline) without evidence 
of resolutiond 
Continue to monitor until values 
normalize, stabilize, or return to 
within baseline valuesd.
PUBLIC COPY
scontin
PY 
scontin
uired if a
OPY
uired if a
he follow
COP
he follow

C C

S
C
S
C
This document cannot be used to support any marketing authorization 
27 
n 
27
at
l
T
l
Follow up
tho
Follow up
ori
Evalua
auth
Evalua
th
g a
tion 
ny
tion 
y of 
a
y of 
ing occur:
rt a
ing occur:
ubject cann
po
ubject cann
comply w
upp
comply w
monit
sup
monit
sch
s
sch

al: Every 
etin
al: Every 
mpt must b
ket
mpt must b
ade to hav
ark
ade to hav
repeat liv
mar
repeat liv
chemis
y m
chemis
and
y 
and
t
y
t
ing
cu
n
to
y
thereof.
tio
f
tio
con
re
con
re
application and any extensions or variations th
nnot 
o
nnot 
with
s
with
toring
ons
toring
hedule. 
sion
hedule. 
Liver c
ens
Liver c
valu
te
valu
t
be 
t
be 
e
ver 
o
ver 
stry value
tion
stry value
additiona
atio
additiona
testing com
aria
testing com
within 4
var
within 4
the s
va
the s
(s(s
pp
at
e
r v
th

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 128 of 136
Table 12‒3:
Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal 
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause). 
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor. 
c Details provided in Section 12.6.1.1. The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist. 
d Unless an alternative monitoring schedule is agreed by the Investigator and UCB responsible physician. Determination of stabilization is at the discretion of the 
Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
Has been changed to: 
Table 12-3:Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN
≥2xULNb
NA
Hepatology consult.c
Medical Monitor 
must be notified 
within 24 hours 
(eg, by laboratory 
alert) and subject 
discussed with 
Medical Monitor 
ASAP.
Immediate IMP 
discontinuationd.
Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see 
Section 12.6.1.3); 
recommended to 
occur at the site 
Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within baseline 
values.e
≥3xULN
NA
Yes
PUBLIC COPY
lte
Y
lte
enterolo
PY 
enterolo
responsi
OPY
responsi
ponsible p
OP
ponsible p
r PDILI
PUB
r PDILI
PU
be used to support any marketing authorization 
27 
n 
27
at
Follow up
tho
Follow up
ori
Evalua
auth
Evalua
th
g a
nsferase; H
ting
nsferase; H
N=upper lim
keti
N=upper lim
sensitivity s
rke
sensitivity s
discussed 
ma
discussed 
treating ph
y m
treating ph
t. t. 
le physician
any
le physician
hysician, as
rt a
hysician, as
ing
Immedi
ed 
Immedi
d to
on 
us
on 
ments
e us
ments
ed
nnot b
Hepatolog
ot b
Hepatolog
Medica
no
Medica
mus
nn
mus
w
n
w
This document can
l
T
l
b
n
ca
oc
oc
oc
oc
any extensions or variations thereof.
tio
f
tio
HCP=health
here
HCP=health
mit of norm
the
mit of norm
symptoms
s th
symptoms
with the M
ons
with the M
hysician for
tio
hysician for
n. Determin
aria
n. Determin
s needed.
var
s needed.
re
iate
te
iate
ns
Actio
ext
Actio
xte
e
ation and an
gy consult.
d a
gy consult.
al Monitor
nd
al Monitor
t be notifi
an
t be notifi
within 24
n a
within 24 h
a
h
(eg,
tion
(eg, by l
on
by l
alert)
atio
alert)
di
a
di
any
applicat
ap
at

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 129 of 136
Table 12-3:Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥5xULN
NA
NA
Need for hepatology 
consult to be 
discussed. (required 
if ALT or AST 
≥8xULN). Medical 
Monitor must be 
notified within 
24hours (eg, by 
laboratory alert) and 
subject discussed 
with Medical Monitor 
ASAP.
with HCP.
Monitoring of liver chemistry 
values at least twice per week 
for 2 weeks.e

Immediate IMP 
BLIC COPY 
nitor 
LIC
nitor 
PUBL
BL C
y marketing authorization 
27 
n 
27
at
Follow up
tho
Follow up
ori
Evalua
auth
Evalua
th
g a
P.
t
P.
ing
This document cannot be used to support any
l
T
l
s
y
thereof.
tio
f
tio
re
application and any extensions or variations th
on
r v
th

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 130 of 136
Table 12-3:Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN 
(and ≥2x 
baseline) 
and 
<5xULN 
(and ≥2x 
baseline)
<2xULN
No
Discussion with 
Medical Monitor 
required.
Consider need for 
hepatology consult if 
there is no evidence 
of resolution (see 
Follow-up 
requirements) c
Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section 12.6.1.2).
IMP discontinuation 
required if any of 
the following occur:

Subject cannot 
comply with 
monitoring 
schedule. 

Liver chemistry 
values continue 
to increase 

Liver chemistry 
values remain 
≥3xULN (and 
≥2xbaseline) 
after 2 weeks of 
monitoring 
without 
evidence of 
resolution 
Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48hours at 
the site with HCP 
(see Section 
12.6.1.3).
discontinuation required if 
liver chemistry values
continue to increase. After 2 
weeks of monitoring liver 
chemistry values:

Discontinue IMP if levels 
remain ≥3xULN (and ≥2x 
baseline) without evidence 
of resolutione
Continue to monitor until values 
normalize, stabilize, or return to 
within baseline valuese.
PUBLIC COPY
scontin
PY 
scontin
uired if a
OPY
uired if a
he follow
COP
he follow

C C

S
C
S
C
This document cannot be used to support any marketing authorization 
27 
n 
27
at
l
T
l
Follow up
tho
Follow up
ori
Evalua
auth
Evalua
th
g a
tion 
ny
tion 
y of 
a
y of 
ing occu
rt a
ing occur:
a
r:
ubject cann
po
ubject cann
comply w
upp
comply w
monit
sup
monit
sch
s
sch

al: Every 
etin
al: Every 
mpt must b
ket
mpt must b
ade to hav
ark
ade to hav
repeat liv
mar
repeat liv
chemis
y m
chemis
and
y 
and
t
y
t
ing
cu
n
to
y
thereof.
tio
f
tio
disc
re
disc
re
application and any extensions or variations th
nnot 
o
nnot 
with
s
with
toring
ons
toring
hedule. 
sion
hedule. 
Liver c
ens
Liver c
valu
te
valu
t
be 
t
be 
e
ver 
o
ver 
stry value
tion
stry value
additiona
atio
additiona
testing com
aria
testing com
within 4
var
within 4
the s
va
the s
(s(s
pp
at
e
r v
th

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 131 of 136
Table 12-3:Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause). 
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor. 
c Details provided in Section 12.6.1.1. The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist. 
d Details are provided in Section 12.6.1.2.1.
e Unless an alternative monitoring schedule is agreed by the Investigator and UCB responsible physician. Determination of stabilization is at the discretion of the 
Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
PUBLIC COPY
lte
Y
lte
enterolo
PY 
enterolo
CB respo
OP
CB respo
responsib
CO
responsib
ng authorization 
27 
n 
27
at
Follow up
tho
Follow up
ori
Evalua
auth
Evalua
th
g a
This document cannot be used to support any marketing
l
T
l
nsferase; H
ting
nsferase; H
N=upper lim
keti
N=upper lim
sensitivity s
rke
sensitivity s
discussed 
ma
discussed 
treating ph
y m
treating ph
t.t.
sible physic
rt a
sible physic
e physician
ort 
e physician
ing
reof.
tio
f
tio
application and any extensions or variations there
HCP=health
here
HCP=health
mit of norm
the
mit of norm
symptoms
s th
symptoms
with the M
ons
with the M
hysician for
tio
hysician for
cian. Deter
var
cian. Deter
, as needed
r va
, as needed
re

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 132 of 136
Change #19
Section 12.6.1.2, Immediate action: Determination of IMP discontinuation, 
paragraph 2
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) to 
immediate and permanent discontinuation (see Section 6.3.1 and Table 12‒3 for details).
Has been changed to: 
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) to 
immediate discontinuation (see Section 6.3.1 and Table 12‒3 for details).
Change #20
Section 12.6.1.3, Testing: Identification/exclusion of alternative etiology, 
Table 12-4, chemistry
Chemistry
Amylase
ALT, AST
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
Has been changed to: 
Chemistry
Amylase
Sodium, potassium, chloride, glucose, BUN, creatinine
Total bilirubin, ALP, AST, ALT, GGT, total cholesterol, albumin
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
Change #21
Section 15.1, Definition of analysis sets
The following analysis set has been added: 
The PET Per-Protocol Set (PET-PPS) will consist of all randomized subjects who receive at 
least 1 dose of the IMP and have evaluable PET-CT or PET-MRI scan data at Baseline and 
at at least 1 of the post-Baseline assessments.
Change #22
Section 15.8.1, Safety analyses, paragraph 2
Adverse events will be coded according to the most recent version of the Medical Dictionary for 
Regulatory Activities (MedDRA®). The incidence of treatment-emergent adverse events 
PUBLIC COPY 
Y
PY
btain fra
C CO
btain fra
CO
evaluate 
LIC
evaluate 
C C
LI
PU
P
This document cannot be used to support any marketing authorization 
itis or 
aut
itis or 
vestigatio
g au
vestigatio
alternati
mark
alternati
y
an
tionated b
por
tionated b
rt
possible m
upp
possible m
p
up
to
m, chloride
se
m, chloride
ed
n, ALP, AS
e u
n, ALP, AS
us
rubin ≥1.5
t be
rubin ≥1.5
be
CPK and 
not
CPK and 
t b
no
15.1, Def
nt c
15.1, Def
ollowing
men
ollowing
e PET Pe
cum
e PET Pe
least 1
doc
least 1 do
c
do
at at
do
at at l
o
l
C
s
C
pplication and any extensions or variations thereof.
on) to 
of
on) to 
tive etio
ns t
tive etio
ati
ari
bilirubin
or v
bilirubin to
v
to
v
muscle inju
ns o
muscle inju
o
ns
ns
e, glucose
exte
e, glucose
te
ST, ALT,
y e
ST, ALT,
ex
5xULN, ob
any
5xULN, ob
ny
LDH to e
nd a
LDH to e
a
nd
efinition
atio
efinition
g analys
lica
g analys
er
p
er-
p
-
ap
Proto
ppl
Proto
se of the
app
se of the
1 of
a
1 of

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 133 of 136
(TEAEs) will be summarized descriptively by MedDRA system organ class, preferred term, and 
treatment group. Additional tables will summarize TEAEs by intensity and relationship to IMP, 
TEAEs leading to withdrawal from the study, serious TEAEs, and deaths. All AE information 
will be listed.
Has been changed to: 
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA®, version 19.0). The incidence of treatment-emergent adverse events (TEAEs) will be 
summarized descriptively by MedDRA system organ class, preferred term, and treatment group. 
Additional tables will summarize TEAEs by intensity and relationship to IMP, TEAEs leading to 
withdrawal from the study, serious TEAEs, and deaths. All AE information will be listed.
Change #23
Section 15.11, Planned interim analysis and data monitoring
This study will include two unblinded interim analyses, the first after approximately 45 subjects 
have completed 4 weeks of the study and the second when the last randomized subject for this 
study has completed the Week 12 Visit at the end of the Treatment Period or this subject’s 
participation has ended prematurely. The purpose of these interim analyses is for Sponsor key 
personnel to review results from the primary efficacy analysis and a subset of the analyses of 
secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
Management decisions; consequently, neither analysis and will lead to any formal decision to 
alter or terminate the trial. Interim analyses will be conducted by an unblinded study team and 
will follow internal SOPs for the formal process to control the unblinding of the study for interim 
analysis purposes. This process will ensure that no unnecessary or unintentional unblinding 
occurs. The unblinded team will not disclose any unblinded information to the blinded study 
team and the storage of all unblinded documentation will be held securely and separately from 
the rest of the study documentation and outputs up until the end of the study.
All analyses and unblinding instructions will be prespecified in the interim SAP.
Has been changed to: 
This study will include 3 informal unblinded interim analyses; the first after approximately 
45 subjects have completed 4 weeks of the study, the second when the last randomized subject 
not participating in the PET-MRI or PET-CT substudy has completed the Week 12 Visit at 
the end of the Treatment Period or has withdrawn prematurely from the study, and the third 
when the last randomized subject has completed the Week 12 Visit at the end of the 
Treatment Period or this subject’s participation has ended prematurely. 
The purpose of these interim analyses is for Sponsor key personnel to review results from the 
primary efficacy analysis and a subset of the analyses of secondary efficacy and safety outcomes 
to facilitate additional Clinical Planning or Portfolio Management decisions; consequently, none 
of the interim analyses will lead to any formal decision to alter or terminate the study. 
Interim analyses will be conducted by an unblinded study team and will follow internal SOPs for 
the formal process to control the unblinding of the study for interim analysis purposes. This 
process will ensure that no unnecessary or unintentional unblinding occurs. The unblinded team 
will not disclose any unblinded information to the blinded study team and the storage of all 
PUBLIC COPY
he T
Y
he T
of these 
PY 
of these 
ficacy an
OP
ficacy an
acilitate a
CO
acilitate a
ther ana
C C
ther ana
yses wil
LIC
yses wil
rmal pro
BLI
rmal pro
will ensu
UB
will ensu
ll not d
PU
ll not d
nde
P
nde
t cannot be used to support any marketing authorization 
will be
oriz
will be
nt group. 
thor
nt group. 
s leading 
uth
s leading 
e liste
au
e listed.
au
d.
ring
ket
ring
r approxim
mark
r approxim
t randomi
ma
t randomi
ment Perio
ny m
ment Perio
nterim an
any
nterim an
alysis
rt a
alysis and
a
and
dditional 
ort 
dditional 
ysis and w
ppo
ysis and w
be condu
upp
be condu
ess to con
sup
ess to con
e that no u
to s
e that no u
sclose any
d to
sclose any
d docume
ed 
d docume
on and ou
use
on and ou
nstruction
be u
nstruction
to: 
ot
to: 
de 
nn
de 3 info
no
3 info
completed
ann
completed
ing in the
t ca
ing in the
ocument 
he Treatm
nt c
he Treatm
e last ran
men
e last ran
ment Per
me
ment Per
he purpos
ocu
he purpos
This do
primary 
doc
primary 
to fac
s d
to fac
of 
s 
of 
ion and any extensions or variations thereof.
g
imately 45
ns 
imately 45
mized subj
ion
mized subj
iod or this
atio
iod or this
nalyses is 
riat
nalyses is 
d a subset
var
d a subset
Clinical P
r va
Clinical P
will lead t
or 
will lead t
ucted by a
ns o
ucted by a
ntrol the u
ions
ntrol the u
unnecess
sio
unnecess
y unblind
ens
y unblind
entation w
xten
entation w
utputs up u
ext
utputs up u
ns will be
ny e
ns will be
rmal
nd
rmal unb
d
unb
d 4 weeks
an
d 4 weeks
e PET
on a
e PET
applicatio
-M
ment Perio
tion
ment Perio
ndomized
cat
ndomized
riod or th
plica
riod or th
se of thes
app
se of thes
a
fficacy 
ap
fficacy 
ad

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 134 of 136
unblinded documentation will be held securely and separately from the rest of the study 
documentation and outputs up until the end of the study.
All analyses and unblinding instructions will be prespecified in the interim SAP.
Change #24
Section 15.12, Determination of sample size, first paragraph
A sufficient number of subjects will be enrolled in order to ensure 60 subjects are available at 
Week 12 to compare the change from Baseline in ASDAS between bimekizumab and CZP.
Has been changed to: 
A sufficient number of subjects will be enrolled in order to ensure at least 60 subjects are 
available at Week 12 to compare the change from Baseline in ASDAS between bimekizumab 
and CZP and at least 25 subjects will be enrolled into the PET-CT/MRI substudy.
PUBLIC COPY 
ing authorization 
e at 
ho
e at 
CZP.
th
CZP.
subjects ar
ng a
subjects ar
This document cannot be used to support any marketi
een bimek
ting
een bimek
RI substu
ket
RI substu
reof.
are 
re
are 
application and any extensions or variations the
ekizumab
here
ekizumab
udy.
the
udy.

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 135 of 136
20
DECLARATION AND SIGNATURE OF INVESTIGATOR
I confirm that I have carefully read and understood this protocol and agree to conduct this 
clinical study as outlined in this protocol, according to current Good Clinical Practice and local 
laws and requirements.
I will ensure that all subinvestigators and other staff members read and understand all aspects of 
this protocol.
I have received and read all study-related information provided to me.
The objectives and content of this protocol as well as the results deriving from it will be treated 
confidentially, and will not be made available to third parties without prior authorization by 
UCB.
All rights of publication of the results reside with UCB, unless other agreements were made in a 
separate contract.
Investigator:
Printed name
Date/Signature
PUBLIC COPY 
Date
CO
Date
OP
ing authorization 
be treated
uth
be treated
zation by 
au
zation by 
t any marketi
ments wer
eting
ments wer
This document cannot be used to support a
Signature
ort
Signature
t a
reof.
y
o
y
ariations the
re made in
here
re made in
application and any extensions or va
e
o
e
va

UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 136 of 136
21
SPONSOR DECLARATION
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.

Approval Signatures
Name:
as0013-protocol-amend-3
Version:
1. 0
Document Number:
CLIN-000130278
Title:
AS0013 Protocol Amendment 3
Approved Date:
06 Mar 2019
Document Approvals
Approval
Verdict: Approved
Name: 
Capacity: Medical
Date of Signature: 05-Mar-2019 09:01:24 GMT+0000
Approval
Verdict: Approved
Name:
Capacity: Clinical
Date of Signature: 05-Mar-2019 20:20:19 GMT+0000
Approval
Verdict: Approved
Name:
Capacity: Clinical
Date of Signature: 06-Mar-2019 11:03:07 GMT+0000
C COPY 
CO
ent Ap
CO
ent Ap
UBLIC C
C C
PU
pport any marketing authorization 
rt
provals
port 
provals
to suppo
po
s
Name:
pp
Name:
Capac
sup
Capac
Da
su
Da
used to
to
This document canno
not be u
no
p
or variations thereof.
va
s
o
s
or
or
sions 
city: Medic
ons
city: Medic
te of Signa
ion
te of Signa
extensisi
xte
Name:
ens
Name:
Cap
e
Cap
D
application and
nd any e
nd
s o
s